angiotensin
convert
enzym
inhibitor
acei
standard
care
treatment
congest
heart
failur
aldosteron
breakthrough
occur
acei
use
dog
human
combin
blockerneprilysin
inhibitor
show
superior
reduc
mortal
human
patient
heart
failur
compar
enalapril
pharmacodynam
evalu
healthi
dog
show
efficaci
alter
system
raa
without
caus
advers
effect
aim
prospect
blind
random
studi
compar
pharmacodynam
effect
placebo
dog
preclin
myxomat
mitral
valv
diseas
mmvd
evalu
safeti
profil
dog
cardiac
diseas
dog
weigh
kg
acvim
stage
mmvd
enrol
dog
clinic
signific
pulmonari
hypertens
system
diseas
exclud
dog
medic
known
alter
raa
dog
receiv
pimobendan
throughout
studi
period
patient
evalu
three
time
point
day
day
day
echocardiographi
thorac
radiograph
cxr
doppler
system
arteri
pressur
sap
complet
blood
count
serum
biochem
profil
plasma
natriuret
peptid
concentr
urinari
aldosteron
creatinin
ratio
ualdo
c
evalu
day
day
dog
randomli
alloc
treatment
group
mgkg
bid
placebo
group
attend
pharmacist
investig
veterinari
technician
owner
blind
treatment
serum
renal
enzym
electrolyt
concentr
sap
recheck
day
echocardiographi
cxr
sap
renal
panel
plasma
concentr
ualdo
c
recheck
day
thirteen
dog
recruit
n
placebo
n
median
percent
increas
ualdo
c
day
day
significantli
lower
group
p
compar
placebo
group
median
percent
decreas
concentr
day
day
statist
differ
group
p
statist
differ
seen
echocardiograph
cxr
sap
biochem
profil
measur
time
point
group
advers
event
note
owner
dog
either
group
studi
suggest
effici
inhibit
raa
dog
cardiomegali
secondari
mmvd
comparison
placebo
safe
regard
sap
renal
enzym
electrolyt
concentr
advers
effect
note
dog
take
futur
studi
compar
acei
evalu
concomit
use
diuret
evalu
day
effect
warrant
trimethylamin
tmao
oxid
product
trimethylamin
produc
gastrointestin
microbiota
certain
dietari
nutrient
includ
cholin
elev
plasma
concentr
tmao
cholin
shown
associ
presenc
sever
cardiovascular
diseas
peopl
independ
predictor
advers
cardiac
event
mortal
prospect
studi
investig
whether
differ
concentr
circul
tmao
cholin
dog
degen
mitral
valv
diseas
dmvd
compar
healthi
control
control
thirti
dog
recruit
includ
dog
chf
secondari
dmvd
dog
asymptomat
dmvd
control
echocardiographi
perform
fast
plasma
concentr
tmao
cholin
carnitin
fraction
measur
data
compar
among
three
group
use
anova
test
trimethylamin
p
total
p
carnitin
ester
carnitin
ester
free
carnitin
ratio
ef
ratio
significantli
higher
dog
chf
compar
asymptomat
dmvd
trimethylamin
p
cholin
p
total
p
carnitin
ester
free
carnitin
ef
ratio
significantli
higher
dog
chf
compar
control
differ
detect
asymptomat
dmvd
dog
control
dog
dmvd
chf
higher
concentr
tmao
compar
asymptomat
dmvd
dog
control
prospect
studi
warrant
determin
tmao
concentr
alter
dietari
gut
microflora
modif
whether
alter
tmao
concentr
could
impact
diseas
progress
loop
diuret
provid
symptomat
relief
congest
heart
failur
yet
stimul
system
raa
hypothes
two
potent
loop
diuret
torsemid
furosemid
approxim
equipot
dosag
similar
diuresi
would
compar
effect
circul
raa
six
healthi
male
beagl
random
receiv
torsemid
po
furosemid
po
placebo
day
separ
experi
crossov
design
washout
period
experi
blood
collect
day
urin
collect
end
day
repeat
measur
analysi
bonferonni
correct
variabl
adjust
p
investig
use
tukey
method
hour
urin
product
differ
significantli
diuret
day
torsemid
caus
greater
diuresi
furosemid
howev
signific
differ
averag
diuresi
signific
differ
diuret
urinari
excret
na
k
though
furosemid
caus
less
kaliuresi
torsemid
serum
renin
angiotensin
ii
aldosteron
urin
ratio
significantli
increas
diuret
group
compar
placebo
day
signific
differ
paramet
diuret
creatinin
bun
concentr
rose
compar
diuret
group
remain
within
refer
interv
dog
approxim
equipot
dosag
torsemid
furosemid
produc
compar
raa
activ
torsemid
greater
kaliuret
effect
decreas
support
torsemid
hypothes
block
capabl
object
assess
diagnost
util
feasibl
use
french
intracardiac
echocardiographi
ice
cathet
acuson
evalu
cardiac
structur
function
consciou
hors
sedat
xylazin
ten
appar
healthi
hors
texa
univers
teach
herd
underw
physic
exam
transthorac
echocardiographi
tte
ice
french
right
jugular
introduc
place
proxim
neck
continu
ecg
record
procedur
use
simultan
ecg
telemetri
three
posit
describ
associ
puls
wave
doppler
pw
continu
wave
doppler
cw
color
doppler
cd
imag
plane
standard
referenc
intracardiac
posit
common
landmark
posit
confirm
simultan
tte
posit
cranial
right
atrium
allow
visual
right
atrium
right
ventricl
tricuspid
valv
cranial
caudal
vena
cava
align
adequ
cd
cw
pw
evalu
tricuspid
valv
assess
regurgit
inflow
clockwis
rotat
allow
visual
aortic
valv
ascend
aorta
long
axi
pulmon
valv
short
axi
adequ
cd
evalu
posterioflexion
provid
adequ
align
transaort
pw
cw
posit
mid
right
atrium
allow
visual
left
ventricular
outflow
tract
aortic
valv
left
atrium
depth
imag
plane
result
suboptim
cd
evalu
anteroflexion
counterclockwis
rotat
allow
visual
mitral
valv
interatri
septum
foramen
oval
left
atrium
pulmonari
vein
associ
ostia
cd
evalu
adequ
right
ventricl
allow
visual
mitral
valv
interventricular
septum
left
ventricl
long
diagnost
left
ventricl
possibl
positon
procedur
well
toler
mild
intermitt
ventricular
supraventricular
arrhythmia
resolv
ice
cathet
reposit
conclud
ice
feasibl
safe
allow
acquisit
repeat
diagnost
imag
plane
consciou
sedat
hors
could
potenti
use
clinic
situat
tte
may
technic
difficult
perform
poorli
toler
hors
sotalol
class
iii
drug
commonli
prescrib
treatment
ventricular
tachyarrhythmia
dog
effect
sotalol
mediat
increas
action
potenti
durat
prolong
atrial
ventricular
repolar
via
antagon
delay
rectifi
potassium
current
effect
demonstr
independ
sotalol
properti
howev
blockad
may
result
reduc
myocardi
contractil
also
contribut
slow
sinu
rate
patient
exist
heart
diseas
cardiodepress
drug
effect
may
clinic
relev
yet
inotrop
properti
sotalol
dog
aim
studi
investig
inotrop
chronotrop
effect
sotalol
healthi
awak
dog
ten
adult
dog
recruit
veterinari
commun
oregon
state
univers
colleg
veterinari
medicin
dog
consid
healthi
base
histori
physic
exam
oscillometr
blood
pressur
measur
transthorac
echocardiographi
electrocardiogram
dog
also
baselin
hour
holter
monitor
perform
sotalol
dose
mgkg
oral
administ
day
follow
second
evalu
includ
diagnost
test
physic
exam
paramet
blood
pressur
measur
holter
data
echocardiograph
measur
includ
left
ventricular
lv
volum
strain
measur
evalu
baselin
measur
assess
normal
compar
statist
pair
normal
distribut
data
wilcoxon
sign
rank
test
distribut
data
data
avail
dog
correct
made
multipl
comparison
ten
dog
includ
studi
mean
age
year
rang
year
mean
weight
kg
rang
kg
mean
sotalol
dose
administ
mgkg
heart
rate
exam
significantli
p
lower
bpm
bpm
maximum
heart
rate
holter
monitor
also
significantli
p
lower
sotalol
bpm
baselin
bpm
sever
echocardiograph
indic
systol
function
alter
compar
baselin
fraction
shorten
fs
use
mm
measur
significantli
reduc
sotalol
interquartil
rang
iqr
mm
compar
baselin
iqr
mm
p
p
measur
respect
similarli
eject
fraction
ef
via
simpson
method
disk
smod
significantli
p
lower
sotalol
baselin
sotalol
increas
lv
dimens
increas
measur
p
p
respect
signific
differ
left
ventricular
volum
global
longitudin
circumferenti
strain
twist
torsion
result
studi
suggest
sotalol
neg
inotrop
chronotrop
effect
healthi
dog
standard
echocardiograph
measur
systol
function
show
small
statist
signific
decreas
sotalol
treatment
mean
reduct
ef
smod
lack
signific
imag
may
reflect
variabl
measur
small
sampl
size
effect
sotalol
dog
structur
heart
diseas
prospect
assess
elucid
clinic
signific
decreas
systol
function
implic
reduct
patient
risk
heart
failur
transven
pacemak
implant
definit
treatment
patholog
bradyarrhythmia
though
report
complic
rate
histor
high
purpos
studi
determin
surviv
time
complic
rate
dog
underw
transven
pacemak
implant
larg
number
institut
addit
wish
identifi
factor
may
predispos
patient
develop
complic
multicent
retrospect
analysi
dog
underw
transven
pacemak
implant
januari
decemb
perform
arrhythmia
type
gener
locat
number
lead
complic
rate
surviv
time
evalu
complic
categor
major
versu
minor
time
develop
surviv
time
evalu
curv
total
dog
identifi
male
neuter
femal
spay
median
age
year
rang
year
present
arrhythmia
includ
degre
av
block
sick
sinu
syndrom
sss
high
grade
degre
av
block
atrial
standstil
miscellan
six
hundr
three
pacemak
implant
perform
case
surviv
intraop
period
patient
receiv
singl
chamber
dual
chamber
vdd
pace
system
activ
passiv
ventricular
fixat
lead
use
pacemak
gener
place
subcutan
cervic
region
caudal
scapula
total
case
surviv
discharg
overal
median
surviv
time
month
month
month
month
sss
month
signific
differ
surviv
time
sss
p
major
complic
includ
lead
dislodg
episod
lead
perfor
episod
infect
episod
signific
complic
episod
seventeen
infect
involv
gener
cervic
placement
caudal
scapula
approach
reach
statist
signific
p
minor
complic
includ
seroma
format
episod
minor
issu
episod
pace
complic
includ
oversens
episod
undersens
episod
intermitt
loss
captur
episod
dysfunct
requir
pace
mode
switch
episod
nois
revers
episod
conduct
block
high
heart
rate
episod
transven
pacemak
implant
associ
rel
high
complic
rate
predispos
factor
specif
complic
unabl
identifi
associ
longer
surviv
time
compar
sss
though
differ
bradyarrhythmia
atenolol
antagonist
commonli
prescrib
cat
affect
hypertroph
obstruct
cardiomyopathi
tradit
oral
dose
mg
per
cat
oral
tablet
highli
bioavail
peak
atenolol
concentr
occur
hour
post
administr
cat
howev
result
sever
studi
indic
owner
complianc
may
poor
oral
treatment
felin
disposit
present
specif
challeng
owner
chronic
oral
medic
administr
previou
veterinari
studi
investig
transderm
atenolol
equival
oral
atenolol
dosag
found
major
cat
receiv
transderm
atenolol
therapeut
plasma
atenolol
concentr
hour
administr
none
therapeut
plasma
atenolol
concentr
hour
administr
result
rais
question
regard
direct
substitut
transderm
dose
equival
oral
dose
inher
variabl
compound
medic
therefor
goal
studi
optim
transderm
atenolol
formul
assess
atenolol
dosag
amount
frequenc
healthi
cat
use
formul
hypothes
optim
transderm
atenolol
formula
higher
transderm
dosag
rate
administ
result
therapeut
ngml
atenolol
concentr
healthi
cat
collabor
oregon
state
univers
osu
colleg
pharmaci
research
creat
transderm
atenolol
formul
optim
drug
releas
good
permeat
manner
differ
concentr
atenolol
gel
hypomellos
carrier
carbom
base
evalu
vitro
diffus
studi
use
upright
diffus
cell
sampl
subsequ
analyz
atenolol
content
use
liquid
chromatographi
candid
gel
highest
vitro
perfus
rate
polym
membran
appli
sampl
obtain
nape
ear
cat
sampl
place
diffus
cell
measur
skin
permeabl
atenolol
excis
skin
half
cell
result
indic
applic
atenolol
gel
ear
gave
significantli
greater
permeat
one
topic
formul
suggest
optim
perform
transderm
applic
vivo
optim
atenolol
formul
concentr
mgml
appli
healthi
cat
enlist
osu
veterinari
commun
enrol
cat
abnorm
note
physic
examin
blood
pressur
measur
electrocardiogram
ecg
echocardiographi
baselin
complet
blood
count
chemistri
evalu
cat
receiv
escal
dose
transderm
atenolol
day
day
treatment
transderm
atenolol
administ
blood
sampl
collect
atenolol
serum
concentr
hour
topic
applic
phlebotomi
hour
administr
ecg
also
perform
averag
heart
rate
hr
measur
gradual
taper
transderm
atenolol
subsequ
occur
day
enrol
cat
success
complet
drug
trial
cat
experienc
advers
two
cat
initi
receiv
maximum
transderm
dose
mg
serum
atenolol
concentr
subtherapeut
ngml
hour
transderm
atenolol
dose
increas
mg
cat
studi
use
higher
atenolol
dosag
week
washout
period
three
cat
complet
updat
studi
protocol
higher
atenolol
dosag
two
cat
therapeut
serum
atenolol
concentr
hour
cat
near
therapeut
concentr
ngml
target
ngml
hour
hour
timepoint
cat
therapeut
serum
atenolol
concentr
cat
near
therapeut
serum
atenolol
concentr
hour
dose
cat
therapeut
serum
atenolol
concentr
hr
data
cat
reduct
hr
compar
baselin
hr
hour
averag
reduct
bpm
cat
reduct
hr
hour
averag
reduct
bpm
compar
baselin
hr
result
pilot
studi
suggest
formul
transderm
atenolol
administ
mg
provid
therapeut
serum
atenolol
concentr
attend
hr
reduct
clinic
healthi
cat
preliminari
data
requir
valid
larger
cohort
cat
german
shepherd
dog
gsd
predispos
develop
patent
ductu
arteriosu
pda
reportedli
prone
type
iii
pda
anatomi
dog
type
iii
anatomi
consid
favor
candid
intervent
object
studi
describ
pda
anatomi
baselin
characterist
procedur
outcom
gsd
pda
medic
record
gsd
diagnos
pda
underw
surgic
ligat
transcathet
devic
closur
retrospect
review
german
shepherd
dog
pda
often
present
clinic
sign
concurr
congenit
heart
diseas
arrhythmia
dog
typic
matur
present
median
month
rel
balanc
sex
distribut
femal
patent
ductu
arteriosu
anatomi
classifi
gsd
type
ii
anatomi
common
three
dog
unusu
anatomi
type
iv
type
v
median
minim
ductal
diamet
mdd
popul
larger
previous
report
mdd
mix
popul
rang
mm
depend
upon
imag
modal
success
closur
achiev
amplatz
canin
duct
occlud
acdo
dog
via
surgic
ligat
dog
case
type
iii
anatomi
confirm
popul
major
gsd
type
ii
pda
anatomi
amen
acdo
deploy
predisposit
larg
mdd
occasion
unusu
pda
anatomi
suggest
transesophag
echocardiographi
may
benefici
optim
procedur
plan
breed
loop
diuret
activ
classic
circul
system
raa
increas
renin
angiotensin
ii
angi
angii
aldosteron
novel
raa
compon
includ
angiotensin
metabolit
angiii
angiv
angii
metabolit
hypothes
torsemid
furosemid
equipot
dosag
would
significantli
commensur
increas
level
novel
compon
mirror
chang
classic
raa
six
healthi
male
beagl
random
receiv
torsemid
po
furosemid
po
placebo
day
separ
experi
design
separ
washout
period
blood
collect
day
urin
sampl
collect
end
day
serum
aldosteron
quantifi
via
liquid
spectrometri
ms
angiotensin
metabolit
quantifi
equilibrium
analysi
attoqu
diagnost
vienna
austria
urin
aldosteron
quantifi
via
radioimmunoassay
beckman
coulter
use
calcul
urin
ratio
ualdo
c
repeat
measur
analysi
bonferonni
correct
variabl
adjust
p
investig
use
tukey
method
serum
angi
angii
angiv
aldosteron
ualdo
c
significantli
increas
diuret
group
compar
placebo
day
increas
paramet
greatest
torsemid
group
fail
reach
signific
serum
angiii
increas
diuret
therapi
yet
valu
differ
significantli
placebo
novel
compon
circul
raa
significantli
increas
therapi
torsemid
furosemid
mirror
chang
classic
raa
purpos
studi
compar
repeat
select
transthorac
measur
acquir
echocardiographi
guid
echocardiographi
normal
consciou
dog
determin
optim
number
repetit
requir
maxim
precis
modal
five
consciou
dog
kg
underw
transthorac
examin
four
investig
sg
cardiologist
cardiologist
ch
cardiologist
rf
cardiolog
resid
dog
imag
five
time
investig
investig
limit
three
studi
singl
day
measur
perform
investig
acquir
imag
line
later
time
one
addit
investig
mm
cardiologist
complet
five
examin
one
dog
two
day
three
differ
investig
sg
rf
perform
measur
line
blind
result
repeat
imag
acquisit
variabl
measur
variabl
quantifi
averag
coeffici
variat
cv
lower
upper
limit
bound
coeffici
variat
calcul
use
exact
theori
logist
regress
upper
limit
repetit
use
determin
highest
precis
modal
evalu
left
ventricular
size
highest
repeat
cv
lowest
variabl
imag
acquisit
cv
measur
cv
repeat
imag
acquisit
cv
measur
cv
slightli
better
imag
acquisit
cv
measur
cv
variabl
cv
also
slightli
better
cv
left
atrial
aortic
ratio
measur
higher
repeat
cv
less
variabl
cv
volum
assess
imag
acquisit
cv
measur
cv
assess
left
ventricular
size
achiev
accept
precis
repetit
left
ventricular
size
assess
requir
repetit
respect
data
may
use
design
studi
protocol
plan
use
echocardiograph
assess
outcom
variabl
taurin
carnitin
defici
associ
dilat
cardiomyopathi
dcm
dog
littl
known
etiolog
recognit
dcm
atyp
breed
fed
diet
gfd
prompt
studi
diet
histori
echocardiogram
dog
diagnos
dcm
ncsu
evalu
dog
group
diet
gfd
ngfd
group
gfd
group
subdivid
dog
fed
common
brand
brand
echocardiograph
paramet
compar
group
dog
dcm
fed
gfd
receiv
includ
pair
unrel
housem
taurin
carnitin
defici
identifi
among
gfd
dog
test
taurin
carnitin
dog
dcm
fed
ngfd
test
taurin
defici
vegetarian
dog
eat
weigh
less
greater
normal
lv
diamet
diastol
lviddn
systol
lvidsn
lower
spheric
index
si
compar
dog
eat
weight
p
lviddn
p
lvidsn
p
si
p
compar
dog
eat
ngfd
weight
p
lviddn
p
lvidsn
p
si
p
dog
eat
gfd
regardless
brand
greater
lviddn
p
greater
lvidsn
p
lower
si
p
dog
eat
ngfd
preval
congest
heart
failur
differ
gfd
ngfd
group
echocardiogram
dog
dcm
fed
gfd
specif
suggest
advanc
diseas
pathophysiolog
compar
dog
eat
ngfd
synthet
brain
natriuret
peptid
caus
natriuresi
diuresi
vasodil
raa
antagon
dog
experiment
induc
congest
heart
failur
chf
howev
unclear
whether
dog
natur
occur
chf
would
respond
similarli
purpos
pilot
studi
evalu
efficaci
synthet
canin
given
subcutan
dog
natur
occur
chf
seven
male
dog
compens
acvim
stage
c
chf
due
myxomat
mitral
valv
diseas
receiv
singl
dose
subcutan
ugkg
frusemid
mgkg
ugkg
mgkg
respect
studi
design
washout
period
treatment
heart
rate
hr
blood
pressur
bp
plasma
concentr
cgmp
fraction
excret
sodium
fena
potassium
fek
measur
h
follow
treatment
urin
output
uop
urinari
cgmp
product
upcgmp
measur
h
follow
treatment
effect
evalu
use
linear
mix
model
restrict
maximum
likelihood
estim
signific
taken
p
frusemid
result
signific
increas
uop
fena
fek
h
post
treatment
howev
differ
two
treatment
alon
affect
paramet
chang
hr
bp
observ
treatment
plasma
concentr
increas
significantli
within
h
treatment
treatment
contain
fell
baselin
h
post
treatment
although
signific
differ
plasma
concentr
cgmp
observ
upcgmp
increas
significantli
h
follow
treatment
subcutan
result
increas
plasma
concentr
upcgmp
howev
detect
biolog
effect
hr
bp
uop
fena
fek
contrast
data
obtain
dog
experiment
induc
chf
though
investig
recommend
possibl
dog
natur
occur
chf
may
reduct
natriuret
peptid
respons
duchenn
muscular
dystrophi
dmd
genet
diseas
caus
progress
muscl
weak
cure
dmd
affect
boy
typic
die
due
respiratori
cardiac
failur
golden
retriev
muscular
dystrophi
grmd
genet
homolog
model
use
increasingli
studi
pathogenesi
potenti
treatment
dmd
grmd
dog
develop
cardiomyopathi
similar
dmd
diseas
progress
well
defin
studi
evalu
echocardiographi
cardiac
mri
adult
grmd
dog
differ
age
left
heart
systol
function
wall
thick
myocardi
strain
assess
echocardiographi
featur
evalu
cardiac
mri
includ
lv
function
chamber
size
myocardi
mass
late
gadolinium
enhanc
lge
separ
ten
grmd
dog
evalu
circumferenti
strain
twice
period
taken
togeth
result
show
gradual
declin
systol
function
grmd
dog
decreas
eject
fraction
ef
echocardiographi
correl
well
age
identifi
month
approxim
age
ef
fall
circumferenti
strain
appear
sensit
ef
earli
diseas
detect
declin
diseas
progress
evid
lv
chamber
dilat
provid
proof
dilat
cardiomyopathi
lge
imag
show
lv
later
wall
lesion
earlier
involv
anterior
septum
grmd
dog
conclus
studi
show
natur
histori
grmd
cardiomyopathi
larg
parallel
dmd
addit
circumferenti
strain
ef
good
biomark
diseas
progress
inflammatori
respons
occur
congest
heart
failur
human
dog
previou
felin
cardiomyopathi
research
suggest
inflamm
play
role
diseas
process
object
studi
assess
circul
acut
phase
protein
felin
patient
congest
heart
failur
chf
due
primari
cardiomyopathi
cm
studi
popul
includ
chf
cat
asymptomat
cm
cat
healthi
control
panel
serum
acut
phase
protein
measur
use
spatial
proxim
analyt
reagent
captur
luminesc
sparcl
kit
clinic
echocardiograph
data
collat
cm
cat
surviv
statu
chf
cat
record
analysi
varianc
anova
student
test
fisher
exact
test
spearman
rho
cox
proport
hazard
model
use
statist
analysi
cat
chf
higher
serum
compar
healthi
control
higher
serum
amyloid
compar
asymptomat
cm
healthi
control
higher
ceruloplasmin
compar
asymptomat
cm
p
univari
surviv
analysi
model
serum
glycoprotein
agp
level
found
associ
higher
risk
death
chf
cat
p
multivari
analysi
suggest
serum
agp
p
bodi
weight
p
laao
ratio
p
independ
prognost
factor
chf
cat
find
suggest
system
inflammatori
respons
occur
felin
congest
heart
failur
due
primari
cardiomyopathi
acut
phase
protein
use
clinic
paramet
biomark
diseas
monitor
prognost
felin
cardiomyopathi
cardiomyopathi
cm
common
acquir
felin
cardiac
diseas
frequent
result
congest
heart
failur
chf
low
cardiac
output
poor
peripher
perfus
may
caus
multisystem
injuri
pancreat
measur
felin
pancreat
lipas
immunoreact
fpli
immunoreact
tli
aid
assess
pancreat
pancreat
exocrin
function
previou
studi
assess
associ
cardiac
diseas
chf
pancreat
human
dog
aim
prospect
studi
assess
fpli
tli
valu
healthi
cat
cat
primari
cm
without
chf
addit
retrospect
evalu
pancreat
histolog
cat
cm
perform
cat
prospect
recruit
three
group
healthi
control
h
group
primari
cm
cm
group
cm
activ
histor
chf
determin
cardiologist
chf
group
includ
cat
underw
physic
exam
blood
pressur
echocardiogram
fpli
tli
complet
blood
count
cbc
chemistri
panel
cat
evid
hypertroph
cardiomyopathi
hcm
also
total
measur
routin
pancreat
histopatholog
cat
affect
primari
cm
retrospect
review
anatom
pathologist
histolog
evid
pancreat
injuri
differ
group
assess
test
associ
assess
fisher
exact
test
total
cat
includ
classifi
h
cm
chf
group
statist
differ
age
bodi
weight
bodi
condit
score
group
cm
diagnos
includ
hcm
cm
chf
hypertroph
obstruct
cardiomyopathi
cm
chf
unclassifi
cardiomyopathi
cm
chf
restrict
cardiomyopathi
chf
chf
group
cat
activ
chf
pulmonari
edema
pleural
effus
time
blood
collect
gastrointestin
sign
includ
vomit
cm
chf
anorexia
cm
chf
weight
loss
cm
chf
median
valu
control
cm
chf
group
differ
fpli
tli
five
cm
chf
cat
fpli
valu
greater
felin
refer
rang
cm
cat
increas
tli
valu
cm
cat
deceas
tli
valu
activ
chf
statist
associ
abnorm
fpli
tli
result
p
p
retrospect
pancreat
histopatholog
cat
cm
found
spectrum
morpholog
lesion
potenti
relat
pancreat
ischemia
includ
exocrin
vacuol
focal
multifoc
coagul
necrosi
saponif
adipos
tissu
cat
possibl
pancreat
ischemia
activ
histor
chf
common
felin
pancreat
lesion
also
identifi
includ
islet
amyloidosi
mild
moder
lymphocyt
inflamm
periductular
fibrosi
preliminari
data
demonstr
statist
signific
differ
pancreat
biomark
cardiomyopath
cat
without
chf
potenti
relev
histopatholog
pancreat
chang
identifi
suggest
biomark
may
vari
time
diseas
sever
reflect
injuri
myocardi
diseas
preval
categori
acquir
cardiac
diseas
cat
result
ventricular
diastol
systol
dysfunct
elev
left
atrial
pressur
left
atrial
enlarg
lae
frequent
preced
congest
heart
failur
chf
addit
left
atrial
function
may
declin
progress
myocardi
diseas
affect
cat
left
atrium
may
enlarg
variou
direct
although
convent
measur
echocardiographi
use
right
parastern
view
index
aortic
diamet
la
ao
maxim
diamet
right
parastern
view
also
util
assess
la
size
measur
volum
calcul
replac
linear
measur
chamber
quantif
human
canin
echocardiograph
exam
aim
retrospect
studi
compar
la
size
convent
linear
measur
calcul
la
volum
lav
compar
minim
maxim
valu
hypothesi
lav
would
provid
superior
sensit
se
specif
sp
identifi
cat
chf
without
chf
medic
record
review
cat
complet
echocardiograph
exam
perform
oregon
state
univers
veterinari
teach
hospit
januari
juli
cat
categor
three
group
healthi
cat
h
group
normal
echocardiogram
clinic
diagnosi
cardiomyopath
cat
cm
group
echocardiogram
consist
primari
cardiomyopathi
without
clinic
radiograph
evid
chf
chf
cat
chf
group
echocardiogram
consist
primari
cardiomyopathi
clinic
radiograph
evid
chf
hyperthyroid
hypertens
cat
exclud
seven
measur
la
size
made
includ
cat
minim
la
ao
la
aom
maxim
la
ao
la
aom
accord
hansson
method
minim
lav
maxim
lav
right
parastern
view
lavmrla
lavmrla
minim
lav
maxim
lav
left
apic
view
lavmlap
lavmlap
maxim
left
atrial
diamet
lad
right
parastern
view
volum
calcul
use
monoplan
modifi
simpson
method
disc
mod
volum
measur
also
index
bodi
weight
kg
minim
measur
made
p
wave
maximum
measur
made
wave
simultan
record
ecg
receiv
oper
curv
use
assess
area
curv
auc
optim
associ
se
sp
distinguish
group
total
cat
includ
studi
classifi
healthi
cm
chf
healthi
cat
younger
cm
chf
group
p
group
differ
bodi
weight
lav
measur
rla
lap
view
statist
differ
p
la
aom
lavmlap
result
largest
auc
distinguish
cm
chf
cat
auc
auc
respect
index
lav
bodi
weight
increas
auc
volum
measur
seven
measur
poor
auc
result
distinguish
h
cm
cat
la
aom
valu
optim
sensit
specif
distinguish
cm
chf
cat
se
sp
lavmlap
raw
index
valu
optim
sensit
specif
distinguish
cm
chf
cat
ml
se
sp
mlkg
se
sp
result
studi
indic
la
volum
superior
linear
measur
la
size
distinguish
cm
chf
cat
interestingli
minim
la
size
volum
result
higher
auc
correspond
maximum
measur
contrast
current
recommend
time
point
measur
la
ao
minimum
la
size
volum
may
better
discriminatori
factor
atrial
contractil
function
declin
worsen
myocardi
diseas
develop
chf
canin
degen
mitral
valv
diseas
dmvd
chronic
variabl
progress
condit
dog
dmvd
left
apic
systol
murmur
consist
clinic
find
physic
examin
heart
murmur
intens
significantli
posit
associ
echocardiograph
measur
left
heart
chamber
size
diseas
sever
find
evalu
longitudin
studi
aim
evalu
whether
chang
heart
murmur
intens
reflect
longitudin
chang
echocardiograph
dimens
cohort
dog
variabl
affect
dmvd
clinic
data
sourc
record
dog
visit
research
clinic
one
occas
daili
rate
chang
left
atrial
aortic
root
ratio
la
ao
left
ventricular
intern
diamet
diastol
normalis
bodyweight
kg
lviddn
calcul
interv
multipli
aid
data
handl
interpret
separ
linear
mix
effect
model
construct
rate
chang
lviddn
la
ao
respect
murmur
intens
score
use
levin
scale
classifi
accord
whether
increas
decreas
maintain
interv
enter
explanatori
variabl
addit
explanatori
variabl
includ
model
record
first
examin
interv
patient
age
breed
sex
weight
murmur
grade
lviddn
la
ao
acvim
stage
treatment
statu
furosemid
pimobendan
angiotensin
convert
enzym
inhibitor
acei
spironolacton
post
hoc
estim
margin
mean
calcul
categor
variabl
remain
signific
multivari
analys
enter
pairwis
comparison
determin
group
differ
coeffici
statist
signific
data
visit
enter
cohort
dog
chang
murmur
intens
significantli
associ
rate
chang
lviddn
p
multivari
analysi
alongsid
murmur
grade
patient
age
breed
lviddn
la
ao
treatment
statu
acei
chang
murmur
intens
also
associ
rate
chang
la
ao
separ
multivari
analysi
p
alongsid
patient
acvim
stage
lviddn
la
ao
treatment
statu
furosemid
rate
chang
echocardiograph
measur
greatest
murmur
intens
increas
lviddn
b
la
ao
b
follow
interv
murmur
intens
chang
lviddn
b
la
ao
b
lowest
murmur
intens
decreas
lviddn
b
la
ao
b
pairwis
comparison
coeffici
highli
signific
p
associ
chang
heart
murmur
intens
rate
cardiac
remodel
provid
evidenti
support
util
longitudin
monitor
murmur
grade
clinic
practic
increas
murmur
grade
may
indic
rapid
rate
dmvd
progress
occur
could
use
recommend
echocardiograph
evalu
giant
breed
includ
turkish
kangal
dog
prone
myocardi
diseas
speckl
track
echocardiographi
ste
use
measur
strain
dog
measur
clinic
normal
dog
breed
need
canin
clinic
practic
object
prospect
studi
obtain
ste
data
routin
echocardiograph
examin
turkish
kangal
dog
refer
valu
healthi
adult
turkish
kangal
dog
includ
scan
normal
clinic
condit
obtain
standard
echocardiograph
paramet
ste
data
five
dog
drop
studi
due
poor
imag
qualiti
therefor
total
dog
includ
statist
analysi
dog
femal
male
mean
age
dog
dog
ste
data
obtain
three
scan
plane
mean
peak
radial
strain
apex
mean
peak
radial
strain
papillari
muscl
level
mean
peak
radial
strain
base
mean
peak
circumferenti
strain
apex
mean
peak
circumferenti
strain
papillari
muscl
level
mean
peak
circumferenti
strain
base
conclus
techniqu
part
normal
echocardiograph
examin
turkish
kangal
dog
clinic
condit
result
similar
part
result
avali
one
report
perform
matur
irish
wolfhound
howev
order
compar
use
ste
data
report
futur
studi
design
larger
popul
turkish
kangal
dog
cardiolog
disord
westrup
u
mcevoy
fj
speckl
track
echocardiographi
matur
irish
wolfhound
dog
technic
feasibl
measur
error
refer
interv
acta
veterinaria
scandinavica
insulin
metabol
might
play
role
felin
hypertroph
cardiomyopathi
hcm
aggrav
inflamm
studi
investig
associ
echocardiographi
morpholog
cardiac
inflammatori
marker
insulin
metabol
cat
asymptomat
hypertroph
cardiomyopathi
ahcm
asymptomat
cat
diastol
septum
ivsd
andor
left
ventricular
wall
lvwd
includ
inform
consent
owner
examin
fast
cat
includ
auscult
bodyweight
bw
bodi
condit
score
bc
echocardiographi
ivsd
lvwd
measur
basal
mid
lvwd
ivsd
apic
ivsd
note
maximum
number
area
blood
sampl
analyz
serum
amyloid
saa
insulin
glucos
statist
analysi
p
investig
whether
measur
significantli
increas
valu
effect
left
atrial
remodel
gener
versu
focal
hypertrophi
correl
measur
cat
increas
bc
p
insulin
p
p
p
correl
present
p
p
p
p
p
p
saa
p
p
age
correl
la
max
p
glucos
p
bw
bc
correl
p
p
p
insulin
p
glucos
p
p
respect
cat
la
remodel
n
higher
p
p
p
p
cat
gener
hypertrophi
n
higher
p
p
p
p
saa
p
result
suggest
role
insulin
metabol
inflamm
ahcm
research
contribut
ahcm
need
purpos
studi
determin
whether
mitral
valv
plasti
mvp
cardiopulmonari
bypass
would
better
improv
prognosi
dog
mitral
valv
diseas
mvd
treatment
intern
medicin
studi
retrospect
review
medic
record
identifi
dog
mvd
underw
surgic
repair
medic
manag
mvd
intern
medicin
group
dog
studi
dog
group
treat
chronic
ace
inhibitor
pimobendan
diuresi
thiazid
spironoracton
furosemid
torsemid
vasodil
amlodipin
nitroglycerin
isosorbid
sildenafil
surgeri
group
dog
mitral
valv
regurgit
mean
age
year
mean
bodi
weight
kg
underw
mitral
valv
plasti
cardiopulmonari
bypass
cpb
juli
octob
intern
medicin
group
median
surviv
time
day
stage
day
stage
c
day
stage
case
dog
die
due
heart
failur
surgic
group
discharg
ratio
stage
c
respect
median
surviv
time
undefin
almost
patient
surviv
surviv
ratio
stage
c
respect
mean
surviv
time
day
stage
day
stage
c
day
stage
one
dog
die
renal
failur
stage
day
caus
death
stage
c
technic
problem
protamin
shock
residu
pulmonari
damag
unknown
caus
death
stage
heart
failur
residu
pulmonari
damag
renal
failur
result
suggest
mvp
effect
medic
therapi
treatment
mvd
earlier
surgeri
recommend
phrenic
nerv
palsi
pnp
one
complic
open
chest
surgeri
aim
present
retrospect
studi
evalu
incid
pnp
mitral
valv
repair
dog
total
dog
underw
mitral
valv
repair
pnp
diagnos
use
inspiratori
chest
radiograph
day
surgeri
case
left
diaphragm
rais
interv
right
diaphragm
sign
respiratori
distress
effort
respir
also
observ
assess
incid
pnp
recoveri
time
relationship
occurr
pnp
surviv
rate
occurr
respiratori
failur
aortic
time
surgeri
pnp
diagnos
case
day
surgeri
case
time
discharg
hospit
week
surgeri
case
postop
examin
one
case
postop
examin
pnp
develop
nine
patient
die
hospit
nine
patient
die
respiratori
insuffici
p
occurr
pnp
associ
aortic
time
find
suggest
incid
pnp
mitral
valv
repair
high
dog
although
recoveri
time
shorter
human
pnp
alon
affect
prognosi
howev
postop
risk
factor
case
exhibit
respiratori
diseas
activ
myofibroblast
valv
interstiti
cell
vic
identifi
express
alpha
smooth
muscl
actin
thought
play
central
role
mediat
canin
degen
mitral
valv
diseas
dmvd
cell
transform
endmt
development
mechan
activ
valvulogenesi
wherebi
endotheli
cell
migrat
interstitum
transform
mesenchym
phenotyp
studi
object
investig
whether
endmt
could
sourc
high
cellular
densiti
myofibroblast
vic
found
canin
dmvd
mitral
valv
collect
dog
median
age
year
determin
echocardiographi
free
mitral
regurgit
control
group
median
whitney
score
dog
median
age
year
dmvd
degen
group
median
whitney
score
sequenti
histolog
section
mitral
valv
stain
movat
pentachrom
immunohistochemistri
platelet
endotheli
cell
adhes
molecul
marker
endotheli
cell
phenotyp
heparin
growth
factor
control
degen
mitral
valv
show
posit
stain
cell
valv
surfac
within
vessel
papillari
muscl
consist
normal
valvular
vascular
endotheli
cell
respect
degen
mitral
valv
cell
also
found
within
valv
interstitum
area
vic
suggest
activ
endmt
degen
valv
mediat
endotheli
cell
migrat
focal
area
posit
stain
observ
degen
mitral
valv
endmt
appear
activ
canin
dmvd
could
sourc
myofibroblast
vic
mediat
degen
chang
purpos
studi
determin
abil
telemetri
estim
arrhythmia
sever
hospit
dog
compar
holter
monitor
ten
dog
arrhythmia
hospit
heart
rate
rhythm
simultan
monitor
use
telemetri
holter
monitor
telemetri
assess
train
icu
technician
everi
hour
heart
rate
rhythm
record
arrhythmia
scale
use
grade
arrhythmia
sever
grade
sinu
vpc
grade
singl
vpc
grade
acceler
idioventricular
grade
bigemini
trigemini
grade
couplet
triplet
grade
ventricular
tachycardia
r
phenomenon
holter
data
analyz
cardiologist
arrhythmia
grade
assign
time
period
report
icu
technician
arrhythmia
grade
also
determin
holter
data
report
highest
grade
note
previou
hour
cohen
weight
kappa
analysi
use
compar
agreement
icu
holter
grade
time
period
analysi
use
compar
holter
grade
prior
hour
holter
grade
clinic
unaccept
agreement
found
icu
report
grade
holter
grade
well
holter
grade
prior
hour
holter
grade
result
show
train
icu
technician
often
incorrectli
assess
sever
arrhythmia
hourli
evalu
inconsist
estim
sever
arrhythmia
pulmonari
hypertens
develop
secondari
multitud
diseas
process
dog
result
abnorm
increas
pulmonari
arteri
pressur
dysfunct
right
heart
pulmonari
interstiti
vascular
patholog
sildenafil
common
medic
treatment
use
veterinari
patient
pimobendan
minim
investig
potenti
treatment
purpos
retrospect
studi
evalu
effect
sildenafil
monotherapi
versu
combin
therapi
sildenafil
pimobendan
dog
moder
sever
pulmonari
hypertens
clinic
record
review
inclus
criteria
includ
dog
moder
sever
pulmonari
hypertens
estim
systol
pulmonari
arteri
pressur
greater
mmhg
andor
evid
signific
right
heart
dysfunct
deem
secondari
pulmonari
hypertens
exclus
criteria
includ
lack
follow
examin
pulmonari
hypertens
secondari
left
side
heart
diseas
qualiti
life
score
pre
post
treatment
surviv
time
time
cardiac
event
estim
systol
pulmonari
arteri
pressur
pre
post
treatment
evalu
group
total
dog
enrol
studi
combin
therapi
significantli
improv
qualiti
life
score
p
signific
differ
group
surviv
time
cardiac
event
estim
systol
pulmonari
arteri
pressur
pre
post
treatment
median
time
cardiac
event
group
month
p
median
surviv
month
sildenafil
monotherapi
month
combin
therapi
p
conclus
combin
therapi
sildenafil
pimobendan
versu
sildenafil
monotherapi
significantli
improv
surviv
time
time
cardiac
event
pulmonari
pressur
gradient
improv
patient
qualiti
life
myxomat
mitral
valv
diseas
mmvd
common
cardiac
diseas
dog
howev
caus
mechan
specif
tissu
pathway
diseas
remain
unclear
anim
model
evalu
clinic
affect
valv
dog
suggest
serotonin
signal
play
role
develop
mmvd
evid
interact
two
tissu
pathway
hypothesi
pilot
studi
abnorm
pathway
function
inhibit
would
result
dysregul
tissu
growth
uncontrol
serotonin
pathway
studi
design
random
blind
control
experiment
trial
spragu
dawley
rat
assign
equal
six
treatment
group
salin
neg
control
serotonin
posit
control
inhibit
posit
control
inhibit
plu
serotonin
synergist
inhibitor
plu
cyproheptadin
serotonin
antagonist
inhibitor
plu
clopidogrel
antiplatelet
group
treat
day
sacrif
heart
collect
stain
hematoxylin
eosin
h
e
histopatholog
examin
result
score
base
previous
publish
method
mitral
valv
patholog
score
rang
chang
sever
chang
median
rang
treatment
group
follow
neg
control
posit
control
posit
control
synergist
serotonin
antagonist
antiplatelet
test
compar
distribut
histolog
score
across
group
statist
signific
p
like
due
small
sampl
size
signific
overlap
histolog
score
group
pilot
studi
identifi
obviou
relationship
abnorm
pathway
function
serotonin
mitral
valv
rat
howev
variabl
valv
orient
affect
tissu
section
may
preclud
identif
chang
group
special
stain
immunohistochemistri
pend
may
help
provid
identifi
chang
group
distemp
import
infecti
diseas
endem
region
brazil
number
dog
death
caus
canin
distemp
viru
cdv
increas
pathogen
death
toll
also
reach
wide
rang
carnivor
speci
caus
mass
mortal
wildlif
worldwid
also
consid
countri
alreadi
control
finland
distemp
previous
control
case
report
pup
natur
infect
distemp
viru
publish
recent
letter
publish
warn
colleagu
risk
canin
distemp
uk
proven
viru
import
histopatholog
effect
cardiovascular
system
although
scarc
research
present
studi
evalu
viru
activ
heart
natur
infect
dog
help
echocardiographi
electrocardiographi
holter
examin
distemp
diagnosi
confirm
posit
pcr
test
data
collect
compar
nine
healthi
dog
agreement
hypothesi
influenc
distemp
viru
cardiovascular
system
studi
found
cdv
affect
directli
indirectli
excitatori
special
conduct
system
heart
describ
tabl
holter
evalu
distemp
infect
dog
reveal
decreas
heart
rate
variabl
absenc
arrhythmia
studi
reveal
delay
conduct
cardiac
impuls
also
autonom
dysfunct
character
increas
sympathet
tone
echocardiographi
reveal
dilat
cardiac
chamber
mitral
valv
diseas
mvd
cardiovascular
diseas
highest
incid
among
small
dog
patient
mvd
remain
asymptomat
other
develop
sign
congest
heart
failur
chf
treatment
base
specif
drug
diet
control
sign
chf
thu
reduc
clinic
sign
promot
qualiti
life
patient
dietari
treatment
includ
sodium
restrict
nutrient
supplement
includ
omega
fatti
acid
essenti
fatti
acid
within
chain
metabol
gener
product
substanc
activ
addit
increas
incorpor
cell
membran
caus
chang
ionic
channel
cardiomyocyt
make
cell
less
suscept
arrhythmia
vasodil
hypolipidem
activ
blood
pressur
bp
modul
also
report
howev
clinic
studi
evalu
effect
supplement
dog
mvd
given
effect
propos
prospect
studi
evalu
possibl
benefit
dietari
supplement
dog
dvm
total
dog
evalu
carrier
mvd
dog
stage
stage
asymptomat
myocardi
remodel
c
clinic
sign
chf
recruit
evalu
inclus
criteria
could
diseas
one
group
n
receiv
canin
dri
food
mg
kg
epa
mg
kg
dha
control
group
n
receiv
food
without
supplement
anim
evalu
everi
three
month
period
month
mean
bp
measur
ambulatori
electrocardiograph
holter
examin
echocardiograph
examin
chest
dog
receiv
standard
pharmacolog
treatment
accord
acvim
consensu
qualit
data
submit
fisher
exact
test
quantit
data
compar
treatment
use
test
time
use
test
adopt
signific
level
condit
supplement
alter
bp
valu
echocardiograph
measur
level
radiograph
evalu
valu
vh
decreas
vertebr
heart
size
vertebra
vertebra
p
maintain
pulmonari
pattern
compat
senil
featur
electrocardiograph
evalu
show
preval
respiratori
sinu
arrhythmia
lower
incid
atrial
ventricular
arrhythmia
control
group
time
like
develop
type
arrhythmia
compar
group
chanc
ratio
test
ci
p
thu
conclud
supplement
fatti
acid
decreas
volumetr
overload
demonstr
reduct
vh
prevent
arrhythmia
dog
mvd
mitral
valv
diseas
mvd
character
degener
valvar
leaflet
promot
chang
cellular
constitu
lead
valvar
insuffici
preclin
period
character
absenc
myocardi
remodel
pharmacolog
treatment
recommend
current
specif
diet
dog
cardiac
diseas
avail
commerci
includ
addit
sodium
restrict
supplement
nutrient
includ
fatti
acid
essenti
fatti
acid
produc
eicosanoid
activ
metabol
thu
reduc
product
inflammatori
substanc
call
cardioprotect
inflammatori
activ
directli
relat
develop
cardiac
cachexia
syndrom
observ
dog
chronic
mvd
effect
modul
heart
rate
hr
blood
pressur
bp
antiarrhythm
hypolipidem
activ
also
report
howev
clinic
studi
yet
perform
evalu
effect
dog
mvd
propos
prospect
studi
evalu
possibl
benefit
dietari
supplement
dog
mvd
without
cardiac
remodel
dog
recruit
classifi
stage
asymptomat
without
myocardi
remodel
one
group
n
receiv
dri
food
supplement
mg
kg
epa
mg
kg
dha
control
group
n
receiv
feed
without
supplement
anim
evalu
everi
three
month
period
month
clinic
evalu
assess
bodi
condit
bc
muscular
condit
mc
score
bp
measur
electrocardiograph
holter
electrocardiograph
examin
echocardiographi
thorac
radiograph
hematolog
serum
biochemistri
evalu
inflammatori
cytokin
tnf
il
il
protein
crp
measur
qualit
data
submit
fisher
exact
test
quantit
data
compar
time
mean
test
adopt
signific
month
mainten
clinic
paramet
bc
mc
observ
supplement
alter
bp
valu
echocardiograph
measur
chest
hematolog
paramet
serum
biochemistri
level
cytokin
crp
also
chang
one
dog
evolv
stage
month
electrocardiograph
evalu
predomin
respiratori
sinu
arrhythmia
low
occurr
atrial
arrhythmia
frequent
heart
rhythm
sinu
arrest
atrioventricular
block
degre
thu
conclud
supplement
fatti
acid
nt
chang
clinic
cardiovascular
laboratori
paramet
dog
mvd
stage
right
pulmonari
arteri
distens
rpad
index
use
dog
pulmonari
hypertens
ph
secondari
heartworm
diseas
myxomat
mitral
valv
diseas
patent
ductu
arteriosu
hypothesi
rpad
index
correl
tricuspid
regurgit
pressur
gradient
trpg
assess
echocardiographi
predict
surviv
time
dog
ph
secondari
variou
caus
two
hundr
dog
referr
institut
includ
retrospect
studi
medic
record
review
right
pulmonari
arteri
distens
index
acceler
time
peak
pulmonari
arteri
flow
eject
time
pulmonari
arteri
flow
et
record
dog
owner
contact
follow
right
pulmonari
arteri
distens
index
prad
correl
trpg
p
dog
rpad
index
significantli
shorter
surviv
time
surviv
group
significantli
shorter
surviv
time
surviv
group
right
pulmonari
arteri
distens
index
correl
trpg
predict
clinic
outcom
dog
ph
caus
variou
diseas
indic
use
evalu
sever
ph
dog
absent
tricuspid
regurgit
system
hypertens
persist
increas
blood
pressur
health
problem
associ
target
organ
damag
tod
systol
blood
pressur
sbp
classifi
base
risk
futur
tod
defin
american
colleg
veterinari
intern
medicin
acvim
hypertens
consensu
statement
intern
renal
interest
societi
iri
stage
system
follow
categori
sbp
defin
mmhg
minim
risk
mmhg
low
risk
mmhg
moder
risk
mmhg
high
risk
blood
pressur
control
becom
difficult
achiev
hypertens
progress
therefor
earli
effect
treatment
essenti
prevent
hypertens
emerg
reduc
tod
risk
aim
retrospect
studi
compar
sbp
variabl
seven
day
sever
hypertens
dog
treat
amlodipin
calcium
channel
blocker
ccb
ramipril
enzym
inhibitor
acei
telmisartan
angiotensin
receptor
blocker
arb
either
monotherapi
combin
therapi
medic
record
octob
decemb
evalu
dog
diagnos
system
hypertens
sbp
mmhg
includ
system
hypertens
studi
commonli
associ
hyperadrenocortic
epilepsi
tumor
chronic
kidney
diseas
patient
sbp
measur
mean
indirect
doppler
method
seven
day
treatment
antihypertens
drug
patient
treat
ccb
n
mean
valu
sbp
administr
mmhg
mmhg
seven
day
treatment
mean
sbp
decreas
mmhg
p
mean
sbp
two
six
dog
decreas
mmhg
patient
treat
arb
n
mean
sbp
decreas
mmhg
p
one
week
day
mmhg
versu
day
two
six
patient
receiv
arb
reach
target
bp
sbp
dog
receiv
antihypertens
therapi
combin
ccb
acei
n
mean
sbp
reduc
mmhg
p
one
week
day
mmhg
versu
day
mmhg
six
dog
sbp
minim
risk
categori
combin
ccb
arb
n
associ
significantli
lower
sbp
reduc
mmhg
p
compar
patient
sbp
prior
treatment
day
mmhg
versu
day
mmhg
also
five
ten
patient
treat
therapi
reach
target
bp
signific
differ
ccb
arb
combin
ccb
acei
regard
decreas
sbp
high
risk
hypertens
patient
p
dog
treat
combin
ccb
arb
sbp
significantli
decreas
compar
patient
receiv
therapi
p
also
seven
day
antihypertens
therapi
dog
ccb
arb
achiev
target
bp
versu
ccb
arb
ccb
acei
conclus
antihypertens
drug
class
differenti
effect
blood
pressur
variabl
greater
reduct
dog
treat
ccb
arb
combin
ccb
arb
may
effici
treatment
lower
sbp
high
risk
hypertens
patient
aim
studi
report
evid
macroscop
histopatholog
find
compat
myocard
six
natur
infect
dog
dirofilaria
immiti
case
collect
retrospect
privat
veterinari
clinic
locat
barranquilla
includ
studi
dog
complementari
test
echocardiographi
electrocardiogram
troponin
immunochromatographi
test
filaria
necropsi
heart
specimen
taken
preserv
stain
haematoxylin
eosin
echocardiographi
normal
case
n
patient
electrocardiograph
abnorm
elev
tropinin
found
case
macro
microscop
chang
visibl
evalu
heart
signific
macroscop
find
diffus
white
yellow
area
epicardium
chang
sever
right
side
heart
also
case
epicardium
larg
area
red
color
surround
left
circumflex
coronari
arteri
dissect
perform
case
yellow
white
spot
appear
right
atrium
endocardium
present
hemorrhag
zone
tricuspid
valv
case
endocardi
hemorrhag
zone
observ
left
atrium
near
mitral
valv
addit
one
case
level
mitral
valv
black
spot
observ
near
septal
leaflet
histopatholog
find
includ
acut
diffus
myocard
acut
myocard
infarct
parasit
thrombi
activ
chronic
myocard
necrot
myocard
studi
report
case
myocard
dog
dirofilaria
immiti
right
side
heart
shown
affect
also
left
side
dog
without
pulmonari
hypertens
right
congest
heart
failur
ventricular
septal
defect
vsd
common
congenit
defect
cat
hors
larg
defect
may
caus
volum
overload
congest
heart
failur
pulmonari
hypertens
anticip
poor
prognosi
pulmonari
arteri
band
pab
report
palli
surgic
option
hemodynam
consequenti
vsd
cat
dog
pab
surgeri
result
increas
right
ventricular
systol
pressur
thu
decreas
pressur
gradient
across
vsd
subsequ
shunt
volum
minim
data
veterinari
literatur
assess
outcom
follow
pab
surgeri
aim
studi
evalu
outcom
mortal
rate
anim
underw
pab
surgeri
oregon
state
univers
veterinari
teach
hospit
five
anim
cat
poni
underw
pab
surgeri
includ
retrospect
studi
median
age
diagnosi
month
rang
month
median
weight
cat
kg
rang
kg
kg
poni
echocardiograph
variabl
indic
enlarg
median
left
atrial
aortic
ratio
la
ao
rang
median
vsd
aortic
diamet
ratio
vsd
ao
rang
median
vsd
flow
veloc
ms
rang
ms
two
cat
symptomat
radiograph
evid
congest
heart
failur
prior
pab
surgeri
median
vh
three
cat
avail
radiograph
surgic
procedur
patient
left
later
thoracotomi
umbil
tape
use
cat
pab
nylon
sutur
use
poni
median
surgic
time
hour
rang
hour
median
total
anesthesia
time
hour
rang
hour
major
complic
record
anim
surviv
discharg
avail
patient
median
year
rang
year
serial
echocardiographi
reveal
median
reduct
la
ao
rang
median
reduct
vsd
flow
veloc
rang
anim
found
develop
heart
failur
follow
pab
surgeri
although
cat
remain
symptomat
exercis
intoler
cat
heart
failur
surgeri
remain
aliv
month
without
current
heart
failur
therapi
respect
result
studi
indic
pab
viabl
palli
treatment
option
hemodynam
signific
vsd
potenti
excel
outcom
presenc
heart
failur
prior
pab
surgeri
may
neg
affect
outcom
although
larger
studi
need
assess
prognost
factor
thu
far
two
publish
studi
suggest
specif
genet
loci
associ
dilat
cardiomyopathi
dcm
phenotyp
doberman
pinscher
dp
pyruv
dehydrogenas
kinas
delet
one
mutat
easili
test
use
buccal
swab
gene
mitochondri
protein
control
shift
glycolysi
oxid
phosphoryl
depend
nutrient
avail
cardiomyocyt
must
produc
synchron
ventricular
contract
oxid
phosphoryl
prefer
method
energi
gener
higher
level
atp
yield
hypothes
dp
defici
unabl
switch
oxid
phosphoryl
thu
continu
use
glycolysi
time
constant
relianc
upon
glycolysi
energi
product
becom
detriment
heart
unabl
gener
suffici
energi
healthi
cardiac
function
switch
away
fuel
sourc
prefer
matur
heart
fatti
acid
toward
glucos
along
lactat
common
featur
cardiomyopathi
believ
exacerb
cardiac
remodel
ultim
manifest
ventricular
enlarg
arrhythmia
systol
dysfunct
studi
skin
biopsi
obtain
isol
dermal
fibroblast
dp
dcm
echocardiogram
holter
monitor
genet
test
splice
site
mutat
dp
phenotyp
featur
dcm
heterozyg
homozyg
mutat
display
significantli
reduc
oxygen
consumpt
rate
decreas
cell
viabil
mitochondri
stress
activ
intrins
mitochondri
mediat
apoptot
pathway
condit
high
unstarv
low
starv
nutrient
avail
vitro
follow
treatment
viru
aav
cell
starv
treat
cell
show
signific
improv
mitochondri
function
increas
viabil
starv
condit
compar
cell
treat
restor
function
cell
observ
follow
administr
provid
strong
support
translat
gene
therapi
approach
clinic
realm
doberman
systol
murmur
common
healthi
cat
cat
cardiac
diseas
angl
form
junction
interventricular
septum
ascend
aorta
aortosept
angl
aosa
might
contribut
murmur
gener
studi
aim
determin
whether
systol
murmur
associ
smaller
aosa
aosa
differ
hocm
cat
compar
cardiomyopath
normal
cat
aosa
influenc
age
gender
echocardiograph
record
search
felin
studi
contain
store
cine
loop
right
left
ventricular
outflow
view
contemporan
cardiovascular
exam
exclus
criteria
includ
congenit
cardiac
malform
mark
anemia
hyperthyroid
hypertens
systol
diastol
aosa
measur
made
triplic
cat
includ
classifi
normal
n
hocm
n
hcm
n
cardiomyopathi
n
mean
systol
aosa
smaller
cat
murmur
compar
without
p
signific
although
weak
neg
correl
exist
aosa
murmur
grade
aosa
hocm
cat
smaller
aosa
normal
cat
differ
cat
hcm
cardiomyopathi
aosa
smaller
diastol
systol
cat
combin
p
cat
murmur
p
hocm
cat
p
aosa
differ
male
femal
among
age
group
year
year
year
find
suggest
smaller
aosa
could
associ
murmur
develop
cat
surgeri
cardiopulmonari
bypass
cpb
dog
difficult
mismatch
cpb
prime
volum
patient
blood
volum
investig
whether
mitral
valv
plasti
mvp
possibl
dog
dog
year
bodi
weight
rang
kg
median
kg
underw
mvp
cpb
includ
patient
divid
three
group
group
blood
prime
group
postop
transfus
group
criteria
blood
transfus
includ
hematocrit
ht
less
andor
hemoglobin
hb
less
gdl
cpb
perform
ultrafiltr
patient
among
dog
receiv
transfus
receiv
blood
prime
receiv
postop
transfus
ht
significantli
higher
cpb
averag
ht
p
higher
cpb
vs
p
vs
p
predispos
factor
blood
prime
bodi
weight
kg
ci
p
sensit
specif
ht
cpb
ci
p
sensit
specif
conclud
possibl
perform
mvp
without
blood
transfus
dog
depend
bodi
weight
ht
cpb
studi
purpos
clarifi
chang
blood
ga
surgeri
mitral
valv
plasti
surgeri
perform
use
cardiopulmonari
bypass
cpb
subject
dog
mitral
regurgitationfor
anesthesia
inhal
anesthesia
combin
moder
hypothermia
method
time
conduct
blood
ga
sampl
examin
pre
initi
cpb
partial
start
cpb
total
aortic
rebeat
aortic
declamp
post
complet
cpb
case
case
show
acidosi
one
case
exhibit
alkalosi
decreas
rebeat
l
post
l
addit
lactat
increas
post
l
total
l
post
l
increas
seven
case
observ
show
mmhg
less
post
seven
case
improv
extub
perform
postop
postur
chang
respiratori
manag
lastli
final
low
pre
increas
post
base
result
studi
shown
cpb
lean
toward
acidosi
thought
chang
recogn
lactat
hypothermia
method
long
oper
suggest
surgeri
abl
maintain
blood
circul
better
result
furthermor
regardless
state
preoper
patient
final
improv
case
consid
possibl
maintain
oxygen
appropri
azotemia
situat
frequent
seen
patient
mitral
regurgit
mr
declin
renal
function
prognost
factor
time
cardiac
surgeri
studi
examin
effect
hemodialysi
hd
cardiopulmonari
bypass
dog
undergo
mitral
valv
plasti
mvp
azotem
dog
mr
separ
group
mean
bun
mgdl
cre
mgdl
perform
hd
hd
group
mean
bun
mgdl
cre
mgdl
perform
hd
nipro
osaka
japan
set
circuit
dialyz
fuso
pharmaceut
industri
ltd
tokyo
japan
use
dialys
bun
cre
valu
preoper
postop
surgeri
day
discharg
month
surgeri
compar
compar
preoper
day
bun
cre
significantli
lower
group
surgeri
first
day
surgeri
discharg
bun
hd
group
significantli
lower
first
day
third
day
one
month
postop
compar
group
signific
differ
cre
group
suggest
hd
show
effect
lower
renal
valu
periop
period
dog
decreas
renal
function
undergo
mvp
case
group
declin
renal
function
sever
renal
valu
discharg
stabl
hd
mean
bun
mgdl
cre
mgdl
mean
bun
mgdl
cre
mgdl
complic
due
azotemia
observ
farther
studi
necessari
patient
decreas
renal
function
verifi
use
limit
hd
thyroid
hormon
play
import
role
regul
cardiac
function
sever
studi
human
pediatr
surgeri
report
reduct
thyroid
hormon
hormon
replac
heart
surgeryth
purpos
studi
defin
effect
cardiopulmonari
bypass
concentr
thyroid
hormon
dog
dog
mitral
valv
regurgit
age
year
bodi
weight
kg
underw
mitral
valv
plasti
mvp
cardiopulmonari
bypass
cpb
juli
octob
hormon
tsh
total
thyroxin
free
measur
use
chemiluminesc
enzym
immunoassay
postop
day
discharg
patient
show
mark
decreas
thyroid
hormon
concentr
decreas
myocardi
contract
depress
prescrib
levothyroxin
sodium
oral
everi
hr
tsh
median
ngml
rang
median
measur
limit
median
pgdl
measur
limit
significantli
depress
hour
surgeri
subject
tsh
return
time
discharg
day
subject
levothyroxin
treatment
group
significantli
increas
howev
fraction
shorten
eject
fraction
evalu
echocardiographi
significantli
improv
start
treatment
anesthesia
time
durat
cpb
time
length
hospit
day
differ
treatment
group
advers
effect
treatment
group
result
indic
canin
patient
undergo
mvp
cpb
might
present
euthyroid
sick
syndrom
addit
studi
necessari
clar
administr
inject
glucocorticoid
report
precipit
congest
heart
failur
cat
prospect
clinic
trial
aim
investig
mechan
oral
glucocorticoid
could
predispos
cat
progress
heart
diseas
system
healthi
cat
allerg
dermat
n
given
oral
prednisolon
dose
mgkg
daili
day
follow
taper
washout
match
control
cat
n
receiv
treatment
clinicopatholog
echocardiograph
hemodynam
variabl
measur
prior
glucocorticoid
administr
baselin
day
prednisolon
treatment
day
day
multipl
linear
regress
model
use
assess
effect
prednisolon
treatment
time
studi
variabl
signific
chang
blood
glucos
blood
pressur
sodium
potassium
cardiac
biomark
echocardiograph
measur
occur
prednisolon
treatment
time
point
expect
hematolog
biochem
chang
occur
prednisolon
treatment
includ
mild
increas
monocyt
count
serum
albumin
calcium
cholesterol
triglycerid
p
indic
red
blood
cell
mass
decreas
baselin
treatment
control
cat
day
p
like
due
repeat
blood
sampl
fructosamin
increas
baselin
cat
day
p
p
triglycerid
level
hematolog
biochem
chang
mild
within
refer
rang
result
studi
suggest
prednisolon
result
clinic
relev
hemodynam
diabetogen
effect
system
healthi
cat
pulmonari
arteri
hypertens
pah
character
pulmonari
arteri
muscular
right
ventricular
hypertrophi
rvh
poor
treatment
outcom
guard
prognosi
human
dog
sorafenib
shown
potent
revers
cardiopulmonari
remodel
pah
human
patient
effect
toceranib
veterinari
tyrosin
kinas
inhibitor
unknownthi
studi
compar
effect
toceranib
sorafenib
pulmonari
arteri
remodel
rvh
rat
sinc
recent
show
imatinib
significantli
revers
cardiopulmonari
remodel
use
experiment
model
also
investig
potenti
use
toceranib
treatment
pah
rat
random
receiv
sorafenib
mgkg
toceranib
mgkg
water
oral
daili
two
week
rvh
pulmonari
arteri
muscular
messeng
rna
mrna
protein
level
target
receptor
tyrosin
kinas
evalu
sorafenib
significantli
revers
rvh
r
rvh
p
natriuret
peptid
bnp
mrna
level
r
bnp
besid
low
medium
high
dose
sorafenib
reduc
proport
fulli
muscular
pulmonari
arteri
fmpa
r
fmpa
respect
contrast
toceranib
group
show
weaker
revers
r
rvh
r
bnp
r
fmpa
signific
reduct
rvh
bnp
mrna
level
observ
rat
highest
dose
toceranib
fmpa
reduc
highest
dose
toceranib
aggrav
lowest
dose
pulmonari
growth
factor
receptor
beta
mrna
express
significantli
downregul
treatment
group
except
lowest
dose
toceranib
group
phosphoryl
protein
level
repres
pdgfr
downstream
signal
significantli
suppress
dose
sorafenib
sole
highest
dose
toceranib
furthermor
toceranib
lower
dose
significantli
upregul
pulmonari
protein
light
chain
beta
mrna
level
suggest
impair
autophagi
conclus
toceranib
elicit
weaker
revers
properti
pulmonari
arteri
remodel
rvh
therefor
low
dose
toceranib
comparison
sorafenib
may
promis
therapeut
agent
cardiopulmonari
remodel
pah
obes
common
nutrit
diseas
cat
increas
preval
excess
bodi
fat
predispos
anim
deleteri
effect
heart
function
systol
blood
pressur
sbp
alter
arrhythmia
radiograph
echocardiograph
chang
describ
howev
much
inform
regard
effect
obes
cardiovascular
system
cat
studi
aim
evalu
effect
cardiovascular
system
domest
cat
compar
cat
normal
bodi
condit
cat
alloc
two
group
obes
cat
cat
normal
bodi
condit
submit
sbp
measur
electrocardiogram
ecg
chest
radiograph
evalu
cardiac
silhouett
vertebr
heart
size
vh
echocardiograph
measur
evalu
establish
relationship
data
obtain
bodi
weight
bodi
condit
score
bc
bodi
mass
index
bmi
sbp
vh
statist
higher
obes
anim
contrast
normal
cat
obes
cat
mean
sbp
seven
anim
present
valu
exceed
mmhg
normal
cat
sbp
hypertens
observ
three
anim
vh
analys
present
valu
obes
normal
cat
respect
ecg
evalu
reveal
sinu
rhythm
obes
cat
normal
cat
sinu
rhythm
present
cat
sinu
tachycardia
one
cat
heartrat
obes
normal
cat
respect
obes
cat
present
higher
valu
normal
cat
paramet
except
interventricular
septum
diastol
ivsd
statist
differ
differ
left
ventricular
free
wall
diastol
lvfwd
one
statist
signific
p
test
appli
verifi
possibl
correl
echocardiograph
paramet
bmi
bc
bodi
weight
shown
posit
relationship
lvfwd
bodi
weight
bc
aorta
ao
bodi
weight
bmi
left
atrium
la
bodi
weight
left
ventricular
intern
diamet
diastol
lvidd
bodi
weight
quadrat
relationship
also
observ
left
root
diamet
ratio
la
ao
bodi
weight
addit
relationship
lvfwd
bmi
although
consid
signific
present
p
valu
slightli
obes
cat
show
higher
bp
vh
normal
cat
led
increas
echocardiograph
measur
studi
shown
obes
promot
cardiac
function
impair
studi
cat
therefor
import
monitor
anim
sinc
even
asymptomat
one
may
present
chang
cardiac
paramet
studi
aim
measur
heart
rate
variabl
holstein
cow
fetus
neonat
descript
evalu
continu
fetomatern
neonat
electrocardiogram
record
perinat
period
heart
rate
hr
heart
rate
variabl
hrv
assess
fetomatern
electrocardiographi
ecg
fetomatern
measur
taken
six
time
neonat
six
time
calv
heart
rate
variabl
variabl
analyz
holstein
cow
neonat
signific
chang
observ
matern
fetal
rr
interv
hr
fetus
standard
deviat
interv
sdnn
decreas
significantli
ms
ms
p
root
mean
squar
success
differ
rmssd
chang
significantli
fetal
heart
rate
rr
interv
differ
statist
day
deliveri
bpm
ms
day
calv
bpm
ms
variabl
sdnn
rmssd
variabl
lf
hf
significantli
differ
p
fetal
neonat
stage
fetomatern
ecg
reliabl
techniqu
detect
cardiac
signal
bovin
fetus
last
day
gestat
decreas
valu
sdnn
rmssd
reflect
shift
toward
sympathet
domin
calv
increas
high
frequenc
decreas
low
frequenc
variabl
indic
activ
vagal
nerv
follow
heart
respiratori
modul
equin
matern
pheromon
emp
use
tool
calm
equin
face
new
stress
situat
forc
physiolog
adapt
alter
relat
mainli
increas
heartrat
hr
behavior
alter
studi
aim
assess
effect
emp
treatment
colt
undergo
hoof
trim
first
time
employ
behavior
heartrat
variabl
hrv
main
paramet
assess
colt
averag
age
month
underw
hoof
trim
first
time
anim
divid
two
group
random
doubl
blind
experiment
design
employ
treatment
emp
placebo
administ
holter
monitor
put
place
minut
procedur
start
hr
measur
convent
method
hrv
measur
two
moment
minut
trim
immedi
trim
paramet
analysi
conduct
student
test
signific
level
p
result
display
tabl
statist
signific
differ
note
hr
measur
convent
method
group
b
present
decreas
howev
statist
signific
differ
observ
holter
test
compar
group
measur
heart
rate
variabl
hrv
report
accept
method
assess
level
stress
numer
express
neurohormon
effect
exert
heart
rate
normal
valu
physiolog
paramet
larger
breed
often
use
refer
valu
poni
howev
heart
rate
increas
smaller
anim
adult
poni
higher
adult
warmblood
hors
littl
known
effect
pregnanc
signal
heart
rate
variabl
valu
equin
speci
studi
aim
determin
physiolog
rang
heart
rate
beat
per
minut
heart
rate
variabl
equin
mare
differ
month
gestat
month
ecg
record
made
month
data
use
analysi
heart
rate
hr
hrv
assess
matern
electrocardiographi
ecg
matern
measur
taken
ten
time
heart
rate
variabl
analyz
signific
chang
observ
fourth
tenth
month
pregnanc
rr
interv
ms
ms
hr
bpm
bpm
p
correspond
smallest
largest
valu
respect
signific
chang
observ
standard
deviat
interv
sdnn
p
root
mean
squar
success
differ
rmssd
p
analysi
demonstr
signific
increas
mean
rr
interv
hr
progress
pregnanc
also
establish
hrv
influenc
hr
higher
hr
associ
lower
hrv
mare
renal
dysfunct
caus
primari
cardiovascular
diseas
consid
class
cardiovascular
renal
disord
cvrd
small
anim
medicin
cvrd
cardiac
patient
novel
research
area
studi
aim
evalu
cvrd
cat
congest
heart
failur
chf
primari
cardiomyopathi
cm
measur
cardiac
renal
function
marker
client
own
cat
diagnos
primari
cm
chf
asymptomat
referr
cardiolog
servic
enrol
twenti
healthi
cat
use
control
serum
brain
naturet
peptid
symmetr
dimethylarginin
sdma
creatinin
level
measur
refer
laboratori
relev
clinic
inform
surviv
statu
chf
cat
record
analysi
varianc
anova
student
test
spearman
rho
cox
proport
hazard
model
use
statist
analysi
sdma
creatinin
level
posit
correl
significantli
differ
among
three
group
cat
chf
cat
higher
serum
asymptomat
cm
cat
healthi
control
cat
higher
sdma
creatinin
healthi
control
p
cat
chf
die
higher
p
sdma
p
creatinin
p
compar
survivor
howev
neither
marker
signific
prognost
factor
multivari
surviv
analysi
model
studi
result
suggest
cvrd
present
chf
cat
primari
cardiomyopathi
furthermor
sdma
novel
biomark
cat
chf
primari
cm
could
use
diseas
manag
prognost
sudden
cardiac
death
associ
ventricular
arrhythmia
report
famili
rhodesian
ridgeback
dog
examin
ambulatori
electrocardiograph
holter
record
rhodesian
ridgeback
report
asymptomat
owner
record
least
hour
data
evalu
presenc
ventricular
supraventricular
ectopi
number
ventricular
prematur
complex
vpc
hour
complex
ectopi
quantifi
dog
experienc
vpc
hour
consid
abnorm
complex
ventricular
ectopi
grade
follow
grade
isol
uniform
vpc
grade
bigemini
trigemini
grade
couplet
triplet
grade
r
nonsustain
ventricular
tachycardia
dog
sustain
ventricular
tachycardia
dog
examin
male
femal
fewer
hour
supraventricular
ectopi
rang
age
month
median
month
dog
male
male
castrat
femal
hour
statist
differ
age
median
month
rang
month
experienc
median
number
vpc
hour
rang
complex
grade
rang
two
dog
also
frequent
supraventricular
prematur
complex
preliminari
studi
identifi
asymptomat
ventricular
ectopi
approxim
rhodesian
ridgeback
examin
less
year
age
addit
supreventricular
ectopi
also
infrequ
observ
consequ
turbul
flow
chang
fluid
shear
stress
around
mitral
valv
chang
platelet
function
may
involv
pathogenesi
myxomat
mitral
valv
diseas
mmvd
aim
studi
investig
whether
chang
coagul
vari
sever
mmvd
dog
retrospect
review
chart
dog
mmvd
classif
mmvd
dog
base
acvim
stage
compar
result
follow
test
white
blood
cell
count
wbc
platelet
count
plt
mean
platelet
volum
mpv
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fibrinogen
fib
protein
crp
antithrombin
iii
atiii
fibrin
degrad
product
fdp
activ
clot
time
act
platelet
function
pf
clot
rate
cr
total
dog
evalu
dog
acvim
stage
dog
stage
c
dog
stage
fibrinogen
crp
significantli
increas
diseas
progress
p
dog
stage
significantli
higher
wbc
plt
pf
compar
dog
stage
p
signific
differ
mpv
pt
aptt
atiii
fdp
among
group
platelet
function
activ
declin
dog
mmvd
wbc
crp
fib
increas
consist
increas
inflamm
mmvd
progress
inflammatori
respons
may
play
import
role
increas
platelet
function
mitral
valv
function
deterior
arteri
thromboembol
ate
condit
cat
howev
current
test
identifi
cat
risk
ate
concentr
may
help
identif
cat
might
develop
ate
goal
retrospect
studi
compar
concentr
cat
cardiomyopathi
develop
ate
within
year
test
cat
develop
ate
within
year
medic
record
search
cat
form
cardiomyopathi
test
cat
classifi
group
cat
occult
cardiomyopathi
ocm
group
cat
cardiomyopathi
congest
heart
failur
without
ate
chf
group
cat
cardiomyopathi
develop
ate
ate
group
cat
enrol
cat
chf
ate
group
p
significantli
higher
concentr
ocm
group
howev
concentr
differ
chf
ate
group
roc
curv
gener
use
concentr
ate
ocm
group
auc
confid
interv
p
youden
index
j
estim
optim
cutoff
point
pmoll
sensit
specif
divid
cat
use
cutoff
point
cat
concentr
pmoll
larger
left
atrium
thicker
left
ventricl
lower
fraction
shorten
prospect
studi
need
evalu
util
pmoll
assess
risk
ate
cat
cardiomyopathi
left
atrial
ruptur
lar
uncommon
complic
myxomat
mitral
valv
diseas
usual
lead
patient
die
suddenli
hour
dog
surviv
long
period
time
congest
heart
failur
chf
previous
hypothet
reduc
long
term
surviv
doppler
deriv
echocardiograph
paramet
influenc
atrial
pressur
peak
earli
e
left
ventricular
fill
wave
veloc
e
isovolum
relax
time
e
ivrt
ratio
usual
provid
inform
congest
heart
failur
although
echocardiograph
predict
chf
time
lar
diagnosi
would
help
prognosi
reduct
left
atrial
pressur
due
chamber
empti
pericardi
space
could
hinder
predict
analysi
studi
retrospect
review
hospit
record
dog
diagnosi
lar
base
necropsi
andor
echocardiograph
find
includ
follow
criteria
myxomat
mitral
valv
diseas
mitral
regurgit
flow
alias
color
doppler
studi
fill
left
atrium
la
ao
ratio
right
parastern
view
pericardi
effus
organ
echogen
materi
suggest
cloth
within
pericardi
space
dog
die
non
cardiac
caus
includ
six
dog
met
criteria
inclus
male
femal
differ
breed
toy
poodl
n
pinscher
n
chihuahua
n
mean
age
year
rang
year
mean
bodi
weight
kg
rang
kg
clinic
sign
includ
cough
weak
colaps
tachypnea
dog
n
systol
system
arteri
blood
pressur
lower
mmhg
dog
hospit
diagnosi
system
arteri
blood
pressur
greater
mmhg
therapi
intraven
crystalloid
dobutamin
n
noradrenalin
n
andor
pericardiocentesi
n
thorac
radiograph
perform
time
lar
diagnosi
dog
mark
interstiti
alveolar
perihilar
infiltr
chf
group
remaind
dog
pulmonari
abnorm
also
prior
histori
decompens
heart
failur
group
mean
surviv
time
group
day
rang
day
significantli
longer
p
compar
chf
group
day
rang
day
two
dog
group
still
aliv
conclus
studi
chf
group
differ
compar
echocardiograph
la
ao
ratio
rang
vs
rang
respect
doppler
deriv
mean
peak
e
wave
ms
rang
ms
vs
ms
rang
ms
respect
mean
e
ivrt
index
rang
vs
rang
respect
predict
valu
e
ivrt
ratio
congest
heart
failur
found
dog
radiograph
evid
decompens
congest
heart
failur
cardiac
tamponad
found
two
dog
one
group
inform
provid
retrospect
studi
reinforc
hypothesi
absenc
congest
heart
failur
dog
lar
associ
better
long
term
outcom
predict
chf
base
isol
echocardiograph
e
ivrt
ratio
accur
dog
lar
secondari
myxomat
mitral
valv
diseas
better
investig
studi
includ
larger
popul
diabet
mellitu
dm
common
endocrinopathi
dog
impact
cardiovascular
system
still
unclear
speci
human
medicin
serum
fructosamin
concentr
sfc
use
cardiovascular
prognost
grow
aim
studi
evalu
correl
among
systol
blood
pressur
sbp
sfc
insulin
dose
use
diabet
dog
studi
design
includ
diabet
dog
treatment
nph
insulin
mean
dose
u
ukg
rang
ukg
period
month
month
patient
assess
doppler
vascular
method
verifi
sbp
agreement
acvim
guidelin
sfc
measur
colorimetr
assay
eighteen
diabet
dog
kg
twelv
healthi
control
dog
year
kg
pair
breed
sex
age
includ
significantli
posit
correl
sbp
sfc
diabet
dog
r
p
well
control
dog
r
p
insulin
dose
sbp
correl
approach
signific
r
p
also
correl
time
diagnosi
sbp
r
p
find
suggest
associ
sfc
hypertens
dog
result
emphas
import
sbp
monitor
diabet
dog
suggest
insulin
dose
may
import
factor
time
diagnosi
risk
factor
hypertens
canin
diabet
patient
amiodaron
predominantli
class
iii
drug
also
block
sodium
channel
calcium
channel
receptor
commonli
use
treatment
tachyarrhythmia
notabl
ventricular
tachyarrhythmia
lipophil
iodin
medic
amiodaron
uniqu
pharmacolog
structur
properti
distinguish
warrant
care
surveil
certain
metabol
process
composit
lead
inhibit
activ
result
decreas
triiodothyronin
product
amiodaron
main
metabolit
desethylamiodaron
may
also
block
bind
respect
receptor
amiodaron
induc
thyroid
dysfunct
document
peopl
aim
determin
amiodaron
alter
thyroid
function
dog
treat
signific
tachyarrhythmia
record
institut
review
find
dog
treat
tachyarrhythmia
amiodaron
whose
retriev
inform
complet
regard
amiodaron
dose
thyroid
function
test
start
amiodaron
ten
dog
identifi
record
evalu
data
regard
histori
signal
medic
echocardiograph
find
cardiac
medic
electrocardiogram
find
total
thyroid
stimul
hormon
tsh
level
initi
amiodaron
amiodaron
dose
length
time
initi
amiodaron
post
tsh
test
median
age
evalu
patient
year
rang
male
femal
sexual
intact
patient
eight
dog
initi
receiv
therapi
mexiletin
monotherapi
sotalol
monotherapi
mexiletinesotalol
dual
therapi
sotaloldiltiazem
dual
therapi
two
dog
receiv
medic
prior
evalu
amiodaron
institut
commonli
dog
systol
dysfunct
congest
heart
failur
intoler
particular
tachyarrhythmia
refractori
antiarrhythm
median
mainten
amiodaron
dose
mgkgd
rang
preced
median
amiodaron
load
dose
mgkgd
rang
day
median
valu
nmoll
rang
median
tsh
valu
ngml
rang
median
nmoll
rang
median
tsh
ngml
rang
wilcoxon
analysi
show
tsh
increas
p
amiodaron
initi
median
time
thyroid
test
day
rang
day
rang
tsh
start
drug
median
time
test
day
rang
day
rang
tsh
clinic
sign
hypothyroid
note
time
recheck
amiodaron
administr
shown
alter
thyroid
function
human
retrospect
studi
aim
find
relationship
amiodaron
administr
thyroid
paramet
dog
studi
popul
tsh
increas
amiodaron
administr
though
sign
hypothyroid
observ
knowledg
thyroid
paramet
chang
previous
document
dog
treat
amiodaron
addit
prospect
evalu
larger
popul
need
determin
signific
find
purpos
studi
assess
effect
mitral
valv
plasti
mvp
treat
pulmonari
hypertens
ph
secondari
mitral
valv
diseas
dog
dog
year
age
preoper
ph
underw
mvp
cardiopulmonari
bypass
includ
ph
diagnos
peak
tricuspid
valv
regurgit
tr
veloc
ms
echocardiographi
cardiac
examin
perform
oper
month
month
sildenafil
administ
dog
residu
ph
sever
heart
overload
flatten
ventricular
septum
andor
clinic
sign
exercis
intoler
cyanosi
observ
median
tr
ms
rang
ms
preoper
examin
death
due
residu
ph
month
surgeri
ph
improv
patient
month
tr
disappear
patient
tr
veloc
decreas
median
ms
rang
ms
eleven
patient
exhibit
residu
ph
median
tr
ms
rang
ms
sildenafil
administ
patient
ph
neg
prognost
factor
dog
mitral
valv
regurgit
result
suggest
mvp
effect
treatment
dog
ph
secondari
mitral
valv
diseas
studi
need
clarifi
prognosi
treatment
patient
exhibit
residu
ph
surgeri
detect
equin
kidney
injuri
initi
stage
intervent
like
success
hinder
limit
marker
earli
renal
damag
hors
nag
lysosom
enzym
renal
tubular
cell
releas
urin
tubular
insult
shown
promis
earli
identif
acut
kidney
injuri
human
speci
aim
studi
valid
assay
urinari
nag
unag
hors
correl
unag
index
marker
renal
tubular
dysfunct
enzymat
assay
valid
use
coeffici
variat
cv
spike
recoveri
linear
dilut
urin
plasma
collect
nonazotem
azotem
hors
spearman
rank
correl
wilcoxon
rank
sum
test
use
compar
unag
index
plasma
creatinin
urinari
fraction
excret
sodium
fena
urinari
uggt
index
cv
percent
recoveri
spike
linear
dilut
satisfactori
signific
correl
unag
index
plasma
creatinin
unag
index
fena
median
unag
indic
significantli
higher
azotem
hors
hors
increas
fena
hors
increas
uggt
index
urinari
nag
measur
hors
show
correl
current
biomark
renal
dysfunct
addit
work
need
determin
time
increas
unag
index
rel
onset
kidney
injuri
hors
evalu
clinic
util
equin
patient
urinari
tract
infect
retrospect
studi
equin
hospit
lemirr
jean
de
scienc
cliniqu
de
de
canada
urinari
tract
infect
uti
uncommon
hors
data
limit
equin
patient
escherichia
coli
report
frequent
isol
bacteria
sever
bacteria
identifi
goal
retrospect
studi
describ
clinic
sign
identifi
pathogen
quantifi
microbi
sensit
profil
clinic
record
case
present
equin
hospit
rewiev
case
includ
bacteriuria
identifi
threshold
unit
form
coloni
cultur
base
previou
studi
macleay
kohn
case
identifi
preval
uti
equin
case
trakehn
holstein
hors
significantli
overrepres
compar
hospit
popul
p
uti
frequent
femal
p
urinari
tract
infect
associ
diagnost
involv
urinari
tract
bladder
empti
problem
case
bacteria
isol
cultur
escherichia
coli
enterococcu
spp
common
bacteria
repres
respect
isol
bacteria
enrofloxacin
ceftiofur
commonli
use
antibiot
especi
begin
hospit
respect
isol
bacteria
sensibl
drug
seventi
percent
isol
bacteria
resist
result
place
context
two
equin
patient
repres
isol
bacteria
evalu
respons
treatment
limit
studi
design
conclus
uti
uncommon
hors
identifi
breed
sex
predisposit
gram
posit
neg
bacteria
identifi
high
preval
resist
bacteria
repres
therapeut
challeng
hors
urinari
tract
infect
hospit
set
incid
acut
kidney
injuri
hospit
human
dog
rang
mild
decreas
kidney
function
mark
effect
mortal
length
hospit
cost
treatment
incid
acut
kidney
injuri
hospit
hors
unreport
studi
aim
appli
valid
canin
score
system
assess
incid
acut
kidney
injuri
hospit
hors
hypothes
incid
acut
kidney
injuri
hors
similar
report
speci
clinic
record
hospit
adult
hors
august
review
hors
must
hospit
day
serum
creatinin
concentr
measur
twice
hors
diagnos
primari
renal
patholog
azotaem
baselin
serum
biochemistri
exclud
veterinari
acut
kidney
injuri
score
system
appli
base
percentag
increas
serum
creatinin
concentr
baselin
stage
stage
stage
stage
hors
includ
acut
kidney
injuri
classifi
stage
stage
hors
stage
acut
kidney
injuri
incid
acut
kidney
injuri
popul
hospit
hors
similar
report
dog
human
serum
creatinin
concentr
could
monitor
hospit
hors
allow
identif
earli
treatment
acut
kidney
injuri
work
requir
establish
impact
stage
acut
kidney
injuri
long
term
equin
health
cerebrospin
fluid
csf
analysi
import
compon
evalu
neurolog
hors
lumbosacr
ls
centesi
routin
practic
howev
csf
collect
space
first
second
cervic
vertebra
also
describ
purpos
studi
compar
collect
time
csf
cytolog
result
equin
protozo
myeliti
epm
titer
two
collect
site
healthi
adult
hors
hors
complaint
neurolog
diseas
use
cerebrospin
fluid
collect
site
random
order
continu
data
analyz
use
linear
model
count
data
use
neg
binomi
regress
statist
signific
set
p
cerebrospin
fluid
collect
significantli
lower
mean
protein
concentr
mgdl
versu
mgdl
ls
p
red
blood
cell
count
cellsul
vs
cellsul
ls
p
lower
percentag
neutrophil
vs
ls
p
collect
time
total
nucleat
cell
count
percentag
mononuclear
cell
epm
titer
serum
csf
epm
titer
ratio
significantli
differ
collect
site
advers
effect
detect
either
techniqu
cerebrospin
fluid
space
provid
accept
altern
ls
csf
collect
decreas
likelihood
clinic
import
blood
contamin
sampl
purpos
studi
describ
epidemiolog
clinicopatholog
find
hospit
adult
hors
foal
eastern
equin
enceph
medic
record
adult
hors
foal
admit
veterinari
teach
hospit
examin
case
present
sign
diffus
brain
diseas
serolog
diagnosi
eastern
equin
enceph
case
met
inclus
criteria
data
retriev
includ
season
admiss
signal
physic
examin
neurolog
evalu
clinicopatholog
find
present
well
durat
hospit
treatment
case
outcom
avail
histor
inform
ie
vaccin
statu
treatment
prior
referr
also
includ
median
age
present
year
rang
year
thoroughbr
quarter
hors
breed
common
case
typic
admit
summer
less
frequent
spring
fall
winter
common
find
upon
physic
examin
abnorm
mentat
n
dementia
seen
case
fever
prior
present
report
case
mean
rang
evid
admiss
case
mean
f
rang
f
approxim
half
recumb
activ
report
case
cerebrospin
fluid
analysi
reveal
gross
discolor
case
high
protein
concentr
mgdl
case
total
nucleat
cell
count
typic
high
high
neutrophil
count
case
median
durat
hospit
day
rang
day
attribut
rapid
progress
neurolog
diseas
result
recumb
mortal
rate
high
hors
surviv
discharg
eastern
equin
enceph
hors
sever
rapidli
progress
typic
fatal
neurolog
condit
diet
exercis
regim
prescrib
type
polysaccharid
storag
myopathi
recommend
type
pssm
howev
treatment
respons
document
retrospect
questionnair
use
captur
clinic
sign
warmblood
hors
wb
n
recommend
low
nonstructur
carbohydratefat
supplement
diet
exercis
regimen
owner
healthi
control
wb
also
provid
inform
muscl
glycogen
concentr
measur
fluorometr
wb
n
determin
abnorm
elev
compar
hors
myopathi
n
significantli
wb
perform
declin
reluct
collect
control
wb
diet
exercis
recommend
wb
owner
report
improv
clinic
sign
howev
hors
advanc
expect
train
reluct
go
forward
collect
persist
approxim
one
third
hors
glycogen
concentr
wb
variabl
median
significantli
differ
wb
histopatholog
conclus
diet
exercis
recommend
ideal
may
improv
elimin
clinic
sign
wb
glycogen
concentr
mani
wb
abnorm
elev
cyclophosphamid
alkyl
agent
commonli
includ
chemotherapeut
protocol
equin
neoplasia
includ
lymphoma
dosag
regularli
use
equin
chemotherapeut
protocol
extrapol
speci
cyclophosphamid
dose
optim
report
hors
dose
intens
refer
dose
activ
drug
time
multipl
studi
human
anim
cancer
shown
increas
chemotherapeut
dose
intens
correl
increas
effect
chemotherapeut
drug
dose
escal
strategi
gradual
dose
increas
care
monitor
toxic
util
determin
highest
toler
dose
therebi
achiev
higher
dose
intens
maximum
efficaci
purpos
report
describ
cyclophosphamid
dose
escal
equin
chemotherapi
nine
hors
includ
follow
medic
record
search
case
recruit
via
acvim
laim
oncolog
diplom
listserv
seven
hors
multicentr
lymphoma
two
hors
cutan
lymphoma
rich
larg
lymphoma
common
immunohistochem
classif
n
initi
dose
cyclophosphamid
rang
iv
furosemid
administ
concomitantli
drug
administ
includ
doxorubicin
vincristin
lomustin
cytosin
arabinosid
chlorambucil
valacyclovir
corticosteroid
cyclophosphamid
dose
escal
hors
maximum
dose
iv
iv
iv
advers
effect
attribut
cyclophosphamid
administr
note
one
hors
hors
develop
grade
lethargi
pelvic
limb
edema
follow
cyclophosphamid
dose
sign
resolv
without
treatment
hors
experienc
advers
effect
previou
subsequ
cyclophosphamid
dose
iv
two
pregnant
mare
receiv
cyclophosphamid
dose
without
advers
reaction
appar
detriment
effect
fetal
health
find
suggest
cyclophosphamid
dose
escal
may
use
treatment
equin
lymphoma
achiev
higher
chemotherapeut
dose
intens
minim
advers
effect
therapeut
dose
cyclophosphamid
may
higher
hors
previous
use
studi
warrant
determin
optim
dose
cyclophosphamid
hors
prognosi
associ
equin
lymphoma
often
grave
treatment
often
studi
evalu
outcom
follow
chemotherapi
hors
treat
lymphoma
purpos
studi
report
outcom
hors
lymphoma
treat
chemotherapeut
protocol
eleven
hors
includ
follow
medic
record
search
case
recruit
via
acvim
laim
oncolog
diplom
listserv
eight
hors
multicentr
lymphoma
three
hors
cutan
lymphoma
rich
larg
lymphoma
common
immunohistochem
classif
n
three
hors
posit
biopsi
sampl
neoplast
tissu
chemotherapeut
agent
includ
cyclophosphamid
n
vincristin
n
lomustin
n
n
doxorubicin
n
cytosin
arabinosid
n
chlorambucil
n
cisplatin
n
adjunct
treatment
includ
corticosteroid
n
valacyclovir
n
complet
remiss
achiev
hors
partial
respons
achiev
hors
stabl
diseas
achiev
hors
hors
die
treatment
overal
respons
rate
hors
associ
lymphoma
achiev
complet
remiss
two
pregnant
mare
treat
one
mare
surviv
foal
overal
median
surviv
time
month
rang
month
median
surviv
time
multicentr
lymphoma
n
month
rang
month
median
surviv
time
cutan
lymphoma
n
month
rang
month
seven
hors
exhibit
total
advers
effect
directli
attribut
chemotherapi
advers
effect
grade
accord
grade
system
grade
alopecia
n
grade
combin
neutropenia
lymphopenia
n
grade
lymphopenia
n
grade
lethargi
n
grade
gastrointestin
sign
n
grade
inject
site
reaction
n
grade
hypersensit
n
grade
hypersensit
n
grade
hypersensit
n
higher
grade
advers
effect
commonli
associ
doxorubicin
administr
n
includ
one
hors
die
hour
report
limit
retrospect
natur
particularli
variat
treatment
howev
find
show
chemotherapi
use
success
treatment
equin
lymphoma
advers
effect
commonli
mild
occur
approxim
treat
case
primari
hyperparathyroid
uncommon
larg
anim
object
studi
describ
diagnost
find
efficaci
treatment
equid
primari
hyperparathyroid
case
recruit
retrospect
review
record
cornel
univers
via
acvim
listserv
queri
inclus
criteria
equid
hypercalcemia
one
follow
high
parathyroid
hormon
pth
normal
pth
high
calcium
neg
protein
histopatholog
identif
parathyroid
adenoma
sixteen
hors
one
mule
fulfil
inclus
criteria
common
present
complaint
includ
weight
loss
hypercalcemia
anorexia
colic
median
ioniz
calcium
present
mmoll
rang
mmoll
refer
rang
mmoll
median
pth
concentr
pmoll
rang
pmoll
refer
rang
pmoll
suspect
abnorm
parathyroid
tissu
local
equid
ultrasonographi
andor
technetium
sestamibi
scintigraphi
five
five
success
excis
tumor
locat
thorac
inlet
surgeri
result
complet
cure
one
tumor
excis
howev
hors
remain
hypercalcem
follow
surgeri
four
addit
case
treat
surgic
five
treat
medic
two
treat
also
remain
hypercalcem
parathyroid
adenoma
equid
success
local
ultrasonographi
andor
scintigraphi
surgic
excis
appear
like
success
singl
abnorm
gland
identifi
thorac
inlet
decreas
adiponectin
concentr
link
lamin
prone
phenotyp
equid
insulin
dysregul
equin
metabol
syndrom
em
high
molecular
weight
hmw
form
adiponectin
close
link
insulin
sensit
thiazolidinedion
drug
increas
total
hmw
adiponectin
concentr
improv
insulin
sensit
human
thiazolidinedion
drug
pioglitazon
oral
absorb
hors
safe
afford
manag
hypothesi
pioglitazon
would
decreas
insulin
respons
oral
sugar
increas
hmw
adiponectin
concentr
hors
poni
two
cohort
healthi
equid
hors
mean
hennek
bodi
condit
score
bc
poni
mean
bc
treat
pioglitazon
mgkg
per
os
h
day
serum
hmw
adiponectin
concentr
measur
elisa
day
treatment
oral
sugar
test
ost
perform
day
repeat
measur
anova
sidak
multipl
comparison
test
use
data
analysi
cohort
compar
poni
hors
insulin
dysregul
id
equid
defin
hors
poni
insulin
concentr
ost
minut
insulin
concentr
significantli
lower
pioglitazon
minut
time
point
ost
poni
p
id
equid
p
hors
p
hmw
adiponectin
significantli
higher
treatment
hors
p
baselin
endpoint
poni
p
baselin
endpoint
id
equid
baselin
endpoint
lower
insulin
concentr
ost
increas
hmw
adiponectin
concentr
indic
posit
effect
pioglitazon
treatment
metabol
derang
equid
em
methylglyox
mg
sever
inflammatori
marker
increas
human
diabet
metabol
syndrom
object
prospect
studi
determin
concentr
mg
inflammatori
marker
tumor
necrosi
macrophag
chemoattract
differ
hors
without
insulin
dysregul
determin
combin
toler
test
cgit
hors
recruit
hors
abnorm
physic
examin
complet
blood
cell
count
incomplet
data
sign
pituitari
par
intermedia
dysfunct
exclud
test
cgit
perform
overnight
grain
fast
serum
sampl
store
biomark
test
via
previous
valid
elisa
colorimetr
assay
age
bodi
condit
score
bc
cresti
neck
score
cn
baselin
glucos
baselin
insulin
triglycerid
also
record
characterist
hors
categor
insulin
dysregul
compar
hors
met
inclus
criteria
hors
determin
insulin
dysregul
age
bc
baselin
glucos
triglycerid
mg
differ
significantli
two
group
hors
univari
analysi
baselin
insulin
significantli
associ
insulin
dysregul
p
multivari
logist
regress
note
hors
cn
time
higher
odd
insulin
dysregul
ci
p
studi
inflammatori
marker
mg
good
predictor
insulin
dysregul
enteroinsular
axi
eia
compris
intestin
factor
incretin
promot
insulin
releas
suppress
glucagon
secret
insulinotrop
peptid
gip
main
incretin
eia
alter
could
contribut
energi
dysregul
critic
ill
foal
eia
evalu
hors
howev
inform
lack
healthi
sick
newborn
foal
studi
sought
evalu
total
activ
gip
insulin
respons
fast
dextros
oral
intraven
administr
healthi
newborn
foal
oral
intraven
glucos
toler
test
perform
healthi
standardbr
foal
hour
old
follow
hour
fast
bolu
dextros
mgkg
administ
oral
intraven
blood
incretin
insulin
concentr
measur
minut
immunoassay
gip
concentr
decreas
steadili
follow
dextros
mgkg
regardless
rout
administr
baselin
valu
p
total
activ
concentr
show
steadi
decreas
baselin
valu
p
mild
signific
elev
note
minut
foal
allow
nurs
incretin
concentr
increas
baselin
within
minut
nurs
minim
incretin
respons
oral
dextros
rapid
incretin
releas
nurs
indic
mgkg
insuffici
strong
eia
stimul
higher
dextros
dose
requir
factor
milk
may
import
activ
eia
newborn
foal
oral
sugar
test
ost
develop
clinic
diagnost
techniqu
identifi
hors
insulin
dysregul
id
diagnosi
current
base
arbitrari
valu
aim
studi
establish
appropri
insulin
valu
id
differ
time
point
ost
hors
differ
breed
wide
rang
insulin
sensit
subject
modifi
ost
mlkg
dansukk
glykossirap
euglycem
hyperinsulinem
clamp
ehc
hour
apart
use
glucos
dispos
rate
mgkgmin
definit
insulin
resist
ehc
insulin
valu
differ
time
point
ost
calcul
receiv
oper
characterist
roc
curv
analysi
spearman
correl
use
studi
correl
ost
insulin
concentr
minut
oral
sugar
test
deriv
minut
insulin
concentr
respect
indic
id
use
ehc
gold
standard
optim
sensit
specif
diagnos
id
respect
time
point
minut
respect
time
point
minut
respect
time
point
minut
oral
sugar
test
deriv
insulin
concentr
minut
invers
relat
rho
p
result
indic
ost
insulin
concentr
use
diagnosi
id
base
singl
blood
sampl
aim
studi
determin
hyperinsulinaemia
could
reduc
lamin
prevent
poni
use
inhibitor
velagliflozin
poni
vari
degre
insulin
dysregul
base
oral
glucos
test
g
dextrosekg
bw
receiv
either
velagliflozin
mgkg
po
sid
n
placebo
n
throughout
studi
mainten
diet
lucern
hay
fed
week
follow
challeng
diet
g
nsckg
bwday
day
second
day
diet
challeng
blood
glucos
serum
insulin
measur
h
feed
result
express
geometr
mean
ci
maximum
concentr
glucos
lower
p
velagliflozin
group
mm
versu
mm
control
likewis
maximum
concentr
insulin
lower
treat
poni
miuml
versu
miuml
control
p
fourteen
control
develop
obel
grade
lamin
wherea
none
poni
p
clinic
sign
advers
effect
velagliflozin
could
valuabl
tool
prevent
lamin
treatment
insulin
dysregul
suscept
anim
oral
glucos
test
ogt
current
recommend
diagnosi
insulin
dysregul
id
hors
suffer
id
prone
lamin
especi
expos
high
amount
sugar
would
desir
reduc
amount
diagnost
glucos
furthermor
reduc
glucos
amount
enabl
variou
rout
applic
aim
studi
determin
whether
dosag
glucos
per
kg
bodyweight
bw
instead
bw
would
use
clinic
set
suffici
distinguish
insulin
sensit
insulin
dysregul
hors
eighteen
iceland
hors
differ
sex
age
bodyweight
uncertain
metabol
statu
test
applic
bw
logt
bw
mogt
bw
ogt
glucos
dissolv
water
administ
via
blood
sampl
collect
five
hour
analyz
insulin
glucos
blood
glucos
concentr
significantli
lower
logt
compar
ogt
p
minut
significantli
lower
mogt
compar
ogt
minut
p
applic
insulin
concentr
minut
significantli
lower
logt
compar
mogt
p
ogt
p
statist
differ
insulin
concentr
detect
mogt
ogt
minut
p
moreov
insulin
dynam
mogt
ogt
allow
satisfi
differenti
insulin
sensit
insulin
dysregul
hors
sum
reduct
glucos
bw
ogt
recommend
without
loss
diagnost
valu
diagnosi
insulin
dysregul
adult
hors
frequent
perform
use
karo
light
corn
syrup
howev
karo
light
syrup
readili
avail
worldwid
composit
avail
corn
syrup
may
vari
lead
differ
insulin
glucos
result
studi
evalu
agreement
two
formul
corn
syrup
karo
light
crown
lili
white
studi
consist
two
experi
experi
hors
allow
access
hay
pastur
prior
ost
experi
hors
fast
overnight
prior
ost
studi
corn
syrup
formul
order
random
oral
sugar
test
perform
one
week
apart
blood
drawn
measur
blood
glucos
insulin
concentr
prior
administr
corn
syrup
minut
administr
corn
syrup
blood
glucos
measur
use
handheld
glucomet
serum
insulin
measur
use
radioimmunoassay
data
analyz
normal
insulin
concentr
log
transform
normal
chang
glucos
insulin
concentr
time
point
area
curv
auc
maximum
concentr
cmax
time
cmax
tmax
compar
formul
use
two
way
analysi
varianc
repeat
measur
bland
altman
analysi
use
determin
agreement
insulin
concentr
formul
signific
differ
karo
crown
syrup
formul
individu
time
point
insulin
glucos
concentr
either
experi
p
signific
differ
area
curv
tmax
cmax
insulin
glucos
concentr
karo
compar
crown
syrup
p
analysi
insulin
concentr
indic
mean
bia
limit
agreement
experi
mean
bia
limit
agreement
experi
insulin
concentr
minut
studi
suggest
hors
similar
glucos
insulin
respons
two
formul
corn
syrup
equin
metabol
syndrom
em
pituitari
par
intermedia
dysfunct
ppid
common
hormon
disord
hors
coexist
patient
aim
studi
combin
two
diagnost
tool
diagnos
ppid
em
within
minut
hypothesis
measur
valu
insulin
respons
test
hormon
trh
stimul
test
perform
combin
would
differ
valu
obtain
test
perform
independ
hors
test
em
ppid
use
insulin
respons
test
trh
stimul
test
respect
classifi
em
ppid
em
ppid
control
combin
test
insulin
trh
inject
simultan
result
compar
among
protocol
pair
test
wilcoxon
sign
rank
test
analysi
base
independ
test
hors
consid
control
em
ppid
em
ppid
independ
combin
test
condit
significantli
affect
acth
concentr
trh
inject
chang
percentag
reduct
blood
glucos
insulin
inject
compar
within
group
overal
p
one
control
hors
combin
test
result
larger
increas
acth
trh
inject
consist
diagnosi
ppid
combin
trh
stimul
test
insulin
sensit
test
appear
attract
rapid
tool
diagnos
em
ppid
time
hors
earli
identif
hors
affect
insulin
dysregul
id
allow
veterinarian
recommend
prevent
measur
reduc
risk
lamin
oral
sugar
test
ost
use
light
corn
syrup
klc
valid
screen
test
id
posit
insulin
minut
veterinarian
owner
often
use
whatev
type
corn
syrup
conveni
despit
brand
differ
sugar
content
dog
human
fructos
increas
hepat
glucos
metabol
lower
insulin
glucos
respons
ost
similar
effect
hors
would
increas
number
fals
neg
ost
screen
ost
use
klc
glucos
maltos
ost
use
fox
corn
syrup
fc
high
fructos
corn
syrup
perform
twice
seven
arabian
hors
previous
diagnos
id
via
ost
frequent
sampl
intraven
glucos
toler
test
differ
area
curv
auc
peak
concentr
insulin
glucos
assess
use
anova
signific
p
repeat
assess
use
plot
signific
differ
note
klc
fc
either
auc
peak
concentr
howev
insulin
result
compar
id
posit
insulin
cut
test
fructos
correctli
identifi
hors
id
time
ost
without
fructos
identifi
id
test
base
fructos
substanti
impact
glucos
metabol
hors
may
interfer
insulin
respons
ost
vitamin
e
essenti
neuromuscular
function
oral
supplement
natur
rrr
mainstay
therapi
hors
hypovitaminosi
e
howev
subset
hors
object
pilot
trial
evalu
safeti
efficaci
inject
prepar
deliv
subcutan
hypothes
inject
would
increas
serum
cerebrospin
fluid
csf
concentr
healthi
adult
hors
six
mix
breed
hors
mare
geld
two
untreat
hors
mare
geld
enrol
phase
hors
randomli
assign
receiv
iuml
subcutan
oral
administr
moder
tissu
reaction
follow
inject
necessit
adjust
prepar
reduct
concentr
iuml
follow
washout
period
hors
receiv
reciproc
treatment
phase
ii
new
prepar
equival
dose
concentr
serum
csf
collect
period
determin
hplc
differ
baselin
serum
csf
concentr
residu
effect
note
indic
appropri
washout
serum
p
csf
concentr
increas
significantli
iuml
product
administ
serum
concentr
peak
inject
formul
may
therefor
use
case
refractori
oral
supplement
howev
caution
warrant
due
mark
local
tissu
reaction
observ
hors
hypophosphatemia
hypokalemia
hypomagnesemia
associ
variou
diseas
equid
despit
interact
analyt
energi
metabol
evalu
concentr
critic
ill
equid
lipid
disord
frequent
perform
therefor
incid
abnorm
patient
remain
unclear
medic
record
hospit
small
equid
poni
multipl
breed
american
miniatur
hors
donkey
greater
year
age
serum
triglycerid
concentr
greater
mgdl
admit
review
relationship
biochem
analyt
assess
analysi
patient
surviv
discharg
euthan
die
patient
stratifi
quartil
base
triglycerid
concentr
quartil
mgdl
quartil
mgdl
quartil
mgdl
quartil
mgdl
equid
triglycerid
quartil
like
surviv
triglycerid
concentr
quartil
p
hypophosphatemia
p
mgdl
hypokalemia
k
meql
hypomagnesemia
total
mg
mgdl
observ
case
respect
potassium
concentr
significantli
correl
triglycerid
concentr
p
equid
triglycerid
concentr
quartil
like
hypokalem
p
hypophosphatemia
associ
surviv
equid
hypertriglyceridemia
hypophosphatemia
surviv
evalu
phosphoru
potassium
magnesium
recommend
equid
dyslipidemia
lipidom
enabl
global
screen
effect
stimulu
like
exercis
lipid
metabol
chang
lipidom
arabian
hors
endur
race
influenc
perform
studi
inform
lack
thoroughbr
racehors
object
assess
effect
exercis
lipidom
racehors
four
thoroughbr
geld
similar
bodi
condit
age
use
hors
hous
barn
fed
diet
hors
underw
treadmil
exercis
fatigu
slope
venou
plasma
sampl
obtain
immedi
evalu
use
untarget
lipidom
approach
west
coast
metabolom
center
data
analyz
use
princip
compon
analysi
rm
anova
signific
set
p
plasma
lipid
detect
known
spectra
retent
index
link
librari
entri
exercis
plasma
level
eight
lipid
chang
significantli
like
reflect
occurr
lipolysi
briefli
increas
unsatur
fatti
acid
acid
decreas
satur
fatti
acid
icosano
heptadecano
lauric
myrist
acid
phospholipid
sphingomyelin
observ
pilot
studi
provid
valuabl
inform
regard
chang
lipidom
thoroughbr
associ
supramaxim
exercis
serv
refer
guid
futur
studi
racehors
metabolom
hors
persist
depress
left
atrial
la
mechan
function
prognost
indic
recurr
atrial
fibril
af
cardiovers
object
prospect
studi
character
la
mechan
function
warmblood
hors
success
transven
electr
cardiovers
tvec
af
use
standard
echocardiographi
speckl
track
analys
recent
describ
feasibl
method
quantifi
la
function
healthi
hors
aim
provid
proof
concept
use
detect
compromis
la
booster
pump
function
hors
warmblood
hors
atrial
fibril
success
tvec
continu
normal
sinu
rhythm
least
one
month
thereaft
includ
studi
echocardiographi
perform
tvec
maximum
la
area
laamax
la
diamet
ladmax
well
activ
passiv
la
fraction
area
chang
fac
measur
use
view
focus
left
atrium
la
dimens
measur
allometr
scale
bodi
weight
kg
global
longitudin
peak
strain
sl
strain
rate
srl
activ
booster
pump
function
measur
record
use
analys
measur
judg
relat
previous
establish
refer
interv
friedman
anova
dunn
multipl
comparison
test
perform
detect
differ
timepoint
linear
regress
analysi
perform
describ
associ
sl
srl
convent
measur
la
size
function
consid
repeat
measur
within
hors
p
consid
signific
thirteen
warmblood
hors
fulfil
inclus
criteria
measur
indic
timepoint
feasibl
hors
wherea
sever
la
enlarg
prevent
measur
hors
la
contractil
dysfunct
tvec
detect
hors
base
activ
la
fac
global
sl
activ
la
fac
chang
time
p
remain
refer
limit
hors
global
sl
significantli
increas
tvec
p
time
sl
hors
within
lower
rang
refer
interv
srl
refer
interv
hors
tvec
within
refer
limit
hors
tvec
p
strain
strain
rate
significantli
associ
activ
fac
passiv
fac
laamax
ladmax
lower
sl
srl
larger
atria
studi
show
use
detect
compromis
la
contractil
function
hors
convers
af
nsr
use
tvec
strain
strain
rate
neg
relat
la
enlarg
clinic
valu
predict
risk
recurr
atrial
fibril
establish
futur
studi
monensin
highli
toxic
hors
inadvert
ingest
result
cardiac
dysfunct
death
object
prospect
studi
determin
cardiovascular
athlet
outcom
hors
expos
monensin
physic
examin
exercis
stress
test
ecg
exercis
echocardiographi
perform
hors
expos
feed
four
hors
examin
within
week
exposur
acut
period
hors
examin
day
subacut
period
hors
examin
month
rest
chronic
period
inform
obtain
telephon
interview
approxim
month
exposur
hors
three
hors
present
acut
period
die
euthan
hors
clinic
sign
cardiac
anomali
rest
nineteen
hors
examin
subacut
period
cardiac
anomali
upon
physic
examin
cardiac
examin
rest
exercis
four
month
exposur
hors
cardiac
abnorm
upon
physic
examin
cardiac
examin
rest
exercis
sixteen
month
exposur
hors
known
outcom
return
intend
use
includ
hors
cardiac
anomali
previou
month
clinic
outcom
hors
expos
subleth
dose
monensin
highli
variabl
commonli
result
cardiac
dysfunct
lead
exercis
intoler
even
death
accuraci
precis
devic
measur
blood
pressur
nibp
hors
variabl
devic
valid
central
invas
blood
pressur
stand
hors
object
studi
compar
invas
pressur
obtain
carotid
arteri
ibpc
facial
arteri
ibp
nibp
arteri
cathet
place
transvers
facial
arteri
routin
carotid
arteri
sonograph
guidanc
nibp
coccyg
measur
use
commerci
oscillometr
devic
mindray
passport
correct
vertic
distanc
base
tail
heart
base
measur
obtain
baselin
high
dobutamin
low
acepromazin
blood
pressur
mean
bia
sd
bia
pearson
product
correl
r
calcul
data
obtain
hors
mean
biassd
biasr
ibpc
ibp
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
mean
biassd
biasr
ibpc
nibp
mmhg
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
mean
biassd
biasr
ibp
nibp
mmhg
mmhg
systol
mmhg
mmhg
mean
mmhg
mmhg
diastol
pressur
measur
ibpc
without
surgic
approach
feasibl
ibp
accept
surrog
ibpc
interchang
circumst
nibp
devic
test
accept
accuraci
precis
systol
pressur
follow
acvim
suggest
criteria
approxim
criteria
mean
blood
pressur
diastol
pressur
measur
less
accur
precis
continu
glycolysi
erythrocyt
blood
collect
may
caus
artifactu
vitro
increas
methylglyox
consequ
metabolit
sodium
fluorid
naf
inhibit
enolas
glycolysi
pathway
hypothes
equin
blood
collect
naf
tube
would
result
valid
lower
valu
compar
serum
tube
concentr
would
stabl
month
blood
collect
serum
naf
tube
hors
kept
ice
centrifug
separ
serum
plasma
sampl
frozen
analysi
month
previous
valid
commerci
assay
colorimetr
assay
kit
biovis
inc
milpita
ca
usa
valu
measur
blood
collect
serum
tube
mean
sd
concentr
month
respect
naf
tube
mean
concentr
month
respect
significantli
differ
p
serum
naf
sampl
compar
month
month
within
naf
tube
type
p
use
naf
tube
recommend
equin
blood
collect
determin
concentr
use
serum
tube
result
inflat
inaccur
valu
furthermor
storag
month
appear
result
sampl
degrad
interpret
caution
activ
platelet
contribut
human
sepsi
complic
multipl
organ
failur
aim
prospect
studi
determin
platelet
activ
clinic
case
equin
system
inflammatori
respons
syndrom
sir
adult
hors
poni
fulfil
least
two
criteria
adapt
includ
standard
human
protocol
measur
activ
platelet
pla
fluoresc
flow
cytometri
plrp
establish
hors
activ
platelet
determin
increas
present
platelet
activ
pla
measur
vitro
activ
platelet
collagen
ten
healthi
adult
hors
poni
serv
control
statist
analysi
includ
proof
normal
distribut
follow
anova
bonferroni
test
includ
hors
poni
sir
significantli
activ
platelet
pla
nativ
plrp
control
sir
control
p
respect
p
pla
respect
p
six
hors
surviv
trend
activ
pla
hors
furthermor
trend
reduc
vitro
activ
collagen
detect
first
studi
demonstr
increas
platelet
activ
fluoresc
flow
cytometri
clinic
case
equin
sir
likewis
platelet
activ
could
prognost
factor
patient
antiplatelet
therapi
eg
clopidogrel
could
addit
therapeut
option
clinic
case
sir
inflammatori
diseas
prevent
complic
improv
outcom
sinc
initi
discoveri
equin
hepaciviru
eqhv
viru
detect
hors
popul
countri
across
five
contin
eqhv
seropreval
report
high
eqhv
ribonucl
acid
rna
preval
rang
molecular
serolog
indic
eqhv
infect
never
report
equid
african
contin
therefor
investig
eqhv
preval
south
african
hors
subsequ
viral
genet
characteris
would
contribut
understand
global
epidemiolog
emerg
viru
studi
serum
sampl
thoroughbr
foal
age
analys
ns
antibodi
ab
luciferas
immunoprecipit
system
lip
eqhv
rna
quantit
polymeras
chain
reaction
farm
origin
situat
western
cape
provinc
south
africa
descript
analysi
perform
studi
associ
eqhv
infect
statu
age
gender
identifi
eqhv
isol
sequenc
subsequ
phylogenet
analysi
genom
portion
locat
ab
detect
sampl
highest
seropreval
report
yet
equin
popul
rna
preval
within
previous
report
rang
increas
associ
decreas
preval
ab
increas
preval
eqhv
viraemia
south
african
eqhv
strain
cluster
separ
publish
sequenc
eqhv
strain
conclus
eqhv
circul
south
african
thoroughbr
popul
appear
preval
hors
popul
worldwid
infect
serovar
leptospira
interrogan
leptospira
kirschneri
import
caus
abort
acut
renal
failur
recurr
uveiti
rare
neonat
diseas
hors
rapid
elisa
market
dog
studi
evalu
perform
elisa
idexx
snap
lepto
compar
microscop
agglutin
test
mat
use
serum
experiment
natur
infect
hors
serum
sampl
obtain
previou
studi
hors
experiment
infect
leptospira
interrogan
serovar
pomona
n
serum
natur
infect
hors
randomli
select
sampl
submit
anim
health
diagnost
center
cornel
univers
identifi
posit
mat
serovar
n
random
select
mat
neg
sampl
also
includ
test
n
sampl
n
test
idexx
snap
lepto
perform
test
kit
compar
mat
accuraci
measur
term
rel
sensit
specif
point
posit
mat
relationship
mat
titer
probabl
posit
idexx
snap
lepto
assess
use
logist
regress
analysi
result
indic
test
kit
high
specif
sensit
poor
titer
moder
titer
excel
titer
idexx
snap
lepto
provid
rapid
test
evid
antibodi
respons
leptospira
speci
hors
excel
specif
high
sensit
increas
titer
leptospirosi
associ
abort
acut
renal
diseas
often
result
mat
titer
test
kit
may
allow
prompt
field
determin
leptospirosi
statu
case
leptospirosi
worldwid
veterinari
public
health
concern
emerg
infecti
diseas
hors
spirochet
directli
transmit
contamin
urin
placent
fluid
semen
infect
tissu
reservoir
host
flood
water
seropreval
infect
serovar
vari
geographi
yet
diagnosi
use
gold
standard
microscop
agglutin
test
mat
mere
confirm
high
exposur
rate
subclin
infect
complic
diagnosi
aim
studi
use
quantit
pcr
urin
appar
healthi
hors
determin
period
preval
leptospir
shed
correl
find
mat
result
establish
associ
client
base
survey
data
regard
hors
manag
environ
serum
urin
collect
healthi
hors
may
decemb
serum
use
determin
ggt
creatinin
concentr
six
serovar
mat
canicola
hardjobovi
icterhemorrhaegia
pomona
grippotyphysa
bratislava
urin
sampl
submit
pcr
test
leptospir
dna
client
consent
survey
data
collect
subject
potenti
risk
factor
includ
drink
water
sourc
exposur
livestock
dog
geograph
locat
season
precipit
two
hors
posit
urin
pcr
leptospirosi
shed
preval
yet
high
mat
titer
hors
neg
urin
pcr
one
month
later
without
treatment
percent
hors
seroreact
mat
least
one
serovar
bratislava
detect
frequent
other
appar
healthi
hors
infrequ
shed
leptospira
spp
urin
yet
seroreact
clinic
normal
hors
high
confirm
high
exposur
rate
leptospira
spp
central
midwest
studi
target
serovar
specif
pcr
test
incorpor
pcr
test
hors
clinic
affect
leptospirosi
bacteri
viral
microbiota
often
inhabit
share
microenviron
howev
interest
potenti
contribut
promot
health
diseas
recent
gain
attent
object
studi
character
nasal
bacteri
microbiota
healthi
hors
control
hors
shed
equin
herp
use
next
gener
sequenc
technolog
nasal
bacteri
microbiota
control
hors
singl
farm
experienc
outbreak
character
use
illumina
miseq
platform
target
region
rrna
gene
hors
fever
limb
edema
posit
pcr
nasal
swab
within
one
week
first
case
confirm
posit
control
hors
anim
farm
show
clinic
sign
outbreak
neg
pcr
nasal
bacteri
microbiota
healthi
significantli
differ
commun
membership
jaccard
index
structur
yu
clayton
index
parsimoni
amova
p
hors
shed
lower
bacteri
rich
median
rang
vs
p
even
shannoneven
vs
p
divers
vs
p
control
hors
healthi
hors
higher
rel
abund
firmicut
median
bacteroidet
hors
respect
p
base
lefs
analysi
enrich
phylotyp
control
hors
predominantli
phylum
firmicut
wherea
phylotyp
enrich
infect
hors
proteobacteria
actinobacteria
genera
brachybacterium
dietzia
arthrobact
psychrobact
moraxella
significantli
associ
shed
wherea
genera
includ
lactobacillu
unclassifi
genera
famili
clostridial
lachnospiracea
enrich
control
hors
studi
provid
basi
gener
hypothes
investig
role
interact
play
health
diseas
adult
hors
streptococcu
equi
subspeci
equi
protein
sem
titer
use
confirm
complic
strangl
infect
titer
evalu
immunolog
risk
complic
prior
vaccin
titer
interpret
sem
titer
howev
specif
refer
data
interpret
lack
purpos
studi
compar
sem
titer
clinic
diseas
display
hors
determin
titer
interpret
consist
clinic
sign
hors
follow
outbreak
equi
serum
collect
measur
sem
titer
hors
week
select
hors
week
week
hors
categor
diseas
uncompl
strangl
persist
guttur
pouch
infect
day
andor
complic
case
metastat
abscess
format
purpura
hemorrhagica
exampl
base
clinic
find
develop
clinic
sign
equi
infect
affect
hors
uncompl
strangl
persist
guttur
pouch
infect
complic
case
persist
guttur
pouch
infect
complic
case
sixteen
hors
titer
week
hors
sem
titer
evid
strangl
complic
later
time
point
sem
titer
declin
hors
test
week
level
outbreak
demonstr
sem
titer
significantli
elev
hors
may
strangl
infect
complic
still
prudent
monitor
hors
high
titer
ensur
complic
absent
dorsal
displac
soft
palat
ddsp
well
describ
race
even
though
link
ddsp
lower
airway
inflamm
suggest
race
treatment
choic
remain
surgic
ddsp
also
describ
sport
although
effort
made
correl
lower
airway
inflamm
retrospect
studi
perform
period
year
overground
endoscopi
perform
sport
hors
present
privat
referr
practic
complaint
cough
respiratori
nois
poor
perform
hors
ddsp
ddsp
associ
cough
hors
nois
hors
silent
hors
tracheal
wash
perform
case
addit
bronchoalveolar
lavag
perform
case
tracheal
inflamm
present
hors
lower
airway
inflamm
present
hors
bacteri
cultur
tracheal
wash
posit
hors
fungal
cultur
posit
hors
medic
treatment
attempt
hors
involv
topic
treatment
furacin
dmso
andor
inhal
corticosteroid
bronchodil
antimicrobi
therapi
appropri
avail
case
includ
recheck
overground
endoscopi
hors
recheck
respiratori
sampl
hors
phone
contact
hors
treatment
success
case
hors
stop
cough
make
nois
perform
expect
treatment
failur
occur
chronic
case
case
ddsp
occur
tie
back
surgeri
studi
show
sport
hors
popul
ddsp
associ
lower
airway
inflamm
larg
proport
case
manag
medic
holcomb
sj
derksen
fj
stick
ja
robinson
ne
pathophysiolog
dorsal
displac
soft
palat
hors
parent
ej
acv
martin
bb
tullen
ep
ross
mw
dorsal
displac
soft
palat
hors
treadmil
examin
vet
surg
deniau
v
rossignol
f
et
al
physiolog
measur
preval
lower
airway
diseas
trotter
dorsal
displac
soft
palat
equin
vet
j
davidson
ej
martin
bb
boston
rc
parent
ej
exercis
upper
respiratori
videoendoscop
evalu
nonrac
perform
hors
abnorm
respiratori
nois
andor
poor
perform
equin
vet
j
nk
receptor
antagonist
maropit
citrat
zoeti
servic
commonli
use
cat
dog
mitig
nausea
vomit
hors
vomit
nausea
poorli
understood
like
recogn
speci
dog
cat
maropit
signific
viscer
analges
properti
well
investig
use
receptor
antagonist
hors
report
purpos
studi
determin
pharmacokinet
profil
maropit
citrat
seven
adult
hors
singl
intraven
iv
mgkg
intragastr
ig
mgkg
dose
random
crossov
design
perform
blood
sampl
collect
serial
maropit
administr
plasma
maropit
concentr
measur
use
pharmacokinet
paramet
determin
use
noncompartment
analysi
mean
sd
plasma
maropit
concentr
min
iv
administr
elimin
h
volum
distribut
lkg
mean
sd
maximum
concentr
follow
ig
administr
elimin
h
oral
bioavail
variabl
maropit
concentr
achiev
ig
administr
compar
canin
felin
howev
concentr
iv
administr
lower
higher
dog
cat
respect
elimin
longer
dog
shorter
cat
studi
describ
pharmacokinet
profil
singl
dose
maropit
hors
serv
basi
pharmacolog
investig
ischem
intestin
injuri
disrupt
mucos
barrier
function
diseas
strangul
obstruct
hors
prostaglandin
pg
play
import
role
mucos
recoveri
solubl
epoxid
hydrolas
seh
inhibitor
may
modul
product
pg
studi
aim
determin
whether
seh
inhibitor
acid
modul
recoveri
mucos
barrier
function
follow
ischem
injuri
porcin
jejunum
ten
juvenil
pig
anesthet
complet
ischem
injuri
induc
jejunum
minut
mucos
tissu
collect
mount
uss
chamber
bath
oxygen
ringer
solut
tissu
untreat
control
treat
equilibr
transepitheli
electr
resist
ter
data
calcul
everi
minut
recoveri
period
seros
fluid
sampl
collect
time
point
assess
concentr
signific
increas
level
tissu
treat
compar
untreat
tissu
p
untreat
tissu
significantli
reduc
ter
compar
tissu
p
p
howev
statist
differ
tissu
treat
without
conclud
novel
modul
pg
level
result
increas
tissu
injur
ischemia
without
significantli
impair
recoveri
barrier
function
therefor
may
futur
use
treat
anim
diseas
strangul
obstruct
purpos
studi
evalu
pharmacokinet
activ
metabolit
dipyron
adult
hors
follow
intraven
administr
four
differ
dose
regimen
dipyron
administ
intraven
iv
healthi
adult
hors
nine
day
parallel
design
laboratori
studi
hors
randomli
assign
receiv
mgkg
mgkg
mgkg
mgkg
blood
collect
predetermin
time
administr
plasma
concentr
measur
use
high
perform
liquid
chromatographytandem
mass
spectrometri
lcmsm
method
valid
use
hors
rapidli
detect
plasma
reach
maximum
measur
concentr
c
max
first
time
point
dose
studi
follow
first
dose
c
max
increas
linearli
rang
follow
multipl
dose
signific
accumul
occur
area
curv
auc
increas
disproportion
dose
mgkg
signific
differ
includ
increas
minimum
concentr
vs
averag
concentr
vs
h
vs
h
note
dipyron
administ
mgkg
compar
p
signific
differ
note
clearanc
auc
tau
higher
dose
shorter
dose
interv
result
nonlinear
pharmacokinet
follow
multipl
dose
may
result
drug
accumul
dose
regimen
util
studi
may
repres
alter
metabol
atyp
myopathi
season
pastur
myopathi
toxic
rhabdomyolysi
hors
link
ingest
hypoglycin
hga
contain
seed
seedl
acer
tree
speci
although
toxic
effect
hga
metabolit
methylenecyclopropylacet
acid
mcpa
studi
sever
speci
remain
unclear
anim
rumin
graze
similar
pastur
hors
appear
unaffect
object
studi
investig
hypothesi
appar
low
suscept
sheep
due
either
low
bioavail
hga
hga
degrad
rumin
fluid
rel
increas
mcpa
sensit
hors
muscl
hga
concentr
measur
valid
liquid
spectrometri
method
serum
sampl
clinic
healthi
ewe
hors
graze
sycamor
pastur
addit
sycamor
seed
homogen
incub
equin
gastric
fluid
sheep
rumin
fluid
sampl
hour
extract
assay
hga
concentr
final
primari
cell
cultur
hors
sheep
muscl
sampl
expos
rang
mcpa
concentr
cytotox
effect
compar
mtt
assay
data
analys
use
u
anova
test
similar
concentr
hga
detect
serum
sheep
rang
hors
ngml
graze
contamin
pastur
statist
signific
differ
hga
concentr
follow
sycamor
seed
homogen
incub
either
gastric
rumen
fluid
compar
sheep
cell
hors
cell
significantli
higher
vitro
compromis
mcpa
concentr
p
studi
reveal
sheep
hors
absorb
hga
follow
sycamor
seedl
ingest
evid
hga
degrad
exposur
rumen
fluid
primari
hors
cell
sensit
sheep
cell
activ
hga
metabolit
low
concentr
suggest
greater
muscl
metabol
inhibit
mcpa
hors
sheep
though
studi
necessari
work
potenti
explain
appar
dispar
suscept
hga
intox
speci
cephalosporin
administr
induc
high
shed
rate
esbl
enterobacteriacea
human
object
prospect
evalu
effect
differ
antimicrobi
treatment
fecal
shed
enterobacteriacea
hors
hors
present
univers
zurich
randomli
alloc
receiv
penicillin
gentamicin
pg
n
cefquinom
cef
n
antibiot
treatment
need
antimicrobi
treatment
noamd
n
fecal
sampl
taken
admiss
day
day
admiss
day
day
discharg
day
sampl
cultur
differ
group
analys
use
test
odd
ratio
repeat
measur
anova
preval
day
differ
group
p
hors
treat
cef
pg
like
shed
enterobacteriacea
compar
noamd
day
p
p
respect
day
p
p
respect
esbl
count
increas
day
day
group
cef
p
pg
p
noamd
p
esbl
bacteri
count
significantli
higher
pg
group
compar
cef
noamd
group
p
p
respect
also
significantli
higher
cef
group
compar
noamd
group
p
hospit
antimicrobi
treatment
increas
colon
enterobacteriacea
administr
cefquinom
induc
higher
shed
rate
compar
administr
penicillingentamicin
standard
antibiosi
highlight
need
reduc
antimicrobi
use
overal
mitochondri
product
especi
mitochondri
dna
human
studi
presum
due
bacteri
evolutionari
origin
therefor
releas
tissu
necrosi
may
import
contributor
inflammatori
respons
hors
aim
studi
determin
inflammatori
respons
mitochondri
product
vitro
equin
whole
blood
assay
mitochondria
isol
liver
tissu
system
healthi
hors
cell
lysi
centrifug
mitochondria
fragment
serial
dilut
pb
ad
aliquot
whole
blood
healthi
hors
mix
rpmi
medium
one
aliquot
serv
neg
control
aliquot
incub
rotat
hour
inflammatori
respons
determin
measur
supernat
use
murin
fibroblast
bioassay
mitochondri
fragment
caus
inflammatori
effect
equin
whole
blood
produc
increas
releas
plasmasupernat
fit
sigmoid
curv
increas
product
lowest
dilut
mitochondri
fragment
pgml
dilut
compar
pgml
whole
blood
incub
fragment
releas
mitochondri
fragment
local
tissu
damag
inflamm
necrosi
might
contribut
clinic
sever
sir
possibl
offer
mechan
develop
sir
hors
absenc
obviou
gastrointestin
diseas
infect
work
warrant
investig
signific
inflamm
caus
mitochondri
fragment
hors
includ
novel
therapi
electrocardiogram
indispens
tool
diagnosi
arrhythmia
electr
conduct
disord
equin
heart
howev
sever
electrocardiograph
variabl
may
influenc
factor
speci
age
gender
breed
morphofunct
constitut
highlight
import
know
normal
characterist
distinct
speci
breed
develop
stage
studi
aim
assess
electrocardiograph
develop
frontal
plane
deriv
last
day
pregnanc
day
birth
donkey
pega
breed
therefor
electrocardiogram
conduct
electrocardiographi
devic
frontal
plane
deriv
minut
without
sed
tranquil
anesthet
result
shown
tabl
observ
physiolog
patholog
cardiac
arrhythmia
electr
conduct
disord
anim
assess
heartrat
observ
frontal
plane
deriv
present
minim
chang
studi
moment
pregnanc
predomin
cardiac
rhythm
observ
femal
sinu
tachycardia
heartrat
increas
birth
got
closer
bpm
day
birth
bpm
birth
bifid
biphas
p
wave
predomin
moment
observ
signific
differ
durat
pr
interv
ms
frontal
plane
deriv
qt
interv
ms
deriv
well
signific
increas
r
wave
amplitud
electrocardiograph
paramet
pregnant
donkey
diverg
term
durat
amplitud
morpholog
contrast
donkey
equin
breed
find
highlight
import
obtain
specif
valu
distinct
speci
breed
pregnanc
stage
safer
prenat
care
achiev
key
gene
involv
transport
calcium
across
sarcoplasm
reticulum
sr
encod
protein
ryanodin
receptor
ryr
releas
sr
sr
calcium
atpas
serca
pump
back
sr
newli
discov
regulatori
micropeptid
mrln
pln
sln
inhibit
serca
therebi
control
intracellular
contractil
transcript
express
protein
abund
micropeptid
hors
unknown
purpos
studi
determin
rel
express
equin
regulatori
gene
left
ventricl
right
atrium
gluteal
muscl
rna
extract
tissu
collect
hors
revers
transcrib
cdna
transcript
abund
quantifi
use
data
normal
gapdh
within
sampl
data
compar
use
anova
gluteal
use
baselin
result
correct
multipl
test
gluteal
muscl
compar
right
atrium
left
ventricl
highest
express
sln
mrln
express
low
level
wherea
sln
found
abundantli
express
serca
inhibitor
gluteal
muscl
pln
higher
express
right
atrium
left
ventricl
atrium
ventricl
express
higher
level
compar
gluteal
muscl
differenti
express
newli
discov
micropeptid
suggest
vari
role
regul
serca
differ
tissu
new
express
data
complement
find
speci
open
explor
role
serca
inhibitor
equin
skelet
cardiac
diseas
safeti
pharmacokinet
acetaminophen
apap
inn
paracetamol
determin
use
healthi
adult
thoroughbr
geld
commerci
avail
apap
mgkg
mg
tablet
administ
oral
singl
dose
follow
multipl
dose
everi
hour
day
blood
sampl
collect
determin
plasma
apap
concentr
use
serum
biochemistri
gastroscopi
perform
prior
initi
dose
follow
final
dose
follow
singl
dose
mean
maximum
concentr
cmax
ugml
hour
tmax
apap
remain
presum
therapeut
concentr
ugml
two
hour
undetect
hour
elimin
signific
accumul
note
follow
multipl
dose
averag
cmax
apap
follow
repeat
oral
dose
ugml
tmax
hour
hour
sdh
significantli
decreas
pre
ul
post
ul
p
total
bilirubin
significantli
increas
pre
mgdl
post
mgdl
p
follow
last
dose
statist
signific
chang
note
gastroscopi
score
pre
mean
post
mean
p
dose
simul
suggest
higher
dose
andor
shorter
dose
interv
may
indic
studi
demonstr
safeti
acetaminophen
repeat
oral
dose
day
studi
also
confirm
mgkg
dose
use
previou
clinic
report
reach
propos
therapeut
concentr
oral
administr
fed
hors
howev
shorter
hour
dosag
interv
may
requir
improv
efficaci
studi
describ
pharmacodynam
oral
doxycyclin
streptococcu
equi
subsp
zooepidemicu
infect
tissu
chamber
model
adult
hors
six
healthi
adult
light
breed
hors
includ
studi
median
age
year
rang
year
tissu
chamber
tc
implant
subcutan
neck
allow
median
heal
time
day
rang
day
prior
zooepidemicu
inocul
day
ml
unit
cfu
inocul
tc
doxycyclin
hyclat
mgkg
po
q
h
mix
poloxam
gel
xanthum
gum
administ
day
tc
fluid
sampl
inocul
day
total
solid
measur
quantit
cultur
total
nucleat
cell
differenti
cell
count
rectal
temperatur
measur
daili
day
match
pair
sign
rank
test
use
compar
distribut
cytolog
cfu
result
inocul
day
tc
fluid
steril
cytolog
show
mild
inflamm
total
solid
median
gl
rang
gl
neutrophil
median
rang
macrophag
median
rang
lymphocyt
median
rang
two
hors
develop
transient
hyperthermia
median
rang
hors
develop
abscess
tc
site
day
signific
increas
total
nucleat
cell
count
p
total
solid
p
cfu
concentr
p
occur
tc
cytolog
profil
also
chang
significantli
character
increas
proport
neutrophil
decreas
proport
macrophag
lymphocyt
p
find
consist
septic
reaction
tc
inocul
failur
doxycyclin
treatment
conclus
oral
dose
formul
doxycyclin
hyclat
use
studi
fail
cure
zooepidemicu
infect
tc
model
pharmacokinet
dexmedetomidin
describ
hors
undergo
anaesthesia
arthroscopi
procedur
dexmedetomidin
administ
intraven
bolu
hors
subcutan
inject
hors
blood
sampl
collect
minut
clinic
observ
includ
systol
mean
arteri
diastol
blood
pressur
heart
rate
concentr
dexmedetomidin
plasma
sampl
determin
use
valid
lcm
method
dexmedetomidin
concentr
data
analys
use
monolix
lixoft
franc
fit
popul
model
consist
pk
model
absorpt
elimin
rate
constant
dexmedetomidin
median
min
median
central
compart
appar
volum
distribut
l
median
subcutan
bioavail
median
absorpt
rate
constant
min
follow
optim
pharmacokinet
paramet
lock
pharmacodynam
variabl
assess
sequenti
model
strategi
paramet
model
identifi
model
reject
model
statist
support
inclus
simpler
power
model
effect
dexmedetomidin
blood
pressur
paramet
describ
rise
blood
pressur
effect
dexmedetomidin
heart
rate
detect
studi
identifi
dexmedetomidin
rapidli
incomplet
absorb
subcutan
administr
higher
plasma
concentr
intraven
administr
associ
increas
blood
pressur
compar
subcutan
administr
result
suggest
need
dosag
adjust
base
rout
administr
dexmedetomidin
plasma
phosphat
concentr
p
plasma
calcium
concentr
ca
chang
human
sepsi
system
inflammatori
respons
syndrom
hors
easili
measur
paramet
might
use
biomark
equin
colic
studi
aim
determin
use
p
ca
prognost
diagnost
biomark
hors
colic
record
hors
present
colic
includ
coliti
review
control
healthi
teach
hors
p
ca
ca
p
compar
hors
colic
control
addit
comparison
made
hors
strangul
inflammatori
colic
lesion
survivor
correl
haematocrit
white
cell
count
wcc
fibrinogen
examin
record
colic
case
control
includ
colic
case
significantli
higher
p
increas
significantli
lower
ca
decreas
ca
p
decreas
control
differ
p
ca
ca
p
colic
lesion
group
ca
significantli
lower
strangul
inflammatori
lesion
compar
control
p
ca
p
significantli
lower
inflammatori
lesion
compar
control
p
weak
signific
correl
found
p
haematocrit
wcc
fibrinogen
ca
paramet
ca
p
significantli
correl
fibrinogen
haematocrit
wcc
ca
p
significantli
correl
associ
p
ca
ca
p
surviv
neither
p
ca
ca
p
use
alon
biomark
contribut
overal
clinic
pictur
nine
american
quarter
hors
foal
age
rang
day
month
singl
farm
central
ohio
present
osu
cvm
evalu
diarrhea
lethargi
inappet
one
foal
die
within
hour
admiss
two
foal
euthan
within
hour
admiss
poor
respons
resuscit
one
suspect
gastrointestin
ruptur
anoth
rotaviru
pcr
perform
fece
posit
foal
one
foal
posit
clostridium
difficil
fecal
cultur
rest
neg
clostridium
perfringensdifficil
salmonella
coronaviru
four
foal
discharg
hospit
within
week
persist
inappet
lethargi
failur
thrive
subsequ
diagnos
pylor
outflow
obstruct
base
gastroscopi
persist
nasogastr
reflux
barium
gastrographi
one
foal
caudal
esophag
strictur
euthan
poor
respons
treatment
three
foal
euthan
due
pylor
outflow
obstruct
discharg
necropsi
perform
foal
reveal
sever
gastric
distent
pyloricduoden
stenosi
gastroduoden
ulcer
egu
suspect
associ
rotaviru
incid
multipl
case
pylor
outflow
obstruct
associ
rotavir
enter
document
well
hors
human
neonat
egu
foal
common
preval
rang
frequent
clinic
inappar
rare
lesion
may
produc
strictur
gastric
outflow
obstruct
report
describ
gastric
outflow
obstruct
diagnos
multipl
foal
associ
outbreak
rotaviru
septicemia
lead
caus
mortal
newborn
foal
progesteron
mainli
known
role
pregnanc
howev
also
precursor
adrenocort
neuroact
steroid
like
play
import
function
equin
neonat
human
studi
demonstr
progesteron
modul
immun
predispos
inflammatori
condit
howev
mechan
progesteron
influenc
outcom
sick
foal
remain
unclear
goal
studi
measur
blood
concentr
inflammatori
cytokin
serum
amyloid
saa
healthi
hospit
foal
determin
associ
progesteron
sever
diseas
mortal
hypothes
hospit
foal
higher
progesteron
cortisol
concentr
associ
inflammatori
respons
diseas
sever
mortal
foal
n
divid
three
group
base
sever
diseas
septic
n
sick
sn
n
healthi
n
hospit
foal
sn
septic
divid
two
group
base
surviv
survivor
blood
sampl
collect
admiss
hormon
measur
radioimmunoassay
cytokin
elisa
progesteron
cortisol
interleukin
concentr
significantli
higher
septic
sn
compar
healthi
foal
p
leukocyt
neutrophil
count
well
igg
concentr
lower
saa
concentr
significantli
higher
hospit
compar
healthi
foal
p
interleukin
concentr
significantli
higher
survivor
igg
interleukin
concentr
posit
correl
progesteron
significantli
lower
neg
correl
saa
p
result
suggest
progesteron
addit
cortisol
may
involv
adrenocort
respons
stress
critic
ill
could
influenc
inflammatori
respons
sick
foal
first
studi
associ
progestogen
marker
inflamm
hospit
foal
antibodi
tnf
blocker
use
human
sepsi
anim
model
sepsi
fda
approv
use
hors
us
object
pilot
studi
evalu
singl
dose
novel
antibodi
neonat
foal
sepsi
studi
clinic
trial
foal
age
hour
sepsi
defin
sepsi
score
sick
defin
rectal
temperatur
blood
glucos
mgdl
enrol
foal
administ
antibodi
mgkg
sq
placebo
match
volum
salin
sq
along
concurr
treatment
underli
diseas
foal
assess
daili
eight
day
studi
veterinarian
nineteen
septic
foal
varieti
diagnos
enrol
studi
thirteen
foal
treat
antibodi
six
foal
treat
placebo
surviv
analysi
show
statist
signific
differ
surviv
studi
termin
antibodi
treat
foal
comparison
placebo
p
abnorm
clinic
sign
clinic
patholog
chang
relat
underli
diseas
inject
site
reaction
note
foal
treat
antibodi
show
improv
surviv
studi
termin
comparison
score
baselin
antibodi
well
toler
administ
septic
neonat
foal
mgkg
proxi
predict
insulin
sensit
respons
calcul
basal
plasma
glucos
insulin
concentr
describ
use
hors
invers
relationship
respons
insulin
sensit
hors
clamp
ehc
method
measur
complex
techniqu
limit
use
research
insulin
sensit
quantifi
use
ehc
hors
differ
breed
wide
rang
includ
clinic
patient
diagnos
insulin
dysregul
quantit
measur
express
mean
glucos
dispos
rate
mi
valu
basal
plasma
glucos
insulin
concentr
calcul
proxi
determin
blood
sampl
collect
prior
ehc
proxi
estim
quantit
insulin
sensit
check
quicki
reciproc
squar
root
insulin
risqi
well
proxi
respons
basal
insulin
concentr
bic
modifi
ratio
mirg
homeostasi
model
assess
function
calcul
spearman
correl
use
evalu
correl
proxi
assess
ehc
strong
posit
linear
correl
rho
p
proxi
risqi
quicki
proxi
function
bic
mirg
invers
relat
rho
p
quantit
measur
mi
use
proxi
estim
respons
offer
attract
altern
larg
popul
studi
rel
simpl
inexpens
assess
necessari
measur
adrenocorticotrop
hormon
acth
becom
common
diagnost
method
util
diagnosi
pituitari
par
intermedia
dysfunct
ppid
hors
adrenocorticotrop
hormon
reportedli
understood
fragil
whole
blood
sampl
affect
heat
time
spent
cell
consequ
recommend
refriger
whole
blood
sampl
prior
centrifug
separ
plasma
within
hour
collect
plasma
sampl
ship
day
collect
respect
laboratori
plasma
frozen
shipment
imper
veterinarian
understand
freez
plasma
neg
effect
stabil
rest
acth
concentr
object
studi
determin
stabil
acth
plasma
freez
differ
length
time
prior
determin
rest
acth
concentr
plasma
sampl
obtain
hors
rest
acth
level
measur
day
baselin
time
variabl
storag
method
plasma
sampl
store
either
c
sampl
place
ice
pack
store
plasma
sampl
store
day
store
day
store
ice
pack
day
prior
determin
rest
acth
concentr
plasma
sampl
ship
anim
health
diagnost
center
cornel
univers
ithaca
ny
measur
rest
acth
concentr
within
storag
method
acth
level
time
compar
baselin
day
plasma
use
pair
ie
hors
serv
control
p
consid
statist
signific
data
summar
mean
standard
error
se
percent
chang
baselin
cfb
mean
acth
level
day
plasma
store
pgml
declin
pgml
day
day
cfb
never
vari
day
cfb
although
reach
statist
signific
p
trend
toward
signific
degrad
observ
mean
acth
level
day
plasma
store
pgml
declin
pgml
day
cfb
statist
signific
p
day
although
decreas
trend
observ
mean
acth
level
day
plasma
store
ice
pack
pgml
declin
pgml
day
signific
degrad
p
acth
observ
day
none
storag
method
result
sampl
degrad
differ
significantli
baselin
trend
toward
degrad
observ
day
store
sampl
day
store
sampl
signific
degrad
observ
acth
plasma
sampl
store
ice
pack
day
freez
plasma
short
period
time
c
least
day
result
statist
signific
degrad
plasma
acth
compar
plasma
baselin
sampl
studi
conduct
evalu
effect
freez
plasma
acth
concentr
larger
popul
hors
aim
studi
evalu
effect
weight
gain
achiev
provid
healthi
hors
fat
rich
diet
follow
pastur
insulin
sensit
blood
pressur
serum
cortisol
concentr
weight
gain
induc
standardbr
mare
fed
fat
supplement
forag
diet
time
daili
requir
week
hors
turn
pastur
week
insulin
sensit
measur
weight
gain
week
pastur
use
euglycem
hyperinsulinem
clamp
method
bodi
weight
bodi
condit
bc
blood
pressur
serum
cortisol
monitor
throughout
studi
hors
becam
obes
weight
gain
period
bc
mean
arteri
blood
pressur
increas
gradual
weight
gain
period
significantli
higher
initi
valu
end
weight
gain
period
mmhg
vs
mmhg
mean
arteri
blood
pressur
remain
higher
level
pastur
mmhg
insulin
sensit
chang
weight
gain
vs
mgkgmin
x
mul
improv
week
pastur
mgkgmin
x
mul
serum
cortisol
concentr
increas
weight
gain
period
nmoll
vs
nmoll
remain
elev
pastur
period
conclus
obes
associ
increas
blood
pressur
associ
chang
insulin
sensit
patholog
fractur
occasion
report
age
hors
pituitari
par
intermedia
dysfunct
ppid
suggest
ppid
may
associ
loss
bone
thick
densiti
purpos
studi
compar
cortic
bone
thick
densiti
third
metacarp
bone
hors
ppid
ppid
par
intermedia
pi
histolog
score
n
age
hors
without
ppid
pi
histolog
score
n
young
hors
young
year
n
follow
euthanasia
right
third
metacarp
bone
remov
ct
scan
perform
imag
use
measur
thick
mm
densiti
hounsfield
unit
hu
region
interest
dorsal
palmar
medial
later
cortic
midpoint
diaphysi
data
analyz
anova
anova
rank
signific
p
differ
found
palmar
cortex
thick
ppid
young
young
greater
later
cortex
thick
ppid
young
greater
ppid
young
bone
densiti
signific
p
differ
detect
palmar
hu
ppid
young
young
greater
although
minor
differ
found
cortic
bone
thick
hu
group
consist
effect
ppid
compar
young
difficult
separ
effect
age
ppid
statu
conclus
substanti
chang
third
metacarp
cortic
thick
densiti
found
cohort
ppid
hors
hyperlipemia
common
problem
hospit
equid
medic
record
hospit
equid
year
age
median
age
year
rang
year
triglycerid
concentr
mgdl
admit
review
breed
includ
donkey
american
miniatur
hors
poni
breed
quarter
hors
friesian
american
paint
hors
arabian
belgian
warmblood
tennesse
walk
hors
morgan
percent
femal
geld
stallion
percent
surviv
discharg
die
euthan
degre
hyperlipemia
associ
surviv
common
primari
diagnosi
enterocol
diagnos
form
colic
medic
surgic
diagnos
includ
primari
hyperlipemia
botul
pneumonia
dystocia
guttur
pouch
empyema
lymphoma
percent
treat
via
voluntari
alimentari
intak
administ
intraven
dextros
ivd
administ
enter
nutrit
via
nasogastr
tube
administ
ivd
thirteen
percent
treat
partial
parenter
nutrit
often
combin
nasogastr
feed
intraven
dextros
fourteen
percent
treat
insulin
averag
durat
hospit
day
hyperlipemia
hospit
equid
common
comorbid
disord
necessarili
requir
expens
intens
treatment
prognosi
surviv
fair
associ
degre
hypertriglyceridemia
mycobacterium
avium
subsp
paratuberculosi
map
etiolog
agent
paratuberculosi
chronic
contagi
enter
diseas
rumin
econom
loss
potenti
role
map
crohn
diseas
human
justifi
studi
paratuberculosi
manag
practic
limit
exposur
suscept
anim
map
effect
reduc
diseas
preval
test
cull
infect
cow
object
retrospect
studi
studi
associ
manag
practic
map
statu
dairi
herd
case
herd
map
isol
least
environment
sampl
control
herd
clinic
case
paratuberculosi
neg
consecut
yearli
environment
sampl
select
among
herd
enrol
voluntari
paratuberculosi
control
program
exposur
measur
use
risk
assess
questionnair
complet
enrol
cultur
map
achiev
use
bactec
detect
system
multivari
logist
regress
use
evalu
associ
risk
factor
map
herd
statu
herd
size
significantli
associ
posit
map
herd
statu
ci
farm
buy
cow
herd
per
year
last
year
significantli
greater
odd
map
posit
compar
close
herd
ci
risk
factor
consist
literatur
priorit
control
program
past
year
preval
bovin
leukemia
viru
blv
infect
increas
north
america
includ
atlant
canada
herd
individu
cow
level
occur
despit
increas
awar
diseas
deleteri
effect
face
manag
practic
aim
reduc
diseas
transmiss
object
identifi
risk
factor
associ
preval
cow
hypothes
well
previous
establish
risk
factor
manag
practic
associ
calf
rear
fli
control
would
affect
blv
preval
risk
assess
manag
program
questionnair
develop
distribut
bovin
veterinarian
atlant
canada
dairi
farm
ship
milk
bulk
tank
milk
btm
sampl
collect
januari
april
elig
particip
btm
sampl
test
elisa
level
antibodi
estim
preval
result
combin
demograph
inform
collect
farm
mean
btm
elisa
result
multivari
linear
regress
perform
investig
associ
risk
factor
preval
blv
infect
one
hundr
return
particip
provinc
atlant
canada
new
brunswick
newfoundland
nova
scotia
princ
edward
island
factor
significantli
associ
increas
level
blv
preval
includ
histori
clinic
blv
within
herd
increas
ci
histori
purchas
cattl
increas
ci
signific
differ
preval
associ
needl
inject
fli
control
rectal
sleev
practic
use
bull
natur
breed
import
factor
associ
increas
blv
preval
includ
histori
prior
diagnosi
clinic
blv
histori
purchas
cow
unknown
blv
statu
studi
signific
associ
previous
establish
risk
factor
increas
preval
blv
infect
gastro
intestin
nematod
gin
signific
impact
small
rumin
product
multipl
speci
parasit
common
differ
parasit
differ
pathogenesi
investig
differ
popul
gin
import
plan
control
strategi
understand
interact
parasit
host
well
surveil
region
divers
determin
specif
popul
involv
anthelmint
resist
sever
method
identif
avail
fecal
cultur
morpholog
examin
larval
stage
parasit
pcr
howev
method
time
consum
low
throughput
andor
requir
specif
expertis
origin
develop
deep
amplicon
sequenc
nematod
rdna
nemabiom
quantifi
speci
composit
cattl
gin
recent
adapt
valid
use
small
rumin
field
applic
nemabiom
includ
epidemiolog
studi
nematod
speci
affect
sheep
flock
western
canada
identif
parasit
popul
resist
anthelmint
complement
fecal
egg
count
reduct
test
inform
gather
use
deep
amplicon
sequenc
provid
import
qualit
quantit
inform
epidemiolog
resist
statu
differ
speci
gastrointestin
parasit
essenti
make
inform
decis
treatment
control
current
develop
nemabiom
approach
screen
directli
anthelmint
drug
resist
mutat
gin
popul
purpos
prospect
studi
describ
bacteri
commun
nasopharynx
np
prewean
dairi
calv
without
ultrasonograph
lung
lesion
addit
object
includ
evalu
effect
previou
antibiot
therapi
age
np
microbiota
composit
total
holstein
heifer
calv
enrol
separ
studi
investig
genom
resist
bovin
respiratori
diseas
brd
follow
period
calv
examin
twice
use
thorac
ultrasound
clinic
respiratori
score
earli
exam
week
old
late
exam
week
old
popul
case
control
select
undergo
deep
np
swab
current
studi
case
defin
presenc
signific
ultrasonograph
lung
lesion
lobe
complet
consolid
control
defin
lack
lesion
np
swab
taken
time
exam
calf
inform
collect
farm
manag
softwar
swab
place
phosphat
buffer
solut
store
follow
dna
extract
region
rrna
gene
amplifi
use
pcr
librari
sequenc
use
miseq
platform
gener
sequenc
process
mothur
output
taxonomi
divers
data
analyz
rstudio
divers
data
analyz
use
gener
linear
model
comparison
rel
abund
ra
genera
group
perform
use
kruskal
walli
test
multipl
linear
regress
use
investig
impact
time
point
exam
antibiot
treatment
month
prior
examin
ra
genera
total
swab
case
control
collect
two
swab
lost
transport
therefor
swab
case
control
obtain
calv
use
analysi
swab
collect
late
exam
overal
common
genera
acinetobact
sp
escherichia
sp
mycoplasma
sp
pasteurella
sp
psychrobact
sp
alpha
divers
differ
case
control
p
earli
late
time
point
p
ra
mycoplasma
sp
higher
control
p
ra
pasteurella
sp
tend
higher
control
p
ra
mycoplasma
sp
pasteurella
sp
affect
exam
time
point
antibiot
treatment
p
p
respect
author
knowledg
first
studi
evalu
commun
dynam
np
microbiota
calv
without
ultrasonograph
lung
lesion
expect
identifi
higher
ra
mycoplasma
sp
control
calv
previou
studi
shown
higher
ra
mycoplasma
sp
calv
brd
compar
healthi
calv
futur
studi
need
better
understand
discrep
includ
metagenom
studi
infer
speciat
determin
pathogen
identifi
mycoplasma
genu
would
also
import
know
durat
ultrasound
lesion
affect
ra
pathogen
bacteria
studi
help
demonstr
complex
identifi
np
microbiota
chang
associ
diseas
statu
may
impact
futur
attempt
util
np
microbiota
characterist
diagnosi
treatment
brd
cryptosporidium
parvum
occup
exposur
risk
veterinari
personnel
pose
risk
patient
gener
c
parvum
oocyst
environment
hardi
resist
standard
disinfect
rapid
detect
earli
implement
prevent
measur
key
risk
reduct
object
studi
evalu
commerci
avail
rapid
test
detect
c
parvum
comparison
immunofluoresc
antibodi
test
ifa
use
test
bovin
fecal
sampl
diagnost
test
evalu
perform
fecal
sampl
collect
per
rectum
calv
less
month
age
studi
popul
stratifi
diseas
statu
healthi
scour
sampl
fix
test
via
commerci
avail
rapid
test
market
use
human
healthcar
ifa
recogn
gold
standard
test
method
isol
submit
genet
type
overal
moder
agreement
among
test
evalu
kappa
statist
ci
preval
sampl
higher
use
rapid
test
compar
ifa
among
sampl
health
statu
record
cryptosporidium
identifi
commonli
among
scour
calv
rapid
test
ifa
healthi
calv
rapid
test
ifa
irrespect
test
method
use
evalu
demonstr
rapid
test
may
use
tool
manag
risk
hospit
set
show
rel
high
preval
cryptosporidium
among
appar
healthi
calv
abomas
patholog
condit
report
calv
current
descript
mainli
limit
find
object
retrospect
studi
describ
clinic
present
outcom
calv
primari
diagnosi
abomas
medic
archiv
centr
hospitali
universitair
de
search
use
term
refer
abomasum
exclus
calv
clinic
factor
andor
older
three
month
old
twenti
calv
clinic
diagnosi
abomas
includ
median
age
day
old
rang
day
calv
holstein
median
clinic
durat
prior
admiss
hour
rang
day
abomas
tympani
posit
succuss
abnorm
mucou
membran
color
dehydr
depress
recumb
tachycardia
rang
beatsmin
tachypnea
rang
breathsmin
frequent
clinic
sign
note
hematolog
biochem
profil
reveal
hyperlactatemia
rang
mmoll
hypochloremia
rang
mmoll
left
shift
neutrophil
toxic
chang
hypoglycemia
rang
mmoll
hyperkaliemia
rang
mmoll
acidemia
rang
neutropenia
rang
base
univari
statist
analysi
fatal
outcom
significantli
p
relat
dehydr
recumb
hypothermia
metabol
acidosi
hypoproteinemia
leucopenia
neutropenia
fatal
rate
necropsi
perform
calv
confirm
clinic
diagnosi
abomas
guard
prognosi
calv
clinic
clinicopatholog
find
shown
associ
fatal
outcom
concept
exist
gut
virom
recent
although
presenc
virus
pathogen
calf
intestin
document
year
contrast
bacteri
microbiota
littl
known
regard
develop
establish
factor
modifi
gut
virom
neonat
period
object
studi
character
fecal
virom
healthi
diarrheic
neonat
dairi
calv
twenti
diarrheic
calv
dc
age
day
healthi
control
calv
hc
enrol
viral
nucleic
extract
perform
use
commerci
kit
synthesi
viral
cdna
complet
use
primer
contain
fix
plu
random
nonam
twenti
sampl
hc
mix
equimolar
quantiti
set
well
dc
sampl
total
pool
sampl
sequenc
use
raw
sequenc
qualiti
assess
use
fastqc
read
remov
trimmomat
use
cluster
read
sequenc
ident
five
repres
sequenc
cluster
use
perform
de
novo
assembl
use
spade
lefs
use
obtain
molecular
marker
use
diagnosi
caudoviral
virus
mainli
virus
belong
myovirida
famili
found
pool
total
contig
could
associ
neonat
calf
diarrhea
identifi
avail
annot
databas
sequenc
belong
retrovirida
famili
found
predominantli
associ
dc
escherichia
phage
found
pool
compos
dc
group
hc
share
enterobacteria
phage
sensu
lato
dc
share
escherichia
coli
type
phage
result
demonstr
limit
knowledg
viral
sequenc
limit
exist
annot
dataset
detect
sequenc
associ
virus
could
support
hypothesi
gastrointestin
diseas
neonat
calv
consequ
complex
interact
sever
microorgan
gut
object
studi
evalu
util
digit
brix
refractomet
estim
serum
immunoglobulin
concentr
neonat
goat
blood
collect
alpin
goat
kid
hour
age
prior
receiv
colostrum
hour
age
receiv
colostrum
day
age
serum
harvest
protein
measur
use
digit
brix
refractomet
optic
refractomet
beckman
colorimetr
method
commerci
laboratori
linear
regress
correl
coeffici
analysi
perform
result
brix
x
optic
brix
x
laboratori
colorimetr
optic
x
laboratori
colorimetr
signific
relationship
three
serum
protein
analysi
method
high
degre
posit
correl
digit
brix
optic
refractomet
p
r
moder
posit
correl
laboratori
colorimetr
measur
digit
brix
p
r
optic
refractomet
p
r
regress
analysi
show
digit
brix
percentag
could
use
predict
serum
protein
gdl
thu
adequ
passiv
transfer
matern
immunoglobulin
digit
brix
refractomet
demonstr
util
estim
serum
immunoglobulin
assess
passiv
transfer
statu
goat
kid
surviv
rate
downer
cow
treat
farm
hospit
set
estim
identifi
prognost
indic
could
use
reduc
unnecessari
treatment
anim
poor
prognosi
primari
object
studi
predict
prognosi
associ
downer
cow
treat
referr
hospit
secondari
object
identifi
prognost
factor
associ
outcom
retrospect
studi
includ
recumb
dairi
cattl
older
month
present
case
inform
regard
histori
age
lactat
statu
durat
recumb
hospit
outcom
durat
number
day
flotat
therapi
diagnosi
blood
analysi
result
cbc
biochemistri
obtain
multivari
logist
regress
model
built
explor
associ
hematolog
biochemistri
paramet
surviv
overal
surviv
rate
cow
surviv
significantli
younger
recumb
shorter
period
time
lower
fibrinogen
valu
higher
neutrophil
count
arriv
cow
surviv
final
cow
surviv
significantli
lower
valu
ast
ck
bun
creatinin
phosphoru
higher
total
valu
arriv
cow
surviv
increas
fibrinogen
ast
creatinin
valu
significantli
associ
lower
odd
surviv
conclud
overal
surviv
rate
downer
cow
treat
flotat
therapi
approxim
histor
element
cbc
biochemistri
valu
use
select
case
better
chanc
surviv
macrolid
import
antimicrobi
may
use
agent
control
infecti
ovin
abort
econom
anim
health
human
health
impact
pregnant
ewe
given
singl
dose
tulathromycin
subcutan
drug
concentr
measur
fetal
plasma
matern
plasma
amniot
fluid
cathet
surgic
place
fetal
vasculatur
amnion
day
gestat
sampl
hour
administr
matern
plasma
sampl
collect
time
point
hour
serum
concentr
pharmacokinet
valu
ewe
similar
previous
report
ewe
tulathromycin
present
fetal
plasma
amniot
fluid
indic
therapeut
potenti
use
organ
compart
though
concentr
lower
found
matern
plasma
notabl
pharmacokinet
fetu
quit
differ
found
ewe
plasma
concentr
reach
plateau
hour
remain
concentr
remaind
sampl
period
hour
rais
question
drug
handl
metabol
fetu
bovin
respiratori
diseas
brd
remain
major
econom
problem
dairi
industri
aim
prevent
diseas
well
reduc
antimicrobi
use
warrant
evalu
potenti
altern
system
abl
inactiv
common
bacteri
viral
brd
pathogen
vitro
administr
oral
sodium
iodid
nai
significantli
increas
concentr
respiratori
fluid
dairi
calv
suggest
potenti
prevent
strategi
respiratori
diseas
object
studi
evalu
effect
oral
administ
nai
brd
treatment
frequenc
wean
weight
dairi
calv
femal
dairi
calv
age
day
hous
individu
hutch
ranch
central
california
use
studi
calv
divid
treatment
nai
oral
day
day
control
group
treatment
subset
calv
group
treatment
calv
control
calv
given
respiratori
ultrasound
score
day
baselin
day
medic
treatment
record
entir
studi
period
calv
weigh
wean
ultrasound
score
chang
ultrasound
score
baselin
respiratori
score
treatment
calv
day
significantli
higher
respect
control
calv
addit
higher
respiratori
ultrasound
score
treatment
calv
higher
odd
treat
respiratori
diseas
control
despit
appar
increas
respiratori
diseas
treatment
group
averag
daili
gain
wean
weight
differ
group
find
studi
support
use
oral
nai
prevent
strategi
respiratori
diseas
dairi
calv
among
differ
present
bovin
respiratori
diseas
activ
pneumonia
actp
defin
infect
lower
airway
sign
inflamm
import
diagnos
institut
appropri
treatment
thorac
ultrasonographi
tu
seem
promis
data
scant
regard
accuraci
diagnosi
actp
object
studi
estim
accuraci
tu
posit
maxim
depth
consolid
depth
compar
refer
test
wisconsin
clinic
respiratori
score
chart
crsc
posit
serum
haptoglobin
concentr
hap
posit
diagnosi
actp
calv
use
model
methodolog
lcm
one
popul
veal
calv
one
dairi
calv
enrol
tu
crsc
hap
imperfect
test
perform
day
calf
bilater
tu
perform
screen
mid
ventral
portion
lung
caudal
heart
caudal
site
well
right
parenchyma
cranial
heart
cranial
site
depth
tu
record
note
separ
caudal
cranial
site
accuraci
tu
estim
lcm
three
test
conduct
two
popul
actp
preval
popul
low
ad
cranial
site
littl
effect
tu
accuraci
use
depth
caudal
site
posterior
sensit
specif
median
estim
bci
bci
respect
observ
conclus
suggest
use
depth
caudal
heart
detect
actp
neonat
diarrhea
account
total
death
dairi
calv
studi
calv
investig
microbiota
impact
diarrhea
studi
character
fecal
microbiota
microbi
commun
identifi
possibl
relationship
microbiota
profil
health
statu
five
rotavir
diarrheic
calv
age
day
healthi
control
calv
enrol
viral
infect
confirm
fece
five
calv
without
e
coli
salmonella
cryptosporidium
coronaviru
infect
select
illumina
miseq
sequenc
use
sequenc
region
rrna
gene
signific
differ
commun
membership
structur
identifi
healthi
rotavir
diarrheic
clave
base
linear
discrimin
analysi
effect
size
lefs
repres
genera
lactobacillu
subdoligranulum
blautia
bacteroid
escherichia
clostridium
close
affili
rotavir
diarrhea
calv
result
present
provid
new
inform
regard
intestin
microbiota
rotavir
diarrhea
calv
associ
health
statu
fecal
microbi
divers
also
associ
diseas
statu
diarrhea
result
suggest
possibl
benefici
effect
lactobacillu
spp
health
growth
promis
ocular
squamou
cell
carcinoma
oscc
common
malign
neoplasia
beef
cattl
caus
signific
econom
loss
cattl
produc
genet
select
ocular
pigment
reduc
preval
certain
breed
surgic
excis
clean
margin
cur
lesion
difficult
manag
treatment
modal
case
radiat
therapi
photodynam
therapi
limit
tertiari
referr
hospit
recent
immunomodul
drug
approv
mix
mammari
carcinoma
dog
cat
sarcoid
hors
via
intralesion
inject
product
mycobacteri
cell
wall
extract
immunomodul
effect
work
immunotherapi
activ
natur
killer
cell
monocyt
macrophag
report
describ
use
two
matur
bovin
oscc
anim
consid
companion
anim
client
agre
would
enter
food
chain
buck
bull
examin
rapidli
grow
mass
lower
lid
medial
canthu
durat
extirp
perform
local
block
sedat
reoccurr
note
sutur
remov
mass
debulk
cryotherapi
appli
aggress
reoccurr
occur
within
two
week
total
four
intralesion
inject
administ
two
week
interv
month
therapi
bull
regress
oscc
bull
continu
well
reoccurr
time
month
first
appoint
longhorn
cow
examin
extens
ocular
periocular
mass
sever
month
durat
extirp
region
debulk
perform
gener
anesthesia
intralesion
inject
perform
initi
surgeri
twice
week
interv
initi
result
promis
howev
owner
report
longhorn
health
regress
difficulti
chew
hear
develop
head
tilt
could
see
remain
eye
extern
growth
surgic
site
found
dead
pastur
one
morn
three
month
initi
surgeri
limit
case
seri
hope
util
oscc
case
understand
treatment
agent
may
appropri
altern
treatment
econom
emot
valuabl
anim
consum
main
object
present
studi
evalu
efficaci
three
differ
dose
mycobacterium
cell
wall
fraction
mcwf
follow
intrauterin
iu
infus
chemoatract
dairi
cow
without
sign
clinic
endometr
addit
function
activ
polymorphonuclear
leukocyt
pmnl
attract
mcwf
measur
byreact
oxid
speci
ro
test
follow
uteru
lavagew
hypothesis
influx
function
pmnl
uteru
achiev
differ
mcwf
concentr
manner
follow
iu
administr
anticip
increas
presenc
activ
pmnl
would
benefici
effect
reproduct
perform
dairi
cow
reduc
incid
clinic
subclin
endometr
end
histolog
puerpuerium
thu
improv
concept
rate
studi
conduct
commerci
dairi
oper
milk
holstein
cow
experiment
studi
protocol
review
approv
institut
anim
care
committe
prior
studi
start
forti
lactat
cow
averag
day
postpartum
select
studi
purpos
inclus
criteria
includ
histori
easi
calv
retain
placenta
absenc
sign
clinic
endometr
averag
bodi
condit
score
scale
prior
mcwf
treatment
baselin
statu
uterin
line
determin
cytolog
examin
stain
slide
evalu
microscop
determin
percentag
pmnl
per
cell
follow
cytolog
assess
cow
randomli
assign
four
experiment
group
cow
per
group
day
cow
control
group
treat
iu
proven
pmnl
attract
dissolv
ml
nacl
anim
mcwf
group
receiv
iu
dose
either
mcwf
dilut
nacl
total
volum
hour
later
uterin
cytolog
sampl
spot
corpu
uteri
taken
subject
new
cytomorpholog
analysi
pmnl
count
addit
uterin
lavag
sampl
obtain
immedi
second
cytolog
sampl
pmnl
activ
analyz
sort
fac
use
commerci
kit
within
hour
post
collect
strength
respiratori
burst
oxid
burst
individu
cell
calcul
multipli
percentag
oxid
burst
posit
pmnl
mean
fluoresc
intens
mfi
use
follow
formula
obi
oxid
burst
posit
cell
mfi
data
subject
statist
analysi
use
anova
follow
multipl
comparison
test
none
cow
elev
pmnl
count
prior
treatment
determin
cytolog
post
treatment
pmnl
count
group
elev
howev
statist
signific
differ
note
group
receiv
ml
mcwf
p
p
respect
even
though
statist
signific
differ
observ
control
mcwf
group
trend
pmn
increas
increas
respect
p
p
compar
day
fac
analysi
ro
activ
reveal
similar
ro
experiment
group
control
mcwf
group
respect
calcul
obi
demonstr
cow
receiv
mcwf
highest
reaction
respect
compar
control
mcwf
data
reproduct
perform
show
cow
mcwf
group
cow
mcwf
control
group
pregnant
day
post
insemin
total
case
subclin
case
clinic
endometr
observ
mcwf
treat
cow
cow
control
group
diagnos
subclin
clinic
case
within
day
post
treatment
overal
mcwf
potenti
attract
signific
number
pmn
uteru
follow
iu
administr
mcwf
attract
pmn
stronger
oxid
burst
activ
could
lead
acceler
clearanc
case
postpartum
infect
dose
mcwf
appear
suffici
iu
administr
addit
larger
studi
underway
demonstr
efficaci
mcwf
dose
prevent
treatment
subclin
clinic
endometr
dairi
cow
pharmacokinet
drug
complex
novel
pharmacokinet
model
mammari
gland
provid
use
descript
process
contribut
time
cours
drug
milk
major
applic
milk
drug
pharmacokinet
determin
milk
discard
time
studi
util
dataset
describ
milk
pirlimycin
concentr
cow
clinic
mastiti
treat
dose
regimen
pirlimycin
milk
concentr
determin
triplic
microbiolog
method
milk
pirlimycin
concentr
volum
milk
product
milk
analyz
minim
pharmacokinet
model
model
includ
compart
quarter
predict
milk
pirlimycin
concentr
quarter
level
whole
gland
probabl
distribut
pharmacokinet
paramet
estim
use
method
monolix
hypothet
popul
cow
gener
use
mont
carlo
simul
milk
discard
time
determin
simul
popul
result
method
compar
method
recommend
regulatori
agenc
compar
milk
discard
time
gener
method
suggest
longer
milk
discard
time
necessari
cohort
cow
mastiti
predict
popul
method
sensit
rang
milk
product
volum
select
simul
novel
method
util
avail
data
includ
data
assay
quantif
limit
studi
demonstr
viabil
popul
model
estim
milk
discard
time
augment
innat
mucos
defens
mechan
iodin
effect
kill
bovin
bacteri
viral
respiratori
pathogen
vitro
could
valuabl
prevent
strategi
respiratori
diseas
dairi
calv
object
studi
determin
kinet
iodin
nasal
secret
follow
oral
administr
inorgan
iodin
nai
order
assess
feasibl
use
nai
prevent
bovin
respiratori
diseas
vivo
femal
holstein
calv
age
week
hous
davi
ca
use
prospect
clinic
studi
calv
consum
nai
ad
milk
baselin
sampl
blood
nasal
secret
collect
consecut
sampl
obtain
hour
sampl
submit
diagnost
lab
analysi
iodin
concentr
via
mass
spectrometri
iodin
concentr
significantli
elev
baselin
level
nasal
secret
p
serum
p
time
point
sampl
serum
nasal
fluid
iodin
concentr
peak
hour
serum
mean
concentr
nasal
fluid
mean
concentr
advers
effect
notic
calv
studi
show
oral
administr
nai
increas
iodin
concentr
airway
fluid
dairi
calv
effect
concentr
vitro
could
augment
upper
respiratori
defens
mechan
studi
need
determin
sodium
iodid
effect
prevent
strategi
respiratori
diseas
dairi
calv
object
retrospect
studi
describ
signal
histori
clinicopatholog
endoscop
ultrasonograph
radiograph
find
well
treatment
outcom
adult
cattl
diagnos
pharyng
lacerationtraumamed
record
cattl
month
age
admit
veterinari
teach
hospit
januari
januari
pharyng
perforationtrauma
identifi
oral
endoscop
examin
review
case
met
inclus
criteria
case
one
primari
complaint
dysphagia
swell
pharyng
area
twelv
cow
histori
administ
bolu
monensin
calcium
magnet
iodin
aspirin
vitamin
unknown
bolu
report
clinic
sign
includ
subcutan
emphysema
cow
swell
throatlatch
pain
palpat
nasal
discharg
foul
odour
nose
mouth
ptyalism
dyspnea
upper
respiratori
nois
oral
examin
find
report
cow
foreign
bodi
fb
monensin
bolu
lodg
pharynx
observ
cow
pharyng
lacer
without
fb
report
cow
endoscop
examin
perform
cow
fb
lodg
pharynx
observ
cow
cow
perfor
identifi
dorsal
aspect
pharynx
radiograph
neck
throatlatch
perform
cow
fb
detect
cow
rumensin
bolu
magnet
presenc
ga
either
subcutan
fascial
plane
emphysema
pharyng
region
soft
tissu
swell
pneumomediastinum
commonli
report
treatment
attempt
cow
manual
retriev
monensin
bolu
lodg
pharynx
possibl
cow
fb
observ
oral
exam
surgic
remov
fb
carri
cow
cow
monensin
bolu
retriev
magnet
cow
combin
antimicrobi
agent
analges
drug
administ
treat
cow
seventeen
cow
discharg
hospit
wherea
euthan
eight
surviv
cow
pharyng
trauma
associ
monensin
iodin
bolu
magnet
vitamin
bolu
unknown
bolu
cow
suffer
pharyng
trauma
associ
administr
calcium
bolu
euthan
due
sever
clinic
sign
pharyng
trauma
rare
condit
adult
cattl
caus
seriou
morbid
mortal
diagnos
treat
earli
success
treatment
appear
relat
natur
penetr
fb
primari
intraparenchym
brain
tumor
includ
astrocytoma
glioblastoma
oligodendroglioma
collect
compris
approxim
primari
brain
tumor
dog
prognosi
dog
tumor
type
gener
guard
poor
median
surviv
time
regardless
treatment
type
approxim
day
due
numer
challeng
associ
diagnos
grade
treat
report
surviv
outcom
current
gold
standard
therapi
tumor
dog
addit
similar
canin
human
primari
intraparenchym
brain
tumor
lend
translat
opportun
develop
novel
treatment
deliveri
system
canin
brain
tumor
glial
tumor
invad
migrat
along
white
matter
tract
blood
vessel
characterist
exploit
cathet
line
nanofib
particl
develop
structur
mimic
conduit
conform
guid
tumor
cell
away
tumor
site
extracrani
reservoir
studi
describ
techniqu
associ
implant
cathet
dog
natur
occur
histopatholog
confirm
astrocytoma
oligodendroglioma
purpos
studi
evalu
safeti
feasibl
insert
nanofib
cathet
confirm
tumor
cell
migrat
along
intern
cathet
wall
nanofib
cathet
placement
techniqu
evalu
four
dog
prosencephal
neoplasm
imag
characterist
consist
glioma
frameless
surgic
navig
system
stealthstat
surgic
navig
system
medtron
use
guid
cathet
fibercath
tumor
extract
devic
neurolab
small
standard
rostrotentori
craniectomi
window
tumor
center
cathet
placement
confirm
mri
evalu
one
month
reservoir
extract
replac
extract
reservoir
histolog
examin
evid
intralumin
tumor
cell
surgic
outcom
dog
good
microscop
evalu
extract
cathet
confirm
intralumin
tumor
cell
although
studi
small
prove
treatment
efficaci
find
support
hypothes
stereotact
guidanc
nanofib
cathet
safe
feasibl
encourag
tumor
cell
migrat
cranial
caviti
first
stage
larg
clinic
trial
ultim
aim
evalu
safeti
efficaci
nanofib
cathet
treatment
canin
brain
tumor
repetit
transcrani
magnet
stimul
rtm
safe
painless
procedur
appli
human
modifi
activ
specif
neural
circuit
brain
via
electromagnet
induct
magnet
field
gener
produc
small
electr
current
cortic
neuron
order
affect
neuron
function
antiepilept
effect
rtm
demonstr
human
epilepsi
therefor
random
clinic
trial
design
assess
efficaci
safeti
rtm
dog
idiopath
epilepsi
random
assign
treatment
placebo
group
dog
receiv
activ
sham
stimul
respect
dog
group
sedat
whole
procedur
use
anesthet
protocol
group
receiv
repetit
activ
sham
stimul
minut
per
day
five
consecut
day
total
efficaci
procedur
evalu
compar
monthli
seizur
frequenc
msf
monthli
seizur
day
frequenc
msdf
retrospect
period
prospect
period
three
month
sham
stimul
dog
placebo
group
also
receiv
treatment
advers
effect
complic
report
stage
five
dog
includ
four
treatment
one
placebo
group
treatment
group
median
msf
msdf
decreas
p
p
respect
show
statist
trend
potenti
interest
placebo
group
limit
sampl
size
n
permit
statist
current
stage
howev
dog
show
reduct
seizur
frequenc
follow
sham
stimul
seizur
frequenc
reduc
dog
receiv
activ
stimul
afterward
overal
procedur
seem
safe
signific
seriou
advers
effect
complic
report
conclus
preliminari
result
suggest
rtm
safe
procedur
might
decreas
median
msf
msdf
result
improv
seizur
manag
dog
epilepsi
howev
larger
number
dog
requir
group
definit
conclus
made
levetiracetam
lev
cat
approxim
hour
prompt
need
extend
releas
lev
formul
purpos
studi
describ
compar
pharmacokinet
plasma
csf
cat
singl
dose
approv
compound
use
design
nine
clinic
healthi
cat
receiv
singl
dose
mg
approv
po
thirteen
blood
csf
sampl
collect
hour
washout
period
studi
repeat
singl
oral
dose
mg
compound
lev
quantit
immunoassay
plasma
pool
csf
lev
concentr
versu
time
data
subject
noncompartment
pharmacokinet
analysi
data
compar
formul
use
pair
regardless
formul
csf
lev
close
mimick
plasma
concentr
signific
differ
p
formul
limit
plasma
cmax
ugml
approv
compound
tmax
approv
compound
hour
approv
compound
respect
formul
maintain
concentr
human
therapeut
refer
interv
least
hour
studi
demonstr
approv
compound
maintain
human
therapeut
lev
concentr
healthi
cat
hour
oral
administr
support
dose
interv
studi
also
demonstr
plasma
lev
monitor
use
accur
represent
csf
lev
concentr
cat
anatom
model
spine
essenti
surgic
plan
implant
evalu
biomechan
studi
cadav
spine
tradit
use
despit
acquisit
prepar
challeng
addit
model
easili
creat
replic
custom
specif
patient
purpos
studi
compar
print
spinal
model
spine
comput
tomograph
ct
imag
eventu
goal
replac
cadav
spine
hypothes
spatial
accuraci
print
stereolithograph
model
canin
thoracolumbar
vertebr
column
would
differ
cadaver
bone
thoracolumbar
vertebr
column
harvest
adult
canin
cadav
ct
scan
acquir
render
surfac
model
stereolithograph
model
gener
print
stereolithographi
printer
clear
methacryl
photoactiv
resin
cadaver
specimen
prepar
heat
soft
tissu
macer
uniform
measur
acquir
cadav
spine
ct
imag
model
measur
paramet
includ
vertebr
height
vertebr
foramen
height
vertebr
foramen
width
pedicl
width
vertebr
bodi
length
width
cranial
articular
process
width
transvers
process
repeat
measur
acquir
triplic
singl
investig
averag
valu
compar
use
linear
mix
model
random
effect
nest
individu
vertebra
signific
differ
individu
measur
vertebra
cadav
ct
scan
model
cohort
p
stereolithograph
model
canin
thoracolumbar
spine
spatial
accur
may
use
place
cadaver
spine
futur
veterinari
studi
steroid
respons
srma
common
inflammatori
neurolog
disord
dog
retrospect
studi
evalu
popul
north
american
dog
srma
explor
whether
breed
differ
exist
clinic
diseas
cours
treatment
respons
examin
caregiv
percept
effect
srma
qualiti
life
qol
medic
record
dog
present
nc
state
veterinari
hospit
identifi
akc
canin
health
foundat
survey
diagnosi
srma
base
result
cerebrospin
fluid
csf
analysi
review
caregiv
ask
complet
onlin
survey
evalu
impact
srma
dog
caregiv
qol
breed
repres
often
includ
golden
retriev
bernes
mountain
dog
wirehair
point
griffon
boxer
beagl
breed
differ
overal
sever
clinic
sign
csf
find
identifi
higher
csf
nucleat
cell
count
ncc
posit
correl
frequenc
diseas
relaps
p
associ
found
prednison
dose
durat
diseas
relaps
caregiv
percept
dog
qol
treatment
associ
sever
prednison
advers
effect
p
result
suggest
golden
retriev
wirehair
point
griffon
consid
among
breed
predispos
srma
treatment
higher
prednison
dose
correl
sever
advers
effect
wors
qol
appear
improv
clinic
outcom
relationship
csf
ncc
diseas
relaps
warrant
investig
purpos
prospect
clinic
trial
determin
whether
transderm
levetiracetam
lipoderm
vehicl
result
serum
concentr
mcgml
minimum
human
therapeut
interv
follow
day
everi
hour
administr
healthi
cat
identifi
advers
drug
reaction
administr
period
six
staff
student
own
healthi
cat
weigh
kg
enrol
cat
determin
healthi
base
physic
examin
neurolog
examin
pack
cell
volum
total
protein
evalu
serum
biochemistri
panel
appli
inner
pinna
dosag
mgkg
mgml
home
day
day
cat
hospit
serum
levetiracetam
sampl
peripher
venipunctur
time
prior
dose
administr
minut
post
administr
median
rang
time
serum
concentr
mcgml
respect
advers
event
limit
sedat
cat
day
studi
demonstr
thrice
daili
transderm
result
median
serum
concentr
mcgml
throughout
sampl
period
advers
event
minim
addit
studi
necessari
evalu
efficaci
transderm
epilept
cat
brain
tumor
specif
glioma
poor
prognosi
human
veterinari
medicin
new
treatment
need
improv
surviv
time
polycaprolacton
pcl
base
nanofib
line
cathet
repres
novel
biolog
devic
recent
develop
use
treatment
brain
tumor
dog
structur
cathet
shown
allow
tumor
growth
lumen
toward
extracrani
reservoir
outsid
brain
purpos
studi
determin
clinic
safeti
magnet
reson
imag
mri
characterist
associ
use
nanofib
line
cathet
implant
brain
ii
determin
degre
cellular
invas
cathet
reservoir
iii
determin
cerebr
patholog
associ
cathet
placement
healthi
dog
four
healthi
adult
femal
spay
beagl
dog
anesthet
underw
freehand
brain
implant
differ
pcl
base
nanofib
line
cathet
via
small
craniectomi
defect
side
skull
cathet
includ
standard
unlin
cathet
plu
cathet
vari
shape
cathet
standard
silicon
unlin
blunt
nose
ventricular
cathet
control
cathet
b
modifi
silicon
blunt
nose
ventricular
cathet
pcl
nanofib
insert
cathet
c
open
nose
polyurethan
cathet
pcl
nanofib
insert
cathet
blunt
nose
polyurethan
cathet
pcl
nanofib
insert
neurolog
examin
perform
prior
studi
daili
surgeri
standard
brain
mri
intraven
gadolinium
contrast
agent
perform
immedi
day
day
follow
surgeri
dog
human
euthan
histopatholog
analysi
brain
dog
transient
neurolog
sign
present
approxim
week
surgeri
mild
moder
weight
hyperintens
present
mri
like
repres
edema
secondari
inflamm
degre
chang
note
similar
cathet
type
chang
decreas
studi
period
markedli
reduc
day
mri
histopatholog
brain
sampl
found
variabl
amount
astrogliosi
malacia
gitter
cell
repres
inflamm
cathet
lumen
contain
neuropil
differ
degre
degener
malacia
chang
found
grey
white
matter
sever
region
variabl
degre
hemorrhag
associ
type
cathet
chang
sever
cathet
b
cathet
instig
mild
moder
inflamm
base
mri
histopatholog
associ
transient
neurolog
sign
consid
safe
follow
studi
studi
help
understand
expect
cathet
implant
intracrani
glioma
dog
investig
distribut
safeti
metronom
daili
chlorambucil
natur
occur
canin
glioma
eight
pet
dog
newli
diagnos
spontan
glioma
prospect
enrol
chlorambucil
administ
preoper
q
day
continu
postop
death
advers
event
chlorambucil
concentr
surgic
glioma
specimen
cerebrospin
fluid
serum
analyz
dog
addit
receiv
lomustin
postop
dog
monitor
seizur
myoclonu
cytopenia
tumor
recurr
seven
oligodendroglioma
astrocytoma
underw
complet
microsurg
resect
median
surgic
glioma
specimen
chlorambucil
concentr
ng
g
rang
ng
g
rang
serum
concentr
median
cerebrospin
fluid
concentr
ng
ml
rang
ng
ml
chlorambucil
associ
increas
seizur
activ
six
dog
display
prolong
interv
myoclonu
three
dog
develop
asymptomat
thrombocytopenia
month
chlorambucil
median
surviv
day
rang
day
median
overal
surviv
day
rang
day
presenc
intratumor
chlorambucil
indic
alter
blood
brain
barrier
vari
case
case
despit
sporad
previou
report
neurotox
prolong
interv
support
high
safeti
margin
dose
speci
metronom
chlorambucil
well
toler
ventriculoperiton
shunt
obstruct
major
complic
canin
human
hydrocephalu
howev
obstruct
typic
occur
chronic
set
order
develop
ventricular
cathet
hydrocephalu
model
prone
earli
shunt
obstruct
would
benefici
autolog
blood
inject
right
later
ventricl
kg
male
month
old
pig
termin
surviv
procedur
median
intraventricular
intracrani
pressur
mmhg
baselin
mmhg
peak
mmhg
minut
inject
ml
blood
caus
profound
hypertens
hydrocephalu
termin
procedur
first
surviv
pig
could
recov
anesthesia
use
ml
blood
hypertens
hydrocephalu
occur
pig
one
pig
subarachnoid
space
inadvert
inject
hydrocephalu
occur
biweekli
comput
tomographi
week
surviv
procedur
reveal
blood
inject
alon
fail
produc
persist
hematoma
wherea
inject
ml
blood
mix
unit
thrombin
produc
persist
obstruct
due
hematoma
six
pig
addit
treat
ventriculoperiton
shunt
shunt
obstruct
coagul
blood
pig
caus
profound
ventricular
dilat
evid
comput
tomographi
examin
acut
neurolog
deterior
occur
hour
day
fatal
pig
model
obstruct
hydrocephalu
prone
earli
shunt
obstruct
gener
kg
pig
later
ventricl
inject
ml
autolog
blood
thrombin
certain
benzimidazol
fenbendazol
mebendazol
demonstr
vitro
efficaci
glioma
cell
due
inhibit
tubulin
polymer
disrupt
microtubul
format
fenbendazol
produc
effect
mean
inhibitori
concentr
ngml
might
initi
target
therapeut
csf
concentr
studi
aim
describ
time
cours
fenbendazol
plasma
csf
oral
administr
dog
dose
design
target
csf
concentr
approach
ngml
fenbendazol
detect
canin
plasma
csf
use
high
perform
liquid
chromatographi
limit
detect
ngml
ngml
respect
fenbendazol
administ
two
dog
mgkg
detect
dog
subsequ
treat
mgkg
n
mgkg
n
due
advers
effect
result
averag
peak
plasma
concentr
ngml
respect
csf
concentr
detect
less
sampl
highest
csf
concentr
mgkg
ngml
min
howev
dog
given
mgkg
acut
onset
hematochezia
suggest
dose
high
may
clinic
appropri
studi
demonstr
plasma
fenbendazol
concentr
increas
dose
csf
concentr
well
target
ngml
even
mgkg
relev
target
concentr
efficaci
treatment
glioma
remain
determin
futur
studi
might
focu
potent
benzimidazol
mebendazol
vitro
lower
progress
myelomalacia
pmm
dire
complic
associ
acut
spinal
cord
injuri
intervertebr
disc
extrus
ivd
understand
pathophysiolog
diseas
limit
object
retrospect
studi
identifi
risk
factor
develop
pmm
compar
parapleg
dog
without
pain
percept
follow
ivd
develop
diseas
dog
acut
ivd
caus
paraplegia
loss
pain
percept
identifi
canin
spinal
cord
injuri
program
databas
search
medic
record
dog
categor
pmm
ye
base
clinic
progress
andor
histopatholog
signal
onset
durat
sign
categor
steroid
ye
drug
ye
spinal
cord
appear
surgeri
normal
abnorm
locat
lumbar
intumesc
thoracolumbar
amount
disc
materi
retriev
associ
pmm
examin
dog
dog
treat
surgic
use
logist
regress
two
hundr
eight
dog
met
inclus
criteria
histopatholog
confirm
presumpt
pmm
surgic
decompress
without
pmm
surgic
decompress
disc
extrus
lumbar
intumesc
p
longer
time
loss
ambul
surgeri
p
steroid
prior
present
p
significantli
associ
develop
pmm
conclud
dog
ivd
intumesc
increas
risk
pmm
time
surgeri
steroid
use
may
warrant
investig
aim
studi
determin
precis
novel
stereotact
brain
biopsi
devic
dog
canin
cadav
target
point
use
determin
accuraci
first
specif
bone
anchor
secur
canin
cadav
head
afterward
ct
mri
examin
head
perform
two
target
point
correspond
trajectori
defin
mri
left
caudat
nucleu
right
piriform
lobe
base
frame
includ
rigid
needl
placement
port
reach
defin
target
point
construct
print
needl
enter
brain
gyru
penetr
ventricl
frame
secur
bone
anchor
access
brain
creat
use
tool
guid
biopsi
needl
place
needl
placement
port
predetermin
depth
afterward
ct
examin
head
biopsi
needl
place
target
point
perform
needl
placement
error
determin
fusion
mri
ct
examin
error
defin
deviat
mm
needl
tip
anticip
target
point
total
median
needl
placement
error
target
point
mm
rang
outlier
median
needl
placement
error
caudat
nucleu
mm
rang
piriform
lobe
mm
rang
therefor
stereotact
brain
biopsi
devic
reach
higher
accuraci
describ
brain
biopsi
system
purpos
studi
surgic
extract
pituitari
gland
tissu
hors
transcrani
approach
possibl
treatment
option
pituitari
par
intermedia
dysfunct
ppid
ppid
also
known
cush
diseas
one
common
neuroendocrin
diseas
affect
age
hors
current
surgic
treatment
ppid
treatment
method
choic
pergolid
cyproheptadin
treatment
choic
human
dog
cush
diseas
surgic
remov
pituitari
gland
hypothes
intracrani
neurosurgeri
assist
neuronavig
would
allow
accur
extract
pituitari
gland
tissu
hors
studi
consist
total
cadav
hors
head
chosen
random
vari
age
year
old
magnet
reson
imag
mri
n
comput
tomographi
ct
perform
head
follow
imag
registr
neuronavig
biopsi
histopatholog
analysi
perform
sampl
pituitari
gland
tissu
found
sampl
submit
higher
contrast
resolut
mri
compar
ct
provid
improv
accuraci
pinpoint
acquir
pituitari
tissu
autom
tissu
resect
devic
system
show
increas
success
pituitari
tissu
harvest
compar
tradit
blunt
brain
biopsi
needl
success
pituitari
gland
thick
fibrou
capsul
make
use
blunt
biopsi
needl
inappropri
instrument
perform
pituitari
tissu
remov
futur
studi
aim
util
cadav
live
hors
confirm
ppid
ensur
safeti
efficaci
neuronavig
system
aim
studi
follow
morphometr
analysi
featur
associ
cavali
king
charl
spaniel
ckc
syringomyelia
sm
secondari
malform
cm
first
identifi
innov
machin
learn
techniqu
remov
human
bia
recent
studi
suggest
cm
complex
disord
origin
thought
affect
featur
associ
brachycephali
olfactori
bulb
rotat
rostral
flatten
forebrain
sagitt
dicom
anonym
imag
ckc
year
age
obtain
compris
dog
without
sm
wide
central
canal
dilat
ii
dog
sm
syrinx
width
morphometr
analysi
shape
posit
soft
palat
rel
skull
base
natur
rostral
skull
flatten
obtain
sm
dog
distanc
rostral
end
palat
sella
turcica
p
ii
foramen
magnum
basioccipit
p
significantli
reduc
maximum
distanc
palat
centroid
p
howev
reduc
distanc
brain
frontal
bone
highli
signific
p
reduct
distanc
olfactori
bulb
sella
turcica
may
interest
p
discrimin
analysislogist
regress
reveal
rostral
skull
flatten
domin
model
remov
ratio
maximum
distanc
palat
centroid
cerebr
height
cerebrum
height
highli
signific
p
characterist
ckc
sm
includ
osseou
insuffici
skull
chang
shape
soft
palat
implic
machin
learn
technolog
cavali
king
charl
spaniel
ckc
suffer
malform
cm
skull
malform
caus
crowd
caudal
fossa
syringomyelia
sm
affect
dog
show
sign
pain
frequent
show
lumbosacr
pain
tether
cauda
equina
report
peopl
cm
current
morphometr
data
caudal
aspect
vertebr
column
spinal
cord
ckc
purpos
studi
compar
locat
conu
medullari
ckc
breed
hypothes
spinal
cord
termin
caudal
ckc
retrospect
studi
conduct
dog
thoracolumbar
magnet
reson
imag
mri
dog
breed
group
ckc
brachycephal
control
mri
identifi
remov
blind
observ
termin
spinal
cord
determin
sagitt
axial
imag
lumbar
vertebra
sacrum
breed
reveal
analys
perform
among
ckc
spinal
cord
termin
sacrum
dog
compar
sacrum
control
spinal
cord
termin
significantli
caudal
ckc
compar
brachycephal
p
breed
p
differ
control
p
need
investig
whether
tether
cauda
equina
contribut
sign
pain
ckc
canin
cognit
dysfunct
ccd
common
neurobehavior
syndrom
age
dog
especi
japanes
dog
breed
shiba
polyunsatur
fatti
acid
pufa
includ
arachidon
acid
ara
eicosapentaeno
acid
epa
docosahexaeno
acid
dha
constitu
biolog
membran
nervou
tissu
epa
dha
synthes
acid
ala
convers
rate
lower
human
dog
make
prone
defici
human
report
high
erythrocyt
long
chain
fatti
acid
fa
level
appear
associ
better
cognit
function
later
life
lower
risk
cognit
declin
hand
activ
desaturas
desaturas
desaturas
metabol
epa
dha
precursor
report
lower
japanes
western
possibl
due
dietari
cultur
japanes
histor
ingest
epa
dha
directli
seafood
hypothes
japanes
dog
share
histor
similar
diet
japanes
may
lower
desaturas
activ
compar
western
dog
aim
pilot
studi
investig
composit
fa
erythrocyt
membran
plasma
evalu
desaturas
activ
japanes
dog
dog
prospect
studi
shiba
dog
without
ccd
dog
without
ccd
use
fa
pufa
pufa
monounsatur
pufa
satur
pufa
composit
erythrocyt
membran
plasma
measur
blood
sampl
use
ga
chromatographi
differ
shiba
dog
dog
evalu
use
wilcoxson
test
shiba
dog
significantli
lower
composit
epa
median
rang
dha
median
rang
total
fa
median
rang
erythrocyt
membran
compar
dog
median
rang
median
rang
median
rang
p
find
might
suggest
shiba
dog
lower
desaturas
activ
dog
high
incid
ccd
shiba
dog
may
associ
low
composit
fa
erythrocyt
membran
studi
fa
use
dog
unifi
diet
requir
clarifi
metabol
differ
japanes
dog
dog
elucid
associ
fa
ccd
famili
spontan
epilept
cat
fsec
strain
cat
suspect
genet
caus
epilepsi
fsec
coloni
consist
larg
multigener
pedigre
multipl
case
mode
inherit
undetermin
sinc
cat
differ
clinic
present
aim
studi
identifi
loci
influenc
suscept
epilepsi
use
genet
associ
analys
cat
includ
affect
unaffect
fsec
coloni
kindr
coloni
genotyp
use
illumina
infinium
iselect
felin
dna
array
singl
nucleotid
polymorph
snp
remap
felin
genom
assembl
consid
cat
trio
includ
nine
unaffect
parent
one
affect
offspr
five
trio
affect
individu
avail
transmiss
disequilibrium
test
tdt
tdt
indic
strongest
associ
diseas
snp
cat
chromosom
snp
locat
cat
chromosom
posit
mb
howev
signific
obtain
snp
cat
chromosom
also
indic
associ
among
snp
strongest
associ
gene
encod
zinc
finger
protein
present
furthermor
sever
potenti
candid
gene
harbor
suggest
region
detect
analysi
pedigre
diseas
present
fsec
includ
spontan
seizur
induc
seizur
abnorm
electroencephalogram
suggest
form
epilepsi
may
mode
inherit
although
tdt
reach
signific
method
linkag
analysi
whole
genom
sequenc
may
provid
addit
support
toy
breed
dog
overrepres
atlantoaxi
aa
instabl
radiographi
valuabl
howev
publish
toy
radiograph
measur
lack
diagnosi
remain
larg
subject
purpos
studi
establish
object
radiograph
criteria
diagnosi
aa
instabl
toy
breed
dog
neutral
later
ventrodors
radiograph
toy
breed
dog
control
affect
retrospect
review
median
overlap
distanc
overlap
spinou
process
dorsal
arch
mm
control
dog
mm
aa
case
overlap
mm
sensit
specif
radiograph
measur
diagnosi
aa
instabl
perform
three
rel
measur
atlantodent
interv
dorsal
atlantodent
interv
ratio
adidadi
ratio
rel
den
length
angl
three
rel
measur
good
specif
respect
lower
sensit
influenc
bodi
weight
p
absolut
measur
eg
absolut
den
length
atlantoaxi
distanc
significantli
correl
bodi
weight
p
util
diagnosi
aa
instabl
could
establish
decreas
overlap
strongli
support
aa
instabl
adidadi
ratio
rel
den
length
angl
may
provid
support
may
normal
individu
case
vagal
nerv
stimul
valid
treatment
form
refractori
epilepsi
statu
epilepticu
human
medicin
well
migrain
headach
invas
form
use
includ
transcutan
stimul
nerv
affer
vagal
nerv
fiber
project
larg
number
cortic
subcort
locat
brain
exert
inhibitori
effect
lead
widespread
decreas
excit
chang
induc
littl
minut
treatment
everi
hour
properti
exploit
vagal
stimul
seizur
manag
purpos
studi
evalu
efficaci
vagal
nerv
stimul
adjunct
treatment
refractori
idiopath
epilepsi
dog
devic
use
hand
held
gammacor
vet
transcutan
stimul
client
own
dog
recruit
multipl
locat
unit
state
dog
month
histori
seizur
minimum
frequenc
seizur
per
month
week
prior
studi
maintain
either
phenobarbit
andor
potassium
bromid
least
month
dog
randomli
assign
group
group
case
receiv
week
continu
treatment
group
case
receiv
week
treatment
follow
week
treatment
devic
dog
receiv
second
treatment
everi
hour
devic
held
area
shave
skin
coupl
gel
cervic
region
approxim
region
nerv
thirteen
case
recruit
multipl
institut
recruit
dog
age
year
age
normal
neurolog
examin
dog
receiv
either
phenobarbit
potassium
bromid
recruit
case
bloodwork
perform
prior
studi
show
serum
concentr
antiepilept
medic
within
accept
rang
seizur
frequenc
vari
dog
experienc
frequent
solitari
seizur
other
experienc
cluster
seizur
episod
dog
experienc
gener
focal
seizur
mean
pre
trial
seizur
frequenc
group
calcul
group
seizur
everi
day
group
seizur
everi
day
overal
mean
post
trial
seizur
frequenc
group
decreas
group
seizur
everi
day
group
seizur
everi
day
side
effect
limit
dog
experienc
increas
seizur
frequenc
dog
display
neg
avers
behavior
devic
appli
conclus
treatment
modal
repres
possibl
addit
treatment
refractori
epilept
dog
limit
side
effect
cervic
spondylomyelopathi
csm
high
preval
great
dane
order
understand
progress
osseou
chang
aim
perform
clinic
comput
tomograph
ct
studi
great
dane
dog
without
csm
great
dane
previous
diagnos
csm
clinic
normal
great
dane
previous
enrol
prospect
studi
clinic
ct
studi
least
month
diagnosi
twelv
dog
investig
six
six
normal
median
time
ct
studi
month
csm
dog
month
normal
dog
morpholog
morphometr
assess
perform
ct
studi
morpholog
assess
evalu
vertebr
canal
stenosi
classifi
ventral
dorsal
later
combin
regular
degre
prolifer
articular
process
presenc
absenc
foramin
stenosi
also
record
morphometr
assess
includ
vertebr
canal
area
three
separ
locat
per
disc
space
foramin
height
ct
three
dog
develop
new
site
stenosi
three
site
total
wherea
two
clinic
normal
dog
develop
new
lesion
five
site
total
disc
space
commonli
affect
new
site
foramin
stenosi
note
two
four
clinic
normal
group
morphometr
evalu
show
statist
signific
differ
initi
ct
studi
normal
group
studi
observ
develop
compress
lesion
occur
group
major
dog
develop
new
lesion
nerv
growth
factor
ngf
known
major
factor
neuron
plastic
therefor
expect
neuron
plastic
ngf
gene
therapi
neuropath
dog
experi
twelv
dog
divid
group
control
n
therapi
group
n
gene
therapi
group
n
ngf
gene
transfect
perform
intrathec
inject
gene
therapi
group
hour
later
pyridoxin
mgkg
sid
day
inject
subcutan
therapi
group
gene
therapi
group
induc
neuropathi
evalu
impact
ngf
gene
therapi
dorsal
root
ganglia
drg
damag
tubulin
doublecortin
dcx
antigen
chondroitin
sulfat
proteoglycan
cspg
immunohistochem
stain
perform
number
tubulin
immunoreact
neuron
decreas
significantli
therapi
group
compar
control
group
ngf
gene
therapi
amelior
decreas
tubulin
immunoreact
cell
dorsal
root
ganglia
drg
neuron
death
similarli
number
dcx
immunoreact
cell
decreas
significantli
therapi
group
compar
control
group
addit
dcx
immunoreact
therapi
group
concentr
center
drg
neuron
dcx
immunoreact
gene
therapi
group
show
similar
distribut
pattern
dcx
immunoreact
neuron
control
group
control
group
cspg
immunoreact
found
sciatic
nerv
non
gene
therapi
group
cspg
immunoreact
similarli
detect
sciatic
nerv
compar
control
group
ngf
gene
therapi
significantli
increas
express
cspg
sciatic
nerv
compar
non
gene
therapi
group
ngf
gene
therapi
could
power
therapeut
agent
damag
drg
recov
dcx
express
drg
cspg
sciatic
nerv
tradit
cervic
spondylomyelopathi
csm
classifi
form
howev
dog
suffer
form
thoroughli
evalu
goal
report
mri
find
associ
singl
osseou
disc
ligament
compress
dog
diagnos
csm
retrospect
review
magnet
reson
imag
mri
case
previous
diagnos
csm
inclus
criteria
diagnosi
csm
use
mri
presenc
compress
two
direct
locat
compress
lesion
sever
compress
lesion
direct
compress
dorsal
ventral
later
combin
presenc
spinal
cord
hyperintens
record
dog
met
inclus
criteria
doberman
great
dane
major
older
year
age
male
forti
two
dog
dorsal
ventral
spinal
cord
compress
level
also
spinal
cord
compress
one
site
seven
dog
circumferenti
spinal
cord
compress
sever
compress
lesion
spinal
cord
hyperintens
imag
present
dog
find
indic
sizeabl
portion
dog
suffer
combin
compress
import
routin
care
evalu
cervic
level
make
sure
overlook
high
proport
spinal
cord
hyperintens
may
suggest
repres
sever
form
diseas
granulomat
meningoenceph
gme
necrot
meningoenceph
nme
common
idiopath
inflammatori
diseas
central
nervou
system
cn
dog
long
assum
disord
system
medic
therapi
combin
glucocorticoid
immunosuppress
agent
current
mainstay
treatment
due
lack
understand
exact
treatment
mechan
howev
depend
convent
immunosuppress
seriou
advers
side
effect
well
recogn
tyrosin
kinas
tk
play
import
role
pathogenesi
malign
tumor
activ
research
target
therapi
use
tyrosin
kinas
inhibitor
tki
oncolog
area
recent
role
tk
tki
autoimmun
disord
investig
numer
anim
model
human
medicin
object
studi
evalu
express
multipl
tk
mue
tissu
determin
possibl
use
multitarget
tki
treatment
canin
mue
section
gme
nme
total
dog
sampl
use
studi
stain
carri
use
standard
immunohistochem
procedur
develop
use
formalin
fix
tissu
immunohistochem
evalu
assess
stain
posit
tk
stain
intens
distribut
tk
posit
cell
overal
stain
intens
grade
immunostain
weak
immunostain
moder
intens
immunostain
magnif
distribut
posit
stain
cell
cell
affect
evalu
five
separ
field
magnif
grade
follow
sampl
stain
posit
major
sampl
exhibit
rel
intens
stain
broad
distribut
larg
number
sampl
also
weak
moder
stain
variou
distribut
identifi
rel
moder
stain
intens
distribut
sampl
show
weak
restrict
statist
signific
associ
gme
ne
sampl
term
tk
express
p
known
target
convent
multitarget
tki
express
canin
gme
nme
studi
tk
could
involv
key
aspect
pathogenesi
autoimmun
enceph
especi
may
import
role
biolog
activ
diseas
base
proof
target
therapi
tk
may
potenti
new
treatment
modal
gme
nme
electron
von
frey
anesthesiometri
vfa
previous
report
laboratori
other
use
method
mechan
quantit
sensori
test
qst
evalu
neuropath
pain
dog
intraobserv
agreement
previous
shown
good
excel
howev
interobserv
agreement
previous
report
vital
use
techniqu
multicent
veterinari
clinic
trial
neuropath
pain
goal
studi
evalu
interobserv
agreement
sensori
threshold
obtain
use
electron
vfa
group
normal
small
breed
dog
twenti
healthi
dog
recruit
gener
practic
popul
ohio
state
univers
veterinari
medic
center
three
novic
evalu
use
electron
von
frey
devic
iitc
system
measur
mechan
sensori
threshold
st
train
session
conduct
expert
evalu
dog
evalu
three
investig
day
evalu
limb
test
order
random
test
session
separ
minut
mean
st
valu
averag
four
limb
produc
singl
valu
per
dog
comparison
evalu
agreement
evalu
determin
use
correl
coeffici
icc
model
consist
singl
measur
icc
across
three
evalu
indic
moder
agreement
moder
interobserv
agreement
like
suffici
support
use
techniqu
clinic
trial
result
underscor
import
use
singl
evalu
qst
techniqu
canin
neuropath
pain
studi
idiopath
epilepsi
ie
chronic
brain
diseas
caus
epilept
seizur
human
serum
csf
trace
element
profil
chang
ie
patient
previou
studi
suggest
supplement
trace
element
improv
refractori
ie
human
current
report
trace
element
profil
dog
ie
therefor
purpos
studi
determin
trace
element
profil
ie
dog
dog
ie
recruit
june
may
hokkaido
univers
veterinari
teach
hospit
healthi
dog
laboratori
beagl
use
serum
control
csf
control
respect
serum
csf
trace
element
concentr
copper
selenium
rubidium
molybdenum
tin
median
rang
measur
induct
coupl
spectrometri
trace
element
concentr
ie
dog
compar
control
ie
dog
classifi
respond
respons
drug
month
later
start
treatment
trace
element
concentr
respond
compar
ten
dog
ie
enrol
studi
dog
ie
significantli
lower
serum
tin
concentr
ie
control
higher
csf
copper
concentr
ie
control
higher
csf
selenium
concentr
ie
control
signific
differ
trace
element
concentr
respond
howev
dog
sever
refractori
seizur
show
lowest
serum
tin
concentr
high
csf
copper
concentr
result
indic
serum
csf
trace
element
profil
ie
dog
differ
healthi
dog
studi
conduct
clarifi
correl
respons
drug
trace
element
profil
mri
find
evalu
variabl
success
predict
prognosi
dog
spinal
cord
injuri
sci
human
sci
magnet
transfer
mt
diffus
tensor
imag
dti
provid
quantit
valu
correl
neurolog
dysfunct
dog
fail
recov
hypothes
mt
ratio
mtr
would
significantli
higher
fraction
anisotropi
fa
axial
diffus
ad
mean
diffus
md
would
significantli
lower
prospect
studi
consist
dog
ivdh
confirm
mri
surgeri
imag
perform
use
mri
mt
dti
imag
obtain
follow
convent
sequenc
mtr
fa
ad
md
calcul
use
open
sourc
softwar
dog
follow
week
assess
clinic
outcom
via
modifi
frankel
score
statist
analysi
recov
group
compar
use
wilcoxon
sign
rank
test
p
median
rang
mtr
fa
ad
md
group
detail
tabl
statist
differ
mtr
fa
note
group
ad
md
significantli
lower
dog
recov
find
support
quantit
imag
surrog
axon
integr
may
import
prognost
indic
dog
sci
mast
cell
tumor
mct
common
cutan
neoplasm
dog
third
common
intestin
tumor
cat
incid
worldwid
mast
cell
granul
contain
mediat
vasoact
amin
potenti
sequela
mast
cell
degranul
includ
anaphylaxi
gastrointestin
gi
ulcer
patient
mct
treat
acid
suppress
includ
receptor
antagonist
proton
pump
inhibitor
ppi
prevent
gi
ulcer
acid
suppress
ph
independ
effect
includ
alter
leukocyt
cytokin
product
modul
cell
number
function
chang
mast
cell
degranul
abil
mast
cell
granul
requir
acid
ph
contain
atpas
achiev
acid
vacuolar
atpas
relat
h
k
atpas
gastric
pariet
cell
thu
ppi
may
impact
mct
function
surviv
effect
acid
suppress
notabl
ppi
mast
cell
fulli
explor
use
previous
valid
vitro
rat
mast
cell
line
mous
bone
marrow
deriv
mast
cell
bmmc
central
object
evalu
effect
famotidin
ppi
esomeprazol
treatment
mast
cell
degranul
granul
morpholog
cell
death
mast
cell
degranul
cell
death
assess
use
flow
cytometr
assay
respect
chang
granul
morpholog
evalu
via
light
ultrastructur
microscopi
degranul
percentag
cell
significantli
increas
treat
esomeprazol
p
anova
post
hoc
famotidin
vehicl
treatment
structur
chang
observ
acid
suppress
pronounc
esomeprazol
acid
suppress
treatment
alter
mast
cell
degranul
viabil
structur
morpholog
vitro
ppi
pronounc
effect
ongo
work
assess
effect
acid
suppress
therapi
mast
cell
tumor
dog
cat
toceranib
phosphat
tyrosin
kinas
inhibitor
tki
frequent
use
veterinari
medicin
treatment
number
tumor
type
despit
studi
demonstr
lower
dose
toceranib
mgkg
everi
day
provid
drug
exposur
suffici
target
inhibit
reduc
frequenc
advers
event
gastrointestin
gi
toxic
continu
commonli
encount
side
effect
dog
receiv
toceranib
dose
degre
toxic
variabl
among
individu
dog
current
clinic
molecular
marker
identifi
dog
would
benefit
use
concomit
medic
prevent
gi
toxic
critic
develop
gi
toxic
significantli
impact
patient
morbid
qualiti
life
decreas
treatment
intens
increas
cost
treatment
lead
discontinu
therapi
cytokeratin
member
intermedi
filament
famili
cytoskelet
protein
highli
express
epitheli
cell
notabl
gastrointestin
mucos
epithelium
epitheli
cell
undergo
necrosi
andor
apoptosi
releas
fragment
detect
bodili
fluid
serum
plasma
human
circul
level
shown
potenti
clinic
util
prognost
predict
biomark
number
solid
hematopoiet
tumor
type
data
human
lymphoma
studi
indic
serum
level
increas
follow
cytotox
chemotherapi
high
express
correl
patient
experienc
epitheli
toxic
suggest
circul
may
potenti
util
predict
biomark
earli
gastrointestin
toxic
given
lack
clinic
relev
biomark
earli
detect
gi
toxic
veterinari
patient
receiv
drug
object
studi
determin
plasma
level
dog
cutan
subcutan
mast
cell
tumor
mct
receiv
toceranib
therapi
refer
understand
relev
chang
detect
earli
gi
toxic
blood
collect
healthi
dog
year
age
medic
histori
gastrointestin
diseas
recent
gastrointestin
sign
includ
vomit
diarrhea
establish
refer
rang
plasma
level
healthi
control
anim
twenti
five
dog
histopatholog
diagnosi
cutan
subcutan
mct
evid
gross
andor
metastat
diseas
time
evalu
enrol
patient
treat
toceranib
mgkg
eod
receiv
omeprazol
mgkg
sid
dog
receiv
concurr
prednison
andor
concomit
medic
plasma
collect
treatment
dog
day
day
day
day
day
instruct
record
gastrointestin
clinic
sign
day
period
advers
event
ae
defin
grade
accord
publish
criteria
plasma
measur
obtain
control
dog
treat
dog
studi
timepoint
use
commerci
avail
canin
immunosorb
assay
elisa
kit
detect
neobiolab
determin
plasma
vegf
concentr
treat
dog
perform
timepoint
use
canin
vegf
quantikin
elisa
kit
r
system
surrog
biomark
pathway
inhibit
toceranib
preliminari
data
indic
baselin
plasma
level
increas
dog
diagnosi
cutan
subcutan
mct
compar
healthi
control
anim
interestingli
baselin
level
elev
treat
dog
observ
declin
level
period
studi
plasma
concentr
appear
plateau
day
chang
plasma
correl
advers
effect
andor
grade
howev
dog
experienc
gastrointestin
toxic
mild
dog
experienc
grade
gastrointestin
toxic
experienc
grade
ii
toxic
experienc
grade
iii
toxic
patient
experienc
grade
iv
greater
gastrointestin
toxic
studi
despit
small
number
subject
assess
current
studi
data
suggest
plasma
suitabl
biomark
earli
detect
gastrointestin
toxic
dog
howev
investig
fulli
assess
predict
valu
circul
detect
earli
gi
toxic
larger
cohort
patient
requir
gene
mutat
variou
canin
tumor
explor
canin
histiocyt
sarcoma
hs
mutat
gene
report
frequent
observ
howev
report
comprehens
analysi
gene
mutat
canin
hs
object
studi
conduct
comprehens
analysi
mutat
protein
code
gene
dog
hs
whole
exom
sequenc
genom
dna
extract
tumor
tissu
three
dog
histolog
diagnos
hs
analysi
germlin
dna
sequenc
genom
dna
also
extract
normal
tissu
peripher
blood
dog
whole
exom
sequenc
perform
use
illumina
nextseq
align
process
read
canin
refer
genom
canfam
carri
use
genom
analysi
toolkit
varscan
use
call
somat
variant
dog
snpeff
use
annot
variant
extract
somat
variant
filter
read
depth
put
impact
gene
function
variant
gene
known
associ
pathogenesi
human
tumor
valid
use
sanger
sequenc
whole
exom
sequenc
gener
mean
read
depth
uniqu
read
could
map
canin
refer
genom
averag
analysi
data
variant
gene
variant
gene
variant
gene
extract
somat
mutat
dog
respect
variant
mutat
dog
pdgfrb
dog
dog
confirm
sanger
sequenc
studi
reveal
somat
mutat
pdgfrb
gene
canin
hs
previous
report
high
incid
gene
mutat
canin
hs
report
interact
target
mapkerk
pathway
shown
induc
protein
tyrosin
kinas
activ
mapkerk
pathway
fig
although
studi
need
know
frequenc
gene
mutat
find
obtain
present
studi
lead
introduct
molecular
target
therapi
direct
mapkerk
pathway
canin
hs
combin
chemotherapi
cyclophosphamid
doxorubicin
vincristin
prednison
chop
standard
treatment
dog
diffus
larg
lymphoma
dlbcl
chop
afford
durabl
cancer
remiss
dog
dlbcl
dog
benefit
minim
therapi
current
method
prognost
assess
adequ
discrimin
dog
deriv
signific
benefit
chop
howev
biodynam
imag
bdi
novel
imag
technolog
measur
chang
intracellular
motion
induc
within
live
tissu
drug
treatment
shown
promis
mean
predict
tumor
sensit
chemotherapi
previous
show
bdi
perform
ex
vivo
tumor
biopsi
tissu
dog
lymphoma
accur
predict
vivo
respons
doxorubicin
purpos
studi
expand
use
bdi
predict
clinic
outcom
chop
chemotherapi
dog
dlbcl
dog
substag
dblcl
enrol
prospect
clinic
trial
time
studi
enrol
dog
underw
standard
stage
test
surgic
lymph
node
biopsi
provid
tissu
histopatholog
immunohistochem
confirm
dlbcl
dog
subsequ
receiv
treatment
previous
describ
chop
chemotherapi
protocol
primari
clinic
outcom
interest
surviv
pf
defin
time
day
initi
chop
chemotherapi
detect
measur
diseas
progress
death
due
caus
whichev
came
first
time
enrol
portion
dog
lymph
node
biopsi
approxim
reserv
ex
vivo
bdi
within
hour
biopsi
collect
tissu
process
sever
small
fragment
approxim
size
fragment
immobil
well
plate
treat
ex
vivo
doxorubicin
vincristin
prednisolon
well
drug
combin
tissu
sampl
treat
dmso
serv
neg
control
chang
intracellular
motion
follow
ex
vivo
drug
treatment
record
tissu
sampl
dog
approxim
hour
follow
biopsi
collect
machin
learn
classifi
develop
analyz
intracellular
tumor
respons
measur
bdi
associ
respons
poor
favor
clinic
respons
base
upon
pf
classifi
train
approach
first
data
set
dog
ad
data
remain
dog
process
repeat
enrol
dog
clinic
outcom
follow
chop
chemotherapi
evalu
dog
best
object
respons
chemotherapi
complet
remiss
dog
partial
remiss
dog
surviv
time
rang
day
pf
time
studi
popul
segreg
day
day
n
group
machin
learn
classifi
correctli
predict
assign
dog
appropri
group
case
classifi
consist
assign
one
dog
low
pf
day
incorrectli
group
result
suggest
possibl
import
applic
bdi
method
predict
respons
cancer
chemotherapi
drug
purpos
studi
examin
associ
sdma
concentr
dog
cat
differ
type
neoplasia
idexx
laboratori
patholog
databas
use
identifi
case
lymphoma
hemangiosarcoma
mammari
carcinoma
mammari
adenocarcinoma
lipoma
dog
lymphoma
viscer
mast
cell
tumor
cat
potenti
case
need
serum
sdma
creatinin
measur
within
prior
diagnosi
control
anim
randomli
select
clinic
laboratori
databas
dog
cat
case
sdma
creatinin
concentr
compar
case
control
cancer
type
sdma
concentr
significantli
higher
dog
cat
lymphoma
p
significantli
lower
dog
lipoma
mammari
adenocarcinoma
mammari
carcinoma
p
compar
control
creatinin
concentr
significantli
lower
dog
mammari
adenocarcinoma
mammari
carcinoma
cat
lymphoma
compar
control
odd
ratio
confid
interv
ci
calcul
determin
associ
sdma
tumor
type
tabl
result
indic
cat
dog
case
lymphoma
associ
increas
sdma
concentr
larg
portion
case
concurr
creatinin
concentr
within
refer
interv
although
etiolog
increas
sdma
concentr
case
determin
sdma
may
earli
marker
renal
involv
reduc
gfr
recent
diagnos
case
lymphoma
diarrhoea
cid
advers
event
associ
administr
cytotox
anticanc
drug
dog
mani
case
chemotherapi
reduc
qualiti
life
qol
patient
prejudic
prognosi
concurr
treatment
probiot
may
support
function
intestin
microbiota
reduc
preval
sever
cid
assess
impact
probiot
treatment
preval
sever
cid
randomis
crossov
trial
perform
dog
cancer
schedul
receiv
doxorubicin
dog
receiv
treatment
day
start
day
doxorubicin
administr
either
probiot
formul
contain
enterococcu
faecium
ncimb
x
cfu
placebo
cid
assess
form
develop
daili
complet
owner
five
day
start
four
day
treatment
doxorubicin
score
calcul
describ
sever
event
addit
qualiti
life
qol
assess
form
develop
assess
qol
dog
treatment
period
faecal
sampl
collect
administr
doxorubicin
treatment
probiot
placebo
faecal
dna
extract
quantit
polymeras
chain
reaction
develop
detect
quantifi
presenc
specif
probiot
strain
fifti
dog
recruit
took
probiot
formul
placebo
took
either
product
seven
dog
die
cancer
remov
trial
leav
case
evalu
faecal
consist
describ
abnorm
dog
probiot
group
placebo
group
faecal
frequenc
increas
dog
probiot
group
placebo
group
differ
diarrhoea
event
score
whilst
dog
took
either
trial
product
p
addit
differ
qol
score
trial
period
signific
correl
qol
diarrhoea
score
qol
consid
wors
diarrhoea
sever
p
also
signific
correl
qol
tumour
type
dog
lymphoma
describ
significantli
wors
qol
compar
dog
sarcoma
carcinoma
p
probiot
bacteria
could
detect
faec
dog
n
whilst
took
probiot
formul
four
dog
seven
day
treatment
stop
independ
suggest
transient
colonis
gastrointestin
tract
period
probiot
therapi
data
clearli
indic
cid
reduc
qol
qualiti
life
well
preval
sever
cid
improv
treatment
e
faecium
ncimb
day
pathogen
capac
feli
catu
gammaherpesviru
common
infect
domest
cat
unknown
explor
possibl
role
felin
lymphoma
retrospect
studi
carri
dna
ffpe
biopsi
andor
whole
blood
lymphoma
case
exclud
small
cell
tumor
diagnos
histopatholog
n
cytolog
n
test
viral
dna
control
dna
deriv
pair
autolog
uninvolv
ffpe
tissu
n
ffpe
lymph
node
n
whole
blood
n
case
result
viral
test
signal
epidemiolog
data
treatment
receiv
record
neither
molecular
diagnosi
viru
load
relat
outcom
lymphoma
case
compar
control
match
age
sex
molecular
analysi
dna
pair
autolog
uninvolv
tissu
suggest
restrict
dna
tumour
tissu
dnaemia
associ
significantli
shorter
surviv
lymphoma
case
p
observ
could
adequ
explain
differ
treatment
receiv
addit
histori
fight
cat
roam
identifi
novel
epidemiolog
risk
factor
detect
lend
support
aggress
potenti
rout
viru
transmiss
futur
studi
address
viru
localis
express
neoplast
cell
indic
assist
rule
lymphomagen
role
prospect
investig
dnaemia
neg
prognost
marker
felin
lymphoma
warrant
survivin
highli
express
variou
malign
function
inhibitor
apoptosi
small
molecul
potent
inhibitori
activ
survivin
therefor
consid
potenti
new
class
agent
current
studi
screen
variou
canin
tumor
cell
line
suscept
basi
screen
focus
squamou
cell
carcinoma
scc
growth
inhibitori
mechan
scc
cell
investig
among
ten
cell
line
eight
tumor
type
screen
scc
cell
line
show
substanti
suscept
base
find
seven
canin
scc
cell
line
examin
suscept
cytotox
effect
clearli
inhibit
growth
two
cell
line
happi
cell
line
cell
line
highli
express
survivin
happi
cell
inhibit
express
survivin
mrna
protein
level
contrast
survivin
express
protein
level
cell
moreov
suppress
cell
growth
mostli
induct
apoptosi
happi
cell
cell
result
suggest
canin
scc
high
cellular
express
survivin
suscept
survivin
inhibitor
differ
mechan
suppress
survivin
express
name
transcript
level
moreov
found
induc
growth
inhibit
scc
cell
induct
apoptot
cell
death
also
cell
death
use
nanoparticl
possibl
cancer
therapi
intrigu
potenti
studi
current
progress
explor
use
immunotherapi
target
therapi
deliveri
thermal
ablat
pilot
studi
employ
nanoparticl
consist
silicon
gold
due
uniqu
natur
nanoparticl
design
vibrat
expos
appropri
wavelength
light
gener
control
target
heat
hypothesi
heat
gener
laser
light
induc
nanoparticl
vibrat
caus
cancer
cell
death
therebi
provid
definit
therapi
low
grade
mast
cell
tumor
eighteen
low
grade
mast
cell
tumor
cm
random
either
treatment
control
group
dog
receiv
benadryl
hour
pepcid
ac
hour
day
one
dog
receiv
hour
iv
infus
nanoparticl
day
two
treatment
group
dog
light
therapi
appli
tumor
use
diod
laser
nm
dog
evalu
week
four
week
monthli
data
collect
includ
signal
tumor
size
therapi
applic
respons
therapi
durat
respons
toxic
laser
treat
dog
respond
clinic
remiss
one
month
laser
therapi
three
dog
recurr
month
therapi
seriou
long
term
toxic
note
dog
conclus
nanoparticl
laser
ablat
therapi
effect
treat
low
grade
mast
cell
tumor
low
risk
toxic
canin
osteosarcoma
osa
common
primari
bone
tumour
dog
chemotherapi
delay
metastasi
yet
dog
succumb
within
one
year
diagnosi
recent
studi
show
certain
chemotherapeut
sequest
within
acid
endosom
lead
chemoresist
furthermor
high
metabol
demand
cancer
cell
result
preferenti
glycolyt
shift
lead
tumor
acidosi
amilorid
diuret
among
class
proton
pump
inhibitor
prescrib
veterinari
cardiologist
refractori
heart
failur
studi
hypothes
amilorid
sensit
canin
osa
cell
carboplatin
doxorubicin
reduc
sequestr
within
acid
endosom
assess
cell
viabil
apoptosi
perform
three
osa
cell
line
singl
agent
combin
treatment
synerg
combin
evalu
combin
index
ci
calcul
metabol
profil
extracellular
acidif
rate
ecar
oxygen
consumpt
rate
ocr
perform
immunoblot
use
evalu
apoptot
protein
express
amilorid
sensit
canin
osa
cell
doxorubicin
ci
carboplatin
ci
combin
therapi
consist
find
combin
treatment
doxorubicin
significantli
increas
late
apoptosi
p
decreas
necrosi
p
osa
cell
compar
treatment
doxorubicin
alon
cell
treat
amilorid
upregul
protein
involv
apoptosi
downregul
surviv
energet
stress
test
demonstr
metabol
switch
less
glycolyt
phenotyp
signific
decreas
ecar
p
safeti
profil
amilorid
likelihood
synerg
doxorubicin
may
justifi
drug
repurpos
clinic
trial
evalu
canin
osa
transit
cell
carcinoma
tcc
account
canin
malign
tumor
occur
urinari
bladder
prognosi
poor
previou
studi
use
rna
sequenc
show
oncogen
human
epiderm
growth
factor
significantli
activ
gene
pathway
relat
carcinogenesi
canin
tcc
howev
inform
canin
tcc
lack
aim
studi
examin
antitumor
effect
lapatinib
tyrosin
kinas
inhibitor
canin
tcc
cell
line
vitro
vivo
assess
protein
express
dog
tcc
five
canin
tcc
cell
line
tccub
love
sora
ltcc
ctcc
use
cell
incub
lapatinib
express
phosphoryl
downstream
molecul
signal
pathway
analyz
western
blot
cell
prolifer
cell
cycl
apoptosi
examin
methylthiazolyl
tetrazolium
assay
flow
cytometri
dutp
nick
end
label
tunel
method
respect
vivo
experi
canin
tcc
cell
subcutan
inject
nude
mice
lapatinib
vehicl
administ
daili
via
intraperiton
administr
day
endpoint
mice
euthan
tumor
collect
histolog
necrot
area
tumor
tissu
evalu
final
immunohistochemistri
perform
use
urinari
bladder
tissu
dog
tcc
healthi
dog
intens
stain
local
cell
membran
defin
protein
overexpress
protein
express
observ
canin
tcc
cell
line
lapatinib
inhibit
phosphoryl
downstream
molecul
cell
prolifer
manner
cell
cycl
analys
show
lapatinib
significantli
increas
phase
fraction
significantli
decreas
phase
fraction
cell
tunel
stain
show
apoptot
cell
treatment
lapatinib
six
fourteen
day
treatment
tumor
volum
canin
mice
significantli
smaller
lapatinib
group
compar
vehicl
control
group
lapatinib
treatment
significantli
increas
necrot
area
tumor
tissu
immunohistochemistri
show
protein
overexpress
observ
dog
tcc
healthi
dog
studi
demonstr
antitumor
effect
lapatinib
canin
tcc
cell
line
inhibit
signal
induc
cell
cycl
arrest
importantli
lapatinib
also
exert
antitumor
effect
canin
mice
addit
protein
overexpress
half
dog
tcc
result
suggest
lapatinib
therapeut
potenti
dog
tcc
electrochemotherapi
ect
coupl
administr
anticanc
drug
deliveri
electr
puls
increas
drug
uptak
cell
membran
thu
result
improv
efficaci
studi
undertaken
evalu
toler
efficaci
combin
system
bleomycin
local
cisplatin
ect
agent
incomplet
excis
canin
soft
tissu
sarcoma
st
thirti
dog
incomplet
excis
stss
enrol
dog
receiv
intraven
bleomycin
tumor
bed
margin
infiltr
cisplatin
dose
expos
train
permeabil
puls
sedat
precis
five
minut
inject
chemotherapi
agent
sequenc
biphas
puls
last
microsecond
deliv
burst
vcm
use
calip
electrod
second
session
perform
two
week
later
treatment
well
toler
side
effect
minim
dog
evid
recurr
differ
time
remiss
rang
month
four
recurr
one
four
recur
dog
die
lung
metastas
ect
use
combin
bleomycin
cisplatin
appear
effect
treatment
incomplet
resect
stss
dog
could
use
addit
current
option
consider
low
cost
limit
toxic
eas
administr
treatment
canin
histiocyt
sarcoma
ch
nitrosourea
agent
lomustin
ccnu
often
use
ccnu
potent
myelosuppress
agent
caus
cumul
irrevers
hepatotox
indic
need
accur
dose
adjust
howev
ccnu
oral
capsul
drug
thu
fine
dose
adjust
difficult
nimustin
acnu
nitrosourea
agent
intraven
inject
drug
safeti
dog
demonstr
phase
studi
acnu
therefor
attract
agent
treatment
ch
studi
thu
examin
therapeut
potenti
acnu
case
ch
nine
ch
case
gross
diseas
n
adjuv
set
n
treat
acnu
day
therapeut
effect
evalu
overal
surviv
os
interv
pfi
tumor
respons
acnu
evalu
criteria
andor
improv
symptom
median
os
median
pfi
day
rang
day
day
rang
day
respect
tumor
respons
two
case
measur
diseas
cr
sd
five
case
symptom
three
improv
symptom
studi
median
ospfi
appear
similar
report
ch
treat
ccnu
moreov
tumor
regress
andor
improv
symptom
observ
three
dog
acnu
could
potenti
therapeut
agent
ch
result
warrant
investig
acnu
larger
clinic
studi
introduct
accumul
suppressor
cell
mdsc
diminish
antitumor
immun
respons
necessari
control
tumor
growth
progress
mdsc
discrimin
monocyt
possess
strong
immunosuppress
activ
rather
immunostimulatori
properti
exosom
small
vesicl
provid
method
commun
cell
abil
transfer
protein
mirna
hypothes
tumor
cell
secret
exosom
taken
monocyt
promot
mdsc
differenti
defect
myeloid
cell
matur
method
exosom
isol
tumor
cell
line
osteosarcoma
glioma
colon
carcinoma
melanoma
fibrosarcoma
primari
cultur
parent
cell
origin
follow
addit
exosom
monocyt
consecut
day
cell
collect
flow
cytometri
transcript
analysi
cell
prolifer
assay
result
increas
express
mediat
ino
decreas
express
cytokin
tnfa
observ
monocyt
addit
exosom
tumor
line
support
convers
suppressor
phenotyp
flow
cytometri
cell
prolifer
assay
confirm
mdsc
phenotyp
exosom
isol
primari
control
cultur
promot
suppress
function
monocyt
conclus
data
support
hypothesi
exosom
promot
mdsc
differenti
better
mechanist
understand
interact
critic
discoveri
novel
therapeut
target
cancer
treatment
ultim
goal
prevent
convers
monocyt
suppressor
phenotyp
introduct
gold
standard
patient
posit
verif
stereotact
radiat
therapi
srt
comput
tomographi
cbct
avail
clinic
planar
imag
sometim
use
instead
purpos
studi
quantifi
error
inher
orthogon
megavoltag
mv
portal
kilovoltag
kvkv
imag
versu
cbct
use
verifi
setup
boni
target
hypothesi
use
planar
imag
would
necessit
inclus
setup
margin
plan
target
volum
ptv
expans
materi
method
patient
receiv
head
neck
srt
consid
inclus
prospect
clinic
studi
planar
mv
port
kvkv
imag
rotat
cbct
imag
acquir
treatment
manual
refer
imag
set
differ
patient
posit
vertic
later
longitudin
pitch
yaw
roll
match
base
mv
port
kvkv
imag
cbct
compar
result
independ
data
set
evalu
mean
differ
later
longitudin
vertic
direct
mv
port
kvkv
imag
mm
respect
mean
vector
mean
angular
differ
pitch
yaw
mean
differ
mv
port
cbct
imag
mm
respect
mean
vector
mean
angular
differ
mean
roll
detect
cbct
could
quantifi
planar
imag
conclus
mean
shift
discrep
describ
herein
account
setup
margin
srt
failur
could
result
earli
treatment
failur
due
geograph
miss
size
ptv
expans
minim
use
cbct
correct
visibl
posit
error
use
robot
couchtop
meticul
manual
posit
aim
studi
assess
toxic
efficaci
doxorubicin
cytarabin
dc
combin
protocol
dog
acut
myeloid
leukemia
aml
cohort
dog
persist
cytopenia
bone
marrow
cytolog
andor
core
biopsi
diagnosi
aml
treat
day
doxorubicin
mgkg
iv
minut
follow
cytarabin
constant
rate
iv
infus
hour
everi
day
prednison
mgkg
po
also
administ
hematolog
result
advers
effect
outcom
assess
everi
week
dc
therapi
six
dog
treat
dc
protocol
period
two
year
median
age
year
rang
median
weight
kg
rang
kg
dog
present
anemia
leukopenia
thrombocytopenia
two
dog
circul
blast
cell
median
number
treatment
cycl
rang
dose
reduct
requir
dog
due
grade
neutropenia
grade
gastrointestin
advers
effect
giae
one
dog
develop
dilat
cardiomyopathi
dcm
cumul
doxorubicin
dose
two
dog
still
aliv
day
diagnosi
one
dog
die
due
dcm
day
cytopenia
remiss
three
dog
die
progress
aml
day
diagnosi
respect
improv
cytopenia
note
two
dog
die
within
day
dc
protocol
overal
well
toler
four
dog
surviv
longer
month
studi
larger
sampl
size
warrant
pleiotrop
cytokin
play
pivot
role
innat
adapt
immun
also
promis
cytokin
treat
cancer
despit
grow
interest
use
immunotherapeut
agent
report
immunolog
clinic
effect
cancer
dog
studi
gener
recombin
canin
determin
biolog
effect
immun
effector
cell
confirm
safeti
vivo
clinic
immunomodulatori
effect
combin
metronom
cyclophosphamid
evalu
canin
patient
variou
tumor
type
determin
safeti
immunolog
effect
inject
intraven
dose
daili
day
monitor
day
treatment
outcom
dog
cancer
evalu
prospect
clinic
trial
low
dose
cyclophosphamid
po
sid
continu
administr
week
day
administr
cyclophosphamid
daili
inject
intraven
day
although
sever
dog
experienc
tempor
mild
pyrexia
signific
advers
event
detect
inject
administr
combin
metronom
cyclophosphamid
remark
increas
number
nk
cell
activ
significantli
decreas
number
regulatori
cell
peripher
blood
patient
associ
improv
clinic
outcom
result
suggest
safe
tremend
potenti
antitumor
therapi
dog
epidemiolog
studi
suggest
residenti
radon
exposur
may
increas
risk
primari
lung
cancer
peopl
howev
studi
limit
subject
mobil
outsid
home
limit
may
overcom
evalu
associ
dog
cat
hypothes
rate
primari
pulmonari
neoplasia
would
increas
dog
cat
resid
counti
higher
environment
radon
level
systemat
retrospect
review
medic
record
ten
veterinari
school
identifi
dog
cat
diagnos
primari
lung
tumor
patient
radon
exposur
determin
correl
patient
zip
code
publish
counti
epa
radon
level
counti
pulmonari
neoplasia
rate
determin
use
averag
annual
counti
catdog
popul
rate
compar
radon
zone
use
anova
subsequ
pairwis
comparison
record
review
identifi
dog
cat
primari
pulmonari
neoplasia
veterinari
school
high
n
n
low
n
radon
level
averag
counti
level
rate
canin
pulmonari
neoplasm
higher
high
environment
radon
area
pcil
compar
counti
pcil
p
low
pcil
radon
p
signific
differ
pulmonari
neoplasia
rate
radon
level
cat
p
higher
environment
radon
level
may
play
role
develop
primari
pulmonari
neoplasia
dog
studi
investig
residenti
radon
level
along
environment
factor
warrant
fulli
defin
potenti
effect
radon
develop
primari
pulmonari
neoplasia
dog
cat
canin
cutan
lymphoma
character
rapid
progress
poor
prognosi
cutan
lymphoma
low
respons
treatment
dog
lymphoma
nel
lower
surviv
time
compar
dog
epitheliotrop
form
el
low
rate
respons
system
chemotherapi
associ
multidrug
resist
mdr
cell
mechan
mdr
may
includ
protein
involv
transport
lung
protein
lrp
major
vault
protein
found
overexpress
mani
chemoresist
primari
tumor
includ
lymphoma
associ
poor
respons
treatment
aim
studi
investig
lrp
express
dog
cutan
lymphoma
immunohistochemistri
perform
sampl
nel
el
use
polyclon
antibodi
rabbi
spring
bioscienc
dako
mous
clone
santa
cruz
biotech
lrp
immunoreact
analyz
percentag
label
cell
consid
posit
cell
label
predomin
immunophenotyp
case
sampl
posit
lrp
median
posit
cell
nel
el
median
overal
surviv
time
month
anim
partial
respons
treatment
conclus
despit
high
express
lrp
canin
cutan
lymphoma
differ
nel
el
form
overal
surviv
time
effect
treatment
option
inoper
metastat
recurr
canin
pheochromocytoma
lack
human
specif
germlin
mutat
drive
develop
pheochromocytoma
target
abnorm
small
molecul
inhibitor
effect
treatment
strategi
similar
mutat
may
exist
dog
thu
treatment
similar
small
molecul
inhibitor
toceranib
phosphat
palladia
may
provid
surviv
advantag
purpos
studi
assess
role
palladia
treatment
inoper
metastat
recurr
canin
pheochromocytoma
retrospect
medic
record
dog
diagnosi
pheochromocytoma
treatment
palladia
review
inform
regard
respons
palladia
observ
side
effect
overal
outcom
five
dog
identifi
fit
inclus
criteria
five
experienc
clinic
benefit
partial
respons
stabl
diseas
base
period
stage
evalu
interv
dog
partial
respons
week
interv
two
dog
stabl
measur
primari
diseas
week
week
interv
two
dog
stabl
metastat
diseas
least
week
week
base
limit
seri
case
result
suggest
palladia
biolog
activ
dog
measur
primari
metastat
pheochromocytoma
prospect
clinic
studi
warrant
fulli
defin
role
palladia
treatment
canin
pheochromocytoma
melanoma
common
malign
tumor
oral
caviti
dog
incur
infiltr
bone
lung
metastasi
tradit
therapeut
approach
less
effect
tumor
cell
reli
glycolysi
rather
mitochondri
oxid
phosphoryl
energi
product
even
condit
term
warburg
effect
sinc
warburg
effect
characterist
tumor
cell
glucos
metabol
consid
therapeut
target
regard
studi
investig
contribut
glucos
transport
cell
growth
canin
melanoma
canin
melanoma
cell
cultur
dulbecco
modifi
eagl
medium
contain
gl
glucos
fetal
bovin
serum
cell
growth
measur
tetrazolium
bromid
reduct
assay
cell
prolifer
three
day
manner
treat
transport
inhibitor
cell
growth
clearli
attenu
observ
mrna
glucos
transport
subtyp
dominantli
express
canin
melanoma
protein
express
confirm
western
blot
investig
contribut
glut
subtyp
cell
growth
knockdown
cell
transfect
sirna
cell
growth
inhibit
also
observ
express
prolifer
marker
inhibit
knockdown
cell
wherea
inhibit
less
knockdown
cell
henc
suggest
dominantli
contribut
cell
growth
canin
melanoma
conclus
like
glucos
transport
promis
therapeut
target
canin
melanoma
serotonerg
signal
system
major
regul
osteogenesi
bone
homeostasi
role
system
canin
osteosarcoma
biolog
larg
unexplor
serotonin
receptor
express
canin
osteosarcoma
cell
line
incub
tumor
cell
specif
receptor
agonist
antagonist
decreas
cell
viabil
induc
apoptosi
vitro
evid
suggest
serotonin
system
element
present
canin
osteosarcoma
may
repres
novel
therapeut
target
investig
presenc
serotonerg
compon
vivo
examin
express
five
serotonin
system
associ
gene
archiv
appendicular
osteosarcoma
sampl
three
gene
encod
serotonin
receptor
evalu
along
gene
serotonin
transport
serotonin
synthesi
express
assess
use
situ
rna
hybrid
evalu
ucb
use
screen
adequ
residu
rna
presenc
magnitud
express
correl
tumor
grade
vascular
invas
necrosi
matrix
cellular
densiti
pleomorph
expect
find
express
gene
amongst
tumor
sampl
express
magnitud
would
correl
histolog
tumor
featur
appendicular
osteosarcoma
tumor
sampl
examin
contain
suffici
residu
rna
analysi
express
detect
analyz
tumor
sampl
howev
averag
express
transcript
cell
gene
correl
identifi
gene
express
magnitud
rel
histolog
tumor
featur
conclus
identifi
express
certain
serotonerg
system
gene
canin
osteosarcoma
tumor
sampl
assess
express
associ
protein
product
warrant
help
determin
element
may
potenti
role
osteosarcoma
biolog
repres
viabl
therapeut
target
introduct
understand
genom
landscap
canin
osteosarcoma
osa
critic
translat
model
object
studi
develop
first
resolut
map
singl
nucleotid
variant
snv
insertionsdelet
variant
cnv
gene
fusion
structur
variant
sv
somat
alter
clonal
architectur
osa
method
whole
genom
wg
exom
rna
sequenc
perform
match
primari
appendicular
osa
metastat
pulmonari
tumor
match
normal
sampl
dog
hiseqx
read
read
platform
use
mcdonnel
genom
institut
cancer
informat
pipelin
adapt
canin
genom
result
mean
wg
exom
coverag
respect
mean
synonym
mutat
rate
low
patient
share
one
commonli
mutat
gene
harbor
missens
mutat
exon
mutat
common
match
primari
metastat
tumor
includ
loss
heterozygos
loh
extens
pten
delet
primari
tumor
sampl
conclus
genom
landscap
canin
human
pediatr
osa
similar
suffer
point
mutat
loh
result
complet
loss
allel
common
earli
event
key
driver
canin
osa
applic
establish
method
human
tumor
genom
analysi
canin
sampl
reveal
widespread
genom
instabl
seen
human
tumor
introduct
doxorubicin
anthracyclin
antibiot
caus
cumul
cardiotox
dog
studi
aim
character
overal
incid
risk
factor
clinic
cardiotox
method
medic
record
dog
receiv
three
dose
doxorubicin
review
dog
consid
clinic
cardiotox
lack
heart
diseas
develop
syncop
collaps
exercis
intoler
congest
heart
failur
sudden
death
doxorubicin
treatment
result
case
studi
popul
develop
clinic
cardiotox
median
time
treatment
initi
clinic
sign
develop
day
dog
develop
clinic
cardiotox
higher
cumul
dose
doxorubicin
higher
bodi
weight
dog
receiv
infus
rather
minut
infus
also
like
develop
clinic
cardiotox
boxer
dog
higher
incid
cardiotox
associ
found
dexrazoxan
administr
dose
interv
chemotherapi
drug
total
dog
echocardiogram
ecg
prior
first
doxorubicin
treatment
least
one
subsequ
evalu
dog
clinic
cardiotox
signific
decreas
fraction
shorten
baselin
compar
fraction
shorten
chang
unaffect
dog
develop
arrhythmia
associ
cardiotox
conclus
overal
incid
develop
clinic
cardiotox
risk
factor
identifi
includ
higher
cumul
dose
higher
bodi
weight
boxer
dog
longer
infus
time
decreas
fraction
shorten
develop
arrhythmia
serum
recommend
sampl
use
measur
cortisol
use
immulit
technolog
howev
cortisol
stabl
edta
plasma
serum
use
edta
plasma
significantli
affect
result
obtain
immulit
addit
magnesium
mg
potenti
overcom
effect
edta
kemppainenet
al
j
vet
diagnost
invest
press
object
compar
effect
edta
without
addit
mg
measur
cortisol
immulit
canin
sampl
pair
canin
serum
sampl
leftov
use
indic
diagnost
test
obtain
edta
concentr
plasma
sampl
unknown
like
vari
depend
degre
underfil
tube
cortisol
measur
serum
sampl
without
mg
ad
use
previous
valid
autom
chemiluminesc
enzym
immunoassay
immulit
statist
analysi
use
repeat
measur
anova
compar
measur
concentr
test
use
dunnett
method
perform
concentr
serum
without
ad
mg
control
group
detect
differ
concentr
plasma
without
mg
data
analyz
use
pair
signific
set
p
level
blood
sampl
dog
includ
cortisol
valu
significantli
differ
plasma
serum
sampl
without
mg
cortisol
concentr
measur
edta
plasma
higher
serum
sampl
respect
p
addit
mg
plasma
significantli
decreas
measur
cortisol
concentr
p
p
respect
addit
mg
cortisol
concentr
measur
edta
plasma
longer
significantli
differ
measur
serum
howev
concentr
measur
edta
plasma
remain
significantli
differ
serum
use
edta
plasma
significantli
increas
measur
concentr
cortisol
obtain
immulit
addit
mg
plasma
sampl
overcom
effect
edta
measur
cortisol
thu
edta
plasma
use
maxim
cortisol
stabil
mg
ad
sampl
assay
via
immulit
osmot
diuresi
consid
caus
polyuria
diabet
mellitu
howev
peopl
mutat
renal
cotransport
diabet
patient
treat
drug
block
transport
profound
glycosuria
without
polyuria
purpos
studi
determin
isol
renal
glycosuria
induc
polyuria
cat
studi
approv
univers
anim
ethic
committe
studi
consist
four
studi
period
separ
washout
period
eight
healthi
male
cat
randomli
alloc
control
treatment
dapagliflozin
daili
base
previou
pilot
studi
four
studi
period
record
daili
food
water
intak
urin
output
urin
aliquot
collect
blood
obtain
begin
end
studi
period
data
analyz
linear
model
includ
treatment
fix
effect
cat
random
effect
statist
signific
set
dapagliflozin
induc
increas
urin
glucos
loss
mmold
vs
mmold
differ
daili
urinari
excret
sodium
potassium
chlorid
group
also
differ
water
intak
vs
ml
bodi
weight
vs
g
urin
product
vs
ml
result
call
question
gener
accept
hypothesi
osmot
diuresi
primari
caus
polyuria
diabet
mellitu
human
rodent
develop
endocrin
pancrea
control
tightli
regul
transcript
factor
two
pair
box
homeobox
gene
arx
play
central
role
alloc
endocrin
progenitor
toward
specif
respect
note
adulthood
speci
express
shown
contribut
reprogram
exocrin
cell
induct
arx
express
lead
reprogram
recent
discov
diabet
cat
increas
number
cell
exocrin
pancrea
stain
posit
marker
prolifer
prolifer
cell
nuclear
antigen
pcna
particular
nearbi
islet
prolifer
increas
reprogram
effici
rodent
hypothes
cell
may
anticip
reprogram
cat
aim
studi
test
diabet
cat
increas
number
cell
endocrin
exocrin
pancrea
express
development
marker
suggest
reprogram
diabet
control
cat
pancrea
collect
within
hour
death
immunohistochemistri
tissu
section
stain
insulin
glucagon
arx
number
cell
posit
marker
combin
count
imag
magnif
exocrin
pancrea
islet
result
compar
group
test
expect
compar
control
diabet
cat
less
cell
islet
median
rang
vs
median
rang
scatter
exocrin
pancrea
median
rang
vs
median
rang
number
cell
differ
diabet
cat
insulinglucagon
cell
islet
control
median
rang
vs
median
rang
islet
diabet
cat
cell
median
rang
vs
median
rang
cell
median
rang
vs
median
rang
percentag
rel
number
cell
higher
diabet
cat
cat
cell
none
control
vs
diabet
cat
arxglucagon
cell
exocrin
pancrea
control
median
rang
vs
median
rang
none
marker
combin
differ
group
exocrin
pancrea
islet
diabet
cat
decreas
number
cell
along
increas
number
cell
suggest
may
chang
earlier
stage
differenti
new
form
increas
number
islet
cell
insulin
glucagon
diabet
cat
may
indic
transform
vice
versa
howev
absolut
number
cell
low
collect
data
suggest
histolog
evid
reprogram
cell
present
diabet
cat
event
occur
islet
exocrin
pancrea
reason
behind
increas
number
arxglucagon
cell
exocrin
pancrea
diabet
cat
unclear
insulin
glargin
uml
insulin
degludec
synthet
insulin
analog
use
peopl
basal
insulin
predict
compar
glargin
uml
peopl
durat
action
hour
allow
flexibl
daili
schedul
administr
hypothes
would
longer
durat
action
compar
healthi
cat
six
healthi
cat
receiv
ukg
sq
inject
two
differ
day
week
apart
blood
glucos
bg
measur
everi
min
glucos
administ
intraven
variabl
rate
goal
maintain
bg
mgdl
isoglycem
clamp
glucos
infus
rate
use
measur
exogen
insulin
action
test
use
assess
normal
normal
distribut
paramet
compar
use
pair
onset
action
toa
similar
min
min
p
end
action
tea
durat
action
tdur
longer
vs
tdur
min
vs
min
respect
p
tea
min
vs
min
respect
p
signific
differ
two
formul
base
preliminari
data
therefor
better
suit
insulin
formul
cat
renal
proteinuria
associ
subclin
clinic
hypothyroid
peopl
howev
littl
known
effect
renal
proteinuria
thyroid
statu
companion
anim
purpos
studi
determin
thyroid
statu
assess
total
free
hormon
tsh
differ
ill
dog
proteinur
versu
ill
proteinur
dog
defin
urin
proteincreatinin
ratio
upc
neg
urin
cultur
ill
dog
prospect
enrol
studi
dog
underw
physic
examin
complet
blood
count
serum
chemistri
urinalysi
thyroid
panel
urin
proteinur
dog
submit
cultur
upc
descript
statist
student
use
determin
differ
group
signific
p
ill
proteinur
dog
ill
dog
enrol
studi
serum
total
protein
concentr
higher
dog
p
though
albumin
level
differ
group
p
median
upc
proteinur
dog
rang
interestingli
proteinur
dog
significantli
higher
mean
serum
cholesterol
dog
p
signific
differ
mean
p
p
found
proteinur
dog
howev
mean
tsh
significantli
higher
proteinur
dog
p
result
suggest
renal
proteinuria
influenc
thyroid
homeostasi
consid
interpret
thyroid
statu
dog
hyperthyroid
cat
commonli
treat
may
result
iatrogen
hypothyroid
although
thyroid
stimul
hormon
tsh
stimul
test
use
assess
thyroid
reserv
sever
studi
hypothyroid
dog
limit
data
avail
cat
studi
test
hypothesi
treat
cat
diagnos
iatrogen
hypothyroid
use
tsh
stimul
test
low
low
high
tsh
prospect
studi
treat
cat
week
total
thyroxin
tsh
measur
tsh
stimul
test
perform
previous
publish
criteria
canin
hypothyroid
studi
tsh
stimul
test
respons
matur
adult
control
cat
use
defin
group
criteria
treat
cat
divid
hypothyroid
euthyroid
post
stimul
post
stimul
pre
post
ratio
intermedi
post
stimul
ratio
group
cat
diagnos
hypothyroid
high
tsh
low
hypothyroid
cat
low
base
laboratori
refer
interv
ri
therefor
ri
insensit
test
felin
hypothyroid
cat
intermedi
thyroid
function
euthyroid
group
cat
high
tsh
low
one
cat
low
euthyroid
cat
low
also
high
tsh
measur
tsh
recommend
diagnosi
iatrogen
felin
hypothyroid
thyroid
stimul
hormon
tsh
stimul
test
use
assess
thyroid
reserv
studi
hypothyroid
dog
howev
limit
data
avail
cat
purpos
studi
assess
effect
mild
moder
concurr
ill
respons
euthyroid
cat
tsh
stimul
test
prospect
studi
matur
adult
cat
full
examin
includ
systol
blood
pressur
routin
hematolog
biochemistri
urinalysi
measur
urin
ratio
total
thyroxin
free
thyroxin
tsh
tsh
stimul
test
perform
cat
thought
year
older
recruit
howev
age
shelter
cat
could
alway
verifi
hospit
cat
cat
receiv
medic
exclud
cat
divid
group
base
physic
examin
laboratori
result
group
concurr
ill
detect
group
mild
concurr
ill
eg
moder
dental
diseas
stabl
iri
stage
ii
chronic
kidney
diseas
group
moder
concurr
ill
eg
untreat
moder
sever
hypertens
anemia
hypoalbuminemia
proteinuria
andor
hypokalemia
result
report
median
rang
concentr
ratio
concentr
tsh
administr
ratio
compar
group
use
kruskal
walli
twelv
cat
own
cat
two
cat
diagnos
hyperthyroid
exclud
evalu
remain
cat
baselin
ratio
signific
differ
p
ratio
group
group
group
group
therefor
effect
ill
tsh
stimul
test
result
studi
diabet
human
erythrocyt
lower
antioxid
capac
increas
protein
lipid
oxid
byproduct
consequ
hyperglycemia
hyperlipidemia
similarli
erythrocyt
diabet
cat
increas
heinz
bodi
format
may
suggest
increas
oxid
stress
topic
yet
thoroughli
investig
furthermor
remiss
diabet
cat
shown
associ
less
mark
hyperglycemia
normal
serum
cholesterol
possibl
antioxid
capac
cat
achiev
remiss
higher
without
remiss
thu
assess
erythrocyt
oxid
stress
increas
antioxid
capac
decreas
diabet
cat
antioxid
capac
differ
case
without
remiss
oxid
statu
amelior
treatment
healthi
cat
cat
newli
diagnos
diabet
affect
obviou
concurr
diseas
enrol
diabet
cat
receiv
insulin
glargin
diet
month
remiss
defin
euglycemia
without
insulin
week
blood
collect
first
admiss
month
erythrocyt
use
quantifi
carbonyl
protein
oxid
byproduct
thiol
group
antioxid
membran
advanc
oxid
protein
product
aopp
protein
oxid
byproduct
thiobarbitur
acid
reactiv
substanc
tbar
lipid
peroxid
byproduct
thiol
cytoplasm
nonparametr
test
use
comparison
eleven
healthi
cat
diabet
cat
includ
diabet
cat
achiev
remiss
compar
control
diabet
cat
diagnosi
higher
median
membran
carbonyl
nmolmg
rang
vs
nmolmg
rang
p
lower
cytoplasm
thiol
rang
vs
rang
p
cytoplasm
tbar
lower
diabet
cat
nmolmg
rang
vs
nmolmg
rang
p
month
membran
carbonyl
remain
higher
p
cytoplasm
thiol
tbar
lower
p
p
respect
differ
cat
without
remiss
document
except
cytplasm
aopp
lower
remiss
month
p
conclus
diabet
cat
erythrocyt
increas
protein
oxid
byproduct
reduc
antioxid
capac
suggest
increas
oxid
stress
oxid
statu
amelior
treatment
possibl
oxid
stress
persist
need
longer
treatment
durat
decreas
reason
behind
reduc
tbar
diabet
cat
remain
elus
lastli
oxid
statu
differ
cat
without
remiss
assess
malign
canin
adrenocort
tumor
at
remain
challeng
previou
studi
link
molecular
marker
surviv
time
dog
adrenalectomi
make
difficult
give
reliabl
prognosi
aim
studi
identifi
molecular
prognost
marker
larg
cohort
canin
at
could
enhanc
insight
individu
prognosi
could
also
provid
potenti
futur
treatment
target
dog
hypercortisol
due
underw
adrenalectomi
author
institut
inform
avail
includ
studi
three
class
potenti
prognost
factor
review
firstli
clinic
data
includ
bodi
weight
age
time
surgeri
gender
neuter
statu
tumor
size
secondli
immunohistochem
label
index
thirdli
mrna
express
factor
associ
prolifer
at
includ
univari
analysi
perform
cox
proport
hazard
model
continu
variabl
log
rank
test
bivari
variabl
multivari
analysi
perform
use
multipl
linear
regress
forward
select
median
surviv
time
month
univari
analysi
signific
prognost
factor
tumor
volum
hazard
ratio
hr
maxim
diamet
tumor
cm
label
index
independ
predictor
poor
surviv
conclus
import
predictor
poor
surviv
label
index
express
result
show
import
includ
stain
histopatholog
assess
canin
at
moreov
sinc
pharmacolog
manipul
possibl
consider
impact
express
prognosi
indic
great
potenti
treatment
target
canin
at
near
futur
object
studi
evalu
safeti
lispro
insulin
treatment
cat
diabet
ketoacidosi
dka
compar
time
requir
resolv
hyperglycemia
ketosi
acidosi
dka
cat
treat
lispro
regular
insulin
hospit
popul
cat
dka
enrol
random
prospect
blind
clinic
trial
cat
blood
glucos
bg
glucosuria
blood
ph
blood
bohb
concentr
enrol
cat
randomli
assign
receiv
iv
continu
rate
infus
lispro
regular
insulin
administ
initi
dose
adjust
previous
describ
doi
six
cat
enrol
treatment
group
advers
event
observ
associ
iv
lispro
administr
median
time
resolut
hyperglycemia
bg
significantli
shorter
cat
treat
lispro
rang
compar
cat
treat
regular
insulin
p
signific
differ
median
time
resolut
ketosi
bohb
acidosi
ph
lispro
versu
regular
insulin
treat
cat
also
differ
median
time
hospit
discharg
lispro
versu
regular
insulin
treat
cat
respect
two
cat
studi
group
euthan
due
comorbid
conclud
lispro
insulin
safe
effect
regular
insulin
resolut
metabol
derang
dka
cat
previou
studi
dog
found
improv
cortisol
stabil
measur
ethylenediaminetetraacet
acid
edta
plasma
interchang
serum
plasma
cortisol
total
thyroxin
free
thyroxin
measur
radioimmunoassay
interestingli
studi
use
chemiluminesc
immunoassay
found
increas
edta
concentr
sampl
tube
fill
affect
alkalin
phosphatas
secondari
enzym
lead
significantli
differ
human
parathyroid
hormon
concentr
studi
evalu
effect
edta
measur
adrenocorticotrop
hormon
acth
cortisol
thyroid
stimul
hormon
tsh
healthi
dog
use
siemen
whole
blood
forti
dog
aliquot
three
sampl
tube
plain
complet
fill
edta
tube
fill
edta
tube
handl
storag
condit
ident
sampl
analyz
day
acth
cortisol
tsh
measur
sampl
plot
regress
use
assess
agreement
risk
error
respect
proport
error
found
serum
plasma
sampl
acth
cortisol
tsh
systemat
error
also
found
result
confirm
signific
differ
sampl
type
directli
interchang
incomplet
fill
edta
tube
associ
significantli
higher
cortisol
concentr
significantli
lower
acth
concentr
compar
complet
fill
edta
tube
measur
chemiluminesc
immunoassay
serum
use
cortisol
tsh
plasma
complet
fill
edta
tube
use
acth
radioact
iodin
therapi
consid
treatment
choic
felin
hyperthyroid
human
thyroid
neoplasia
toxic
nodular
goiter
administr
recombin
human
thyroid
stimul
hormon
increas
thyroid
iodin
uptak
therebi
allow
lower
dose
radioact
iodin
use
treatment
similar
strategi
could
valuabl
treat
felin
hyperthyroid
primari
object
studi
investig
effect
administr
iodin
uptak
hyperthyroid
cat
random
crossov
design
cat
hyperthyroid
treat
placebo
treatment
separ
day
follow
treatment
thyroid
scintigraphi
perform
administ
assess
radionuclid
uptak
hour
time
point
serum
thyroid
hormon
profil
also
measur
visit
thyroid
iodin
uptak
mean
sd
hour
differ
among
placebo
treatment
p
independ
administr
cat
sever
increas
serum
thyroid
hormon
concentr
greater
radioact
iodin
uptak
hour
p
hour
p
compar
cat
mild
increas
administr
perform
studi
would
expect
lower
radioact
iodin
dose
need
treatment
investig
altern
strategi
increas
thyroid
uptak
radioact
iodin
warrant
hypoadrenocortic
dog
confirm
perform
acth
stimul
test
although
rare
hypoadrenocortic
differenti
diagnosi
mani
clinic
clinicopatholog
find
canin
patient
therefor
simpl
inexpens
way
rule
desir
prospect
studi
perform
test
hypothesi
urin
cortisol
creatinin
ratio
uccr
specif
basal
cortisol
diagnosi
hypoadrenocortic
dog
clinic
sign
clinicopatholog
abnorm
hypoadrenocortic
reason
differenti
diagnosi
enrol
case
exclud
receiv
prior
therapi
glucocorticoid
mitotan
trilostan
urin
uccr
obtain
dog
prior
perform
acth
stimul
test
total
dog
enrol
dog
diagnos
hypoadrenocortic
serum
cortisol
mcgdl
dog
diagnos
nh
uccr
rang
hypoadrenocortic
dog
nh
group
basal
cortisol
rang
nh
group
diagnosi
hypoadrenocortic
sensit
specif
basal
cortisol
respect
use
uccr
sensit
specif
diagnosi
hypoadrenocortic
uccr
significantli
specif
basal
cortisol
basal
cortisol
result
suggest
uccr
allow
hypoadrenocortic
rule
patient
compar
basal
cortisol
monitor
control
diabet
mellitu
challeng
especi
cat
reagent
strip
use
assess
presenc
degre
glucosuria
may
aid
assess
diabet
control
purpos
prospect
studi
evalu
accuraci
bayer
detect
glucosuria
cat
litter
hour
glucos
ad
previous
frozen
felin
urin
sampl
achiev
urin
sampl
approxim
glucos
concentr
mgdl
sampl
pad
detect
glucos
cut
reagent
strip
ad
clay
petri
dish
soak
drop
one
urin
sampl
estim
urin
glucos
concentr
determin
train
blind
observ
compar
color
chang
piec
color
chart
packag
insert
immedi
per
manufactur
instruct
minut
exposur
urin
chi
squar
test
use
compar
distribut
categor
accur
overestim
underestim
time
point
signific
set
p
level
refer
rang
correl
color
color
chart
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
devis
lack
publish
concentr
rang
accord
rang
glucos
concentr
accur
measur
immedi
soak
sampl
inaccur
measur
sampl
underestim
minut
accuraci
improv
sampl
inaccur
measur
underestim
hour
beyond
accur
measur
inaccur
measur
major
underestim
categor
chang
significantli
time
p
specif
read
minut
thu
use
cat
litter
accur
read
obtain
minut
time
point
color
chang
remain
stabl
although
approxim
accuraci
product
tend
underestim
glucos
concentr
cat
urin
agonist
administr
document
increas
blood
glucos
concentr
number
speci
object
studi
describ
effect
dexmedetomidin
glucos
regul
healthi
cat
random
crossov
studi
use
healthi
cat
washout
period
use
assess
effect
dexmedetomidin
iv
salin
glucos
lactat
cortisol
insulin
glucagon
fatti
acid
nefa
concentr
baselin
min
post
administr
nonparametr
distribut
establish
test
comparison
group
perform
wilcoxon
match
pair
sign
rank
test
comparison
within
group
perform
friedman
test
use
dunn
multipl
comparison
analys
signific
differ
identifi
group
within
salin
group
within
dexmedetomidin
group
insulin
cortisol
lactat
concentr
signific
differ
p
observ
within
dexmedetomidin
group
increas
blood
glucos
concentr
min
mmoll
min
mmoll
compar
mmoll
decreas
serum
glucagon
concentr
min
pgml
min
pgml
compar
pgml
decreas
serum
nefa
concentr
min
mmoll
min
mmoll
compar
mmoll
conclus
transient
effect
dexmedetomidin
glucos
homeostasi
unlik
affect
clinic
practic
prospect
studi
investig
verac
recent
retrospect
studi
found
signific
neg
correl
serum
total
thyroxin
glucos
concentr
cat
end
use
hyperthyroid
cat
model
determin
effect
rang
serum
concentr
would
serum
glucos
concentr
studi
approv
univers
anim
ethic
committe
apriori
power
analysi
indic
six
cat
per
group
would
suffic
detect
differ
mgdl
repeat
measur
serum
glucos
cat
power
ten
hyperthyroid
cat
randomli
alloc
crossov
design
receiv
treatment
carbimazol
treatment
withheld
experiment
design
consist
four
studi
period
separ
washout
period
collect
serum
day
four
studi
period
measur
serum
glucos
data
analyz
linear
model
includ
fix
effect
cat
random
effect
statist
signific
set
serum
glucos
concentr
median
mgdl
interquartil
rang
rang
affect
chang
serum
median
interquartil
rang
rang
p
contrast
previou
find
studi
suggest
serum
hyperthyroid
cat
may
substanti
affect
serum
glucos
concentr
object
studi
determin
characterist
outcom
cat
undergo
surgic
treatment
phpt
retrospect
studi
medic
record
data
collect
via
telephon
cat
undergo
surgic
treatment
histopatholog
evalu
resect
tissu
includ
cat
divid
ioniz
calcium
ica
group
correspond
percentil
studi
popul
ica
result
cat
includ
studi
mean
cat
age
year
mean
cat
bodi
weight
kg
ica
refer
rang
cat
median
mmoll
iqr
cat
underw
cervic
exploratori
surgeri
abnorm
tissu
identifi
remov
cat
histopatholog
diagnosi
parathyroid
adenoma
cat
parathyroid
endocrin
carcinoma
cat
parathyroid
hyperplasia
cat
parathyroid
cystadenoma
cat
discharg
cat
hypercalcemia
hypocalcemia
cat
ica
within
refer
rang
overal
median
surviv
time
day
ci
surviv
time
significantli
associ
ica
group
p
hypocalcemia
discharg
p
hypercalcemia
discharg
p
diagnosi
carcinoma
p
cohort
cat
parathyroid
adenoma
common
caus
phpt
surgic
treatment
result
favor
surviv
time
amino
acid
metabol
dog
might
influenc
prolong
endogen
exogen
hypercortisolemia
dog
suffer
chronic
hypercortisolemia
display
varieti
clinic
sign
cush
syndrom
shown
result
disrupt
amino
acid
aa
metabol
human
lack
inform
chang
aa
profil
dog
hyperadrenocortic
hac
therefor
object
present
studi
determin
chang
circul
aa
concentr
dog
hac
dog
newli
diagnos
hyperadrenocortic
pdh
enrol
studi
healthi
beagl
also
includ
control
serum
concentr
aa
alanin
arginin
asparagin
aspart
cystein
glutam
glutamin
glycin
histidin
isoleucin
leucin
lysin
methionin
phenylalanin
prolin
serin
taurin
threonin
tryptophan
tyrosin
valin
analyz
use
mhz
nuclear
magnet
reson
spectromet
orthogon
partial
least
analysi
plot
show
separ
pdh
healthi
dog
dog
pdh
show
signific
increas
median
serum
concentr
arginin
p
aspart
p
signific
decreas
glutamin
p
serin
p
compar
healthi
dog
studi
show
circul
concentr
aa
affect
dog
pdh
indic
chronic
hypercortisolemia
may
precipit
disturb
aa
metabol
studi
necessari
clarifi
associ
aa
profil
consequ
hypercortisolemia
dog
canin
diabet
mellitu
common
diseas
may
parallel
human
type
diabet
recent
identifi
varianc
serum
metabolom
profil
fast
diabet
healthi
dog
similar
previous
identifi
human
patient
given
obtain
fast
sampl
diabet
dog
difficult
practic
purpos
studi
expand
effort
compar
untarget
metabolom
profil
diabet
healthi
control
dog
serum
diabet
dog
healthi
control
dog
analyz
liquid
spectrometri
profil
dog
breed
andor
bodi
weight
match
time
sampl
collect
approxim
match
pair
metaboanalyst
util
data
analysi
identifi
differ
metabolom
profil
two
group
base
heat
map
analysi
known
unknown
metabolit
clear
cluster
metabolit
diabet
control
group
observ
diabet
dog
compar
healthi
control
dog
mani
metabolit
significantli
p
downregul
includ
involv
tryptophan
metabol
well
sever
amino
acid
fewer
metabolit
significantli
p
upregul
includ
microbi
deriv
citramal
organ
acid
acid
multipl
metabol
perturb
includ
list
similar
previous
found
fast
diabet
dog
sum
metabolom
profil
differ
diabet
healthi
dog
parallel
found
fast
dog
metabolom
alter
may
give
insight
pathogenesi
canin
diabet
futur
studi
confirm
find
develop
target
assay
detect
metabolit
may
use
biomark
canin
diabet
warrant
studi
shown
serum
cortisol
concentr
increas
corticotrop
hyperplasia
due
environment
stress
agent
observ
explain
physiolog
effect
caus
stress
nevertheless
studi
tri
correl
chronic
exposur
stress
axi
activ
dog
hyperadrenocortic
hac
develop
present
work
aim
clarifi
whether
dog
hac
pdh
expos
stress
situat
throughout
live
compar
healthi
anim
questionnair
regard
tempera
social
social
interact
level
environment
enrich
daili
habit
develop
owner
recent
diagnos
pdh
healthi
dog
invit
answer
questionnair
twenti
newli
diagnos
pdh
dog
includ
studi
subject
match
forti
healthi
dog
control
group
sex
age
breed
ratio
exclus
criteria
control
group
hac
suspicion
chronic
glucocorticoid
therapi
glucocorticoid
exposur
last
month
odd
ratio
estim
confid
interv
ci
report
less
equal
consid
statist
signific
dog
hac
ten
time
expos
neuter
ci
p
howev
significantli
correl
found
social
isol
confin
exposur
can
food
plastic
toy
phobia
separ
anxieti
hac
even
variabl
studi
consid
potenti
stress
reliev
suggest
protect
effect
result
emphas
neuter
potenti
hac
develop
instig
studi
possibl
mechan
behind
diabet
mellitu
dm
one
common
endocrin
diseas
cat
date
known
diagnost
test
patient
characterist
time
diagnosi
predict
diseas
cours
diabet
remiss
potenti
affect
cat
peopl
comput
tomograph
angiographi
cta
use
evalu
pancreat
endocrin
function
predict
patient
becom
diabet
pancreatectomi
purpos
studi
describ
cta
characterist
pancrea
cat
chronic
dm
compar
find
healthi
control
cat
prospect
studi
cat
natur
occur
dm
present
year
age
match
healthi
control
cat
util
sedat
cta
exam
pancrea
perform
cat
time
arteri
enhanc
time
peak
portal
enhanc
pancreat
attenu
arteri
portal
attenu
ratio
p
determin
cat
compar
group
student
use
statist
analys
mean
time
arteri
enhanc
control
diabet
cat
mean
time
peak
portal
enhanc
control
cat
chronic
diabet
cat
statist
differ
time
arteri
enhanc
mean
time
peak
portal
enhanc
p
mean
pancreat
attenu
control
cat
arteri
portal
hu
delay
compar
diabet
cat
attenu
hu
respect
signific
differ
pancreat
attenu
group
p
mean
p
statist
differ
p
group
normal
cat
ratio
diabet
cat
time
peak
portal
enhanc
use
differenti
normal
sedat
cat
chronic
dm
use
cta
cta
find
warrant
investig
identifi
possibl
associ
endocrin
function
diabet
remiss
cat
field
diabet
research
mani
studi
cell
therapi
conduct
use
mesenchym
stem
cell
research
intend
shed
light
influenc
canin
mesenchym
stem
cell
condit
medium
cm
vitro
insulin
resist
model
induc
differenti
adipocyt
possibl
mechan
involv
phenomenon
insulin
resist
model
develop
differenti
adipocyt
cell
condit
media
cm
hour
insulin
receptor
glucos
transport
type
examin
marker
insulin
resist
neutral
antibodi
ad
model
block
biolog
activ
contain
cm
quantit
revers
transcriptas
pcr
western
blot
analysi
use
assess
mrna
protein
level
marker
data
compar
anova
use
graphpad
prism
softwar
rel
protein
express
level
augment
cm
treatment
group
compar
model
control
indic
benefici
effect
dm
probabl
action
secret
factor
refer
previou
studi
fibroblast
growth
propos
contribut
factor
mechan
action
ad
neutral
antibodi
insulin
resist
model
result
significantli
diminish
protein
level
observ
support
assumpt
accordingli
studi
advoc
potenti
msc
cm
altern
insulin
sensit
discov
signal
factor
associ
paracrin
effect
diabet
mellitu
dm
recent
associ
alter
intestin
microbiota
consequ
intestin
dysbiosi
increas
intestin
permeabl
alter
microbi
metabolit
suspect
contribut
host
inflammatori
state
insulin
resist
human
diabet
shown
chang
bile
acid
ba
metabol
may
detriment
glycem
control
purpos
studi
examin
ba
metabol
dog
dm
relat
find
chang
intestin
microbiota
adult
dog
clinic
diagnosi
dm
prospect
enrol
along
healthi
control
dog
fecal
microbiota
analyz
rrna
gene
illumina
sequenc
fecal
concentr
primari
cholicchenodeoxychol
secondari
lithocholicdeoxycholicursodeoxychol
ba
measur
use
ga
chromatographi
mass
spectrometri
u
test
compar
median
valu
healthi
control
dog
dm
statist
signific
set
p
ten
diabet
dog
healthi
control
enrol
fecal
microbi
divers
lower
dm
dog
compar
healthi
control
pca
base
unweight
unifrac
distanc
metric
reveal
signific
cluster
dog
group
howev
linear
discrimin
analysi
effect
size
lefs
detect
differenti
abund
bacteri
taxa
lda
score
gammaproteobacteria
overrepres
erysipelotrichia
clostridia
bacteroidia
underrepres
dm
dog
compar
healthi
control
p
total
primari
ba
increas
dm
dog
compar
healthi
control
p
lithochol
acid
decreas
p
dog
dm
result
indic
dog
dm
intestin
dysbiosi
associ
ba
alter
pattern
dysbiosi
alter
ba
composit
similar
seen
human
dm
investig
necessari
determin
whether
dysbiosi
caus
consequ
dm
whether
associ
poor
glycem
control
differenti
inflammatori
bowel
diseas
ibd
alimentari
small
cell
lymphoma
lsa
predomin
form
chronic
enteropathi
cat
often
challeng
perform
immunohistochemistri
ihc
clonal
test
ie
pcr
antigen
receptor
rearrang
parr
adjunct
routin
histopatholog
assess
may
improv
diagnost
accuraci
endoscop
biopsi
eb
sampl
make
differenti
evid
suggest
poor
agreement
eb
sampl
collect
upper
small
intestin
usi
lower
small
intestin
lsi
area
sampl
patient
howev
perform
lower
gastrointestin
endoscopi
lge
along
upper
gastrointestin
endoscopi
uge
result
increas
cost
anesthesia
time
compar
uge
alon
goal
studi
evalu
diagnost
util
ihc
clonal
test
diagnosi
ibd
lsa
cat
assess
level
agreement
eb
sampl
usi
lsi
determin
diagnost
util
procur
lsi
sampl
total
cat
ce
gastrointestin
sign
week
durat
retrospect
n
prospect
n
enrol
veterinari
specialti
hospit
san
diego
ca
cat
uge
lge
perform
eb
sampl
obtain
site
case
retrospect
prospect
review
singl
pathologist
mra
categor
ibd
possibl
lsa
probabl
lsa
lsa
sampl
also
submit
ihc
clonal
test
previous
describ
base
stain
alon
cat
classifi
ibd
lsa
consider
ihc
clonal
cat
classifi
ibd
lsa
thirteen
case
diagnos
ibd
case
diagnos
possibl
lsa
probabl
lsa
base
stain
alon
subsequ
diagnos
lsa
addit
ihc
clonal
test
use
cohen
kappa
statist
k
agreement
usi
lsi
sampl
moder
k
base
stain
alon
also
moder
k
includ
ihc
clonal
test
lsa
case
diagnos
base
alon
case
diagnos
usi
biopsi
sampl
alon
case
diagnos
lsi
biopsi
sampl
alon
lsa
case
diagnos
ihc
clonal
lsa
diagnos
case
usi
biopsi
sampl
alon
case
lsi
biopsi
sampl
alon
result
show
addit
ihc
clonal
test
stain
increas
number
case
diagnos
lsa
research
warrant
assess
diagnost
accuraci
ihc
clonal
test
determin
chang
diagnosi
correl
patient
outcom
addit
moder
agreement
diagnosi
ibd
lsa
usi
lsi
sampl
lsi
rare
ad
addit
diagnost
inform
gastrointestin
microbiota
complex
ecosystem
play
import
role
host
health
immun
concern
regard
effect
pharmaceut
bacteri
microbiota
human
veterinari
speci
rais
specif
concern
potenti
deleteri
effect
antimicrobi
effect
anthelmint
therapi
bacteri
microbiota
dog
yet
evalu
littl
inform
avail
concern
effect
giardia
speci
cryptosporidium
cani
infectionon
gastrointestin
microbiota
purpos
studi
evalu
fecal
microbiota
adult
research
beagl
chronic
subclin
giardia
spp
c
cani
infect
administr
commerci
avail
prepar
febantel
combin
pyrantel
praziquantel
fpp
bayer
anim
health
shawne
ks
six
healthi
adult
research
beagl
subclin
giardia
spp
infect
c
cani
administ
fpp
direct
manufactur
mouth
daili
day
fecal
sampl
collect
day
fpp
day
first
day
administr
day
day
start
administr
day
fecal
dna
extract
qpcr
assay
perform
assess
abund
total
bacteria
faecalibacterium
turicibact
e
coli
streptococcu
blautia
fusobacterium
c
hiranoni
calcul
previous
publish
dysbiosi
index
di
bacteri
group
di
compar
across
time
point
use
friedman
test
dunn
appropri
statist
signific
set
p
abund
fusobacterium
increas
day
p
otherwis
statist
signific
chang
di
abund
bacteri
group
treatment
fpp
addit
di
group
dog
similar
previous
evalu
healthi
dog
dog
transient
increas
di
result
di
time
point
fpp
administr
consider
alter
fecal
bacteri
microbiota
group
research
beagl
studi
necessari
evalu
effect
anthelmint
agent
gastrointestin
microbiota
dog
previou
studi
reveal
mesenchym
stem
cell
msc
allevi
inflammatori
bowel
diseas
ibd
modul
inflammatori
cytokin
inflam
intestin
howev
mechan
underli
effect
complet
understood
sought
investig
therapeut
effect
canin
adipos
cat
inflammatori
bowel
diseas
mous
model
explor
mechan
regul
inflamm
dextran
sulfat
coliti
mice
infus
intraperiton
colon
tissu
collect
day
data
compar
anova
use
graphpad
prism
softwar
shown
induc
express
macrophag
marker
regul
express
cytokin
colon
quantit
real
analys
demonstr
less
intraperiton
inject
detect
inflam
colon
investig
effect
factor
vitro
transwel
system
use
demonstr
tumour
necrosi
geneprotein
releas
induc
macrophag
vivo
transfect
small
interf
rna
administ
intraperiton
abl
induc
macrophag
phenotyp
switch
inflam
colon
signific
effect
ibd
sever
conclus
amelior
ibd
induc
macrophag
switch
mice
canin
chronic
enteropathi
ce
associ
excess
releas
proinflammatori
mediat
eg
cytokin
human
anim
studi
cytokin
interleukin
il
tumor
necrosi
report
involv
induct
mainten
ce
aim
studi
describ
serum
concentr
dog
ce
healthi
dog
ctrl
dog
ce
includ
studi
serum
concentr
measur
use
previous
analyt
valid
electrochemiluminesc
immunoassay
canin
proinflammatori
panel
ultrasensit
kit
meso
scale
discoveri
data
analyz
use
nonparametr
statist
receiv
oper
characterist
analysi
roc
princip
compon
analysi
pca
signific
set
p
ce
group
compos
male
femal
median
age
year
year
signific
differ
age
sex
identifi
ce
ctrl
dog
serum
concentr
significantli
increas
ce
group
compar
ctrl
dog
result
group
shown
tabl
correl
found
age
sex
serum
cytokin
concentr
use
cutoff
valu
pgml
sensit
discrimin
ce
ctrl
dog
specif
use
cutoff
valu
pgml
sensit
specif
area
curv
tnf
respect
first
princip
compon
pca
explain
varianc
major
contributor
conclus
dog
ce
increas
concentr
unabl
identifi
significantli
alter
concentr
studi
need
assess
util
cytokin
diagnost
prognost
marker
dog
chronic
enteropathi
enterococcu
inhibit
growth
adhes
felin
tritrichomona
foetu
rachel
e
maggi
david
thoma
jodi
juli
katherin
tennesse
colleg
veterinari
medicin
knoxvil
tn
colleg
veterinari
medicin
blacksburg
carolina
state
colleg
veterinari
medicin
raleigh
nc
tritrichomona
foetu
tf
caus
chronic
diarrhea
cat
limit
treatment
option
increas
resist
support
investig
altern
treatment
probiot
emerg
adjunct
therapi
mani
intestin
pathogen
howev
littl
work
done
investig
efficaci
tf
infect
commerci
enterococcu
faecium
efm
novel
probiot
enterococcu
hira
eh
use
evalu
efficaci
inhibit
tf
growth
adhes
vitro
effect
enterococcu
tf
prolifer
evalu
throughout
log
phase
growth
media
potenti
probiot
reduc
tf
adhes
intestin
epithelium
analyz
previous
valid
model
use
porcin
intestin
epitheli
cell
tf
adhes
cytotox
evalu
use
fluoresc
microscopi
crystal
violet
spectrophotometr
analysi
sem
ifa
use
visual
interact
tf
enterococcu
monolay
data
analyz
use
sigmastat
inhibit
tf
growth
observ
concentr
low
tf
efm
p
determin
larg
ph
depend
p
inhibit
tf
replic
observ
enterococcu
indic
viabl
enterococcu
organ
requir
inhibit
pretreat
monolay
enterococcu
significantli
reduc
induc
cytopathogen
p
benefit
observ
enterococcu
introduc
simultan
follow
tf
infect
find
suggest
cat
probiot
contain
enterococci
may
allevi
clinic
ill
result
subsequ
tf
infect
eh
effect
decreas
tf
adhes
intestin
epithelium
compar
efm
p
suggest
superior
novel
probiot
tf
infect
preliminari
result
also
show
eh
effect
reduc
growth
adhes
strain
tf
result
support
investig
efficaci
probiot
adjunct
treatment
combat
tf
infect
cat
miniatur
schnauzer
predispos
idiopath
hyperlipidemia
ih
character
fast
hypertriglyceridemia
htgl
without
hypercholesterolemia
hchol
previou
data
suggest
ih
associ
subclin
inflamm
breed
ih
consid
risk
factor
sever
patholog
condit
includ
pancreat
reduc
gallbladd
motil
proteinuria
might
also
lead
insulin
resist
ir
evalu
homeostat
model
assess
insulin
resist
score
increas
serum
concentr
calprotectin
associ
ir
peopl
associ
report
dog
thu
aim
studi
evalu
indic
ir
popul
miniatur
schnauzer
serum
sampl
clinic
healthi
miniatur
schnauzer
use
studi
studi
questionnair
complet
dog
confirm
health
statu
medic
histori
serum
triglycerid
cholesterol
glucos
calprotectin
concentr
measur
sampl
pair
serum
sampl
avail
dog
ih
week
start
fat
diet
addit
serum
triglycerid
cholesterol
glucos
calprotectin
concentr
serum
insulin
measur
sampl
calcul
insulin
mul
x
glucos
mmoll
statist
analys
perform
use
pair
unpair
group
comparison
likelihood
ratio
test
total
dog
diagnos
ih
htgl
hchol
combin
ih
serum
glucos
concentr
differ
dog
normal
vs
increas
serum
calprotectin
concentr
either
hyperlipidem
normolipidem
group
p
dog
ih
includ
fat
dietari
trial
n
isol
htgl
n
combin
ih
significantli
higher
dog
increas
vs
normal
serum
calprotectin
concentr
p
signific
differ
seen
serum
insulin
glucos
concentr
dog
combin
ih
significantli
higher
p
serum
insulin
concentr
p
higher
proport
dog
increas
serum
calprotectin
concentr
p
dog
isol
htgl
differ
serum
glucos
concentr
detect
resolut
ih
dietari
intervent
fat
diet
associ
decreas
serum
insulin
concentr
p
increas
serum
calprotectin
concentr
p
result
suggest
presum
subclin
inflammatori
phenotyp
miniatur
schnauzer
ih
associ
increas
ir
find
lend
support
ambival
vs
properti
calprotectin
chang
gastrointestin
gi
permeabl
injuri
caus
breakdown
protect
gastrointestin
epitheli
barrier
commonli
occur
human
hors
dog
follow
strenuou
exercis
gastrointestin
injuri
increas
permeabl
rais
risk
ulcer
transloc
intestin
bacteria
caus
sepsi
system
inflammatori
respons
syndrom
sir
current
method
assess
intestin
injuri
permeabl
dog
either
invas
difficult
preform
high
variabl
intestin
fatti
acid
bind
protein
diamin
oxidas
dao
two
enterocyt
protein
absorb
epithelium
intestin
injuri
hypothes
dao
concentr
increas
strenuou
exercis
correl
previous
obtain
assess
intestin
permeabl
injuri
serum
collect
variou
distanc
race
trial
condit
alaskan
sled
dog
dao
level
quantifi
use
commerci
avail
elisa
assay
protein
concentr
correl
gastrointestin
permeabl
sever
gastroduoden
ulcer
previous
obtain
one
author
dao
significantli
increas
p
strenuou
exercis
relationship
exercis
correl
previous
collect
gi
permeabl
studi
establish
potenti
util
serum
dao
assess
gastrointestin
permeabl
injuri
dog
futur
research
continu
valid
easili
quantifi
biomark
investig
potenti
prognost
marker
acut
gastrointestin
injuri
race
sled
dog
chang
gastrointestin
gi
permeabl
injuri
caus
breakdown
protect
gastrointestin
epitheli
barrier
commonli
occur
human
hors
dog
follow
strenuou
exercis
gastrointestin
injuri
increas
permeabl
rais
risk
ulcer
transloc
intestin
bacteria
caus
sepsi
system
inflammatori
respons
syndrom
sir
current
method
assess
intestin
injuri
permeabl
dog
either
invas
difficult
preform
high
variabl
intestin
fatti
acid
bind
protein
diamin
oxidas
dao
two
enterocyt
protein
absorb
epithelium
intestin
injuri
hypothes
dao
concentr
increas
strenuou
exercis
correl
previous
obtain
assess
intestin
permeabl
injuri
serum
collect
variou
distanc
race
trial
condit
alaskan
sled
dog
dao
level
quantifi
use
commerci
avail
elisa
assay
protein
concentr
correl
gastrointestin
permeabl
sever
gastroduoden
ulcer
previous
obtain
one
author
dao
significantli
increas
p
strenuou
exercis
relationship
exercis
discov
correl
previous
collect
gi
permeabl
injuri
studi
establish
util
serum
dao
assess
gastrointestin
permeabl
injuri
dog
futur
research
continu
valid
easili
quantifi
biomark
investig
potenti
prognost
marker
well
assess
therapi
diseas
gastrointestin
injuri
dog
includ
sepsissir
exercis
obes
decompens
heart
diseas
felin
gi
motil
disord
present
diagnost
therapeut
challeng
avail
data
effect
variou
prokinet
drug
cat
tenuou
therefor
recommend
drug
usag
dosag
base
collect
clinic
experi
recent
incretin
focu
interest
benefici
role
glucos
homeostasi
treatment
type
diabet
mellitu
howev
impact
gi
motil
evalu
studi
assess
effect
metoclopramid
erythromycin
exenatid
gastric
empti
ge
gastric
motil
comparison
placebo
random
crossov
design
healthi
cat
administ
placebo
salin
po
sc
metoclopramid
mgkg
sc
erythromycin
mgkg
po
exenatid
sc
consecut
day
follow
minimum
washout
period
cat
random
treatment
group
sonograph
assess
ge
perform
dorsal
recumb
minut
follow
solid
test
meal
daili
energi
requir
interv
thereaft
hour
mean
area
transvers
imag
relax
antrum
obtain
time
point
express
percentag
maxim
antral
area
area
curv
auc
calcul
ge
time
get
determin
motil
index
mi
antral
contract
plot
time
mix
model
anova
cat
random
effect
treatment
fix
effect
use
assess
differ
fraction
get
mi
auc
treatment
posthoc
pairwis
comparison
examin
tukey
test
appropri
rate
ge
follow
metoclopramid
erythromycin
treatment
significantli
faster
compar
placebo
exenatid
statist
signific
differ
fraction
ge
get
follow
metoclopramid
erythromycin
treatment
compar
placebo
p
p
metoclopramid
erythromycin
respect
exenatid
p
p
metoclopramid
erythromycin
respect
rate
ge
follow
administr
exenatid
significantli
slower
compar
placebo
first
half
ge
curv
fraction
ge
p
total
auc
ml
follow
administr
erythromycin
mean
sd
metoclopramid
mean
sd
significantli
larger
p
respect
total
auc
ml
follow
administr
placebo
mean
sd
indic
increas
mi
antral
contract
howev
total
auc
ml
follow
exenatid
administr
mean
sd
differ
obtain
placebo
given
result
indic
metoclopramid
erythromycin
posit
gastric
prokinet
effect
healthi
cat
shorten
ge
time
increas
mi
antral
contract
contrast
exenatid
administ
healthi
cat
delay
ge
gastroesophag
reflux
ger
gener
anesthesia
report
dog
case
lead
esophag
esophag
strictur
format
ph
ger
time
remain
esophag
lumen
thought
play
import
role
develop
esophag
diseas
howev
incid
esophag
strictur
format
ger
unknown
yet
studi
dog
prevent
ger
caus
esophag
damag
aim
studi
determin
esophag
ph
esophag
lavag
affect
lumen
ph
follow
ger
sixti
dog
anesthet
elect
ovariectomi
evalu
ger
dog
identifi
ger
content
ph
includ
studi
esophag
phimped
cathet
milwauke
place
shortli
follow
anesthesia
use
endoscop
guidanc
cathet
tip
place
approxim
cm
cranial
lower
esophag
sphincter
ger
episod
defin
oral
progress
decreas
imped
decrement
ohm
esophag
baselin
record
esophag
ph
remain
conclus
surgeri
esophag
lavag
perform
tap
water
ml
aliquot
instil
gastric
tube
care
suction
interv
minut
post
lavag
esophag
ph
still
anoth
aliquot
instil
suction
ph
pair
test
wilcoxon
match
pair
test
spearman
rank
correl
coeffici
use
analyz
parametr
data
dog
strongli
acid
ger
ph
dog
abl
neutral
esophag
lumen
ph
end
procedur
dog
increas
esophag
lumen
ger
ph
anesthesia
p
dog
neutral
esophag
lumen
ger
ph
esophag
lumen
ger
ph
end
procedur
esophag
lavag
tap
water
increas
lumen
ger
dog
p
volum
water
use
lavag
associ
chang
lumen
ger
ph
r
p
present
studi
show
first
time
dog
capabl
neutral
strongli
acid
ger
dog
unabl
clear
acid
ger
possibl
one
predispos
esophag
strictur
format
esophag
lumen
lavag
water
dog
strongli
acid
ph
increas
esophag
lumen
ger
ph
major
dog
suggest
esophag
lavag
might
benefici
prevent
ger
complic
megaesophagu
high
mortal
rate
associ
difficulti
manag
patient
feed
current
guidelin
avail
determin
best
diet
consist
dog
aim
studi
compar
esophag
clearanc
time
ect
food
differ
consist
dog
congenit
idiopath
assess
esophag
contrast
videofluoroscopi
use
guid
manag
dog
improv
clinic
sign
qualiti
life
dog
congenit
idiopath
includ
evalu
dog
place
bailey
chair
administ
barium
sulfat
oral
three
form
liquid
slurri
within
can
food
meatbal
amount
barium
food
determin
bodyweight
rest
energi
requir
contrast
videofluoroscopi
esophagu
obtain
baselin
everi
minut
minut
stop
sooner
esophag
content
clear
patient
receiv
specif
recommend
manag
base
ect
differ
diet
consist
frequenc
regurgit
presenc
esophag
reflux
decreas
gastric
motil
bodi
condit
score
follow
commun
perform
assess
complianc
respons
manag
chang
clearanc
observ
dog
fed
liquid
dog
fed
slurri
dog
fed
meatbal
signific
differ
p
group
ect
liquid
faster
compar
meatbal
slurri
signific
differ
ect
slurri
meatbal
median
percentag
esophag
clearanc
interquartil
rang
slurri
interquartil
rang
meatbal
median
number
regurgit
per
week
rpw
decreas
significantli
interquartil
rang
time
first
assess
interquartil
rang
time
follow
p
addit
client
perceiv
dog
qualiti
life
much
better
somewhat
better
saw
chang
qualiti
life
time
recheck
video
capsul
endoscopi
vce
imag
modal
report
applic
includ
identif
mucos
lesion
detect
tradit
endoscopi
abdomin
imag
evalu
anthelmint
efficaci
peopl
vce
use
diagnost
manag
protocol
variou
gastrointestin
disord
particularli
obscur
gastrointestin
bleed
unexplain
iron
defici
anemia
ida
object
studi
evalu
use
vce
dog
microcytosi
medic
record
review
identifi
dog
microcytosi
receiv
vce
without
defin
etiolog
base
imag
signal
histori
physic
examin
find
clinicopatholog
data
capsul
endoscopi
find
record
dog
year
old
kg
mix
sex
breed
clinic
sign
includ
pica
melena
hematochezia
vomit
diarrhea
hyporexia
abdomin
radiograph
abdomin
ultrasound
unremark
dog
esophag
transit
time
gastric
empti
time
small
intestin
transit
time
minut
minut
minut
respect
mucos
lesion
identifi
dog
gastric
lesion
includ
erosionulc
hemorrhag
mucos
irregular
polypoid
lesion
intestin
lesion
includ
eros
hemorrhag
irregular
mucosa
mass
duodenum
jejunum
colon
lesion
includ
irregular
mucosa
vce
identifi
lesion
detect
diagnost
modal
dog
microcytosi
unknown
origin
vce
diagnost
tool
could
assist
identif
gastrointestin
lesion
dog
present
microcytosi
diagnost
modal
inconclus
cat
chronic
enteropathi
frequent
undergo
endoscopi
assess
intestin
biopsi
use
histopatholog
immunohistochemistri
clonal
test
pcr
antigen
receptor
rearrang
parr
howev
pauciti
data
find
modal
cohort
healthi
cat
thu
aim
studi
describ
result
histopatholog
immunohistochemistri
parr
endoscop
deriv
duoden
biopsi
specimen
clinic
healthi
cat
twenti
clinic
healthi
cat
underw
veterinari
medic
teach
hospit
texa
univers
anim
care
use
protocol
ca
tissu
specimen
collect
stomach
cat
duodenum
cat
evalu
accord
wsava
score
system
pathologist
mra
blind
health
statu
cat
addit
sampl
evalu
routin
immunohistochemistri
clonal
test
without
disclosur
clinic
statu
cat
cat
median
age
year
year
bodi
weight
kg
kg
bodi
condit
score
sampl
qualiti
report
good
case
histolog
evalu
stomach
reveal
mean
gastric
score
mean
duoden
score
immunohistochemistri
duoden
sampl
reveal
epitheliotrop
andor
lamina
propria
infiltr
case
result
clonal
test
duoden
sampl
reveal
clonal
rearrang
cat
polyclon
rearrang
cat
cat
result
suggest
clonal
rearrang
polyclon
background
result
one
cat
report
consist
pseudoclon
due
low
quantiti
target
dna
interpret
small
cell
lymphoma
base
immunohistochemistri
clonal
test
reach
healthi
cat
one
addit
cat
result
interpret
emerg
small
cell
lymphoma
interpret
enter
given
cat
result
one
cat
deem
uninterpret
due
pseudoclon
conclus
intestin
biopsi
clinic
healthi
cat
commonli
show
abnorm
find
use
histopatholog
immunohistochemistri
clonal
test
without
appar
clinic
signific
sensit
clonal
test
report
high
result
impli
assess
specif
diagnost
modal
warrant
inflammatori
bowel
diseas
ibd
alimentari
small
cell
lymphoma
scl
common
type
chronic
enteropathi
cat
diagnosi
differenti
requir
invas
expens
procedur
name
gastrointestin
endoscopi
histopatholog
assess
biopsi
aim
studi
character
intestin
mucos
proteom
cat
ibd
scl
identifi
potenti
biomark
differenti
diseas
entiti
mucos
proteom
character
duoden
biopsi
cat
ibd
cat
scl
use
differ
gel
electrophoresi
dige
anim
care
use
protocol
ca
duoden
biopsi
healthi
cat
serv
control
anim
care
use
protocol
ca
prior
analysi
cat
underw
comprehens
includ
histopatholog
immunohistochemistri
clonal
test
pcr
antigen
receptor
rearrang
intestin
biopsi
sampl
fluoresc
gel
imag
analyz
use
decydertm
differenti
analysi
softwar
spot
volum
compar
anova
differ
spot
volum
individu
group
compar
student
statist
signific
set
p
protein
spot
signific
differ
group
chang
analyz
liquid
chromatographi
spectrometri
total
spot
identifi
differenti
express
chang
healthi
cat
cat
ibd
scl
p
eight
spot
also
differenti
express
cat
ibd
scl
p
identifi
protein
annexin
apolipoprotein
famili
malat
dehydrogenas
differenti
express
spot
result
show
differ
mucos
proteom
healthi
cat
cat
ibd
cat
scl
protein
might
hold
potenti
develop
biomark
differenti
ibd
scl
cat
chronic
enteropathi
studi
valid
find
warrant
goal
studi
determin
preval
posit
fecal
occult
blood
test
cat
fed
veterinari
prescrib
gastrointestin
formul
diet
fecal
occult
blood
test
identifi
microscop
blood
stool
trace
bleed
gastrointestin
tract
occur
patholog
gastrointestin
lymphoma
chronic
enteropathi
gastric
ulcerseros
fecal
occult
blood
test
gfobt
reli
heme
peroxidas
activ
wide
use
human
medicin
inexpens
diagnost
tool
veterinari
patient
gfobt
presum
dietari
peroxidas
incomplet
research
especi
cat
eleven
clinic
healthi
cat
age
year
old
initi
fed
normal
diet
transit
fed
gastrointestin
diet
period
hydrolyz
protein
purina
ha
gastroenter
purina
en
two
fecal
sampl
test
per
cat
week
use
human
test
two
cat
produc
posit
stool
sampl
first
week
studi
fed
normal
diet
mix
ha
diet
stool
singl
cat
fed
can
en
diet
contain
liver
unlik
dri
form
produc
posit
result
week
studi
addit
cat
produc
posit
stool
result
week
fed
mix
haen
diet
studi
suggest
dietari
protein
sourc
interfer
felin
gfobt
especi
liver
diet
addit
suggest
gfobt
occur
week
follow
diet
chang
gastrointestin
formul
diet
avoid
potenti
transit
diet
infer
essenti
amino
acid
tryptophan
degrad
product
eg
serotonin
import
regul
respons
within
intestin
well
intestin
motil
furthermor
bacteria
metabol
tryptophan
variou
also
serv
signal
molecul
activ
pathway
organ
system
eg
brain
liver
kidney
alter
tryptophan
metabol
associ
inflammatori
bowel
diseas
ibd
human
dietari
supplement
tryptophan
shown
effect
experiment
coliti
model
aim
studi
evalu
chang
pathway
dog
intestin
diseas
fecal
sampl
dog
idiopath
ibd
dog
acut
hemorrhag
diarrhea
ahd
collect
fecal
sampl
healthi
dog
includ
control
group
sampl
extract
use
target
analysi
tsq
alti
tripl
quadrupol
liquid
spectrometri
chromatograph
peak
compar
standard
curv
quantif
adjust
initi
fecal
weight
follow
metabolit
measur
acetylcholin
anthranil
acid
indol
acid
acid
serotonin
tryptamin
tryptophan
tyramin
fecal
metabolit
compar
amongst
group
use
test
follow
dunn
multipl
comparison
test
signific
set
p
ahd
group
anthranil
acid
indol
acid
significantli
increas
respect
serotonin
tryptamin
decreas
respect
compar
healthi
control
fecal
tryptophan
increas
dog
ibd
signific
dog
ahd
p
compar
healthi
control
dog
signific
differ
fecal
metabolit
pathway
found
dog
ahd
compar
healthi
control
dog
studi
need
determin
clinic
implic
differ
idiopath
inflammatori
bowel
diseas
ibd
character
intestin
mucos
inflamm
associ
alter
gut
microbiom
intestin
dysbiosi
treatment
direct
pathophysiolog
mechan
often
includ
dietari
modif
antibiot
andor
immunosuppress
treatment
respons
often
suboptim
relaps
common
make
manag
ibd
challeng
intestin
dysbiosi
present
time
diagnosi
dog
ibd
howev
chang
microbiom
time
dog
undergo
standard
immunosuppresss
therapi
well
character
purpos
studi
evalu
longitudin
chang
intestin
microbiom
dog
ibd
treat
prednison
thirteen
dog
diagnos
idiopath
ibd
previous
fail
respond
treatment
elimin
diet
metronidazol
enrol
stool
sampl
collect
dog
initi
therapi
prednison
week
one
year
begin
treatment
thirteen
healthi
dog
enrol
studi
control
group
stool
sampl
kept
frozen
dna
extract
microbiota
character
use
illumina
sequenc
rrna
gene
data
analyz
use
quantit
insight
microbi
ecolog
qiim
beta
divers
evalu
phylogeni
base
unweight
unifrac
distanc
metric
statist
perform
analysi
similar
anosim
ibd
group
clinic
diseas
sever
cibdai
baselin
score
moder
sever
dog
achiev
partial
complet
remiss
clinic
sign
week
treatment
cibdai
score
significantli
reduc
week
treatment
p
baselin
dog
ibd
show
differ
microbi
composit
compar
healthi
dog
unweight
unifrac
distanc
demonstr
significantli
differ
beta
divers
group
differ
ibd
group
includ
increas
firmicut
p
actinobacteria
reduc
bacteroidet
p
fusobacteria
p
proteobacteria
within
ibd
group
beta
divers
still
significantli
chang
week
p
compar
healthi
control
year
follow
divers
metric
place
microbiom
treat
dog
closer
healthi
dog
still
significantli
differ
healthi
control
result
suggest
treatment
effect
improv
clinic
sign
dysbiosi
associ
ibd
still
present
one
year
initi
immunosuppress
therapi
even
dog
clinic
well
control
virul
clostridium
perfringen
attribut
variou
toxin
recent
newli
describ
toxin
netf
associ
clostridium
perfringen
type
report
dog
acut
hemorrhag
diarrhea
syndrom
ahd
limit
inform
avail
role
toxin
intestin
diseas
dog
aim
studi
evalu
preval
clostridium
perfringen
encod
netf
gene
fecal
sampl
dog
acut
chronic
gastrointestin
diseas
fecal
sampl
dog
analyz
abund
netf
gene
quantit
real
time
pcr
dog
divid
follow
group
healthi
hc
acut
hemorrhag
diarrhea
ahd
acut
hemorrhag
diarrhea
ad
chronic
enteropathi
ce
dog
exocrin
pancreat
insuffici
epi
proport
dog
fecal
sampl
posit
netf
gene
statist
analyz
use
test
graphpad
prism
signific
set
p
total
fecal
sampl
dog
gastrointestin
diseas
posit
clostridium
perfringen
encod
netf
gene
dog
ahd
dog
epi
fecal
sampl
healthi
dog
dog
ce
dog
acut
hemorrhag
diarrhea
detect
limit
pcr
assay
signific
associ
presenc
clostridium
perfringen
encod
netf
gene
ahd
p
studi
fecal
sampl
dog
acut
hemorrhag
diarrhea
commonli
posit
clostridium
perfringen
encod
netf
gene
also
clostridium
perfringen
encod
netf
gene
detect
healthi
dog
dog
acut
diarrhea
dog
chronic
enteropathi
dysbiosi
gastrointestin
microbiota
associ
increas
number
diseas
condit
includ
cancer
human
describ
dog
lymphoma
inde
chemotherapeut
agent
clearli
shown
directli
affect
microbiota
antibiot
often
prescrib
chemotherapi
howev
treatment
probiot
may
stabilis
support
function
microbiota
dysbiosi
randomis
crossov
trial
perform
investig
effect
treatment
day
probiot
bacterium
enterococcu
faecium
ncimb
x
cfu
microbiota
dog
sarcoma
n
receiv
chemotherapi
doxorubicin
faecal
sampl
collect
administr
doxorubicin
treatment
probiot
placebo
faecal
dna
extract
submit
illumina
sequenc
follow
analysi
microbiota
use
qiim
platform
addit
healthi
dog
fed
probiot
prepar
day
faecal
sampl
collect
day
trial
dog
process
ident
quantit
polymeras
chain
reaction
develop
detect
quantifi
probiot
bacterium
faec
analysi
faecal
microbi
commun
reveal
dog
sarcoma
sever
dysbiosi
characteris
signific
reduct
number
observ
speci
p
speci
rich
divers
p
shannon
index
p
comparison
healthi
dog
treatment
probiot
prepar
impact
speci
rich
divers
faecal
microbi
commun
dog
signific
increas
amount
enterobacteriacea
p
faecal
microbi
commun
durat
clinic
trial
probiot
bacteria
significantli
increas
faec
whilst
healthi
sick
dog
took
probiot
formul
p
detect
small
amount
dog
n
seven
day
end
treatment
concurr
antibiot
therapi
affect
dysbiosi
present
faec
dog
sarcoma
mix
model
analysi
p
dog
sarcoma
also
dysbiosi
affect
treatment
probiot
bacterium
e
faecium
ncimb
clinician
awar
chemotherapi
antibiot
therapi
may
lead
increas
enterobacteriacea
faec
immunosuppress
patient
measur
serum
concentr
pancreat
lipas
immunoreact
pli
becom
standard
diagnosi
pancreat
dog
cat
recent
new
test
measur
canin
pli
cpli
vetscan
cpl
rapid
test
use
vetscan
vue
analyz
becom
avail
market
materi
well
analyz
suggest
new
assay
provid
accur
serum
cpli
concentr
within
margin
compar
spec
assay
analyt
clinic
valid
data
assay
publish
goal
studi
evalu
linear
precis
reproduc
vetscan
cpl
rapid
test
leftov
serum
sampl
clinic
submiss
gastrointestin
laboratori
texa
univers
use
studi
assess
linear
good
qualiti
ie
lipem
hemolyz
icter
serum
sampl
throughout
work
rang
cpli
assay
measur
spec
idexx
laboratori
portland
main
analyz
use
vetscan
cpl
rapid
test
assay
abaxi
union
citi
ca
undilut
dilut
observedexpect
ratio
calcul
variabl
assess
good
qualiti
serum
sampl
analyz
time
differ
vue
analyz
time
assess
variabl
good
qualiti
serum
sampl
analyz
differ
day
machin
sampl
analyz
singl
machin
sampl
analyz
machin
observ
expect
ratio
dilut
parallel
rang
mean
variabl
rang
mean
cv
sampl
machin
variabl
rang
mean
cv
sampl
machin
sampl
result
two
sampl
even
three
sampl
diagnost
bin
ie
within
refer
interv
gray
rang
suggest
pancreat
experi
new
vetscan
cpl
rapid
test
vetscan
vue
show
poor
linear
clinic
signific
work
rang
assay
narrow
make
dilut
necessari
sampl
higher
cpli
concentr
also
assay
precis
mean
cv
final
variabl
unaccept
high
mean
cv
affect
actual
diagnost
bin
mani
case
conclus
vetscan
cpl
rapid
test
vetscan
vue
lack
linear
precis
reproduc
malnutrit
associ
increas
mortal
human
inflammatori
bowel
diseas
therefor
aim
studi
determin
histor
clinic
laboratori
paramet
malnutrit
time
diagnosi
dog
enteropathi
ple
due
chronic
enteropathi
ce
lymphangiectasia
affect
mortal
follow
treatment
failur
medic
record
retrospect
search
canin
case
ple
diagnos
ce
lymphangiectasia
histopatholog
intestin
biopsi
neoplast
caus
includ
alimentari
lymphoma
exclud
case
histor
clinic
laboratori
paramet
time
diagnosi
record
obtain
telephon
contact
refer
veterinari
practic
dog
bodi
condit
score
bc
categor
dog
bc
dog
bc
dog
bc
place
group
base
clinician
written
assess
dog
identifi
median
rang
median
rang
median
rang
dog
document
weight
loss
time
diagnosi
sever
moder
mild
loss
two
dog
lost
dog
die
euthan
follow
treatment
failur
signific
effect
bodi
condit
score
percentag
weight
loss
bodi
weight
appetit
serum
albumin
cholesterol
cobalamin
folat
concentr
canin
chronic
enteropathi
activ
index
durat
sign
mortal
p
howev
dog
higher
calor
intak
diagnosi
increas
number
day
death
euthanasia
follow
treatment
failur
p
correl
coeffici
paramet
associ
malnutrit
time
diagnosi
ple
due
ce
lymphangiectasia
dog
studi
predictor
mortal
follow
treatment
failur
therefor
use
predict
respons
treatment
howev
altern
measur
malnutrit
may
requir
definit
investig
role
malnutrit
prognosi
canin
ple
studi
aim
assess
use
buncr
confirm
occult
gastrointestin
gi
hemorrhag
local
lesion
along
gi
tract
medic
record
dog
retrospect
review
buncr
record
patient
present
visibl
gi
hemorrhag
classifi
overt
gi
bleeder
n
dog
present
without
visibl
gi
hemorrhag
classifi
occult
gi
bleeder
n
sign
gi
hemorrhag
develop
hospit
andor
bleed
confirm
via
capsul
endoscopi
laparotomi
necropsi
healthi
blood
donor
act
control
n
gi
lesion
classifi
upper
n
lower
n
upper
lower
n
locat
bleed
identifi
median
valu
compar
among
group
use
test
receiv
oper
characterist
roc
curv
use
identifi
paramet
respect
sensit
specif
signific
set
p
buncr
significantli
higher
dog
overt
occult
gi
bleed
compar
healthi
dog
buncr
overt
gi
bleeder
significantli
higher
occult
gi
bleeder
signific
differ
buncr
dog
lesion
upper
lower
part
gi
tract
valu
buncr
sensit
specif
distinguish
occult
gi
bleeder
healthi
dog
specif
measur
buncr
may
use
predict
occult
gi
bleed
dog
clinic
sign
canin
chronic
enteropathi
ce
indic
gastrointestin
dysfunct
includ
malabsorpt
result
abnorm
composit
materi
within
gastrointestin
tract
may
perpetu
exacerb
clinic
sign
compar
healthi
dog
alter
concentr
fecal
fatti
acid
ffa
dog
variou
acut
chronic
gastrointestin
diseas
report
previous
studi
aim
identifi
subset
dog
ce
character
increas
ffa
concentr
assess
concentr
one
month
treatment
fecal
sampl
collect
dog
activ
sign
chronic
enteropathi
ce
n
healthi
dog
n
analyz
ga
chromatographymass
spectrometri
gcm
use
assay
healthi
refer
interv
calcul
mean
sd
sampl
taken
approxim
one
month
baselin
subset
dog
increas
ffa
concentr
n
also
analyz
u
test
wilcoxon
sign
rank
use
compar
group
statist
signific
set
p
total
ffa
concentr
baselin
significantli
increas
dog
ce
rel
healthi
dog
p
healthi
canin
ffa
refer
interv
found
mgmg
dog
ce
increas
ffa
median
sd
mgmg
p
ffa
concentr
dog
one
month
treatment
significantli
decreas
mgmg
p
longer
statist
differ
healthi
dog
p
longer
exceed
healthi
dog
refer
interv
studi
identifi
increas
ffa
subtyp
ce
demonstr
normal
ffa
concentr
one
month
treatment
identifi
patient
increas
ffa
concentr
treat
patient
highli
digest
moder
low
fat
diet
may
improv
respons
therapi
dog
ce
howev
studi
requir
correl
treatment
clinic
outcom
granulomat
gastroenter
rare
diseas
dog
usual
occur
associ
infecti
diseas
reaction
endogen
substanc
foreign
object
recent
studi
report
miniatur
dachshund
md
predispos
develop
granuloma
like
develop
granulomat
gastroduoden
within
month
surgic
resect
howev
littl
inform
report
diseas
md
therefor
purpos
studi
describ
clinic
characterist
granulomat
gastroenter
md
medic
record
dog
histopatholog
diagnos
granulomat
gastriti
enter
andor
coliti
veterinari
medic
center
univers
tokyo
januari
juli
retrospect
review
inform
signal
clinic
sign
clinicopatholog
data
treatment
protocol
respons
treatment
prognosi
collect
twenti
dog
compris
md
french
bulldog
boston
terrier
miniatur
schnauzer
toy
poodl
pembrok
welsh
corgi
pomeranian
mix
breed
includ
studi
eleven
md
granulomat
lesion
pyloru
andor
duodenum
breed
dog
dog
idiopath
granuloma
pyloru
andor
duodenum
dog
idiopath
granulomat
lesion
jejunum
ileum
andor
colon
remain
dog
diagnos
granulomat
coliti
ie
histiocyt
ulcer
coliti
therefor
analysi
granulomat
gastriti
md
perform
median
age
month
rang
month
male
castrat
femal
spay
dog
six
dog
histori
granuloma
surgic
resect
month
prior
inclus
studi
fever
commonli
observ
median
rang
elev
serum
protein
mgdl
observ
dog
median
mgdl
rang
mgdl
histopatholog
examin
foreign
materi
detect
case
four
dog
initi
underw
pyloroplasti
gastroduodenostomi
resect
granuloma
subsequ
receiv
immunosuppress
therapi
within
month
surgeri
due
recurr
lesion
n
base
veterinarian
decis
n
dog
initi
treat
immunosuppress
drug
result
dog
receiv
immunosuppress
therapi
prednisolon
mgkgday
andor
cyclosporin
mgkgday
initi
immunosuppress
clinic
sign
resolv
serum
protein
concentr
decreas
refer
rang
dog
within
month
nine
dog
show
recurr
lesion
prednisolon
taper
median
durat
initi
immunosuppress
day
rang
day
respond
well
immunosuppress
prednisolon
mgkgday
addit
cyclosporin
azathioprin
median
period
day
rang
day
dog
die
day
initi
present
caus
death
aspir
pneumonia
n
hepat
tumor
n
conclus
immunosuppress
therapi
effect
manag
granulomat
gastriti
md
prevent
vomit
ie
aspir
pneumonia
may
import
ensur
good
prognosi
describ
previou
studi
granulomat
gastriti
like
occur
md
histori
granuloma
seem
risk
factor
howev
sever
case
dog
never
undergon
surgeri
futur
studi
innat
immun
system
dog
case
warrant
inflammatori
colorect
polyp
icrp
emerg
diseas
miniatur
dachshund
md
md
icrp
exhibit
multipl
polyp
sever
neutrophil
infiltr
respond
immunosuppress
therapi
macrophag
polypoid
lesion
describ
play
import
role
neutrophil
infiltr
lesion
produc
interleukin
il
contrari
cytokin
also
report
upregul
polypoid
lesion
signific
pathogenesi
icrp
clarifi
mucos
regulatori
cell
treg
one
cellular
sourc
describ
maintain
gut
health
regul
mucos
inflamm
human
dog
therefor
object
studi
compar
distribut
treg
polypoid
lesion
icrp
colon
mucosa
studi
compris
md
diagnos
icrp
dog
control
subject
control
dog
tissu
biopsi
specimen
polypoid
lesion
obtain
md
collect
tissu
sampl
macroscop
colon
mucosa
md
control
dog
includ
control
sampl
obtain
md
control
dog
use
previou
studi
igarashi
et
al
quantit
polymeras
chain
reaction
use
quantifi
gene
express
interferon
ifn
tumor
necrosi
factor
tnf
transform
growth
forkhead
boxprotein
tissu
sampl
gene
express
data
tumor
necrosi
factor
tnf
present
previou
studi
igarashi
et
al
includ
analysi
number
posit
cell
treg
ioniz
calcium
bind
adapt
molecul
posit
cell
macrophag
determin
use
immunohistochemistri
express
level
test
gene
except
significantli
polypoid
lesion
rate
increas
express
gene
compar
rate
increas
significantli
higher
wherea
rate
increas
significantli
lower
number
treg
polypoid
lesion
significantli
increas
compar
colon
mucosa
md
control
dog
number
macrophag
significantli
differ
group
signific
posit
correl
express
level
gene
gene
r
p
addit
signific
posit
correl
observ
express
level
gene
number
treg
r
p
summari
upregul
significantli
correl
distribut
treg
polypoid
lesion
md
howev
rate
increas
express
level
rel
low
compar
proinflammatori
cytokin
therefor
increas
number
treg
cytokin
polypoid
lesion
consid
reactiv
chang
insuffici
regul
develop
inflamm
analysi
associ
treg
distribut
lesion
prognosi
includ
respons
immunosuppress
therapi
warrantedno
clinic
sign
larg
bowel
diarrhea
common
dog
hous
anim
shelter
often
due
parasit
stress
use
diet
increas
level
dietari
fiber
thought
benefici
manag
case
purpos
studi
determin
whether
feed
commerci
avail
veterinari
diet
pro
veterinari
diet
en
gastroenter
fiber
would
associ
improv
outcom
compar
diet
typic
fiber
level
pro
adult
shred
blend
chicken
rice
formula
affect
dog
hous
singl
shelter
design
approv
shelter
clinic
review
board
fecal
score
determin
train
observ
mask
diet
group
sampl
compar
standard
score
sheet
stool
hard
dri
firm
hard
normal
littl
segment
moist
moist
log
shape
moist
pile
textur
defin
shape
wateri
puddl
qualifi
studi
dog
present
fecal
score
hematochezia
mucu
strain
dog
random
fed
diet
administ
fenbendazol
mgkg
po
daili
day
metronidazol
mgkg
po
twice
daili
day
dog
studi
least
day
includ
data
analysi
proport
dog
fecal
score
less
day
adopt
last
studi
day
day
proport
stool
group
fecal
score
greater
compar
fisher
exact
test
signific
defin
p
total
dog
enter
pilot
studi
dog
per
diet
complet
protocol
date
dog
fed
high
fiber
diet
fecal
score
less
last
day
studi
statist
differ
dog
fed
control
diet
dog
p
proport
stool
fecal
score
significantli
greater
p
dog
fed
control
diet
stool
compar
high
fiber
diet
stool
result
suggest
therapeut
effect
induc
fiber
food
support
feed
diet
dog
acut
larg
bowel
diarrhea
chronic
enteropathi
ce
common
cat
especi
senior
cat
popul
metabolom
complet
set
compound
found
biolog
sampl
chang
metabolom
document
differ
speci
variou
condit
metabolom
hold
potenti
discoveri
diseas
biomark
well
therapeut
target
aim
studi
perform
untarget
analysi
fecal
metabolom
cat
differ
form
chronic
enteropathi
fecal
metabolom
character
cat
ce
use
ultrahigh
perform
liquid
chromatographi
tandem
mass
spectroscopi
prior
analysi
cat
underw
comprehens
work
includ
histopatholog
immunohistochemistri
clonal
test
pcr
antigen
receptor
rearrang
biopsi
determin
phenotyp
fifteen
healthi
cat
similar
age
serv
control
group
differ
healthi
cat
cat
ce
evalu
use
welch
adjust
use
fals
discoveri
rate
express
statist
signific
set
q
differ
cat
idiopath
inflammatori
bowel
diseas
ibd
small
cell
lymphoma
scl
evalu
use
u
test
base
histopatholog
immunohistochemistri
clonal
test
diagnosi
ibd
reach
cat
intestin
small
cell
lymphoma
scl
cat
cat
histopatholog
consist
inflammatori
lesion
clonal
test
intestin
biopsi
reveal
clonal
rearrang
identifi
name
biochem
show
decreas
concentr
found
increas
fecal
sampl
cat
ce
compar
healthi
control
metabol
pathway
found
significantli
alter
cat
ce
includ
tryptophan
metabol
glycolysi
polyunsatur
fatti
acid
metabol
secondari
bile
acid
metabol
random
forest
analysi
reveal
predict
accuraci
differenti
control
cat
ce
arachidon
acid
show
trend
toward
differenti
cat
ibd
scl
p
princip
compon
analysi
show
separ
cluster
healthi
cat
cat
ce
howev
separ
cluster
visibl
differ
type
ce
result
reveal
disrupt
sever
major
metabol
pathway
pathway
associ
inflamm
studi
warrant
determin
whether
identifi
compound
hold
discriminatori
power
differenti
ibd
scl
may
serv
therapeut
target
cat
ce
ultrasonographi
ceu
report
feasibl
evalu
intestin
perfus
healthi
dog
consid
support
diagnosi
monitor
human
patient
inflammatori
bowel
diseas
thu
also
expect
valuabl
dog
chronic
intestin
diseas
prospect
studi
conduct
examin
duoden
perfus
dog
chronic
enteropathi
ce
n
intestin
lymphoma
n
comparison
control
involv
dog
histopatholog
normal
duodenum
n
dog
ce
group
classifi
base
canin
chronic
enteropathi
clinic
activ
index
ccecai
ceu
remiss
ccecai
n
symptomat
ccecai
n
duodenum
imag
intraven
bolu
inject
contrast
agent
mlkg
perfus
paramet
deriv
quantit
analysi
ceu
imag
includ
ttp
peak
intens
pi
area
curv
auc
rate
wir
wor
respect
evalu
pi
significantli
higher
symptomat
ce
median
rang
mean
pixel
valu
mpv
compar
control
mpv
auc
significantli
higher
symptomat
ce
mpvsec
compar
control
mpvsec
remiss
ce
mpvsec
posit
correl
detect
pi
ccecai
ce
dog
signific
differ
perfus
paramet
detect
intestin
lymphoma
ce
well
control
group
conclus
pi
auc
could
detect
chang
duoden
perfus
associ
ce
make
paramet
provid
use
inform
diagnosi
monitor
ce
dog
dysbiosi
play
role
pathogenesi
gastrointestin
gi
diseas
human
anim
medic
intervent
potenti
alter
gi
microbiota
fecal
microbi
transplant
fmt
util
treat
human
patient
gi
diseas
efficaci
fmt
demonstr
sever
studi
involv
human
patient
gi
diseas
also
potenti
advers
effect
use
antibiot
gi
microbiota
report
recent
studi
human
dog
aim
studi
evalu
effect
fmt
antibiot
therapi
gi
microbi
commun
dog
acut
diarrhea
total
fecal
sampl
dog
acut
diarrhea
treat
either
fmt
g
donor
stoolkg
dilut
cc
salin
via
enema
n
metronidazol
mtz
po
bid
day
n
collect
week
week
intervent
fecal
dna
evalu
quantit
pcr
qpcr
analysi
select
bacteri
group
total
bacteria
faecalibacterium
spp
turicibact
spp
streptococcu
spp
e
coli
blautia
spp
fusobacterium
spp
c
hiranoni
result
use
calcul
dysbiosi
index
di
fece
evalu
use
fecal
score
system
nestl
purina
fecal
score
system
di
fecal
score
compar
group
use
wilcoxon
test
presenc
dysbiosi
di
compar
group
use
fisher
exact
test
p
consid
statist
signific
fecal
score
differ
significantli
group
either
p
p
respect
fmt
group
significantli
lower
fecal
score
mtz
group
p
di
differ
significantli
two
group
p
fmt
group
significantli
lower
di
mtz
group
p
p
respect
recoveri
dysbiosi
also
evalu
fmt
group
significantli
lower
rate
dysbiosi
mtz
group
p
likewis
fmt
group
significantli
lower
rate
dysbiosi
mtz
group
p
studi
dog
acut
diarrhea
treat
fmt
show
significantli
lower
fecal
score
dysbiosi
index
dog
treat
metronidazol
week
treatment
studi
requir
determin
whether
differ
clinic
relev
fatti
protein
fabp
kda
cytosol
protein
play
role
intracellular
lipid
transport
fabp
isoform
found
epithelium
gastrointestin
tract
releas
respons
increas
intestin
permeabl
andor
enterocyt
damag
studi
human
rodent
model
shown
increas
serum
fabp
concentr
sever
gastrointestin
disord
aim
studi
evalu
serum
concentr
fabp
healthi
pet
dog
dog
chronic
enteropathi
serum
sampl
collect
dog
chronic
enteropathi
ce
healthi
control
dog
serum
concentr
fabp
measur
use
commerci
avail
canin
specif
elisa
kit
canin
fabp
elisa
kit
bluegen
biotech
china
serum
fabp
concentr
compar
group
use
wilcoxon
test
correl
serum
fabp
concentr
diseas
sever
dog
ce
evalu
use
canin
chronic
enteropathi
clinic
activ
index
ccecai
evalu
use
spearman
p
consid
statist
signific
serum
fabp
concentr
differ
significantli
dog
ce
median
ngml
ngml
healthi
control
dog
median
ngml
ngml
p
serum
fabp
concentr
differ
significantli
dog
ce
median
ngml
ngml
healthi
control
dog
median
ngml
ngml
p
within
ce
group
observ
signific
correl
either
serum
fabp
spearman
p
fabp
spearman
p
ccecai
studi
serum
fabp
concentr
dog
chronic
enteropathi
significantli
differ
compar
healthi
control
dog
also
serum
concentr
fabp
correl
diseas
sever
dog
ce
felin
pancreat
fp
increasingli
diagnos
recent
year
clinic
studi
scarc
retrospect
studi
character
larg
cohort
cat
diagnos
fp
requir
hospit
inclus
criteria
includ
ultrasonograph
evid
pancreat
andor
posit
snap
fpli
test
andor
increas
activ
andor
histopatholog
diagnos
compat
clinic
sign
death
rate
cat
includ
death
cat
euthanasia
owe
clinic
deterior
cat
hospit
median
time
onset
clinic
sign
present
hospit
longer
p
vs
survivor
etiolog
fp
identifi
cat
includ
recent
gener
anesthesia
trauma
hemodynam
compromis
organophosph
intox
weight
loss
p
depress
present
p
frequent
fever
frequent
p
survivor
occurr
pleural
effus
p
acut
kidney
injuri
p
associ
death
present
median
serum
glucos
p
total
p
concentr
lower
median
serum
creatinin
concentr
p
higher
vs
survivor
hypoglycemia
ioniz
hypocalcemia
present
parenter
nutrit
administr
persist
anorexia
hospit
associ
death
p
antibiot
administr
p
associ
surviv
unreport
prognost
factor
warrant
futur
prospect
evalu
ascertain
valid
though
definit
diagnosi
lymphangectasia
requir
histopatholog
assess
visual
assess
shown
sensit
indic
diseas
effort
increas
conspicu
characterist
dilat
lacteal
seen
lymphangectasia
mani
endoscopist
recommend
enter
administr
high
fat
meal
prior
endoscopi
spite
lack
control
studi
report
efficaci
techniqu
use
capsul
endoscopi
investig
effect
high
fat
meal
gastrointestin
transit
time
endoscop
well
ultrasonograph
appear
small
intestin
random
prospect
crossov
studi
four
healthi
dog
baselin
capsul
endoscopi
abdomin
ultrasound
perform
thereaft
administ
differ
high
fat
meal
corn
oil
dairi
cream
differ
time
point
hour
prior
undergo
capsul
endoscopi
abdomin
ultrasound
outcom
assess
includ
gastrointestin
transit
time
appear
intestin
mucosa
assess
capsul
endoscopi
addit
intestin
wall
thick
presenc
mucos
hyperecho
speckl
assess
blind
manner
ultrasound
result
significantli
longer
gastric
transit
time
compar
control
p
also
gastric
retent
capsul
occur
significantli
commonli
dog
fed
either
corn
oil
dairi
cream
p
studi
result
gastric
retent
capsul
hour
none
control
studi
gastric
retent
addit
gastric
retent
occur
significantli
often
dog
fed
corn
oil
dairi
cream
p
though
gastric
retent
limit
number
case
visual
assess
small
intestin
mucosa
could
perform
studi
subject
judg
moder
mark
promin
villi
increas
number
dilat
lacteal
compar
control
studi
small
intestin
wall
thick
differ
significantli
control
dog
howev
mucos
speckl
score
jejunum
significantli
greater
dog
fed
cream
oil
control
dog
p
though
might
increas
promin
duoden
villi
gastric
transit
time
significantli
prolong
result
inabl
capsul
endoscopi
visual
assess
small
intestin
half
case
studi
futur
studi
investig
techniqu
includ
use
tradit
push
endoscopi
overcom
limit
allow
consist
assess
intestin
mucos
appear
novel
inflammatori
marker
evalu
human
anim
increas
concentr
gastric
mucosa
human
helicobact
pylori
infect
previous
report
gastric
mucosa
dog
frequent
colon
sever
helicobact
speci
howev
poor
associ
helicobact
organ
densiti
mucos
inflamm
purpos
studi
evalu
gastric
tissu
local
immunohistochemistri
ihc
dog
determin
correl
densiti
helicobact
organ
contain
cell
lamina
propria
dog
gastric
diseas
healthi
control
dog
local
posit
cell
helicobact
organ
studi
use
gastric
biopsi
dog
chronic
gastriti
healthi
control
dog
obtain
patient
present
emerg
servic
veterinari
teach
hospit
texa
univers
none
gross
histopatholog
lesion
suggest
gastrointestin
diseas
research
dog
universidad
de
calda
dog
receiv
antibiot
corticosteroid
treatment
last
two
week
prior
collect
gastric
biopsi
ihc
perform
use
antibodi
direct
canin
helicobact
spp
respect
stain
lamina
propria
quantifi
classifi
absent
mild
moder
sever
helicobact
densiti
grade
use
similar
criteria
histopatholog
evalu
conduct
follow
world
small
anim
veterinari
associ
wsava
grade
scheme
spearman
rank
correl
use
evalu
possibl
associ
helicobact
densiti
histopatholog
find
u
test
use
compar
ordin
variabl
healthi
sick
dog
stain
found
predominantli
neutrophil
monocyt
less
frequent
observ
fibroblast
epitheli
cell
infiltr
lamina
propria
contain
cell
consid
mild
healthi
anim
absent
express
correl
lamina
propria
neutrophil
p
dog
chronic
gastriti
infiltr
consid
mild
absent
dog
mild
moder
mononuclear
infiltr
dog
normal
gastric
mucosa
helicobact
organ
identifi
dog
dog
gastric
colon
consid
mild
moder
two
dog
sever
colon
helicobact
distribut
includ
superfici
epithelium
lumen
gastric
gland
within
pariet
cell
signific
differ
found
healthi
sick
dog
helicobact
organ
densiti
stain
contrari
helicobact
pylori
infect
human
colon
stomach
helicobact
spp
associ
infiltr
cell
express
also
express
limit
neutrophil
monocyt
canin
gastric
mucosa
correl
infiltr
neutrophil
count
potenti
caus
requir
studi
ihc
express
dog
chronic
gastriti
differ
mucosa
healthi
dog
canin
inflammatori
bowel
diseas
ibd
result
chronic
intestin
inflamm
immun
dysregul
gut
includ
abnorm
immun
respons
commens
intestin
flora
increas
immunoglobulin
ig
gut
bacteria
like
activ
immun
respons
local
system
howev
never
investig
dog
ibd
yet
therefor
studi
investig
whether
humor
immun
respons
commens
gut
bacteria
ibd
greater
healthi
dog
addit
whether
bacteria
potenti
trigger
exacerb
immun
respons
aggrav
gut
homeostasi
fresh
fecal
materi
collect
ibd
dog
clinic
healthi
dog
mean
age
sd
year
respect
patient
diagnost
confirm
endoscop
biopsi
histori
receiv
immunosuppress
medic
work
compar
amount
fecal
bacteria
bind
igg
iga
vivo
ibd
healthi
canin
flow
cytometr
analysi
addit
extent
macrophag
phagocytosi
macrophag
activ
fecal
bacteria
deriv
ibd
vs
healthi
dog
investig
flow
cytometr
analysi
elisa
comparison
group
evalu
use
statist
signific
set
p
level
found
fecal
bacteria
ibd
dog
alreadi
bound
iga
igg
subclass
ig
significantli
higher
level
extens
bacteria
normal
dog
iga
p
igg
p
interestingli
correl
bacteria
degre
score
index
canin
ibd
activ
index
cibdai
mean
sd
r
canin
chronic
enteropathi
clinic
activ
index
ccecai
r
moreov
result
suggest
igg
bound
gut
bacteria
mainli
deriv
local
mucos
immun
activ
system
sinc
serum
incub
e
coli
isol
differ
ibd
healthi
anim
addit
compar
bacteria
normal
control
anim
ibd
fecal
bacteria
significantli
stimul
higher
level
phagocytosi
canin
primari
macrophag
p
well
cell
canin
macrophag
tumor
cell
line
p
upregul
surfac
activ
marker
mhc
ii
respons
group
compar
phagocytosi
ibd
gut
bacteria
activ
macrophag
stimul
higher
product
normal
gut
bacteria
p
contrast
product
primari
macrophag
incub
ibd
fecal
bacteria
significantli
decreas
compar
normal
flora
healthi
dog
p
overal
result
show
ibd
dog
higher
fecal
bacteria
normal
healthi
control
potenti
stimul
greater
immun
respons
determin
macrophag
phagocytosi
activ
suggest
local
humor
respons
gut
bacteria
ibd
play
crucial
role
pathogenesi
result
chronic
activ
inflamm
scenario
characterist
ibd
mani
studi
canin
gastrointestin
diseas
focus
chang
fecal
microbiota
examin
function
chang
studi
fecal
metabolit
metabolit
fatti
acid
primari
bile
acid
associ
diarrhea
human
therefor
aim
studi
quantifi
sever
metabolit
associ
bacteri
group
fece
dog
acut
diarrhea
fecal
sampl
obtain
healthi
dog
n
dog
acut
diarrhea
n
dna
extract
analysi
major
bacteri
group
qpcr
target
ga
spectrometri
assay
use
quantifi
fatti
acid
sterol
bile
acid
concentr
fece
dysbiosi
index
calcul
base
abund
major
bacteri
taxa
di
refer
limit
valu
indic
dysbiosi
statist
analysi
perform
use
mann
whitney
test
signific
set
p
fecal
concentr
stearic
acid
p
arachidon
acid
p
nervon
acid
p
increas
dog
acut
diarrhea
compar
healthi
dog
cholesterol
p
concentr
increas
coprostanol
p
campesterol
p
stigmasterol
p
fucosterol
p
p
sitostanol
p
concentr
decreas
dog
acut
diarrhea
ratio
secondari
bile
acid
total
bile
acid
concentr
decreas
dog
acut
diarrhea
p
dysbiosi
index
significantli
increas
dog
acut
diarrhea
p
compar
healthi
dog
conclus
result
suggest
numer
metabol
chang
occur
concurr
alter
microbiota
dog
acut
diarrhea
fecal
metabolit
pattern
dog
acut
diarrhea
resembl
found
human
bile
acid
fatti
acid
diarrhea
human
mice
pig
paneth
cell
locat
crypt
close
intestin
stem
cell
isc
contain
larg
granul
stain
posit
lysozym
cell
involv
product
growth
factor
necessari
isc
function
produc
antimicrobi
peptid
defect
paneth
cell
function
involv
pathogenesi
differ
intestin
diseas
human
inflammatori
bowel
diseas
colorect
cancer
dog
cat
small
intestin
consist
stain
neg
lysozym
cell
morpholog
resembl
paneth
cell
identifi
light
microscopi
therefor
sought
character
cell
function
repres
paneth
cell
dog
small
intestin
use
full
thick
biopsi
well
primari
cultur
epitheli
cell
enteroid
tissu
piec
acquir
jejunum
healthi
dog
euthan
unrel
project
full
thick
tissu
fix
formalin
salin
routin
process
embed
paraffin
enteroid
cultur
minc
sampl
wash
crypt
enrich
use
edta
chelat
embed
matrigel
grown
intestin
stem
cell
media
rna
situ
hybrid
rna
ish
immunohistochemistri
ihc
use
identifi
cell
stain
posit
previous
report
marker
paneth
cell
mous
human
lysozym
ly
canin
interleukin
canin
beta
defensin
cbd
canin
cathelicidin
cath
frizzl
class
receptor
neurogenin
ephrin
receptor
tyrosin
kinas
addit
isc
marker
use
character
stem
cell
nich
leucin
rich
repeat
g
protein
coupl
hmg
box
transcript
factor
full
thick
section
canin
jejunum
stain
neg
ly
ihc
posit
cath
rna
ish
fulli
differenti
enteroid
day
stain
neg
ly
cath
posit
cell
express
paneth
cell
marker
highli
posit
crypt
full
thick
section
enteroid
howev
posit
stain
also
found
throughout
differenti
cell
villu
tip
although
less
intens
stain
marker
isc
posit
clearli
defin
cell
bottom
crypt
area
full
thick
section
enteroid
stain
pattern
differ
human
mice
cell
seem
dispers
throughout
epithelium
canin
small
intestin
compar
local
within
defin
crypt
mammal
first
time
identifi
cell
function
repres
cell
jejunum
dog
data
lay
foundat
investig
role
cell
canin
intestin
diseas
inflammatori
bowel
diseas
colorect
cancer
previous
identifi
candid
gene
chromosom
use
genom
wide
associ
studi
potenti
associ
inflammatori
bowel
diseas
ibd
german
shepherd
dog
gsd
present
studi
perform
target
two
mb
region
includ
newli
identifi
candid
gene
use
sequenc
captur
array
selectsur
xt
custom
mb
agil
brief
hybrid
dna
librari
prepar
use
selectsur
xt
librari
prep
kit
agil
follow
manufactur
instruct
target
region
downstream
signific
snp
captur
use
sequenc
captur
array
selectsur
xt
custom
mb
agil
subsequ
captur
librari
index
subject
dna
sequenc
illumina
platform
follow
alignmentmap
canin
genom
haplotypecal
use
call
variant
follow
extract
snp
indel
recommend
gatk
best
practic
snp
annot
use
snpeff
variant
effect
predict
vep
tool
variant
divid
differ
group
base
genom
coordin
snp
present
case
diagnos
ibd
control
well
overlap
snp
differ
altern
allel
case
vs
control
group
investig
control
group
known
missens
snp
identifi
exon
gene
identifi
associ
ibd
use
approach
snp
present
control
anim
addit
one
new
missens
snp
detect
moder
impact
control
show
variant
furthermor
snp
known
new
one
upstream
snp
known
new
one
downstream
identifi
control
group
howev
number
variant
one
rest
snp
overlap
group
differ
altern
allel
missens
snp
snp
splice
region
downstream
gene
found
case
group
found
one
missens
snp
moder
impact
deleteri
base
sift
score
one
splice
region
low
impact
case
sequenc
seventeen
snp
known
new
one
identifi
within
upstream
gene
tss
coordin
snp
known
new
one
downstream
two
snp
modifi
impact
locat
within
upstream
hematopoet
cytokin
drive
develop
myeloid
stem
cell
previous
identifi
associ
ibd
approach
use
enrich
list
gene
involv
human
ibd
two
snp
found
downstream
pdlim
protein
doubl
zinc
finger
involv
interact
cytoskelet
organis
involv
ige
synthesi
chitinas
hyperrespons
mucos
surfac
one
new
snp
found
downstream
interestingli
gene
also
associ
higher
risk
develop
human
ibd
summari
identifi
sever
snp
gene
canin
pdlim
base
known
function
correspond
protein
insight
pathogenesi
ibd
gsd
recognit
felin
red
blood
cell
rbc
antigen
mik
presenc
natur
occur
antibodi
result
acut
hemolyt
transfus
reaction
prompt
recommend
perform
blood
crossmatch
prior
cat
first
rbc
transfus
object
retrospect
studi
determin
preval
natur
occur
rbc
alloantibodi
detect
tube
crossmatch
compar
transfus
outcom
felin
patient
without
tube
crossmatch
perform
addit
limit
prospect
studi
undertaken
compar
result
gel
tube
method
felin
crossmatch
medic
record
cat
receiv
rbc
transfus
andor
major
crossmatch
januari
decemb
review
retrospect
inform
record
includ
previou
transfus
histori
major
minor
crossmatch
result
tube
method
volum
prbc
administ
pcv
advers
event
patient
outcom
cat
crossmatch
perform
use
gel
tube
method
comparison
rbc
compat
data
avail
transfus
cat
show
degre
incompat
hemagglutin
major
crossmatch
donor
cat
previous
transfus
cat
incompat
hemagglutin
major
crossmatch
donor
significantli
transfus
group
p
pack
rbc
transfus
administ
cat
tube
crossmatch
perform
cat
prior
first
prbc
transfus
remain
cat
receiv
prbc
median
volum
prbc
administ
first
transfus
mlkg
rang
median
increas
pcv
cat
receiv
prbc
greater
increas
compar
without
crossmatch
febril
transfus
reaction
occur
often
cat
receiv
type
prbc
n
cat
administ
prbc
n
p
cat
receiv
prbc
transfus
surviv
hospit
discharg
crossmatch
associ
improv
surviv
discharg
day
crossmatch
perform
use
tube
gel
method
cat
total
crossmatch
recipi
cat
crossmatch
agreement
result
tube
gel
method
except
cat
major
incompat
donor
tube
gel
method
respect
like
result
subject
grade
differ
result
observ
cat
neg
tube
mix
field
agglutin
gel
result
autocontrol
major
crossmatch
test
donor
attribut
mark
rouleaux
microscop
evalu
salin
replac
tube
crossmatch
support
interpret
rouleaux
rather
hemagglutin
rbc
incompat
note
transfus
cat
suggest
preval
natur
occur
rbc
alloantibodi
suffici
high
justifi
recommend
perform
blood
crossmatch
prior
includ
first
rbc
transfus
cat
use
human
intraven
immunoglobulin
hivig
case
canin
primari
hemolyt
anemia
imha
previous
describ
investig
limit
cost
avail
aim
studi
investig
administr
hivig
time
diagnosi
canin
primari
imha
dog
diagnos
primari
imha
uk
specialti
hospit
prospect
enrol
dog
receiv
prednisolon
dexamethason
alongsid
clopidogrel
patient
random
receiv
two
occas
control
group
addit
immunosuppress
drug
allow
within
first
day
treatment
support
treatment
given
discret
attend
clinician
remiss
defin
stabl
pcv
hour
ten
dog
treatment
group
dog
control
group
achiev
remiss
surviv
hospit
discharg
surviv
time
remiss
significantli
differ
group
volum
pack
red
blood
cell
transfus
normal
bodi
weight
significantli
differ
group
potenti
advers
reaction
occur
two
patient
clinic
sign
may
relat
patient
underli
diseas
treatment
well
toler
patient
signific
advantag
found
small
studi
larger
studi
warrant
identifi
potenti
benefit
blood
product
transfus
use
commonli
veterinari
medicin
similar
type
transfus
reaction
seen
veterinari
patient
seen
human
incid
reaction
dog
cat
consid
higher
peopl
sever
reaction
similar
potenti
reaction
fatal
human
medicin
lack
educ
transfus
medicin
shown
lead
inappropri
blood
product
use
turn
lead
increas
incid
transfus
reaction
veterinari
colleg
core
curricula
provid
limit
educ
area
small
anim
transfus
reaction
improv
veterinari
student
educ
could
lead
earlier
recognit
reaction
well
improv
knowledg
area
prevent
treatment
may
ultim
lead
reduct
patient
morbid
mortal
object
random
control
studi
develop
test
instruct
efficaci
onlin
learn
modul
transfus
reaction
small
anim
evalu
particip
satisfact
modul
hypothesi
student
complet
modul
would
perform
better
two
post
modul
assess
compar
student
receiv
inform
transfus
reaction
tradit
method
ie
verbal
instruct
clinic
case
round
content
modul
develop
veterinari
specialist
area
intern
medicin
critic
care
clinic
patholog
guidanc
educ
specialist
design
instruct
design
coordin
interact
modul
cover
recognit
treatment
prevent
case
exampl
question
common
transfus
reaction
fourth
year
veterinari
student
critic
care
rotat
randomli
select
either
receiv
instruct
modul
treatment
group
receiv
standard
rotat
instruct
transfus
reaction
control
group
two
test
cover
concept
develop
student
randomli
receiv
pretest
start
rotat
posttest
end
week
rotat
immedi
follow
pretest
treatment
group
receiv
learn
modul
modul
satisfact
survey
survey
ask
student
rate
level
agreement
statement
scale
strongli
disagre
agre
student
ask
complet
option
retent
test
compos
question
pre
posttest
month
later
total
student
complet
pre
posttest
includ
studi
student
treatment
group
receiv
modul
control
group
student
also
complet
retent
test
treatment
group
control
group
student
treatment
group
score
significantli
higher
posttest
p
retent
test
p
student
receiv
learn
modul
mean
post
test
score
mean
retent
test
score
treatment
control
group
respect
nineteen
student
treatment
group
complet
satisfact
survey
student
take
survey
indic
modul
easi
use
mean
inform
present
clear
manner
mean
student
agre
modul
good
use
educ
time
mean
conclus
transfus
reaction
instruct
modul
deliv
success
veterinari
student
clinic
rotat
consid
benefici
student
administr
learn
modul
result
significantli
improv
transfus
reaction
knowledg
improv
knowledg
retent
convent
clinic
instruct
method
year
veterinari
student
apheresi
collect
becom
much
common
last
five
year
within
veterinari
commun
evalu
two
standard
human
apheresi
devic
collect
canin
platelet
concentr
perform
hypothes
platelet
concentr
qualiti
would
influenc
apheresi
collect
techniqu
dog
three
canin
donor
chosen
volunt
blood
donor
popul
washington
state
three
canin
donor
chosen
purpos
bred
blood
donor
popul
new
york
state
donor
previous
screen
pcr
ifa
infecti
diseas
defin
acvim
consensu
statement
donor
demonstr
normal
cbc
time
donat
donor
platelet
count
excess
select
apheresi
perform
util
terumo
bct
trima
devic
haemonet
mc
plu
devic
util
standard
human
protocol
provid
manufactur
briefli
trima
devic
protocol
util
continu
separ
techniqu
collect
leukoreduc
platelet
concentr
haemonet
devic
util
discontinu
separ
techniqu
collect
leukoreduc
platelet
concentr
varianc
protocol
includ
use
supplement
intraven
calcium
glucon
trima
protocol
supplement
intraven
salin
haemonet
protocol
donor
group
provid
sedat
andor
anesthesia
appropri
donor
comfort
approxim
x
concentr
collect
residu
plasma
red
blood
cell
return
donor
seriou
advers
reaction
donor
note
immedi
event
platelet
concentr
ship
via
independ
courier
novel
platelet
shipper
laboratori
maryland
platelet
concentr
evalu
autom
coulter
counter
site
prior
shipment
arriv
pool
ph
lactat
measur
via
istat
handheld
analyz
ph
less
ph
measur
standard
ph
meter
unit
evalu
swirl
evid
visual
clump
platelet
size
distribut
evalu
flow
cytometri
apheresi
protocol
manag
without
advers
reaction
donor
immedi
post
apheresi
count
confirm
consist
harvest
x
x
devic
red
blood
cell
contamin
less
x
white
blood
cell
count
less
x
platelet
prepar
haemonet
techniqu
decreas
ph
increas
lactat
compar
platelet
prepar
terumo
techniqu
howev
differ
statist
signific
flow
cytometr
evalu
suggest
higher
popul
platelet
micron
size
rang
concentr
prepar
haemonet
techniqu
signific
differ
techniqu
use
standard
methodolog
evalu
techniqu
provid
platelet
concentr
met
accept
criteria
standard
apheresi
unit
evalu
ear
prick
sampl
possibl
altern
venou
sampl
use
poc
meter
assess
haemoglobin
hb
haematocrit
hct
dog
simultan
venou
ear
prick
blood
sampl
collect
dog
consid
anaem
n
n
polycythaem
n
undergo
blood
sampl
part
clinic
investig
hb
hct
measur
sampl
use
poc
meter
requir
microlit
sampl
volum
previous
valid
hospit
shown
correl
r
standard
laboratori
analys
variat
less
hb
hct
measur
also
obtain
venou
sampl
use
one
two
refer
analyz
dog
pearson
correl
calcul
two
set
poc
result
bia
calcul
express
mean
standard
deviat
agreement
previou
studi
poc
result
hb
hct
venou
sampl
significantli
correl
laboratori
analys
respect
result
hb
hct
ear
prick
sampl
measur
use
poc
devic
significantli
correl
poc
result
venou
sampl
r
calcul
bias
hb
hct
respect
consist
small
degre
peripher
haemoconcentr
howev
sampl
peripher
sampl
differ
venou
sampl
differ
could
clinic
signific
see
figur
measur
hb
hct
use
simpl
ear
prick
test
poc
meter
requir
small
sampl
volum
may
use
altern
convent
venou
blood
sampl
evalu
paramet
dog
howev
small
posit
bia
clinic
signific
variat
newli
develop
oral
direct
factor
xa
anticoagul
rivaroxaban
recent
approv
use
human
patient
thrombosi
clinician
need
appropri
prescrib
drug
correct
indic
guidelin
rivaroxaban
establish
veterinari
medicin
gold
standard
monitor
effect
rivaroxaban
chromogen
assay
clinic
applic
therefor
goal
studi
evalu
clinic
modal
measur
anticoagul
effect
rivaroxaban
use
test
prothrombin
time
pt
thromboelastographi
teg
healthi
dog
four
differ
dose
rivaroxaban
mgkg
oral
administ
six
healthi
beagl
dog
singl
oral
three
consecut
dose
regimen
also
assess
use
citrat
blood
sampl
collect
h
singl
oral
dose
h
consecut
trial
plasma
rivaroxaban
concentr
determin
use
chromogen
assay
pt
teg
analysi
four
activ
rapidteg
tissu
factor
tissu
factor
kaolin
compar
spearman
correl
coeffici
calcul
ratio
peak
baselin
pt
peak
reaction
time
r
teg
baselin
r
teg
concentr
oral
rivaroxaban
administr
exhibit
predict
anticoagul
effect
well
toler
healthi
dog
clinic
sign
minor
major
hemorrhag
gastrointestin
side
effect
dose
group
highest
valu
longest
delay
r
teg
pt
observ
h
administr
rivaroxaban
howev
anticoagul
effect
teg
plasma
rivaroxaban
concentr
decreas
significantli
h
administr
differ
drug
effect
observ
expect
experi
monitor
anticoagul
effect
perform
result
show
concentr
pt
ratio
strongli
correl
r
p
r
ratio
show
signific
correl
rivaroxaban
concentr
measur
use
assay
r
p
r
p
r
p
respect
overal
time
delay
pt
r
valu
teg
h
rivaroxaban
administr
requir
achiev
therapeut
concentr
rivaroxaban
canin
plasma
teg
use
tissu
factor
activ
pt
valid
rivaroxaban
use
therapeut
monitor
rivaroxaban
determin
individu
rivaroxaban
dose
dog
cryoprecipit
cryo
plasma
compon
contain
high
concentr
factor
viii
fviii
von
willebrand
factor
vwf
fibrinogen
due
wide
variat
plasma
fviii
vwf
level
among
healthi
dog
concern
uniform
standard
potenc
cryo
treat
dog
hemophilia
vwd
greyhound
commonli
use
blood
donor
previou
studi
document
lower
plasma
vwf
fibrinogen
content
greyhound
compar
greyhound
plasma
therefor
may
yield
high
potenc
cryo
object
studi
determin
plasma
hemostat
protein
content
good
predictor
cryo
potenc
differ
qualiti
cryo
prepar
greyhound
versu
canin
cryo
produc
protocol
meet
human
blood
bank
standard
ml
unit
blood
collect
greyhound
enrol
blood
donor
program
cryo
prepar
fresh
frozen
plasma
ffp
use
standard
method
blood
compon
volum
record
aliquot
ffp
cryo
unit
analyz
fviii
vwf
fibrinogen
content
recoveri
percentag
total
factor
content
ffp
retain
cryo
unit
calcul
factor
posit
correl
fviii
vwf
fibrinogen
concentr
ffp
respect
factor
content
cryo
p
median
recoveri
greatest
vwf
follow
fibrinogen
fviii
differ
greyhound
differ
median
fviii
iuunit
vwf
iuunit
content
cryo
unit
compar
greyhound
respect
howev
median
fibrinogen
content
cryo
less
greyhound
mgunit
compar
mgunit
p
nevertheless
differ
greyhound
number
cryo
unit
meet
human
blood
bank
standard
hemostat
protein
vwf
greyhound
cryo
doberman
meet
standard
fibrinogen
greyhound
fviii
greyhound
conclus
factor
content
donor
ffp
strongli
associ
cryo
potenc
suggest
blood
donor
may
enhanc
cryo
qualiti
cryo
prepar
greyhound
inferior
breed
justifi
use
plasma
prepar
cryo
cryo
unit
met
human
blood
bank
standard
vwf
fibrinogen
variabl
recoveri
fviii
result
approxim
cryo
unit
fviii
content
human
standard
control
bleed
dog
hemophilia
may
requir
transfus
effect
due
nonuniform
fviii
potenc
singl
cryo
unit
system
inflammatori
respons
syndrom
sir
releas
inflammatori
mediat
occur
hematolog
modif
common
studi
aim
evalu
anemia
nucleat
rbc
nrbc
canin
sir
compar
sever
ill
outcom
retrospect
studi
includ
follow
dog
sir
healthi
chronic
diseas
sir
grade
base
mani
criteria
fulfil
applefast
score
alloc
sir
dog
mortal
rate
assess
day
admiss
hemolyt
hemorrhag
disord
exclud
sir
grade
applefast
score
group
compar
outcom
type
anemia
nrbc
count
evalu
three
studi
popul
outcom
applefast
score
p
sir
grade
p
associ
poor
outcom
sir
group
anemia
present
dog
frequent
type
anemia
mild
moder
microcyt
normocyt
normochrom
anemia
sever
associ
poor
outcom
p
sir
group
show
wors
anemia
pattern
two
group
p
presenc
nrbc
occur
sir
dog
associ
poor
outcom
p
nrbc
count
significantli
higher
sir
group
healthi
dog
p
normochrom
anemia
frequent
find
canin
sir
result
suggest
circul
nrbc
amount
could
addit
neg
prognost
valu
primari
thrombocytopenia
pimt
common
hematolog
disord
dog
although
immunosuppress
dose
prednisolon
normal
platelet
count
case
high
recurr
rate
still
problem
studi
perform
clarifi
relationship
taper
prednisolon
dosag
time
relaps
sixteen
dog
treat
pimt
hokkaido
univers
veterinari
teach
hospit
march
may
retrospect
evalu
relaps
episod
defin
therapeut
cours
remiss
relaps
episod
defin
therapeut
cours
remiss
cessat
prednisolon
concurr
immunosuppress
medic
consid
total
relaps
episod
episod
occur
taper
prednisolon
median
dosag
prednisolon
time
remiss
mgkgday
rang
mgkgday
median
dosag
prednisolon
time
relaps
mgkgday
rang
mgkgday
median
remiss
period
day
rang
day
signific
neg
correl
present
taper
rate
prednisolon
p
remiss
period
relaps
episod
divid
acut
relaps
remiss
period
day
delay
relaps
remiss
period
day
taper
rate
prednisolon
significantli
higher
acut
relaps
episod
delay
relaps
episod
respect
result
suggest
rapid
decreas
prednisolon
dosag
caus
earli
recurr
pimt
greyhound
sever
hematolog
differ
breed
dog
includ
higher
hematocrit
hemoglobin
concentr
lower
neutrophil
platelet
count
also
observ
greyhound
propens
bleed
excess
hour
follow
minor
trauma
routin
surgeri
exact
etiolog
behind
bleed
unknown
howev
sever
studi
postul
may
occur
due
hyperfibrinolysi
dynam
viscoelast
test
use
thromboelastographi
teg
allow
assess
coagul
also
fibrinolysi
teg
perform
previous
greyhound
studi
investig
fibrinolysi
variabl
via
teg
presenc
tissu
plasminogen
activ
tpa
healthi
greyhound
therefor
purpos
studi
evalu
greyhound
appear
hyperfibrinolyt
compar
tissu
teg
tpa
ad
tf
perform
six
healthi
greyhound
six
healthi
laboratori
beagl
tf
reaction
time
r
clot
time
k
rate
clot
format
maximum
amplitud
percent
clot
lysi
minut
reach
amount
clot
lysi
minut
reach
maxim
rate
thrombu
gener
mrtg
time
maximum
rate
thrombu
gener
tmrtg
total
thrombu
gener
tg
maximum
rate
lysi
mrl
time
maxim
rate
lysi
tmrl
clot
lysi
time
clt
record
hematocrit
platelet
count
fibrinogen
also
record
unpair
perform
r
k
mrtg
tmrtg
tg
mrl
tmrl
clt
hematocrit
platelet
count
fibrinogen
u
test
perform
test
p
consid
signific
mrtg
tg
platelet
count
fibrinogen
significantli
lower
k
hematocrit
significantli
higher
greyhound
statist
differ
r
tmrtg
mrl
tmrl
clt
group
note
previou
studi
greyhound
higher
hematocrit
lower
platelet
count
compar
greyhound
appear
significantli
hypocoagul
increas
k
decreas
mrtg
tg
appear
hyperfibrinolyt
compar
possibl
hyperfibrinolysi
greyhound
may
relat
respons
tpa
hyperfibrinolysi
detect
via
tf
set
use
predict
bleed
addit
studi
warrant
investig
mechan
bleed
appreci
breed
whole
blood
imped
platelet
aggregometri
perform
sever
differ
agonist
evalu
platelet
function
although
manufactur
recommend
dispos
store
reagent
month
viabil
reconstitut
reagent
differ
storag
condit
unknown
reagent
viabil
stabl
long
period
time
assay
cost
could
decreas
dramat
therefor
purpos
studi
determin
viabil
reconstitut
arachidon
acid
aa
adenosin
diphosph
adp
platelet
agonist
store
two
condit
month
aliquot
reconstitut
aa
adp
store
monthli
six
month
six
healthi
dog
enrol
studi
physic
examin
complet
blood
count
cbc
diagnost
panel
urinalysi
perform
enrol
dog
platelet
aggregometri
perform
dog
use
fresh
store
aliquot
aa
adp
reagent
day
area
curv
auc
record
platelet
aggregometri
analysi
repeat
measur
rm
analysi
anova
perform
subsequ
time
point
month
compar
fresh
auc
result
dog
appear
clinic
healthi
cbc
diagnost
panel
urinalysi
normal
differ
auc
obtain
fresh
sampl
time
point
either
temperatur
aa
adp
dog
whole
blood
imped
platelet
aggregometri
reagent
aa
adp
viabl
six
month
store
conclud
reagent
store
month
obviat
need
discard
viabl
reagent
decreas
assay
cost
blood
transfus
commonli
use
manag
anemia
condit
howev
potenti
advers
effect
includ
febril
nonhemolyt
transfus
reaction
fnhtr
graft
versu
host
diseas
immunolog
hemolysi
acut
lung
injuri
circulatori
overload
storag
lesion
ie
biochem
biomechan
chang
depend
red
blood
cell
storag
time
white
blood
cell
wbc
storag
period
main
factor
caus
advers
reaction
sever
way
prevent
transfus
reaction
propos
includ
leukoreduct
lr
remov
leukocyt
platelet
filtrat
irradi
ir
blood
prevent
inactiv
lymphocyt
close
monitor
storag
lesion
object
studi
measur
cytokinechemokin
concentr
lr
ir
canin
store
whole
blood
red
blood
cell
rbc
storag
lesion
caus
irradi
lr
compar
blood
sampl
obtain
healthi
beagl
dog
collect
blood
sampl
divid
four
group
sampl
treatment
lr
ir
lr
ir
leukocyt
remov
filtrat
lr
group
gamma
radiat
appli
ir
group
immunolog
factor
wbc
motif
chemokin
ligand
tumor
necrosi
storag
lesion
factor
blood
ph
potassium
hemolysi
evalu
day
aliquot
group
concentr
control
treatment
store
whole
blood
significantli
higher
storag
indic
high
probabl
transfus
reaction
fnhtr
hand
lr
group
show
chang
cytokinechemokin
concentr
storag
lesion
rel
mild
compar
group
irradi
significantli
increas
day
storag
irradi
leukoreduc
blood
increas
day
storag
howev
storag
lesion
hemolysi
increas
potassium
low
ph
observ
day
ir
blood
regardless
lr
conclus
lr
benefici
prevent
transfus
reaction
storag
lesion
howev
ir
canin
whole
blood
suitabl
storag
increas
factor
storag
lesion
ir
leukoreduc
blood
benefici
avoid
immun
reaction
howev
storag
lesion
consid
upon
storag
bacteri
cholecyst
mucocel
format
consid
common
caus
gallbladd
diseas
dog
posit
bacteri
growth
bile
sampl
patient
less
common
suspicion
infecti
culprit
studi
determin
bacteria
resid
gallbladd
healthi
dog
dog
gallbladd
diseas
report
present
studi
perform
sequenc
gallbladd
bile
mucu
dog
without
gallbladd
diseas
character
bacteri
commun
composit
presenc
commens
microbiom
unrecogn
pathogen
bacteria
bile
sampl
obtain
cholecystocentesi
healthi
dog
ctrl
dog
suspect
bacteri
cholecyst
sbc
gallbladd
mucu
obtain
cholecystectomi
dog
mucocel
format
gbm
presenc
eubacteria
examin
aerob
anaerob
cultur
cytolog
fluoresc
situ
hybrid
fish
sampl
underw
dna
extract
pcr
amplif
region
rrna
gene
sequenc
dog
ctrl
group
significantli
younger
median
rang
yr
dog
sbc
yr
gbm
yr
group
p
gbm
dog
higher
neutrophil
count
p
higher
total
serum
bilirubin
p
compar
sbc
dog
ctrl
dog
posit
presenc
bacteria
mean
cultur
cytolog
fish
similar
number
sbc
gbm
dog
posit
result
bacteri
cultur
cytolog
fish
compar
convent
mean
identifi
bacteria
major
ctrl
sbc
gbm
dog
harbor
divers
microbiom
pcr
target
rrna
gene
highli
effect
identifi
bacteria
ie
e
coli
enterococcu
spp
diagnos
cultur
reveal
presenc
cultur
neg
dog
recent
histori
antibiot
remain
rrna
gene
posit
cultur
neg
dog
demonstr
divers
microbiom
consist
predominantli
proteobacteria
neisseriacea
acinetobact
firmicut
staphylococcu
streptococcu
lactococcu
actinobacteria
corynebacterium
propionibacterium
cyanobacteria
streptophyta
bacteroidet
obviou
differ
ctrl
gbm
dog
observ
result
studi
identifi
major
normal
diseas
dog
harbor
rich
divers
bile
microbiom
microbiota
like
contain
previous
unrecogn
benefici
well
deleteri
bacteria
tailor
bile
cultur
media
routin
identifi
bacteria
like
improv
understand
diagnosi
canin
hepatobiliari
diseas
serum
interleukin
chemokin
ligand
protein
crp
ratio
aspart
transaminas
alanin
transaminas
ast
alt
correl
fibrosi
necroinflammatori
activ
human
variou
hepatopathi
object
studi
determin
whether
increas
potenti
biomark
associ
moder
sever
fibrosi
necroinflammatori
activ
dog
variou
hepatopathi
dog
clinic
evid
liver
diseas
healthi
dog
enrol
undergo
liver
biopsi
laparoscopi
laparotomi
serum
crp
ast
alt
measur
within
one
week
schedul
liver
biopsi
liver
histopatholog
evalu
use
metavir
score
system
use
human
medicin
blind
clinic
present
median
serum
approxim
twice
high
dog
high
fibrosi
score
pgml
rang
pgml
compar
dog
low
fibrosi
score
pgml
rang
pgml
margin
signific
p
median
serum
significantli
higher
dog
activ
necroinflamm
pgml
rang
pgml
compar
dog
without
detect
necroinflamm
pgml
rang
pgml
p
consider
overlap
group
neither
serum
crp
ast
alt
ratio
significantli
differ
base
fibrosi
necroinflammatori
score
substanti
variabl
among
dog
singl
measur
limit
diagnost
util
identifi
fibrosi
necroinflamm
respect
dog
variou
chronic
liver
diseas
valu
biomark
explor
monitor
respons
treatment
individu
dog
chronic
hepatopathi
previou
studi
report
respons
corticosteroid
suggest
case
chronic
hepat
ch
dog
like
immun
mediat
howev
corticosteroid
therapi
associ
signific
side
effect
includ
steroid
hepatopathi
confound
interpret
serum
liver
enzym
therapi
thu
altern
immunosuppress
therapi
need
manag
ch
dog
aim
retrospect
collabor
studi
evalu
abil
cyclosporin
cy
induc
remiss
defin
normal
alanin
aminotransferas
alt
dog
presum
immun
mediat
ch
well
assess
toler
secondari
aim
evalu
previous
report
prognost
factor
influenc
abil
attain
remiss
cy
therapi
fifti
dog
diagnos
ch
base
world
small
anim
veterinari
associ
criteria
treat
cy
least
week
met
inclus
criteria
dog
posit
hepat
bacteri
cultur
hepat
copper
ppm
dri
weight
includ
copper
chelat
antibiot
therapi
fail
achiev
remiss
concurr
corticosteroid
therapi
permit
remiss
achiev
prior
cy
initi
descript
statist
use
analyz
categor
variabl
age
gender
breed
side
effect
cy
continu
variabl
cy
dose
time
remiss
alt
concentr
mean
median
rang
standard
deviat
calcul
continu
data
wilcoxon
student
fisher
exact
test
surviv
analysi
use
evalu
impact
prognost
factor
clinic
score
hypoalbuminemia
hyperbilirubinemia
ascit
fibrosi
histopatholog
prolong
ptaptt
remiss
differ
breed
repres
age
rang
year
median
year
percent
femal
spay
male
castrat
common
treatment
gastrointestin
sign
rang
mild
inappet
vomit
diarrhea
gingiv
hyperplasia
seventi
six
percent
achiev
remiss
median
time
remiss
month
month
median
dose
time
remiss
mgkgday
mgkgday
associ
found
prognost
factor
remiss
except
hypoalbuminemia
increas
likelihood
remiss
p
decreas
time
remiss
dog
hypoalbuminemia
p
conclus
cy
therapi
toler
effect
achiev
normal
alt
dog
presum
immun
mediat
ch
previous
report
prognost
factor
neg
impact
abil
achiev
alt
normal
cy
therapi
liver
perform
essenti
role
metabol
vitamin
vd
defici
vitamin
k
anoth
vitamin
common
cat
cholestat
hepatobiliari
diseas
chd
hypothes
vd
level
cat
chd
would
significantli
lower
normal
cat
sick
cat
disord
prospect
case
control
studi
done
compar
cat
chd
diseas
defin
hyperbilirubinemia
increas
alanin
aminotransferas
sick
cat
without
hepatobiliari
diseas
normal
cat
repres
valid
refer
rang
oh
vd
cat
chd
cat
diseas
enrol
parathyroid
hormon
pth
ioniz
calcium
ica
oh
measur
cat
mean
oh
vd
level
significantli
lower
sick
cat
nmoll
nmoll
cat
cholestat
diseas
nmoll
nmoll
compar
refer
rang
nmoll
nmoll
median
ica
pth
cat
chd
significantli
higher
mmoll
pmoll
respect
sick
cat
mmoll
pmoll
respect
six
chd
cat
sick
cat
high
pth
level
overal
chd
cat
sick
cat
oh
vd
defici
insuffici
nmoll
correl
oh
vd
serum
bilirubin
inadequ
oh
vd
may
neg
impact
overal
health
low
level
common
sick
cat
studi
futur
studi
assess
impact
insuffici
vd
level
cat
necessari
assess
optim
treatment
option
congenit
extrahepat
portosystem
shunt
cehpss
topic
interest
veterinari
medicin
combin
systemat
review
design
evalu
exist
evid
regard
effect
differ
cehpss
manag
modal
electron
databas
pubm
cab
direct
googl
scholar
search
without
date
languag
restrict
confer
proceed
major
congress
also
search
studi
describ
outcom
least
one
treatment
modal
dog
cehpss
includ
studi
assess
qualiti
evid
studi
design
studi
group
size
subject
enrol
qualiti
overal
risk
bia
outcom
measur
report
percentag
periop
outcom
clinic
surgicalintervent
outcom
concomitantli
report
confid
interv
studi
includ
seven
confer
abstract
report
periop
andor
clinic
andor
surgicalintervent
outcom
dog
manag
one
surgicalintervent
techniqu
andor
medic
manag
cehpss
identifi
studi
design
prospect
studi
includ
one
random
control
clinic
trial
one
control
clinic
trial
uncontrol
clinic
trial
major
studi
show
overal
high
risk
bia
evalu
low
low
number
case
per
treatment
group
clearli
character
subject
enrol
criteria
direct
comparison
ameroid
constrictor
versu
thin
film
band
reveal
statist
signific
differ
two
techniqu
regard
surgic
outcom
ameroid
constrictor
superior
direct
comparison
also
suggest
ameroid
constrictor
placement
might
better
periop
clinic
surgicalintervent
outcom
ligat
howev
none
comparison
statist
signific
direct
comparison
techniqu
possibl
due
lack
data
indirect
comparison
suggest
ameroid
constrictor
placement
complet
ligat
techniqu
better
periop
clinic
surgicalintervent
outcom
follow
thin
film
band
coil
embol
partial
ligat
outcom
assess
amplatz
vascular
plug
medic
manag
base
small
number
case
allow
accur
interpret
conclus
combin
systemat
review
provid
object
evalu
treatment
option
cehpss
ameroid
constrictor
shown
techniqu
higher
likelihood
provid
good
outcom
complet
ligat
thin
film
band
coil
embol
partial
ligat
shown
effect
techniqu
treatment
cehpss
although
less
ameroid
constrictor
blind
random
studi
low
overal
risk
bia
good
number
case
compar
differ
treatment
modal
routin
includ
postop
imag
assess
cehpss
closur
andor
acquir
portosystem
shunt
develop
essenti
extrahepat
bile
duct
obstruct
ehbdo
usual
tent
diagnos
base
clinic
find
howev
definit
diagnos
obstruct
common
bile
duct
cbd
challeng
without
certain
diagnost
goal
studi
evalu
feasibl
percutan
cholangiographi
upc
determin
cbd
truli
obstruct
term
ehbdo
use
clinic
applic
four
dog
two
cat
tent
diagnos
infect
ehbdo
enrol
studi
upc
perform
cholecystocentesi
remov
bile
decompress
gallbladd
cytolog
culturesensit
less
ml
iodixanol
inject
gallbladd
ventrodors
left
obliqu
ventrodors
left
later
right
later
project
abdomen
made
minut
upc
everi
minut
first
hour
everi
minut
contrast
medium
note
duodenum
patient
cbd
dilat
mm
diamet
contrast
note
duodenum
five
patient
one
dog
diagnos
complet
obstruct
cbd
given
contrast
duodenum
hour
upc
rest
diagnos
cbd
dilat
gallbladd
delay
empti
time
upc
minut
upc
feasibl
techniqu
patient
dilat
cbd
use
confirm
complet
obstruct
cbd
base
studi
term
extrahepat
bile
duct
diseas
use
instead
ehbdo
diagnost
upc
hepatocellular
carcinoma
hcc
common
primari
liver
tumor
dog
howev
clinic
featur
risk
factor
hcc
confirm
therefor
aim
studi
investig
clinic
featur
risk
factor
canin
hcc
medic
record
dog
diagnos
hcc
hokkaido
univers
veterinari
teach
hospit
huvth
may
may
retrospect
review
examin
breed
age
sex
predisposit
hcc
case
came
huvth
studi
period
use
refer
popul
possibl
relat
factor
includ
clinicopatholog
find
concurr
disord
hcc
determin
comparison
two
age
match
control
dog
hcc
case
preval
histolog
confirm
hcc
case
dog
diagnos
hcc
significantli
older
median
year
rang
year
p
refer
popul
median
year
rang
year
welsh
corgi
significantli
predispos
hcc
odd
ratio
ci
p
age
match
case
control
analysi
reveal
thrombocytosi
case
increas
alt
case
increas
alp
case
hypercalcemia
case
significantli
associ
hcc
addit
dog
hcc
least
one
concurr
disord
common
concurr
disord
hyperadrenocortic
dog
odd
hyperadrenocortic
dog
hcc
time
control
cl
p
find
indic
age
increas
risk
develop
hcc
welsh
corgi
predispos
hcc
addit
signific
associ
hcc
hyperadrenocortic
present
suggest
hyperadrenocortic
might
play
role
develop
hcc
dog
gastroduoden
ulcer
report
occur
sequela
hepatobiliari
diseas
dog
reduc
mucos
blood
flow
due
portal
hypertens
increas
gastric
acid
secret
secondari
hypergastrinemia
suspect
potenti
pathogenet
mechan
caus
gastroduoden
ulcer
hypothes
dog
hepatobiliari
diseas
would
hypergastrinemia
studi
aim
compar
serum
gastrin
concentr
among
dog
chronic
hepat
dog
congenit
portosystem
shunt
healthi
control
dog
withhold
food
hour
blood
sampl
collect
dog
chronic
hepat
dog
congenit
portosystem
shunt
healthi
client
own
control
dog
serum
separ
frozen
immedi
store
analysi
gastrin
measur
use
chemiluminesc
immunometr
assay
serum
gastrin
assay
siemen
assay
work
rang
ngl
previous
develop
refer
rang
median
min
max
serum
gastrin
concentr
dog
chronic
hepat
dog
portosystem
shunt
ngl
healthi
control
dog
signific
differ
among
group
p
found
signific
differ
serum
gastrin
concentr
among
dog
chronic
hepat
congenit
portosystem
shunt
healthi
control
dog
studi
warrant
determin
etiolog
gastroduoden
ulcer
dog
hepat
diseas
lyme
diseas
endem
part
north
america
emerg
diseas
other
although
tick
prevent
avail
vaccin
increasingli
common
though
controversi
method
use
prevent
canin
lyme
infect
report
efficaci
canin
lyme
vaccin
highli
variabl
rang
object
research
follow
determin
efficaci
vaccin
borrelia
burgdorferi
north
american
dog
compar
vaccin
dog
receiv
vaccin
use
systemat
review
address
object
monoval
multival
vaccin
consid
elig
intervent
main
outcom
interest
reduct
clinic
ill
follow
exposur
b
burgdorferi
outcom
data
extract
binari
outcom
follow
clinic
sign
assess
separ
lame
anorexia
pyrexia
depress
lymphadenopathi
experiment
analyt
observ
studi
consid
elig
inclus
addit
grey
literatur
search
follow
electron
databas
search
languag
restrict
medlin
web
scienc
cab
abstract
last
search
perform
novemb
thirteen
challeng
trial
three
observ
studi
identifi
elig
twelv
challeng
trial
contain
suffici
data
includ
could
perform
observ
studi
due
insuffici
number
studi
none
challeng
trial
assess
lymphadenopathi
remain
four
clinic
sign
separ
random
effect
perform
except
anorexia
summari
odd
ratio
less
null
valu
overal
find
suggest
north
american
lyme
vaccin
reduc
odd
clinic
ill
dog
follow
exposur
b
burgdorferi
howev
result
interpret
caution
sinc
number
issu
relat
small
sampl
size
studi
qualiti
public
bia
identifi
experiment
field
trial
identifi
highlight
major
gap
literatur
topic
futur
studi
focu
larger
sampl
size
field
condit
babesiosi
caus
virul
hemoprotozoan
babesia
rossi
lead
mark
system
inflammatori
host
respons
neutrophil
form
part
innat
immun
system
myeloperoxidas
predomin
compon
neutrophil
lysosom
protein
azurophil
granul
neutrophil
myeloperoxidas
index
mpxi
reflect
intracellular
myeloperoxidas
content
recogn
marker
neutrophil
activ
aim
studi
determin
whether
mpxi
correl
outcom
dog
babesiosi
caus
b
rossi
b
determin
correl
sever
host
respons
use
cytokin
concentr
data
dog
natur
infect
b
rossi
healthi
control
dog
retrospect
evalu
owner
consent
obtain
enrol
case
togeth
approv
univers
anim
ethic
committe
mpxi
gener
autom
cell
counter
advia
cytokin
concentr
determin
use
multiplex
assay
fifteen
dog
die
mpxi
significantli
higher
dog
p
p
compar
control
dog
die
signific
correl
found
mpxi
r
p
r
p
r
p
coloni
stimul
factor
r
p
monocyt
r
p
find
suggest
signific
neutrophil
activ
present
dog
b
rossi
infect
addit
increas
mpxi
associ
diseas
outcom
correl
sever
host
respons
protein
crp
acut
phase
protein
synthes
liver
measur
serum
crp
use
increasingli
monitor
progress
inflammatori
diseas
canin
patient
purpos
studi
analyt
valid
commerci
avail
immunoturbidimetr
assay
measur
serum
crp
concentr
dog
leftov
serum
sampl
dog
use
analyt
valid
serum
crp
concentr
measur
use
commerci
avail
immunoturbidimetr
canin
crp
assay
gentian
ccrp
gentian
autom
platform
beckman
coulter
follow
valid
variabl
assess
linear
dilut
parallel
precis
variabl
reproduc
variabl
accuraci
recoveri
mix
sampl
known
concentr
crp
concentr
compar
previous
analyt
valid
commerci
avail
immunoassay
eia
canin
crp
tridelta
develop
observ
expect
ratio
dilut
parallel
sampl
rang
mean
sd
sampl
sampl
coeffici
variat
cv
rang
respect
observ
expect
ratio
mixtur
two
serum
sampl
known
concentr
pair
rang
mean
sd
comparison
tridelta
assay
show
relationship
especi
appar
valu
greater
mgl
refer
interv
mgl
measur
tridelta
assay
gentian
result
higher
expect
use
suggest
valu
mgl
gentian
assay
mgl
tridelta
assay
agreement
result
moder
cohen
kappa
statist
evalu
assay
gentian
shown
precis
reproduc
accur
relationship
result
comparison
assay
tridelta
especi
high
concentr
sampl
shown
conclus
gentian
assay
appear
suffici
use
work
need
determin
optim
diagnost
valu
use
assay
direct
flow
cytometri
techniqu
use
detect
platelet
dog
howev
present
requir
sampl
must
process
within
hour
assess
current
avail
assay
limit
wide
spread
use
purpos
studi
develop
clinic
applic
direct
flow
cytometr
assay
detect
canin
platelet
express
percent
igg
igg
direct
flow
cytometri
assay
first
optim
valu
differenti
neg
posit
classif
determin
serial
direct
flow
evalu
platelet
healthi
dog
assay
perform
sampl
healthi
beagl
thrombocytopen
dog
four
time
point
fresh
hour
storag
igg
record
repeat
measur
analysi
anova
perform
storag
time
point
compar
fresh
sampl
use
dunnett
method
averag
coeffici
variat
cv
calcul
sampl
thrombocytopen
dog
evalu
variabl
use
sampl
healthi
dog
differ
among
fresh
hour
sampl
differ
fresh
hour
sampl
differ
among
fresh
hour
sampl
thrombocytopen
dog
base
valu
healthi
thrombocytopen
dog
consist
categor
everi
time
point
averag
cv
thrombocytopen
dog
sinc
sampl
process
evalu
within
hour
assay
use
sampl
requir
ship
central
laboratori
direct
flow
cytometr
assay
reproduc
repres
access
potenti
clinic
use
test
detect
platelet
dog
quantit
revers
transcript
pcr
increasingli
use
studi
diagnos
diseas
small
anim
perform
assay
reli
upon
first
obtain
qualiti
rna
suffici
quantiti
mani
commerci
avail
kit
optim
extract
rna
human
blood
one
design
specif
anim
blood
purpos
studi
use
store
canin
blood
assess
perform
commerci
avail
rna
extract
kit
use
rna
yield
puriti
benchmark
rna
extract
perform
ribopur
thermofish
carlsbad
calif
trizol
thermofish
carlsbad
calif
rneasi
protect
anim
blood
qiagen
germantown
md
rneasi
mini
qiagen
germantown
md
kit
assess
studi
whole
edta
anticoagul
blood
obtain
healthi
dog
store
minimum
one
week
rna
stabil
buffer
rnalat
trizol
protect
stabil
reagent
recommend
manufactur
rna
isol
also
util
manufactur
protocol
kit
dnase
treatment
perform
sampl
indic
manufactur
protocol
includ
use
commerci
avail
kit
qiagen
germantown
md
extract
rna
store
analysi
result
rna
yield
puriti
calcul
use
spectrophotometr
absorb
peak
measur
determin
nucleic
acid
concentr
assess
protein
contamin
median
rna
concentr
compar
amongst
group
test
dunn
test
multipl
comparison
signific
defin
p
ribopur
extract
result
significantli
higher
nucleic
acid
concentr
rneasi
protect
anim
blood
p
rneasi
mini
p
kit
figur
differ
median
rna
concentr
ribopur
trizol
p
differ
median
amongst
kit
indic
signific
differ
protein
contamin
extract
mean
kit
ribopur
trizol
rneasi
protect
anim
blood
rneasi
mini
kit
respect
result
indic
ribopur
kit
isol
greatest
quantiti
genet
materi
evalu
util
revers
transcriptas
control
assess
genom
dna
contamin
extract
necessari
fulli
evalu
rna
puriti
research
use
find
appropri
select
rna
extract
kit
base
prioriti
candida
infect
describ
dog
cat
limit
data
avail
regard
risk
develop
infect
object
studi
investig
risk
factor
associ
develop
candida
urinari
tract
infect
dog
cat
eighteen
dog
eight
cat
candiduriawer
evalu
retrospect
studi
identifi
risk
factor
associ
candiduria
control
dog
cat
bacteri
cystiti
cutan
malassezia
infect
dog
univari
exact
logist
regress
use
estim
odd
ratio
confid
interv
statist
signific
administr
antibacteri
drug
day
diagnosi
associ
candiduria
dog
use
control
bacteri
cystiti
ci
malassezia
infect
ci
antibacteri
drug
administr
also
associ
candiduria
cat
ci
immunosuppress
associ
candiduria
dog
compar
control
malassezia
infect
ci
significantli
bacteri
cystiti
control
ci
lower
urinari
tract
diseas
infect
associ
candiduria
cat
ci
significantli
dog
ci
neither
diabet
mellitu
histori
hospit
significantli
associ
candiduria
either
speci
recent
administr
antibacteri
drug
therapi
potenti
risk
factor
develop
candiduria
popul
judici
use
may
help
prevent
fungal
infect
random
clinic
trial
prospect
evalu
safeti
clinic
efficaci
singl
infus
hyperimmun
plasma
hip
administ
dog
canin
parvoviru
cpv
cpv
dog
random
receiv
either
placebo
n
nacl
mlkg
iv
studi
drug
n
hip
mlkg
iv
within
first
six
hour
hospit
admiss
support
care
standard
group
throughout
durat
hospit
dog
within
hip
group
demonstr
lower
shock
index
mark
p
differ
still
observ
mark
p
blood
lactateconcentr
lower
mark
hip
dog
compar
placebo
dog
p
although
statist
differ
mark
p
differ
durat
hospit
group
p
overal
surviv
hip
group
compar
placebo
group
p
hip
well
toler
advers
event
note
drug
administr
result
studi
indic
hyperimmun
plasma
improv
cardiovascular
paramet
first
hour
hospit
studi
identifi
differ
clinic
sever
improv
durat
hospit
mortal
compar
hip
placebo
dog
futur
studi
evalu
hip
dose
time
hip
administr
rel
diseas
onset
need
better
determin
clinic
benefit
product
babesiosi
import
caus
fever
splenomegali
hemolyt
anemia
dog
babesia
infect
report
domest
european
dog
wild
north
american
fox
howev
infect
domest
dog
north
america
rare
report
due
genet
differ
babesia
organ
caus
canin
babesiosi
detect
b
dna
requir
use
pcr
broader
piroplasma
pcr
primer
north
carolina
state
veterinari
diseas
diagnost
laboratori
recent
valid
implement
novel
pcr
assay
design
amplifi
wide
rang
babesia
spp
use
new
pcr
assay
dog
blood
sampl
n
submit
pcr
test
june
decemb
analyz
babesia
dna
preval
babesia
spp
detect
dog
includ
b
gibsoni
b
voge
b
b
cani
b
coco
b
specimen
evalu
amplif
sequenc
multipl
mitochondri
nuclear
gene
geograph
locat
avail
clinic
data
collat
b
infect
dog
n
resid
north
america
primarili
eastern
southern
us
predomin
sourc
access
known
travel
europ
clinicopatholog
abnorm
b
infect
dog
includ
regen
anemia
n
thrombocytopenia
n
proteinuria
n
splenomegali
n
hyperglobulinemia
n
b
infect
dog
american
pitt
bull
breed
b
pcr
posit
dog
test
b
voge
b
gibsoni
ifa
seroreact
suggest
antibodi
detect
inadequ
fulli
screen
babesiosi
dog
b
coinfect
includ
b
gibsoni
n
mycoplasma
spp
n
one
dog
e
cani
ifa
seroreact
conclud
b
infect
occur
dog
north
america
infect
organ
induc
clinicopatholog
abnorm
consist
babesiosi
clearanc
infect
base
upon
serorevers
neg
pcr
correl
clinic
improv
dog
suspect
infect
north
america
screen
use
pcr
assay
detect
b
parasit
rapidli
progress
glomerulonephr
describ
dog
seroreact
borrelia
burgdorferi
howev
studi
compar
clinicopatholog
differ
dog
nephropathi
pln
dog
pln
studi
hypothes
dog
borrelia
pln
distinct
clinicopatholog
find
compar
dog
borrelia
seroneg
pln
specif
hypothes
seroreact
dog
like
polyarthr
thrombocytopenia
studi
retrospect
preval
studi
one
hundr
eighteen
dog
pln
borrelia
antigen
test
identifi
seroreact
dog
seroneg
dog
clinic
inform
retriev
univers
california
davi
veterinari
medic
teach
hospit
histopatholog
renal
tissu
procur
biopsi
andor
necropsi
dog
pln
review
retriev
retriev
mix
overrepres
seroreact
dog
p
seroreact
dog
like
polyarthr
p
thrombocytopenia
p
azotemia
p
hyperphosphatemia
p
anemia
p
neutrophilia
p
hematuria
glucosuria
pyuria
despit
neg
urin
cultur
like
seroreact
dog
p
histopatholog
consist
glomerulonephr
case
dog
control
dog
p
studi
demonstr
borrelia
seroreact
dog
pln
associ
clinicopatholog
distinct
syndrom
compar
type
pln
earli
recognit
syndrom
base
clinic
find
potenti
improv
outcom
specif
aggress
earli
treatment
antimicrobi
resist
amr
major
problem
human
veterinari
popul
key
way
veterinarian
limit
amr
reduc
overal
antimicrobi
use
acvim
consensu
statement
cultur
sensit
test
c
recommend
prior
commenc
antibiot
practic
time
financ
frequent
limit
often
possibl
therefor
aim
evalu
clinic
need
antibiot
common
condit
suspect
veterinarian
overus
antibiot
chose
studi
haemorrhag
diarrhoea
dog
two
antibiot
often
administ
standard
acid
metronidazol
typic
prescrib
sever
case
haemorrhag
diarrhoea
evid
benefici
patient
clinic
trial
design
determin
whether
dog
haemorrhag
diarrhoea
improv
clinic
outcom
receiv
acid
metronidazol
whether
administr
acid
alon
suffici
dog
present
privat
veterinari
hospit
haemorrhag
diarrhoea
day
durat
recruit
ethic
approv
prospect
placebo
control
blind
treatment
trial
owner
consent
case
randomis
receiv
either
metronidazol
salin
blind
manner
addit
receiv
standard
support
therapi
acid
intraven
fluid
therapi
analgesia
gastroprotect
diagnost
perform
accord
usual
practic
protocol
routin
haematolog
biochemistri
faecal
c
efficaci
treatment
assess
durat
hospitalis
daili
clinic
progress
measur
clinic
score
system
feb
jan
dog
success
complet
clinic
trial
case
receiv
metronidazol
averag
durat
hospitalis
sd
salin
placebo
sd
signific
differ
two
patient
group
dog
trial
show
signific
improv
daili
clinic
score
day
admiss
day
p
statist
signific
differ
daili
clinic
score
compar
patient
group
summari
clinic
trial
two
valuabl
conclus
first
demonstr
two
antibiot
necessari
treatment
haemorrhag
diarrhoea
shown
antibiot
usag
safe
reduc
patient
second
proven
rigor
clinic
trial
perform
practic
absenc
extens
diagnost
hope
similar
trial
examin
possibl
overus
antibiot
common
condit
conduct
futur
peninsula
human
societi
spca
ph
spayneut
clinic
provid
discount
free
servic
feral
cat
san
mateo
counti
suburban
rural
counti
south
san
francisco
feral
cat
receiv
free
servic
must
test
felin
leukemia
viru
felv
felin
immunodefici
viru
fiv
posit
euthan
year
feral
cat
caretak
sought
spayneut
servic
elsewher
avoid
requir
studi
describ
felin
retrovir
preval
among
feral
cat
present
ph
spayneut
clinic
past
year
cat
test
posit
felv
fiv
respect
cat
test
posit
felv
fiv
respect
cat
test
posit
felv
fiv
respect
three
period
preval
fiv
increas
p
preval
felv
decreas
significantli
p
year
studi
significantli
male
femal
p
despit
decreas
admiss
third
period
preval
fiv
male
remain
similar
across
year
p
increas
femal
suggest
fiv
test
continu
among
commun
cat
san
mateo
counti
screen
borrelia
burgdorferi
seroposit
commonli
perform
dog
conjunct
annual
heartworm
test
widespread
canin
test
provid
seropreval
data
use
identifi
emerg
establish
lyme
diseas
risk
area
region
eastern
atlant
central
canada
howev
point
preval
data
uncharacter
popul
limit
one
exampl
absenc
clinic
canin
data
preclud
determin
true
clinic
diseas
preval
signific
clinic
knowledg
gap
lead
confus
potenti
mismanag
dog
given
current
dearth
evid
guid
import
clinic
decis
regard
b
burgdorferi
exposur
infect
along
myriad
infecti
canin
health
concern
concert
effort
beyond
studi
referr
facil
limit
generaliz
primari
practic
need
type
veterinari
longitudin
studi
effort
morri
anim
foundat
golden
retriev
lifetim
studi
reliant
develop
educ
partnership
gener
practic
veterinari
clinic
recruit
engag
studi
particip
ongo
success
specif
object
studi
develop
educ
partnership
veterinari
clinic
veterinari
school
canada
enrol
engag
dog
owner
order
perform
lyme
diseas
canin
health
studi
evalu
seroconvers
rate
dog
b
burgdorferi
ehrlichia
anaplasma
spp
period
assess
incid
clinic
sign
lyme
diseas
compar
seroconvers
identifi
factor
associ
seroconvers
vaccin
tick
prevent
dog
demograph
environ
evalu
client
percept
awar
educ
diseas
prevent
gener
practic
veterinari
clinic
ontario
canada
invit
particip
healthi
dog
month
age
younger
elig
inclus
baselin
visit
blood
test
heartworm
b
burgdorferi
ehrlichia
anaplasma
spp
snap
test
questionnair
complet
enrol
descript
statist
use
assess
questionnair
data
baselin
test
result
live
emerg
establish
lyme
diseas
risk
area
ontario
canada
figur
owner
complet
questionnair
respond
report
major
dog
obtain
local
breeder
puppi
owner
owner
live
suburb
citi
almost
femal
particip
report
awar
lyme
diseas
howev
none
report
famili
household
member
diagnos
lyme
diseas
major
respond
state
knew
caus
lyme
diseas
correctli
identifi
tick
vector
lyme
diseas
howev
half
respond
activ
tri
prevent
tick
attach
sometim
tri
prevent
tick
attach
similarli
respond
undertook
effort
eg
trim
brush
shrub
reduc
tick
properti
despit
high
awar
lyme
diseas
respond
recal
human
health
care
provid
ever
discuss
lyme
diseas
recal
ever
receiv
inform
lyme
diseas
human
health
care
sourc
major
respond
recal
tick
prevent
discuss
veterinarian
administ
tick
prevent
product
dog
puppi
report
vaccin
lyme
diseas
respond
certain
vaccin
occur
baselin
diseas
test
snap
test
pathogen
neg
enrol
puppi
date
n
evalu
baselin
test
result
confirm
high
knowledg
lyme
diseas
form
basi
ongo
futur
research
effort
util
uniqu
studi
popul
borrelia
burgdorferi
caus
agent
lyme
diseas
common
pathogen
known
infect
dog
unit
state
infect
b
burgdorferi
recogn
albeit
uncommon
associ
onset
acut
kidney
diseas
term
acut
lyme
nephriti
less
known
associ
infect
pathogen
onset
chronic
kidney
diseas
dog
retrospect
cohort
studi
perform
determin
dog
detect
antibodi
vlse
peptid
b
burgdorferi
could
associ
increas
risk
kidney
diseas
lyme
serolog
data
obtain
idexx
refer
laboratori
irl
databas
chemistri
urinalysi
result
obtain
irl
databas
juli
januari
patient
expos
vbd
defin
b
burgdorferi
posit
test
result
record
point
time
defin
neg
result
test
event
studi
chronic
kidney
diseas
ckd
defin
concurr
increas
sdma
creatinin
mgdl
minimum
day
inappropri
urin
specif
graviti
usg
b
burgdorferi
evid
posit
antibodi
b
burgdorferi
within
defin
lyme
region
found
confid
interv
p
studi
identifi
associ
dog
posit
lyme
test
result
increas
risk
ckd
fever
aof
common
find
cat
may
indic
infect
pathogen
better
understand
preval
felin
pathogen
fvbp
serolog
molecular
diagnost
assay
use
prospect
screen
cat
aof
fvbp
pcr
use
detect
infect
anaplasma
bartonella
babesia
cytauxzoon
ehrlichia
hepatozoon
mycoplasma
rickettsia
spp
anaplasma
borrelia
burgdorferi
ehrlichia
seroreact
test
test
bartonella
hensela
b
koehlera
b
vinsonii
subsp
berkhofii
seroreact
assess
ifa
test
aof
cat
blood
serum
sampl
correspond
physic
examin
find
cbc
biochemistri
panel
submit
june
decemb
privat
practic
veterinarian
inclus
criteria
includ
flea
andor
tick
exposur
aof
ill
without
obviou
histor
trauma
physic
examin
abscess
caus
owner
agre
return
blood
collect
convalesc
serolog
studi
object
includ
determin
preval
specif
fvbp
cat
aof
identifi
differ
clinicopatholog
abnorm
uninfect
cat
eighti
four
cat
met
inclus
criteria
correspond
convalesc
sampl
submit
cat
cat
resid
primarili
florida
north
carolina
includ
male
femal
pure
breed
mix
breed
averag
age
year
major
case
occur
summer
fall
season
fvbp
detect
pcr
cat
includ
b
hensela
mycoplasma
haemominutum
hepatozoon
spp
haemof
phagocytophilum
c
feli
r
feli
cat
seroreact
bartonella
spp
b
burgdorferi
ehrlichia
spp
anaplasma
spp
compar
acut
convalesc
sampl
n
b
clarridgeaeb
hensela
b
hensela
infect
newli
diagnos
pcr
convalesc
sampl
bartonella
seroreact
seroreact
correspond
acut
sampl
cat
fold
increas
bartonella
titer
acut
convalesc
sampl
one
acut
phagocytophilum
pcr
cat
seroconvert
anaplasma
test
clinicopatholog
data
collect
time
acut
sampl
collect
averag
rectal
temperatur
aof
cat
predomin
clincopatholog
abnorm
includ
heart
murmur
ocular
discharg
neutrophilia
anemia
thrombocytopenia
hyperbilirubinemia
hyperglobulinemia
cat
test
felvfiv
felv
antigen
neg
fiv
seroposit
evalu
potenti
clinicopatholog
risk
factor
cat
group
fvbp
pcr
n
b
hensela
pcr
n
n
result
cat
aof
neutrophilia
significantli
associ
fvbp
p
odd
ratio
ci
b
hensela
p
ci
pcr
result
compar
cat
base
studi
fvbp
common
cat
aof
bartonella
spp
preval
fvbp
howev
preval
rate
compar
rate
report
cat
without
aof
hepatozoon
spp
may
frequent
caus
aof
cat
unit
state
previous
determin
clinician
routin
promot
use
flea
prevent
strategi
cat
consid
fvbp
etiolog
aof
particularli
associ
neutrophilia
dog
commonli
infect
vector
born
pathogen
seroposit
dog
without
clinic
evid
diseas
frequent
identifi
studi
follow
serolog
clinic
statu
dog
cours
year
regard
ehrlichia
anaplasma
borrelia
spp
conveni
popul
dog
belong
staff
student
univers
missouri
colleg
veterinari
medicin
use
dog
age
rang
year
start
studi
preliminari
find
regard
chang
serolog
statu
first
two
year
previous
present
abstract
form
updat
complet
data
dog
suspect
vector
born
diseas
enrol
prospect
studi
dog
underw
physic
exam
owner
complet
histori
questionnair
period
visit
blood
sampl
submit
idexx
laboratori
test
plasma
separ
analyz
use
research
elisa
antibodi
bb
lyme
e
canis
chaffeensi
ech
e
chaffeensi
ew
e
ewingii
ec
e
cani
anaplasma
genu
apl
plati
aph
phagocytophilum
dog
found
seroneg
test
pathogen
test
repeat
q
month
dog
posit
time
point
test
pathogen
test
repeat
q
month
seroposit
dog
treat
antibiot
unless
clinic
ill
develop
three
year
treat
veterinarian
unrel
studi
believ
warrant
antibiot
tick
prevent
use
owner
discret
total
sampl
collect
dog
particip
everi
plan
sampl
point
dog
euthan
one
die
five
move
state
antibodi
ehrlichia
spp
recogn
mani
dog
least
one
occas
antibodi
anaplasma
spp
recogn
dog
dog
ever
posit
borrelia
peptid
serolog
statu
individu
dog
vari
time
point
time
point
seroconvers
revers
seroneg
statu
dog
popul
frequent
seroposit
e
ewingii
e
chaffeensi
howev
dog
clinic
evid
consist
ehrlichiosi
prompt
treatment
evid
seroconvers
intermitt
seroposit
result
common
without
clinic
diseas
dog
may
remain
constantli
intermitt
seroposit
ehrlichia
spp
least
year
without
clinic
obviou
diseas
known
peopl
commonli
acquir
toxoplasma
gondii
infect
ingest
sporul
oocyst
pass
cat
fece
sinc
cat
oblig
carnivor
assum
infect
gondii
ingest
tissu
cyst
prey
speci
howev
incid
clinic
sequela
laboratori
find
associ
gondii
infect
cat
poorli
understood
primari
purpos
studi
optim
human
gondii
sporozoit
antibodi
assay
use
cat
sera
evalu
subsequ
epidemiolog
studi
gener
posit
control
sera
sporozoit
use
assay
titrat
young
adult
cat
fed
sporul
oocyst
strain
gondii
monitor
system
ocular
sign
toxoplasmosi
cat
group
hous
day
enclos
separ
cage
night
enabl
collect
fece
sugar
centrifug
microscop
examin
oocyst
toxoplasma
gondii
igm
igg
antibodi
gondii
tachyzoit
measur
day
ocular
lesion
system
sign
diseas
recogn
oocyst
seen
fece
one
cat
day
one
cat
develop
igm
igg
antibodi
day
one
cat
develop
igg
antibodi
alon
first
detect
day
one
cat
develop
igm
igg
antibodi
day
igg
antibodi
persist
experi
result
confirm
cat
ingest
sporul
gondii
oocyst
becom
infect
shed
lower
level
oocyst
delay
seroconvers
compar
histor
control
fed
tissu
cyst
sampl
collect
use
sporozoit
antibodi
assay
titrat
ongo
studi
natur
expos
cat
quantit
bacteri
cultur
sensit
test
gold
standard
diagnos
bacteri
urinari
tract
infect
sampl
commonli
transport
extern
refer
laboratori
prior
inocul
cultur
media
object
studi
compar
result
bacteri
cultur
sensit
test
canin
felin
urin
sampl
streak
plate
inocul
perform
immedi
sampl
collect
versu
streak
plate
inocul
delay
arriv
refer
laboratori
prospect
observ
studi
includ
urin
sampl
canin
felin
submit
routin
urinalysi
urin
cultur
sensit
test
streak
plate
inocul
urin
sampl
perform
immedi
sampl
collect
receipt
outsid
refer
laboratori
cultur
sensit
result
compar
addit
data
collect
includ
signal
comorbid
presenc
lower
urinari
tract
sign
urinalysi
result
antimicrobi
histori
overal
agreement
immedi
delay
cultur
sampl
collect
via
repres
discrep
cultur
result
howev
versu
cystocentesi
cultur
discrep
deem
clinic
impact
pyuria
significantli
associ
posit
cultur
result
use
extern
refer
laboratori
urin
cultur
sensit
test
gener
reliabl
sampl
store
transport
accord
guidelin
though
discord
result
immedi
versu
delay
cultur
cystocentesi
sampl
like
alter
clinic
decis
discrep
uncommon
leptospir
pulmonari
hemorrhag
syndrom
lph
sever
manifest
leptospirosi
affect
human
anim
associ
high
mortal
pathogen
mechan
lph
poorli
understood
aim
prospect
observ
clinic
studi
examin
whether
solubl
serum
marker
endotheli
cell
activ
dysfunct
alter
dog
leptospirosi
whether
marker
correl
occurr
pulmonari
hemorrhag
outcom
ethic
approv
obtain
studi
prospect
collect
day
healthi
dog
day
serum
sampl
dog
leptospirosi
without
pulmonari
hemorrhag
dog
acut
kidney
injuri
aki
due
caus
includ
dog
deem
healthi
base
unev
histori
normal
physic
examin
dog
leptospirosi
present
consist
clinic
laboratori
imag
find
least
one
microscop
agglutin
test
mat
titr
posit
dog
aki
due
caus
show
neg
mat
one
pair
sampl
convinc
altern
diagnosi
serum
measur
use
commerci
brunschwig
result
compar
group
use
test
associ
diseas
group
outcom
test
use
logist
regress
analysi
diagnost
accuraci
day
predict
occurr
lph
test
use
roc
curv
analysi
median
serum
concentr
significantli
higher
dog
aki
ngml
iqr
n
dog
lph
ngml
iqr
n
compar
heathi
control
ngml
iqr
n
p
median
higher
dog
leptospirosi
without
lph
ngml
iqr
n
compar
control
lower
lph
group
differ
reach
statist
signific
day
sampl
avail
analysi
show
similar
trend
highest
dog
lph
ngml
iqr
n
compar
healthi
control
dog
aki
ngml
iqr
n
leptospirosi
without
lph
ngml
iqr
n
howev
differ
healthi
lph
group
statist
signific
p
signific
associ
diseas
group
outcom
day
predict
develop
lph
reason
accuraci
auc
sensit
ci
specif
ci
find
suggest
context
leptospirosi
overexpress
endotheli
may
associ
develop
pulmonari
hemorrhag
antimicrobi
resist
grow
problem
within
veterinari
human
medicin
much
attent
public
dedic
resist
use
antimicrobi
agent
human
medicin
food
produc
anim
less
known
potenti
exchang
antimicrobi
resist
bacteria
companion
anim
human
washington
state
integr
surveil
antimicrobi
resist
wisar
project
statewid
collabor
span
human
medicin
human
public
health
surveil
veterinari
medicin
veterinari
medic
surveil
within
collabor
effort
examin
rel
frequenc
antimicrobi
resist
phenotyp
select
organ
across
close
interfac
dog
children
examin
data
region
human
pediatr
medic
center
veterinari
clinic
laboratori
veterinari
refer
laboratori
focus
urinari
isol
pediatr
canin
popul
compar
resist
pattern
common
examin
emerg
similar
resist
pattern
examin
resist
e
coli
urinari
tract
isol
five
major
class
antibiot
dog
children
examin
preval
phenotyp
resist
pattern
combin
drug
class
found
canin
urinari
isol
preval
e
coli
resist
class
repres
third
gener
cephalosporin
ceftiofur
higher
resist
human
urinari
isol
ceftriaxon
detect
howev
increas
rate
resist
canin
isol
studi
period
preval
phenotyp
commonli
associ
e
coli
isol
clonal
lineag
featur
resist
cephalosporin
quinolon
also
common
companion
anim
isol
compar
human
isol
find
suggest
higher
rate
e
coli
resist
third
gener
cephalosporin
found
canin
patient
compar
human
pediatr
patient
differ
could
due
differ
sampl
analysi
includ
use
differ
class
repres
deserv
investig
sinc
implic
veterinari
practic
well
public
health
find
also
highlight
import
develop
valid
integr
databas
antimicrobi
human
anim
particular
region
aelurostrongylu
abstrusu
lungworm
known
infect
lower
respiratori
tract
cat
result
bronchiti
pneumonia
although
abstrusu
consid
endem
part
europ
distribut
unit
state
larg
unknown
due
util
insensit
diagnost
test
method
lack
widespread
preval
studi
epidemiolog
data
parasit
presenc
within
unit
state
need
rais
awar
among
veterinari
profession
identifi
region
object
present
studi
compil
commerci
refer
laboratori
data
period
determin
distribut
abstrusu
within
unit
state
base
widespread
fecal
test
cat
result
felin
ova
parasit
p
zinc
sulfat
centrifug
fecal
flotat
test
perform
idexx
refer
laboratori
unit
state
januari
septemb
compil
sort
test
posit
abstrusu
larva
result
baermann
test
current
consid
gold
standard
diagnost
felin
lungworm
also
retriev
time
period
felin
fecal
flotat
test
perform
posit
presenc
abstrusu
larva
addit
baermann
test
conduct
also
posit
report
studi
age
signific
risk
factor
cat
month
rel
risk
confid
interv
p
compar
cat
older
month
contrast
associ
observ
infect
statu
sex
signific
variat
posit
rate
observ
region
northeast
confid
interv
midwest
west
south
major
posit
case
cluster
northeast
great
lake
west
coast
area
unit
state
shown
figur
studi
highlight
emerg
felin
lungworm
unit
state
import
util
appropri
test
accur
diagnos
diseas
compar
gold
standard
baermann
method
fecal
flotat
significantli
less
sensit
detect
abstrusu
larva
traversa
et
al
parasit
vector
like
underestim
true
infect
rate
popul
cat
recent
epidemiolog
surveil
canin
lungworm
angiostrongylu
vasorum
emerg
new
area
europ
greatli
enhanc
introduct
new
serolog
test
liu
et
al
veterinari
parasitolog
region
studi
report
similarli
introduct
higher
throughput
less
diagnost
method
could
help
increas
awar
parasit
among
veterinari
profession
achiev
greater
understand
epidemiolog
factor
improv
care
treatment
clinic
ill
felin
patient
genu
bartonella
consist
pleomorph
gram
neg
bacteria
induc
intraerythrocyt
endotheliotrop
infect
within
vasculatur
dog
human
anim
infect
least
bartonella
speci
document
pet
dog
worldwid
particular
infect
b
hensela
b
koehlera
bartonella
vinsonii
subsp
berkhoffii
report
dog
endocard
vasoprolif
patholog
vascul
myocard
polyarthr
granulomat
lymphaden
hepat
epistaxi
neurolog
symptom
previou
report
evalu
bartonella
seroreact
larg
canin
popul
use
either
indirect
immunofluoresc
antibodi
ifa
assay
lashnit
e
et
al
j
vet
intern
med
doi
elisa
henn
jb
et
al
j
vet
re
current
studi
expand
previou
work
use
whole
cell
protein
lysat
three
clinic
relev
bartonella
speci
antigen
three
separ
elisa
assay
archiv
dog
sera
n
submit
idexx
refer
laboratori
across
censu
region
unit
state
may
august
use
evalu
three
bartonella
elisa
overal
sera
elisa
reactiv
b
hensela
san
antonio
b
vinsonii
subsp
berkhoffii
genotyp
ii
b
koehlera
bk
whole
cell
lysat
respect
dog
sera
reactiv
three
bartonella
sp
elisa
wherea
sera
reactiv
bk
whole
cell
lysat
respect
seroreact
two
bartonella
sp
whole
cell
lysat
one
three
follow
combin
includ
bk
bk
analysi
dog
south
atlant
east
west
south
central
region
higher
overal
bartonella
seroreact
rate
rel
dog
us
censu
region
breed
comparison
indic
toy
dog
less
like
bartonella
seroreact
compar
mix
sport
work
dog
gender
male
vs
femal
signific
impact
bartonella
seroreact
adult
dog
age
year
like
bartonella
seroreact
rel
younger
dog
age
month
whole
cell
elisa
result
concord
previous
publish
dog
seropreval
studi
found
substanti
lower
bartonella
seropreval
rate
dog
compar
cat
geograph
region
variabl
among
individu
dog
seroreact
detect
one
two
three
elisa
result
indic
multipl
antigen
requir
serolog
document
exposur
infect
three
bartonella
speci
canin
heartworm
diseas
potenti
fatal
form
dirofilariosi
caus
dirofilaria
immiti
infect
transmit
via
mosquito
vector
unit
state
overal
preval
canin
heartworm
diseas
declin
significantli
sinc
late
centuri
due
widespread
usag
chemoprophylact
drug
despit
progress
autochthon
transmiss
persist
nationwid
risk
heartworm
infect
unprotect
dog
remain
therefor
dog
screen
annual
use
rapid
test
detect
presenc
heartworm
antigen
blood
recommend
american
heartworm
societi
low
preval
posit
predict
valu
diagnost
screen
test
directli
proport
diseas
preval
within
region
use
consequ
area
preval
heartworm
infect
drop
claim
fals
posit
rate
specif
screen
test
rare
posit
test
result
may
suspect
fals
posit
aim
studi
specif
plu
test
heartworm
hw
antigen
estim
local
posit
predict
valu
ppv
specif
california
counti
better
understand
diagnost
valu
posit
hw
screen
result
area
california
plu
test
hw
antigen
test
result
collect
compar
scandinavia
virtual
autochthon
transmiss
hw
believ
occur
california
although
posit
test
result
scandinavian
clinic
may
due
infect
acquir
elsewher
conserv
consid
posit
hw
test
result
scandinavian
clinic
fals
posit
observ
specif
therefor
defin
proport
scandinavia
plu
hw
test
return
neg
result
duplic
test
singl
patient
within
given
year
remov
dataset
prior
analysi
use
observ
scandinavian
specif
preval
data
companion
anim
parasit
council
http
wwwcapcvetorg
state
test
sensit
calcul
posit
predict
valu
california
counti
use
standard
methodolog
base
bay
theorem
confid
interv
proport
calcul
use
exact
method
plu
hw
antigen
test
result
veterinari
clinic
finland
norway
sweden
analyz
determin
observ
test
specif
scandinavian
test
result
analyz
posit
hw
antigen
give
posit
rate
ci
observ
specif
ci
period
plu
hw
antigen
test
result
identifi
california
veterinari
clinic
repres
counti
posit
hw
antigen
posit
rate
ci
posit
rate
plu
hw
test
california
found
significantli
higher
rate
observ
scandinavia
test
p
therefor
higher
expect
rate
plu
hw
test
posit
sole
attribut
lack
specif
fals
posit
strongli
suggest
actual
presenc
dirofilaria
immiti
california
align
recent
studi
report
hw
infect
among
coyot
mosquito
popul
within
california
huang
et
al
j
med
entomol
nov
addit
signific
variat
hw
posit
rate
observ
counti
within
california
california
counti
least
result
report
capc
studi
period
least
one
dog
test
posit
hw
madera
counti
highest
plu
test
hw
posit
rate
ci
san
benito
counti
lowest
ci
overal
ppv
plu
test
hw
california
estim
well
counti
rang
result
studi
support
test
result
plu
test
due
high
specif
highli
probabl
true
posit
therefor
import
veterinarian
low
preval
region
california
area
unit
state
adher
american
heartworm
societi
guidelin
confirm
unexpect
test
result
retest
ancillari
rapid
test
heartworm
rt
test
refer
laboratori
test
heartworm
pf
antigen
test
canin
influenza
virus
unit
state
strain
origin
hors
usa
strain
avian
strain
asia
first
detect
dog
usa
field
experi
suggest
agent
shed
intermitt
longer
purpos
studi
defin
durat
magnitud
shed
experiment
inocul
dog
descript
pilot
studi
dog
inocul
chamber
usa
field
strain
day
primarili
inocul
dog
pair
anoth
dog
secondari
exposur
day
dog
day
dog
day
dog
day
dog
day
dog
dog
hous
room
contain
pen
clinic
score
rubric
appli
dog
mask
observ
minut
twice
daili
day
oropharyng
swab
collect
daili
qualit
quantit
pcr
assay
dog
develop
clinic
sign
earli
hour
exposur
includ
dog
expos
day
primari
inocul
pen
mate
first
day
primari
inocul
secondari
exposur
dog
total
clinic
score
cough
score
greater
pair
primarili
inocul
dog
direct
contact
dog
last
pcr
posit
day
day
dog
day
dog
day
dog
first
posit
result
one
dog
clinic
ill
never
posit
nucleic
acid
qualit
assay
clinic
sign
minim
dog
day
pcr
assay
result
neg
dog
day
quantit
pcr
assay
result
pend
result
date
suggest
dog
primari
exposur
dose
strain
contagi
day
vancomycin
antibiot
reserv
infect
suscept
antimicrobi
minim
publish
data
vancomycin
use
infect
small
anim
goal
studi
evalu
indic
dose
potenti
advers
effect
surviv
discharg
dog
cat
treat
vancomycin
addit
goal
evalu
vancomycin
treatment
base
current
recommend
best
practic
record
retriev
use
keyword
vancomycin
retrospect
review
record
dog
eight
cat
review
common
indic
vancomycin
includ
infect
involv
integu
hepatobiliari
system
endocard
infect
orthoped
implant
common
cultur
isol
includ
enterococcu
sp
e
coli
aureu
mrsa
common
dose
interv
mgkg
iv
acut
kidney
injuri
defin
iri
guidelin
occur
start
vancomycin
case
neutropenia
allerg
reaction
document
anim
neg
cultur
result
lack
cultur
evid
vancomycin
use
case
case
cultur
result
document
avail
altern
antimicrobi
patient
surviv
discharg
advers
effect
attribut
vancomycin
use
infrequ
dog
cat
patient
studi
surviv
discharg
case
potenti
altern
effect
antimicrobi
lack
cultur
data
support
treatment
vancomycin
infect
angiostrongylu
vasorum
av
emerg
diseas
dog
diseas
may
stimul
regulatori
cytokin
dog
aim
studi
evalu
cytokin
chang
dog
experiment
infect
av
sixteen
beagl
dog
oral
infect
third
stage
larva
eight
dog
treat
anthelmint
av
day
eight
left
untreat
blood
sampl
collect
studi
infect
dog
measur
dog
specif
sandwich
immunoassay
use
electrochemiluminisc
signific
differ
treat
untreat
dog
infect
median
serum
level
dog
infect
pgml
respect
end
studi
median
pgml
respect
untreat
dog
pgml
respect
treat
dog
decreas
significantli
treat
untreat
dog
increas
significantli
untreat
dog
chang
significantli
infect
treat
untreat
dog
surviv
av
host
might
partli
due
increas
regulatori
cytokin
avoid
increas
even
decreas
cytokin
might
anoth
surviv
strategi
parasit
multipl
bartonella
spp
strain
infect
cat
cat
subclin
bartonella
spp
infect
varieti
clinic
laboratori
abnorm
like
fever
endocard
hyperglobulinemia
report
bartonella
hensela
one
common
speci
infect
cat
phase
associ
vascul
mani
studi
bartonella
spp
infect
cat
low
sampl
size
purpos
studi
evalu
associ
bartonella
spp
dna
blood
cat
select
complet
blood
cell
count
abnorm
medic
record
data
base
idexx
search
felin
case
blood
evalu
pcr
assay
amplifi
dna
bartonella
spp
also
result
avail
complet
blood
cell
count
complet
concurr
case
first
classifi
test
blood
donor
suspect
clinic
ill
sampl
state
low
risk
c
feli
exclud
ak
az
co
mt
nm
nv
ut
associ
among
clinic
statu
select
complet
blood
cell
abnorm
ye
bartonella
spp
pcr
assay
result
posit
neg
assess
calcul
odd
ratio
confid
interv
clinic
ill
cat
like
ci
p
posit
bartonella
spp
dna
blood
sampl
blood
donor
cat
sampl
cat
platelet
count
bartonella
spp
dna
blood
sampl
cat
sampl
cat
hematocrit
less
like
ci
p
posit
bartonellaspp
dna
blood
sampl
cat
hematocrit
sampl
sinc
clinic
inform
like
use
flea
control
antibiot
avail
result
interpret
care
addit
estim
bartonella
spp
preval
data
blood
donor
cat
like
lower
select
cat
low
risk
howev
result
seem
confirm
smaller
studi
fail
link
bartonella
spp
anemia
cat
studi
requir
confirm
weak
associ
bartonella
spp
dna
blood
presenc
thrombocytopenia
bartonella
hensela
common
caus
cat
scratch
diseas
clinic
syndrom
peopl
cat
develop
high
level
b
hensela
bacteremia
associ
human
infect
particularli
presenc
ctenocephalid
feli
sever
antibiot
protocol
use
treatment
b
hensela
infect
cat
fail
clear
bacteremia
purpos
studi
assess
safeti
efficaci
high
dose
pradofloxacin
protocol
elimin
b
hensela
bacteremia
experiment
inocul
cat
infect
b
hensela
initi
cat
intraven
inocul
infect
felin
blood
cat
posit
b
hensela
dna
blood
posit
bartonella
spp
igg
serum
week
prior
enter
studi
pradofloxacin
administ
mgkg
po
twice
daili
day
complet
blood
cell
count
perform
prior
pradofloxacin
administr
everi
week
week
bartonella
pcr
assay
bartonella
spp
igg
serolog
perform
prior
pradofloxacin
administr
approxim
everi
week
week
weekli
week
methylprednisolon
acet
administ
mgkg
intramuscular
inject
cat
week
clinic
side
effect
note
pradofloxacin
administr
period
none
cat
develop
anemia
neutrophil
lymphocyt
count
lower
refer
rang
pradofloxacin
administr
cat
neg
b
hensela
dna
blood
sampl
date
one
cat
maxim
igg
titer
intermitt
neg
start
pradofloxacin
administr
sampl
anoth
cat
maxim
igg
titer
neg
last
sampl
collect
studi
pradofloxacin
protocol
use
studi
well
toler
bartonella
hensela
bacteremia
detect
cat
administr
pradofloxacin
even
administr
dose
methylprednisolon
acet
result
suggest
antibiot
effect
organ
clear
spontan
studi
repeat
cat
infect
b
hensela
exposur
infect
c
feli
cat
infect
field
studi
test
hypothesi
aryl
isonitril
compound
significantli
reduc
staphylococcu
pseudintermediu
replic
surviv
plankton
cultur
biofilm
toxic
mammalian
cell
aryl
isonitril
compound
recent
shown
potent
activ
staphylococcu
aureu
panel
compound
synthes
dr
mingji
dai
laboratori
purdu
institut
drug
discoveri
screen
two
pseudintermediu
isol
compound
minimum
inhibitori
concentr
mic
evalu
panel
isol
staphylococcu
pseudintermediu
isol
anim
treat
purdu
univers
veterinari
teach
hospit
obtain
indiana
anim
diseas
diagnost
laboratori
minimum
bactericid
concentr
mbc
mic
test
use
clinic
laboratori
standard
institut
method
efficaci
biofilm
test
use
well
plate
method
toxic
mammalian
cell
canin
kidney
mdck
cell
assess
via
mt
sulfophenyl
inner
salt
assay
mic
mbc
rang
percent
pseudintermediu
isol
inhibit
respect
compound
toxic
mdck
cell
concentr
well
mic
four
compound
test
establish
biofilm
disrupt
percent
biofilm
three
disrupt
percent
biofilm
aryl
isonitril
compound
potent
activ
plankton
pseudintermediu
toxic
mammalian
cell
effect
disrupt
establish
biofilm
compound
hold
great
promis
develop
treatment
pseudintermediu
urinari
tract
infect
uti
common
morbid
canin
affect
approxim
companion
popul
least
lifetim
commonli
isol
bacteri
speci
associ
canin
uti
escherichia
coli
treatment
uncompl
uti
typic
antimicrobi
therapi
small
subpopul
dog
develop
chronic
urinari
tract
infect
repeat
prolong
increasingli
aggress
antimicrobi
therapi
often
use
genet
character
e
coli
associ
canin
uti
would
valuabl
optim
empir
antimicrobi
therapi
choic
understand
associ
clinic
present
pathogenesi
persist
hypothesi
urinari
pathogen
e
coli
upec
associ
canin
uti
divers
yet
predict
associ
specif
virul
eg
toxin
biofilm
antimicrobi
resist
gene
elucid
collect
e
coli
isol
collect
canin
urin
sampl
previous
character
h
antigen
type
antimicrobi
suscept
abil
form
biofilm
subset
isol
n
character
use
whole
genom
sequenc
miseq
platform
thirteen
differ
e
coli
sequenc
type
recov
two
sequenc
type
found
among
multipl
isol
e
coli
sequenc
type
associ
multipl
sampl
collect
patient
three
month
apart
e
coli
sequenc
type
found
three
differ
dog
number
differ
antimicrobi
resist
gene
identifi
includ
aac
aada
aadb
aph
bla
cmi
bla
bla
oxa
bla
tem
cat
cml
cmla
dfra
mph
stra
strb
tet
b
presenc
sever
gene
import
classifi
isol
beta
lactamas
esbl
produc
sequenc
type
repres
three
isol
lack
associ
resist
gene
sequenc
isol
least
one
gene
eaeh
gene
associ
e
coli
attach
found
isol
previous
presenc
one
gene
fimh
strongli
associ
abil
form
biofilm
detect
isol
conclus
escherichia
coli
caus
canin
uti
appear
divers
still
presenc
consist
attach
virul
gene
note
across
sequenc
type
antimicrobi
resist
gene
phenotyp
resist
cephalosporin
detect
sever
sampl
concern
therapeut
choic
anim
handl
consider
work
explor
associ
among
virul
antimicrobi
resist
biofilm
potenti
underway
better
understand
upec
present
pathogenesi
dog
serum
level
creatinin
scr
blood
urea
nitrogen
bun
routin
use
biomark
kidney
function
howev
insuffici
earli
detect
kidney
dysfunct
serum
level
rise
sever
histopatholog
damag
occur
kidney
symmetr
dimethylarginin
sdma
structur
isom
endogen
nitric
oxid
synthas
inhibitor
asymmetr
dimethylarginin
asymmetr
dimethylarginin
metabol
dimethylarginin
dimethylaminohydrolas
wherea
sdma
elimin
renal
excret
studi
investig
serum
level
sdma
anesthesia
dog
dog
anesthet
propofol
n
alphaxalon
n
blood
sampl
collect
hour
initi
anesthesia
immedi
complet
surgic
procedur
level
sdma
measur
idexx
laboratori
measur
scr
bun
perform
marbl
veterinari
medic
center
dog
anesthet
propofol
serum
level
sdma
measur
anesthesia
significantli
higher
measur
anesthesia
p
level
scr
bun
tradit
marker
renal
function
also
increas
addit
bun
scr
level
significantli
posit
associ
sdma
level
r
r
respect
dog
averag
serum
level
sdma
anesthesia
increas
anesthesia
wherea
smaller
increas
detect
scr
bun
studi
increas
serum
sdma
observ
dog
wherea
level
scr
bun
increas
dog
taken
togeth
data
suggest
serum
sdma
concentr
like
sensit
biomark
kidney
dysfunct
canin
viscer
leishmaniasi
cvl
zoonot
diseas
caus
protozoa
leishmania
sp
among
clinic
alter
observ
dog
infect
protozoa
symptom
associ
decreas
renal
function
often
describ
serum
symmetr
dimethylarginin
sdma
recent
evalu
renal
biomark
effici
detect
earli
renal
dysfunct
dog
level
serum
sdma
shown
signific
relationship
glomerular
filtrat
rate
excret
renal
clearanc
dog
studi
evalu
serum
sdma
dog
natur
infect
l
infantum
inclus
criteria
dog
studi
either
posit
elisa
rifi
posit
reaction
snap
leishmania
idexx
dog
regardless
renal
stage
iri
intern
renal
interest
societi
submit
follow
exam
serum
sdma
complet
blood
count
reticulocyt
serum
creatinin
serum
blood
urea
nitrogen
bun
serum
phosphoru
urinalysi
urinari
protein
creatinin
ratio
upc
system
blood
pressur
bp
abdomin
ultrasonographi
dog
divid
iri
stage
risk
stage
stage
stage
stage
stage
correl
renal
marker
sdma
determin
pearson
coeffici
correl
analysi
serum
sdma
shown
relationship
serum
creatinin
r
p
serum
bun
r
p
serum
phosphoru
r
p
relationship
serum
sdma
upc
r
p
serum
sdma
present
neg
relationship
hematocrit
r
p
urinari
densiti
r
p
reticulocyt
neg
relationship
r
p
serum
sdma
relationship
bp
r
p
dog
iri
risk
stage
serum
sdma
increas
iri
stage
iri
stage
iri
stage
iri
stage
dog
hyperphosphatemia
show
increas
serum
sdma
present
data
show
serum
sdma
strong
relationship
sever
paramet
use
evalu
renal
function
serum
creatinin
serum
phosphoru
serum
bun
hematocrit
upc
urinari
densiti
reticulocyt
serum
sdma
weak
relationship
bp
serum
sdma
increas
prior
imag
alter
kidney
ultrasonographi
dog
serum
sdma
also
increas
dog
valu
serum
creatinin
dl
differ
found
iri
stage
consid
serum
sdma
dog
iri
stage
serum
sdma
dl
dog
reclassifi
iri
stage
iri
stage
dog
iri
stage
serum
sdma
dl
dog
reclassifi
iri
stage
iri
stage
conclud
serum
sdma
import
tool
evalu
renal
function
use
routin
evalu
dog
infect
l
infantum
measur
symmetr
dimethylarginin
sdma
use
diagnosi
monitor
kidney
diseas
veterinari
medicin
recent
idexx
introduc
novel
immunoassay
measur
sdma
chemistri
analyz
assay
perform
felin
sampl
publish
elsewher
studi
evalu
catalyst
sdma
test
catalystsdma
sdma
measur
felin
sampl
compar
result
obtain
liquid
spectrometri
techniqu
previous
valid
felin
sampl
serum
sampl
cat
obtain
idexx
refer
laboratori
reflab
sampl
origin
submit
clinic
purpos
request
test
complet
standard
retent
period
day
reflab
typic
dispos
remain
materi
instead
reflab
term
condit
residu
sampl
frozen
use
studi
sampl
thaw
batch
analyz
use
catalystsdma
catalyst
chemistri
analyz
use
refmethod
studi
complet
sever
day
howev
sampl
test
complet
within
four
hour
test
complet
idexx
result
report
confid
limit
parenthes
refmethod
median
sdma
interquartil
rang
iqr
rang
catalystsdma
median
sdma
iqr
rang
statist
differ
exist
sdma
concentr
obtain
two
method
p
u
test
regress
analysi
intercept
slope
tau
pearson
correl
coeffici
r
mean
differ
plot
standard
deviat
loa
plot
show
fix
proport
bia
increas
variat
higher
end
dynam
rang
unlik
impact
clinic
decis
loa
upper
limit
loa
lower
limit
assay
result
nearest
whole
number
assign
one
three
categori
percentag
agreement
concord
two
assay
calcul
good
agreement
result
classif
minim
bia
good
concord
excel
correl
refer
method
provid
confid
catalystsdma
use
measur
felin
sdma
purpos
present
report
complic
three
case
transurethr
ectop
uret
correct
tuclcu
transurethr
cystoscopi
tuc
procedur
choic
correct
ectop
uret
femal
dog
sinc
first
correct
perform
procedur
perform
multipl
institut
report
techniqu
success
rate
signific
complic
failur
complet
correct
incontin
reporteda
year
old
spay
femal
golden
retriev
present
lethargi
abdomin
pain
month
bilater
tuclcu
ultrasound
reveal
larg
hydronephrot
right
kidney
periren
fluid
right
hydrouret
tuc
reveal
complet
occlus
right
neostoma
right
nephrectomi
ureterectomi
perform
owner
insist
commun
receiv
remot
client
year
old
femal
australian
shepherd
diagnos
right
side
hydronephrosi
hydrouret
month
bilater
tuclcu
commun
receiv
remot
client
year
tuclcu
perform
month
old
femal
newfoundland
ultrasound
show
earli
hydronephrosi
hydrouret
monitor
ultrasound
transurethr
cystoscopi
revis
neostoma
recommend
case
last
case
reexamin
tuc
inadequ
respons
tuclcu
portion
left
vagin
ectop
uret
complet
correct
revis
neostoma
residu
vagin
ectop
uret
perform
spontan
closur
neostoma
tuclcu
surgeri
signific
complic
procedur
postop
monitor
tuclcu
case
ultrasound
recommend
diagnos
hydronephrosi
hydrouret
earli
allow
earli
stoma
revis
preserv
involv
kidney
vascular
calcif
import
risk
factor
human
chronic
kidney
diseas
ckd
associ
dysregul
miner
metabol
precipit
calcium
phosphat
start
format
solubl
colloid
primari
calciprotein
particl
cpp
transform
crystallin
secondari
cpp
shorter
durat
transform
step
ie
increas
serum
calcif
propens
associ
increas
mortal
human
ckd
patient
although
vascular
calcif
recogn
cat
ckd
miner
disturb
similar
observ
human
ckd
common
plasma
fibroblast
growth
factor
concentr
marker
miner
disturb
felin
ckd
examin
serum
calcif
propens
cat
vari
degre
renal
dysfunct
relationship
plasma
phosphat
total
calcium
magnesium
total
protein
concentr
calcium
phosphat
product
blood
sampl
prospect
collect
euthyroid
cat
year
old
cat
intern
renal
interest
societi
iri
stage
ckd
cat
iri
stage
ckd
store
c
serum
calcif
propens
measur
function
assay
detect
transform
time
spheric
primari
cpp
elong
secondari
cpp
diagnost
compani
blind
clinic
data
calciscon
switzerland
intact
measur
edta
plasma
use
valid
elisa
assay
kaino
laboratori
tokyo
japan
serum
valu
among
three
group
compar
use
anova
linear
trend
correl
serum
plasma
phosphat
total
calcium
magnesium
total
protein
concentr
calcium
phosphat
product
assess
spearman
rank
correl
rs
mean
valu
standard
deviat
sd
minut
cat
sd
minut
cat
iri
stage
ckd
sd
minut
cat
iri
stage
ckd
mean
differ
among
group
p
signific
linear
trend
p
indic
serum
calcif
propens
increas
group
worsen
kidney
function
serum
invers
correl
plasma
rs
p
total
protein
rs
p
correl
significantli
plasma
creatinin
rs
p
phosphat
rs
p
total
calcium
rs
p
calcium
phosphat
product
rs
p
magnesium
rs
p
preliminari
data
suggest
serum
cat
lose
intrins
properti
inhibit
calcif
declin
renal
function
veloc
serum
calcifi
invers
associ
plasma
total
protein
concentr
may
suggest
dysregul
miner
metabol
chronic
inflamm
underli
mechan
soft
tissu
calcif
cat
research
larger
popul
cat
need
confirm
find
assess
prognost
valu
serum
calcif
propens
cat
ckd
hypercalciuria
suggest
predispos
caus
develop
calcium
oxal
caox
urolithiasi
dog
purpos
studi
identifi
incid
hypercalciuria
via
fast
urin
calcium
creatinin
ratio
uca
cr
dog
evalu
caox
urolithiasi
fast
uca
cr
collect
initi
evalu
consid
increas
ratio
base
previous
publish
data
dog
includ
studi
caox
urolithiasi
confirm
via
quantit
calculi
analysi
ioniz
calcium
ica
routin
serum
chemistri
cbc
urinalysi
avail
evalu
dog
divid
hypercalciur
group
test
use
compar
group
dog
evalu
sixteen
dog
increas
uca
cr
dog
hypercalciuria
higher
median
ioniz
calcium
mgdl
nonhypercalciur
mgdl
dog
sixteen
dog
ica
upper
half
refer
mgdl
urin
specif
graviti
median
vs
lower
total
calcium
vs
mgdl
higher
hypercalciur
group
half
hypercalciur
dog
recurr
calculi
compar
nonhypercalciur
group
fraction
excret
calcium
time
p
time
p
greater
hypercalciur
dog
compar
nonhypercalciur
use
ica
tca
respect
hypercalciuria
may
addit
predispos
factor
calcium
oxal
urolithiasi
possibl
correct
hypercalciuria
decreas
recurr
rate
canin
caox
urolithiasi
focal
segment
glomerulosclerosi
fsg
diseas
caus
irrevers
podocyt
injuri
import
caus
proteinuria
dog
human
common
complex
glomerulopathi
dog
previous
report
preval
approxim
dog
biopsi
suspect
glomerular
diseas
femal
purpos
studi
retrospect
character
clinic
present
prognosi
fsg
dog
clinic
histopatholog
data
caus
death
obtain
review
record
dog
diagnos
fsg
renal
biopsi
submit
intern
veterinari
renal
patholog
servic
ivrp
januari
may
fsg
diseas
character
absenc
immun
complex
deposit
presenc
segment
consolid
glomerulu
extracellular
matrix
often
associ
adhes
bowman
capsul
hyalinosi
kaplan
meier
surviv
analysi
log
rank
test
use
determin
whether
intern
renal
interest
societi
iri
stage
urin
protein
creatinin
ratio
upc
presenc
sever
hypoalbuminemia
g
dl
ascit
edema
biopsi
histori
hypertens
ht
percentag
global
glomerulosclerosi
gs
biopsi
associ
death
renal
diseas
caus
two
sampl
test
proport
use
assess
signific
male
femal
distribut
dog
renal
biopsi
submit
ivrp
proteinuria
studi
period
diagnos
fsg
median
age
year
biopsi
rang
year
dog
femal
p
median
serum
creatinin
concentr
mg
dl
rang
mg
dl
median
serum
albumin
concentr
alb
g
dl
rang
g
dl
ht
document
prior
time
biopsi
dog
median
upc
rang
dog
report
ascit
edema
biopsi
time
data
collect
dog
aliv
deceas
lost
follow
dog
die
caus
death
ac
death
rd
rd
ac
dog
iri
stage
biopsi
significantli
shorter
surviv
post
biopsi
spb
iri
stage
rd
p
ac
p
rd
ac
dog
alb
g
dl
significantli
shorter
spb
dog
alb
g
dl
rd
p
ac
p
rd
ac
dog
ascit
edema
time
biopsi
significantli
shorter
spb
compar
dog
without
rd
p
ac
p
ac
dog
histori
ht
significantli
shorter
spb
compar
ac
dog
without
histori
ht
p
rd
dog
gs
affect
glomeruli
significantli
shorter
spb
rd
dog
gs
p
upc
significantli
associ
spb
rd
ac
dog
retrospect
studi
fsg
similar
preval
previous
report
femal
continu
sever
hypoalbuminemia
iri
stage
associ
poorer
prognosi
dog
fsg
hypertens
associ
shorter
surviv
dog
die
caus
wherea
biopsi
sampl
least
global
glomerulosclerosi
associ
poorer
prognosi
dog
known
death
intent
research
identifi
simpl
diagnost
test
detect
abnorm
calciuresi
predict
calcium
oxal
caox
urolith
presenc
miniatur
schnauzer
investig
impact
postprandi
time
specif
urin
calcium
creatin
uca
cr
identifi
affect
dog
hypothes
signific
differ
exist
fast
postprandi
uca
cr
control
schnauzer
uca
cr
increas
significantli
fast
baselin
one
postprandi
time
point
urin
sampl
collect
miniatur
schnauzer
without
control
caox
urolith
fast
state
hour
feed
standard
diet
chang
uca
cr
baselin
calcul
postprandi
time
urolithiasi
statu
time
point
assess
impact
uca
cr
chang
uca
cr
use
mix
model
anova
base
control
dog
enrol
thu
far
miniatur
schnauzer
significantli
higher
mean
uca
cr
hour
hour
hour
postprandi
timepoint
indic
alter
calciuresi
chang
uca
cr
signific
time
point
within
group
urolith
form
miniatur
schnauzer
excess
calciuresi
provid
insight
mechan
behind
format
caox
urolith
use
ca
cr
ratio
postprandi
sampl
time
critic
simpl
urin
measur
potenti
marker
urolith
presenc
possibl
risk
urolith
format
purpos
studi
describ
popul
dog
escherichia
coli
e
coli
uti
determin
whether
clinic
differ
dog
e
coli
uti
dog
e
coli
uti
hypothes
would
differ
two
popul
characterist
dog
wherea
would
preval
dog
whose
uti
chronic
complic
andor
asymptomat
retrospect
studi
evalu
anim
e
coli
uti
divid
two
group
base
vitro
capabl
e
coli
isol
biofilm
format
establish
use
crystal
violet
assay
medic
record
dog
review
popul
characterist
age
sex
breed
weight
bodi
condit
score
infect
characterist
infect
class
chronic
exposur
antibiot
pyuria
resist
clinic
sign
compar
major
isol
show
capabl
dog
e
coli
uti
lower
likelihood
resist
p
e
coli
uti
statist
signific
differ
popul
characterist
infect
characterist
two
group
conclud
reliabl
clinic
indic
rule
consider
given
possibl
whenev
e
coli
uti
diagnos
addit
associ
mdr
e
coli
may
antimicrobi
toler
confer
biofilm
format
uremia
associ
chronic
kidney
diseas
ckd
shown
profoundli
affect
composit
gut
microbiom
peopl
rat
model
toxic
product
gener
dysbiosi
may
contribut
morbid
progress
ckdindoxyl
sulfat
sulfat
pc
urem
toxin
produc
colon
bacteria
first
studi
object
compar
fecal
microbiom
healthi
older
year
cat
n
cat
stabl
ckd
iri
stage
n
second
object
measur
serum
pc
healthi
older
cat
n
compar
ckd
cat
n
studi
cat
complet
blood
count
chemistri
panel
total
urinalysi
blood
pressur
fecal
flotat
enrol
ckd
cat
creatinin
mgdl
usg
elev
creatinin
least
two
time
point
addit
elev
sdma
ugdl
healthi
cat
year
age
creatinin
mgdl
usg
exclus
criteria
histori
antibiot
probiot
antacid
administr
week
prior
enrol
histori
uncontrol
hyperthyroid
known
suspect
gastrointestin
diseas
fresh
fecal
sampl
collect
owner
place
ice
frozen
within
hour
collect
microbiom
analysi
extract
fecal
dna
use
illumina
sequenc
bacteri
rrna
gene
differ
proport
bacteri
taxa
speci
evalu
use
test
serum
pc
measur
use
lcmsm
median
valu
ckd
cat
healthi
control
cat
compar
use
mann
whitney
test
group
compar
use
kruskal
walli
dunn
post
hoc
analysi
number
observ
speci
chao
significantli
decreas
ckd
cat
compar
healthi
cat
p
p
respect
shannon
divers
index
decreas
ckd
cat
compar
healthi
cat
howev
signific
p
signific
differ
overal
cluster
microbi
commun
ckd
cat
healthi
cat
p
howev
individu
bacteri
group
analyz
base
lda
effect
size
lefs
sever
bacteri
taxa
identifi
significantli
differ
among
group
compar
healthi
cat
ckd
cat
ckd
cat
significantli
decreas
bacteri
popul
belong
genera
holdemania
adlercreutzia
eubacterium
slackia
mogibacterium
signific
differ
function
potenti
microbiota
found
ckd
cat
healthi
cat
correct
multipl
comparison
level
found
significantli
higher
ckd
cat
compar
healthi
cat
p
healthi
control
cat
significantli
lower
level
compar
stage
p
stage
p
ckd
cat
signific
differ
found
stage
stage
ckd
cat
group
pc
level
significantli
differ
ckd
healthi
control
conclus
felin
ckd
associ
decreas
divers
gut
microbiom
significantli
elev
felin
ckd
merit
explor
potenti
therapeut
target
addit
iri
stage
cat
may
suffer
similar
urem
toxin
burden
cat
later
stage
diseas
addit
work
need
understand
interplay
fecal
microbiom
urem
toxin
purpos
studi
evalu
symmetr
dimethylarginin
sdma
creatinin
concentr
cat
urethr
obstruct
uo
determin
valu
correl
valu
cat
admit
treatment
uo
elig
inclus
serum
sdma
creatinin
concentr
assess
present
hour
day
urinalysi
cultur
assess
present
final
cat
exclud
bacteri
growth
cultur
evid
failur
obtain
sampl
twenti
percent
cat
n
exclud
due
urinari
tract
infect
uti
present
mean
sdma
creatinin
significantli
higher
cat
mgdl
respect
compar
without
uti
mgdl
respect
p
cat
met
inclus
criteria
signific
posit
correl
sdma
creatinin
time
uo
p
associ
initi
sdma
sdma
hour
p
day
p
mean
sdma
creatinin
present
mgdl
respect
significantli
higher
compar
final
valu
mgdl
respect
p
sdma
appear
use
marker
azotemia
cat
uo
sdma
reflect
underli
kidney
diseas
uti
may
frequent
cat
uo
histor
suggest
screen
consid
especi
sdma
creatinin
concentr
elev
despit
pyelonephr
commonli
suspect
hospit
patient
definit
diagnosi
remain
challeng
report
diseas
cat
limit
small
number
case
report
goal
character
clinic
sign
well
clinicopatholog
ultrasonograph
chang
cat
pyelonephr
necropsi
report
veterinari
teach
hospit
search
cat
histopatholog
diagnos
pyelonephr
inclus
studi
cat
undergon
full
physic
examin
prior
death
addit
complet
seventeen
cat
identifi
inclus
studi
median
age
year
rang
year
spay
femal
n
preval
castrat
male
n
anorexia
lethargi
vomit
common
present
complaint
common
physic
exam
abnorm
includ
muscl
wast
hypothermia
cardiac
murmur
clinic
sign
classic
associ
pyelonephr
renal
pain
pyrexia
present
cat
respect
serum
chemistri
complet
blood
count
avail
cat
respect
common
clinic
patholog
abnorm
includ
azotemia
hyperphosphatemia
anemia
cat
respect
cat
urinalysi
data
avail
bacteriuria
isosthenur
urin
cat
urinalysi
perform
four
also
urin
sampl
submit
cultur
addit
cat
urin
submit
cultur
without
concurr
urinalysi
four
urin
sampl
submit
cultur
yield
bacteri
growth
e
coli
isol
cultur
cat
abdomin
radiograph
perform
n
renal
abnorm
includ
atyp
size
kidney
n
miner
n
ultrasonograph
appear
kidney
abnorm
cat
inform
avail
n
common
chang
includ
miner
n
pyelectasia
n
histopatholog
sampl
reveal
pure
neutrophil
cellular
infiltr
cat
bacteria
present
case
pyelonephr
diagnos
none
intralesion
bacteria
note
concurr
neutrophil
pyelonephr
present
remain
four
cat
intralesion
bacteria
present
case
find
suggest
cat
pyelonephr
far
less
like
exhibit
classic
physic
exam
find
renal
pain
pyrexia
commonli
assum
addit
like
renal
azotemia
may
evid
activ
infect
urin
sediment
subcutan
ureter
bypass
sub
devic
placement
altern
tradit
ureter
surgeri
howev
outcom
describ
treatment
benign
ureter
obstruct
dog
purpos
evalu
day
short
day
day
paramet
dog
treat
benign
ureter
obstruct
hypothesi
associ
favor
technic
outcom
compar
altern
place
use
medic
record
review
data
twelv
place
nine
dog
bilater
caus
obstruct
includ
ureterolithiasi
extralumin
compress
strictur
eleven
uret
stent
place
prior
need
recurr
strictur
ureter
stent
migrat
placement
success
uret
median
creatinin
month
mgdl
mgdl
respect
seven
dog
histori
urinari
tract
infect
prior
placement
complic
includ
infect
miner
dog
miner
devic
histori
urolithasi
histor
infect
commonli
infect
death
dog
worsen
azotemia
median
surviv
time
day
still
aliv
use
devic
dog
safe
effect
treatment
option
benign
ureter
obstruct
associ
good
prognosi
high
rate
miner
infect
consid
recent
work
emphas
critic
role
tubulointerstiti
hypoxia
develop
progress
renal
fibrosi
ckd
increas
genet
express
mediat
fibrosi
demonstr
ckd
speci
object
studi
character
express
mediat
fibrosi
bank
renal
tissu
cat
experiment
ckd
hypothes
cat
experiment
ckd
would
increas
intraren
express
mediat
compar
control
cat
pilot
studi
includ
bilater
renal
tissu
sampl
cat
previous
undergon
temporari
unilater
renal
ischemia
model
ckd
healthi
cat
control
group
ckd
model
group
tissu
ischem
kidney
ik
group
contralater
kidney
nik
group
evalu
revers
polymeras
chain
reaction
use
character
tissu
express
vascular
endotheli
growth
matrix
metalloproteinas
tissu
inhibitor
metalloproteinas
transform
growth
factor
statist
signific
differ
gene
express
among
group
observ
downregul
ik
nik
group
compar
control
group
convers
mmp
timp
upregul
ckd
tissu
upregul
ik
group
upregul
ik
nik
group
dysregul
major
pathway
renal
fibrosi
identifi
experiment
felin
ckd
futur
studi
investig
pathway
natur
occur
ckd
may
identifi
new
therapeut
target
highli
preval
diseas
urinari
incontin
ui
common
problem
dog
effect
treatment
lack
mani
dog
demonstr
clinic
sign
throughout
life
result
subsequ
complic
owner
frustrat
woman
minim
invas
procedur
low
temperatur
urethr
thermoplasti
ltut
restor
contin
reduc
complianc
periurethr
tissu
control
applic
heat
goal
studi
evalu
outcom
complic
associ
ltut
femal
dog
incontin
dog
underw
extens
medic
evalu
ltut
perform
short
thermoplasti
probe
posit
proxim
urethra
via
fluoroscop
guidanc
heat
periurethr
tissu
perform
differ
plane
total
treatment
site
per
dog
treat
clinician
owner
complet
serial
questionnair
incontin
diari
three
larg
breed
kg
femal
dog
natur
occur
ui
treat
ltut
perform
success
case
without
signific
complic
leakag
strictur
time
dog
rang
month
owner
report
incontin
score
sever
incontin
incontin
improv
score
dog
impact
ui
owner
qualiti
life
decreas
impact
constant
sourc
concern
ltut
well
toler
treat
dog
improv
incontin
owner
qualiti
life
score
evalu
ltut
larger
case
number
ongo
canin
calcium
oxal
caox
urolithiasi
typic
occur
diseas
featur
diseas
previous
report
object
studi
identifi
patient
stone
characterist
juvenil
dog
caox
urolithiasi
compar
matur
inform
juvenil
year
matur
year
dog
caox
urolithiasi
obtain
submiss
minnesota
urolith
center
fisher
exact
test
use
identifi
breed
overrepres
juvenil
group
test
perform
determin
whether
sex
stone
locat
upper
vs
lower
urinari
tract
salt
type
monohydr
vs
dihydr
differ
compar
matur
group
english
p
french
p
bulldog
overrepres
juvenil
group
differ
sex
observ
juvenil
matur
group
juvenil
adult
english
french
bulldog
male
stone
locat
differ
juvenil
matur
dog
howev
stone
group
upper
urinari
tract
juvenil
dog
like
form
dihydr
stone
compar
matur
dog
p
although
monohydr
predomin
group
respect
studi
identifi
two
relat
breed
risk
juvenil
caox
urolithiasi
inherit
risk
factor
particularli
x
chromosom
mutat
investig
due
strong
breed
sex
predisposit
identifi
assess
glomerular
filtrat
rate
gfr
import
veterinari
human
medicin
hyperthyroid
cat
increas
gfr
decreas
success
radioiodin
treatment
henc
use
model
investig
new
minim
invas
techniqu
assess
renal
function
object
prospect
studi
investig
use
minim
invas
transcutan
gfr
tgfr
monitor
assess
renal
function
cat
natur
occur
hyperthyroid
pre
week
post
radioiodin
treatment
eight
hyperthyroid
cat
includ
euthyroid
three
cat
remain
hyperthyroid
significantli
reduc
serum
concentr
plasma
gfr
pgfr
plasma
phl
assess
plasma
sinistrin
clearanc
transcutan
thl
measur
parallel
use
fluoresc
marker
devic
plasma
data
use
calcul
convers
factor
determin
tgfr
thl
overal
pgfr
tgfr
significantli
correl
spearman
correl
r
p
cat
pgfr
decreas
mean
rang
remain
unchang
cat
use
tgfr
decreas
gfr
identifi
cat
decreas
remain
cat
show
mild
increas
respect
although
result
directli
compar
transcutan
gfr
assess
promis
minim
invas
techniqu
allow
gfr
estim
small
anim
research
larger
cohort
necessari
evalu
full
potenti
method
cat
chronic
kidney
diseas
ckd
anecdot
increas
frequenc
side
effect
clavulan
acid
decreas
appetit
vomit
diarrhea
comparison
cat
normal
kidney
function
human
patient
decreas
kidney
function
shown
potenti
penicillin
like
acid
impair
clearanc
much
sever
renal
impair
impair
clearanc
result
higher
serum
concentr
comparison
patient
normal
kidney
function
reduct
dose
interv
recommend
avoid
side
effect
purpos
studi
determin
frequenc
side
effect
cat
without
azotemia
hypothesi
cat
azotem
ckd
increas
frequenc
side
effect
owner
cat
prescrib
clavulan
acid
colorado
state
univers
ohio
state
univers
sent
survey
regard
occurr
side
effect
ye
specif
type
side
effect
vomit
diarrhea
decreas
appetit
none
whether
treatment
alter
result
signal
clinicopatholog
data
obtain
medic
record
cat
survey
return
cat
includ
azotem
ckd
group
creatinin
mgdl
usg
clinic
design
ckd
cat
includ
without
azotem
ckd
group
creatinin
mgdl
cut
group
creatinin
mgdl
chosen
defin
cohort
impair
clearanc
clavulan
acid
common
human
greater
degre
renal
impair
chi
squar
util
assess
distribut
presenc
side
effect
ye
group
preval
specif
side
effect
chang
therapi
survey
return
exclud
incomplet
data
serum
creatinin
avail
cat
categor
azotem
ckd
consist
male
femal
median
age
year
rang
year
median
creatinin
rang
mgdl
cat
categor
azotem
ckd
consist
male
femal
median
age
year
rang
year
median
creatinin
rang
mgdl
owner
report
cat
azotem
ckd
side
effect
specif
side
effect
includ
diarrhea
cat
vomit
cat
decreas
appetit
cat
cat
one
side
effect
owner
report
cat
cat
without
azotem
ckd
side
effect
specif
side
effect
cat
includ
diarrhea
cat
vomit
cat
decreas
appetit
cat
cat
one
side
effect
differ
distribut
side
effect
ye
distribut
specif
type
side
effect
statist
signific
howev
significantli
azotem
ckd
cat
one
side
effect
p
addit
significantli
owner
azotem
ckd
cat
report
alter
treatment
plan
necessit
side
effect
indic
antibiot
stop
chang
support
care
ad
due
side
effect
owner
cat
without
azotem
ckd
report
alter
treatment
plan
p
side
effect
diarrhea
vomit
decreas
appetit
common
clavulan
acid
administr
cohort
may
increas
incid
cat
azotem
ckd
result
alter
treatment
plan
investig
current
underway
determin
find
associ
higher
drug
serum
concentr
clinic
observ
indic
frequenc
caus
urinari
incontin
cat
consider
differ
dog
sinc
compar
studi
cat
report
purpos
studi
determin
proport
morbid
caus
assess
outcom
cat
urinari
incontin
present
michigan
state
univers
veterinari
medic
center
msuvmc
medic
record
cat
present
msuvmc
search
electron
use
keyword
relat
urinari
incontin
cat
includ
diagnosi
urinari
incontin
base
owner
histori
physic
examin
cat
insuffici
inform
confirm
diagnosi
exclud
cat
met
inclus
criteria
affect
cat
includ
castrat
male
intact
male
spay
femal
median
age
onset
clinic
sign
year
rang
month
year
affect
cat
mix
breed
spinal
cord
diseas
identifi
affect
cat
trauma
congenit
lumbosacr
malform
intervertebr
disk
diseas
neoplasia
fibrocartilagin
embolu
manx
syndrom
urethr
diseas
identifi
affect
cat
urethr
strictur
urethr
urethr
stent
perin
urethrostomi
congenit
urethr
sphincter
mechan
incontin
unclassifi
urethr
diseas
bladder
disord
identifi
cat
cystiti
ureter
stent
neoplasia
bladder
atoni
bilater
ureter
ectopia
identifi
one
cat
outcom
avail
case
cat
euthan
cat
regain
contin
cat
remain
incontin
despit
therapi
euthan
cat
spinal
cord
diseas
condit
recov
cat
includ
cystiti
bacteri
uti
idiopath
cystiti
bladder
atoni
urethr
strictur
urethr
conclus
felin
urinari
incontin
rare
condit
commonli
associ
acquir
congenit
spinal
cord
disord
urinari
incontin
cat
gener
associ
poor
prognosi
mani
persist
incontin
despit
therapi
drug
nsaid
overdos
sever
toxic
dog
due
heavili
natur
nsaid
convent
hemodialysi
techniqu
ineffect
therapeut
plasma
exchang
tpe
util
purpos
studi
evalu
techniqu
specif
goal
includ
identif
variabl
present
predict
outcom
evalu
therapeut
complic
determin
effect
adjunct
therapi
canin
patient
underw
tpe
nsaid
overdos
tuft
foster
hospit
small
anim
januari
may
includ
studi
data
regard
present
hospit
treatment
outcom
collect
eleven
case
includ
studi
nsaid
ingest
ibuprofen
six
naproxen
four
deracoxib
one
six
patient
complic
associ
tpe
treatment
common
complic
hemorrhag
case
surviv
discharg
three
develop
acut
kidney
injuri
hospit
one
went
chronic
kidney
diseas
final
outcom
correl
dose
nsaid
ingest
studi
identifi
plasma
exchang
effect
treatment
nsaid
overdos
none
patient
lethal
outcom
despit
high
nsaid
dose
ingest
present
factor
determin
likelihood
acut
kidney
injuri
apart
initi
nsaid
dose
complic
common
manag
support
care
affect
final
outcom
tpe
consid
patient
present
nsaid
ingest
calcium
oxal
account
upper
urinari
tract
stone
cat
concurr
chronic
kidney
diseas
ckd
human
be
calcium
kidney
stone
former
chang
vitamin
metabol
role
vitamin
metabol
ckd
cat
nephrolithiasi
remain
unclear
thu
studi
aim
assess
serum
oh
oh
oh
metabolit
ioniz
calcium
ckd
cat
nephrolithiasi
ckd
cat
iri
stage
n
hypercalcem
stage
n
hypercalcem
stage
n
hypercalcem
nephrolithiasi
base
ultrasound
enrol
hypercalcemia
defin
ioniz
calcium
concentr
higher
mmoll
hypercalcem
cat
n
mmoll
mmoll
mmoll
ioniz
calcium
heparin
whole
blood
serum
concentr
oh
lower
hypercalcem
cat
pgml
pgml
pgml
comparison
normocalcem
cat
pgml
pgml
pgml
hypercalcem
cat
also
lower
serum
oh
ngml
ngml
ngml
oh
ngml
ngml
ngml
normocalcem
cat
ngml
ngml
ngml
oh
ngml
ngml
ngml
oh
serum
pth
refer
rang
pmoll
measur
hypercalcem
cat
suppress
pmoll
cat
stage
pmoll
blood
ioniz
calcium
normal
pth
pmoll
cat
mmoll
stage
hyperphosphatemia
mgdl
detect
one
hypercalcem
cat
stage
proteinuria
detect
one
cat
stage
hypercalcemia
upc
tubular
pattern
result
suggest
ckd
cat
nephrolithiasi
hypercalcemia
differ
vitamin
metabol
compar
normocalcem
cat
character
decreas
oh
oh
oh
hyperparathyroid
rule
two
hypercalcem
cat
possibl
caus
hypercalcemia
may
associ
decreas
degrad
oh
support
lower
oh
concentr
altern
low
oh
could
result
less
substrat
provid
catabol
sinc
hypercalcem
cat
lower
concentr
oh
normocalcem
cat
base
tradit
understand
normal
calcium
regul
seem
paradox
hypercalcemia
would
associ
lower
oh
oh
concentr
cat
normocalcemia
studi
larger
number
cat
need
support
find
well
investig
whether
proteinuria
may
lead
greater
loss
vitamin
protein
vdbp
urin
could
contribut
oh
defici
lower
urinari
tract
diseas
occur
commonli
cat
convent
therapi
involv
modifi
diet
pharmacolog
intervent
tradit
chines
western
herb
recommend
altern
complementari
treatment
purpos
studi
evalu
efficaci
herbal
supplement
hypothes
herbal
supplement
would
associ
increas
urin
volum
decreas
urin
satur
calcium
oxal
struvit
compar
placebo
seven
healthi
male
cat
age
month
year
evalu
use
random
placebo
studi
pairwis
fashion
cat
receiv
treatment
everi
hour
period
approxim
void
urin
sampl
collect
end
treatment
period
sampl
analyz
ph
sodium
potassium
chlorid
calcium
phosphor
magnesium
citrat
oxal
ammonia
creatinin
rel
supersatur
calcium
oxal
struvit
estim
use
iter
comput
program
equil
univers
florida
gainesvil
fl
data
assess
normal
distribut
use
pair
normal
distribut
wilcoxon
sign
rank
distribut
use
statist
analysi
data
analyz
use
statist
test
except
rel
supersatur
urin
volum
test
use
consid
signific
data
cat
use
due
incomplet
urin
collect
cat
urin
satur
struvit
significantli
lower
cat
receiv
supplement
compar
placebo
supplement
placebo
p
urinari
excret
phosphor
lower
cat
receiv
supplement
compar
supplement
rang
placebo
p
differ
analyt
bodi
weight
urin
volum
sever
limit
studi
studi
short
durat
includ
small
number
healthi
form
cat
may
complet
urin
collect
despit
use
modifi
litter
box
signific
decreas
struvit
supersatur
even
limit
suggest
determin
rel
supersatur
better
determin
risk
urolith
format
electrolyt
miner
concentr
excret
herbal
supplement
may
benefici
manag
urinari
diseas
cat
big
kidney
littl
kidney
bklk
syndrom
known
asymmetr
size
kidney
radiographi
due
atrophi
fibrosi
complet
partial
ureter
obstruct
one
side
kidney
compensatori
hypertrophi
contralater
kidney
cat
patient
typic
stabl
show
azotemia
clinic
practic
present
consist
definit
evalu
factor
bklk
syndrom
cat
although
steadi
state
last
long
lethal
situat
new
obstruct
hypertrophi
kidney
occur
ureter
obstruct
felin
medic
surgic
treatment
option
research
indic
surviv
rate
surgic
treatment
group
ureterotomyureterotomi
ureteroneocystostomi
ureter
resect
anastomosi
medic
treatment
group
individu
one
studi
reveal
stent
subcutan
ureter
bypass
sub
treatment
cat
ureter
obstruct
increas
surviv
rate
paramet
associ
diseas
outcom
howev
prognost
factor
cat
obstruct
bklk
syndrom
remain
unclear
aim
studi
character
cat
bklk
syndrom
determin
prognosticprogress
factor
cat
bklk
syndrom
obstruct
uret
state
first
sixteen
healthi
cat
without
abnorm
physic
blood
radiographi
examin
collect
defin
bklk
syndrom
diverg
kidney
abdomin
ventrodors
radiograph
cat
rang
cm
mean
cm
defin
mean
plu
two
standard
deviat
cm
valu
howev
consid
observ
error
measur
exceed
histori
ckd
month
set
criteria
bklk
syndrom
studi
cat
bklk
syndrom
divid
obstruct
group
group
base
ultrasound
find
signific
differ
group
regard
bodi
weight
gender
patient
obstruct
group
neuter
intact
group
p
length
right
kidney
longer
p
ratio
big
kidney
lumber
higher
obstruct
group
p
presenc
urolith
nephrolith
length
differ
two
kidney
show
signific
differ
two
group
p
p
p
blood
examin
obstruct
group
signific
lower
valu
eosinophil
p
reticulocyt
p
cl
p
higher
valu
mchc
p
bun
p
serum
creatinin
p
compar
group
control
group
male
proport
significantli
higher
group
clinic
patholog
variabl
reveal
valu
hb
p
hct
p
rbc
p
alkp
p
urin
ph
p
usg
p
found
significantli
lower
group
contrast
valu
wbc
p
segment
cell
p
bun
p
serum
creatinin
p
higher
group
obstruct
group
divid
surviv
group
group
within
day
surviv
group
significantli
higher
bodi
temperatur
p
hct
p
hb
p
rbc
p
lower
neutrophil
p
ratio
neutrophil
lymphocyt
p
mchc
p
howev
surgeri
intervent
renal
index
includ
bun
serum
creatinin
phosphoru
two
group
meet
signific
differ
except
serum
creatinin
increas
odd
ratio
death
addit
bklk
cat
also
divid
surviv
group
group
within
day
bodi
temperatur
p
reticulocyt
p
hb
p
rbc
p
higher
surviv
group
group
higher
ratio
neutrophil
lymphocyt
p
mchc
p
bun
p
creatinin
p
signific
posit
relat
found
serum
creatinin
length
bigger
kidney
obstruct
group
length
bigger
kidney
signific
differ
surviv
group
p
conclus
bodi
temperatur
hb
rbc
mchc
ratio
neutrophil
lymphocyt
good
prognost
factor
obstruct
bklk
syndrom
surprisingli
length
bigger
kidney
determin
prognosi
renal
diseas
associ
hypoxia
subsequ
inflamm
util
oxygen
modul
tissu
oxygen
statu
mainli
reli
iron
neutrophil
lipocalin
ngal
hemojuvelin
hjv
axi
import
mechan
bodi
iron
homeostasi
regul
ngal
glycoprotein
belong
lipocalin
superfamili
act
promis
renal
biomark
human
dog
cat
urinari
ngal
report
configur
includ
monom
dimer
complex
matrix
human
laboratori
anim
recent
character
canin
felin
urinari
diseas
research
group
play
import
role
regul
degrad
extracellular
matrix
process
angiogenesi
tumor
growth
metastasi
addit
report
involv
renal
fibrosi
chronic
kidney
diseas
ckd
addit
hjv
upstream
modul
axi
identifi
novel
renal
biomark
acut
kidney
injuri
aki
ckd
human
renal
diseas
interestingli
hjv
ngal
serv
modul
inflamm
involv
express
ngal
associ
ngal
prevent
henc
possibl
protein
work
cooper
cours
felin
renal
diseas
resolv
unknown
issu
aim
character
overal
express
profil
three
factor
cat
urinari
diseas
urin
sampl
collect
studi
control
group
contain
cat
aki
group
contain
cat
pyuria
group
includ
cat
accord
iri
stage
ckd
cat
defin
cat
stage
cat
stage
cat
stage
respect
first
elisa
detect
cat
success
establish
addit
previou
report
felin
ngal
elisa
urinari
ngal
concentr
determin
result
show
urinari
ngal
significantli
associ
elev
level
serum
bun
creatinin
phosphat
pyuria
group
highest
concentr
urinari
median
iqr
follow
aki
group
ckd
group
three
significantli
higher
control
group
p
urinari
ratio
umcr
pyuria
group
still
highest
valu
follow
aki
group
ckd
group
control
group
sequenti
felin
ckd
ngal
repres
sever
urinari
ngal
significantli
higher
ckd
stage
ckd
stage
control
group
ckd
stage
howev
urin
may
appropri
indic
ckd
progress
ckd
group
pyuria
group
urinari
ngal
concentr
ratio
urinari
creatinin
signific
correl
spearman
correl
valu
order
howev
correl
could
identifi
aki
group
moreov
detect
felin
hjv
recombin
felin
hjv
prepar
gener
antibodi
felin
hjv
present
express
hjv
detect
felin
urin
western
blot
analysi
quantifi
concentr
hjv
develop
elisa
platform
process
conclus
urinari
promis
biomark
diseas
cat
especi
interpret
urinari
ngal
role
hemojuvelin
felin
renal
diseas
highli
expect
cat
hyperammonemia
document
portal
venou
anomali
advanc
hepat
diseas
defici
cobalamin
arginin
recent
case
seri
report
hyperammonemia
cat
iri
stage
chronic
kidney
diseas
ckd
hypothes
larger
popul
cat
fast
hyperammonemia
would
correl
blood
urea
nitrogen
bun
creatinin
cr
independ
serum
fast
blood
sampl
prospect
collect
ammonia
analysi
cat
renal
azotemia
iri
stage
creatinin
mgdl
blood
ammonia
immedi
process
analyz
clinic
scienc
laboratori
cat
medic
known
decreas
blood
ammonia
antibiot
lactulos
probiot
previous
diagnos
diseas
state
known
increas
ammonia
level
exclud
studi
data
analyz
use
pearson
correl
coeffici
anova
follow
log
transform
enrol
cat
median
age
year
rang
year
male
femal
five
stage
iri
stage
ckd
respectivelyhyperammonemia
document
catsther
signific
moder
posit
correl
bun
ammonia
r
p
correl
ammonia
cr
r
p
ammonia
r
p
differ
mean
ammonia
level
iri
stage
p
hyperammonem
cat
appear
overt
neurolog
sign
urinari
tract
infect
ureas
produc
bacteria
conclus
pilot
studi
cat
renal
azotemia
correl
exist
bun
ammonia
ammonia
cr
futur
studi
need
larger
popul
cat
determin
true
preval
etiolog
effect
hyperammonemia
long
term
prognosi
symmetr
dimethylarginin
sdma
methyl
arginin
deriv
intranuclear
methyl
methyltransferas
releas
circul
proteolysi
sdma
seem
strictli
elimin
renal
excret
concentr
highli
correl
gfr
anim
human
therefor
biomark
earlier
marker
kidney
dysfunct
serum
creatinin
scr
object
prospect
studi
evalu
quantifi
effect
intraven
fluid
therapi
intermitt
hemodialysi
ih
renal
function
random
group
dog
previous
diagnos
iri
stage
chronic
kidney
diseas
ckd
serum
dog
treat
ih
dog
treat
submit
measur
scr
idexx
sdma
dog
treatment
group
receiv
treatment
session
administ
hour
apart
signific
differ
p
seen
treatment
group
howev
dog
hemodialysi
group
affect
clearanc
sdma
x
p
scr
x
p
blood
urea
x
p
signific
correl
also
found
urea
reduct
ratio
urr
sdma
increas
urr
decreas
sdma
x
p
tabl
although
sdma
dialys
biomark
highli
recommend
evalu
context
concurr
urr
better
estim
actual
gfr
despit
remov
ih
sdma
still
better
biomark
scr
evalu
gfr
dog
ckd
felin
idiopath
cystiti
fic
common
bladder
disord
cat
diagnosi
remain
one
exclus
urin
cytokin
may
potenti
biomark
fic
immunosorb
assay
elisa
ideal
quantifi
cytokin
howev
variat
urin
matrix
characterist
interfer
elisa
perform
sinc
elisa
valid
felin
urin
object
evalu
elisa
kit
quantif
felin
urin
urin
collect
healthi
cat
evalu
michigan
state
univers
veterinari
medic
center
normal
urin
sampl
pool
modifi
mimic
diseas
condit
ad
water
hemolyz
blood
spike
high
medium
low
concentr
recombin
cytokin
concentr
determin
use
commerci
avail
elisa
kit
influenc
urin
matrix
variabl
test
perform
evalu
spikerecoveri
test
linear
test
assess
variat
assay
underestim
high
medium
spike
cytokin
concentr
urin
compar
standard
assay
diluent
low
spike
cytokin
concentr
urin
inconsist
detect
urin
spike
achiev
maxim
quantit
recoveri
respect
high
urin
specif
graviti
contribut
significantli
poor
recoveri
p
hematuria
variabl
effect
felin
urin
matrix
characterist
appear
significantli
impact
cytokin
quantif
elisa
studi
need
optim
detect
cytokin
felin
urin
elisa
establish
use
diagnost
biomark
felin
urinari
disord
felin
idiopath
cystiti
fic
common
lower
urinari
tract
diseas
cat
resembl
interstiti
cystitispain
bladder
syndrom
peopl
condit
pathogenesi
diseas
unknown
specif
treatment
investig
molecular
pathway
diseas
function
potenti
involv
pathogenesi
fic
evalu
bladder
mucosa
transcriptom
affect
healthi
cat
urinari
bladder
tissu
collect
healthi
cat
fic
cat
repres
differ
histolog
phenotyp
ulcer
hyperplast
rna
bladder
tissu
isol
sequenc
use
high
throughput
next
gener
sequenc
differenti
gene
express
molecular
pathway
diseas
factor
analysi
perform
use
ingenu
pathway
analysi
ipa
softwar
signific
level
gene
set
enrich
p
identifi
sever
annot
diseas
function
categori
inflammatori
respons
function
regul
ulcer
phenotyp
respect
regul
hyperplast
phenotyp
cellular
growth
prolifer
categori
regul
hyperplast
phenotyp
regul
ulcer
phenotyp
cell
death
surviv
pathway
regul
hyperplast
phenotyp
regul
ulcer
phenotyp
investig
pathway
target
gene
may
provid
insight
pathogenesi
fic
identifi
new
therapeut
target
well
biomark
disord
futur
clinic
applic
intern
renal
interest
societi
iri
also
recommend
chronic
kidney
diseas
ckd
classif
use
serum
symmetr
dimethylarginin
sdma
adjunct
tool
diagnosi
treatment
direct
serum
creatinin
concentr
could
underestim
stage
creatinin
concentr
may
affect
muscl
mass
age
sex
hydrat
statu
may
underestim
degre
kidney
dysfunct
sdma
endogen
marker
gfr
influenc
factor
sdma
concentr
consid
stage
stage
respect
aim
studi
ckd
dog
iri
stage
base
serum
creatinin
concentr
also
investig
whether
sdma
disagr
creatinin
concentr
classif
ckd
stage
studi
group
compos
ckd
dog
ckd
dog
stage
n
stage
n
month
death
evalu
mean
serum
creatinin
concentr
two
ckd
dog
stage
chang
classif
stage
also
dog
serum
sdma
increas
concomitantli
howev
three
ckd
dog
stage
increas
sdma
chang
classif
stage
serum
creatinin
show
underestim
stage
base
serum
creatinin
ckd
dog
stage
two
dog
chang
classif
stage
base
serum
creatinin
concentr
howev
take
sdma
concentr
chang
classif
stage
among
dog
serum
creatinin
mgdl
alreadi
stage
sinc
begin
ckd
dog
stage
respect
creatinin
sdma
concentr
first
visit
mgdl
mgdl
mgdl
mgdl
mgdl
mgdl
find
suggest
mainli
stage
serum
creatinin
concentr
affect
extraren
factor
may
caus
underestim
stage
may
influenc
direct
treatment
prognosi
nine
ckd
dog
stage
decreas
muscl
mass
score
n
n
death
observ
ckd
dog
stage
serum
sdma
sinc
begin
surviv
analysi
take
consider
stage
show
sdma
concentr
surviv
time
day
surviv
sdma
time
day
surviv
day
day
surviv
day
day
respect
conclus
evalu
serum
sdma
concomitantli
serum
creatinin
could
add
import
inform
order
verifi
real
renal
dysfunct
mainli
ckd
dog
classifi
stage
mean
serum
creatinin
concentr
inform
may
help
alert
determin
treatment
prognosi
urinari
protein
creatinin
ratio
upc
measur
total
amount
protein
urin
compar
urinari
creatinin
concentr
identifi
origin
individu
protein
qualit
evalu
urinari
protein
immunodetect
could
add
import
inform
natur
renal
diseas
albuminuria
associ
glomerular
diseas
protein
rbp
vitamin
protein
vdbp
tubular
damag
due
impair
tubular
reabsorpt
low
molecular
weight
protein
normal
found
glomerular
filtrat
hypothesi
studi
qualit
method
eg
western
blot
associ
quantit
method
upc
may
provid
better
assess
evalu
origin
proteinuria
aim
studi
dog
chronic
kidney
diseas
ckd
determin
upc
well
use
immunoassay
western
blot
detect
urinari
albumin
rbp
vdbp
studi
group
compos
ckd
dog
stage
stage
follow
month
death
fifteen
clinic
healthi
dog
differ
breed
age
compris
control
group
coomassi
brilliant
blue
bradford
method
use
upc
determin
abcam
cambridg
abcam
abcam
western
blot
urinari
albumin
rbp
vdbp
detect
control
dog
upc
min
max
one
ckd
dog
stage
proteinuria
base
upc
mean
also
loss
vdbp
tubular
pattern
renal
diseas
remain
ckd
dog
stage
mean
upc
normal
upc
period
howev
qualit
evalu
detect
loss
tubular
protein
rbp
vdbp
loss
glomerular
protein
albumin
loss
tubular
glomerular
protein
level
protein
found
proteinuria
upc
observ
ckd
dog
stage
tubular
pattern
character
predomin
low
molecular
weight
protein
loss
rbp
vdbp
notic
loss
albumin
rbp
similar
magnitud
tubular
glomerular
pattern
mean
upc
ckd
dog
stage
immunodetect
albumin
rbp
vdbp
observ
slight
amount
albumin
loss
detect
find
suggest
sequenti
qualit
evalu
urinari
protein
add
inform
interpret
upc
result
identif
damag
nephron
segment
caus
specif
pattern
protein
loss
could
help
refin
diagnosi
specif
renal
diseas
well
optim
therapi
importantli
detect
albumin
rbp
vdbp
urin
sampl
normal
upc
might
serv
earli
marker
glomerular
tubular
injuri
kidney
play
import
role
miner
bone
disord
recent
studi
dog
cat
shown
serum
fibroblast
growth
factor
increas
earli
stage
chronic
kidney
diseas
ckd
regul
phosphoru
phosphatur
effect
proxim
tubul
inhibit
activ
decreas
circul
calcitriol
oh
also
increas
mrna
express
activ
enhanc
degrad
calcidiol
oh
calcitriol
less
activ
metabolit
oh
trihydroxyvitamin
oh
respect
ratio
oh
oh
indirectli
estim
enzym
activ
increas
ratio
associ
impair
calcidiol
degrad
inactiv
mutat
hypothesi
increas
serum
concentr
dog
ckd
iri
stage
associ
decreas
oh
oh
increas
oh
concentr
recruit
ckd
dog
iri
stage
age
year
fifteen
healthi
dog
rang
age
month
year
use
control
test
use
compar
group
expect
serum
highest
dog
stage
median
rang
pgml
ckd
follow
stage
median
rang
pgml
lowest
healthi
dog
median
rang
pgml
p
lower
serum
oh
concentr
detect
ckd
dog
stage
median
rang
pgml
n
compar
control
dog
median
rang
pgml
stage
median
rang
pgml
n
p
serum
oh
oh
detect
limit
assay
differ
serum
oh
among
group
dog
control
n
median
rang
ngml
ckd
stage
n
median
ngml
ckd
stage
n
median
rang
ngml
p
lowest
serum
oh
observ
ckd
dog
stage
median
rang
ngml
n
follow
stage
median
rang
ngml
n
highest
control
group
median
rang
ngml
n
p
increas
neg
correl
decreas
oh
spearman
rho
p
oh
spearman
rho
p
addit
oh
oh
significantli
correl
spearman
rho
p
ratio
oh
oh
highest
ckd
dog
stage
median
rang
n
follow
stage
median
rang
n
lowest
control
group
median
rang
n
p
result
suggest
increas
serum
may
contribut
reduct
oh
oh
concentrationsin
ckd
dog
play
role
miner
bone
disord
potenti
ckd
progress
fail
identifi
associ
oh
concentr
ckd
dog
spearman
rho
p
lower
oh
oh
concentr
previous
observ
dog
advanc
ckd
stage
low
serum
oh
level
similar
report
mice
human
patient
ckd
high
oh
oh
ratio
observ
studi
fail
confirm
catabol
vitamin
metabolit
assess
oh
reason
oh
concentr
differ
control
ckd
dog
previous
report
investig
studi
studi
larger
sampl
size
need
better
understand
role
catabol
vitamin
dog
ckd
intermitt
hemodialysi
ihd
use
dog
chronic
kidney
diseas
ckd
reduc
chronic
progress
azotemia
hyperkalemia
fluid
overload
monitor
cardiovascular
system
import
treatment
recogn
repercuss
heart
medicin
dispers
p
wave
qt
interv
import
mortal
risk
indic
easili
obtain
differ
maximum
minimum
valu
electrocardiograph
lead
measur
p
wave
qt
interv
dispers
relat
risk
develop
atrial
ventricular
fibril
respect
studi
aim
describ
p
qt
dispers
well
electrocardiograph
chang
observ
dog
ckd
stage
iv
undergo
ihd
anim
classifi
consid
serum
creatinin
urinari
proteincreatinin
ratio
systol
blood
pressur
ten
dog
weigh
kg
includ
studi
electrocardiograph
examin
perform
first
three
session
ihd
result
analyz
use
anova
friedman
test
consid
signific
level
signific
increas
valu
p
maximum
p
qt
maximum
p
qt
minimum
p
howev
chang
p
qt
dispers
signific
p
increas
pr
interv
p
qt
interv
p
decreas
amplitud
r
wave
p
second
session
three
dog
develop
sinu
arrest
anoth
three
develop
supraventricular
arrhythmia
result
obtain
suggest
employ
ihd
dog
may
caus
electrocardiograph
chang
arrhythmia
interfer
atrioventricular
conduct
well
ventricular
depolar
repolar
process
find
highlight
import
electrophysiolog
monitor
anim
submit
therapeut
modal
dietari
intak
sodium
chlorid
greater
kcal
kcalday
consum
associ
increas
calcium
excret
human
recommend
histori
calcium
oxal
urolithiasi
accord
consensu
confer
metabol
diagnosi
medic
prevent
calcium
nephrolithiasi
system
rome
march
cat
feed
food
sodium
content
approxim
kcal
report
increas
urinari
calcium
concomitantli
increas
water
intak
consequ
urin
volum
compar
food
contain
approxim
kcal
food
similar
ca
p
mg
restrict
rel
high
kcal
low
kcal
sodium
content
compar
observ
rel
supersatur
rss
calcium
oxal
similar
calcium
excret
significantli
greater
high
sodium
suggest
benefit
ascrib
lower
urinari
satur
due
increas
urinari
water
offset
increas
urin
calcium
content
long
term
studi
perform
cat
compar
rss
calcium
oxal
recurr
rate
urolith
howev
correl
exist
human
anoth
surrog
calcium
oxal
risk
bonn
risk
index
describ
laub
et
al
propos
better
predictor
futur
calcium
oxal
risk
rel
super
studi
examin
low
high
sodium
felin
dri
food
use
calcium
oxal
titrat
cot
test
first
describ
similar
human
bonn
risk
index
test
cot
test
centrifug
unalt
bodi
temperatur
urin
titrat
sodium
oxal
solut
monitor
precipit
occur
cot
valu
determin
divid
urin
result
amount
oxal
ad
point
precipit
therefor
cot
test
measur
urin
stabil
capac
influenc
composit
urin
reflect
interact
inhibitor
promot
crystal
format
group
healthi
adult
cat
fed
two
commerci
avail
foodsa
b
kcal
sodium
kcal
seri
week
hour
urin
sampl
collect
end
period
evalu
cot
test
perform
equil
softwar
use
calcul
rss
urin
concentr
citrat
oxal
k
na
urin
ph
version
use
analys
repeat
measur
regress
model
use
valu
analyt
depend
variabl
food
independ
variabl
mean
differ
calcul
diet
comparison
analyt
test
perform
alpha
use
determin
statist
signific
urin
ph
p
rss
struvit
p
rss
calcium
oxal
p
significantli
differ
food
urin
cat
fed
low
sodium
food
significantli
p
greater
urin
specif
graviti
vs
phosphoru
ppm
vs
ppm
citrat
concentr
umol
vs
umol
significantli
lower
calcium
ppm
vs
ppm
cot
vs
compar
high
sodium
food
compar
high
sodium
food
low
sodium
food
improv
urinari
crystal
capac
measur
cot
test
lower
urin
calcium
concentr
respect
calcium
oxal
crystal
format
factor
associ
increas
urin
stabil
includ
urin
citrat
urin
phosphoru
significantli
increas
respect
felin
urin
typic
metast
calcium
oxal
complex
affect
mani
factor
increas
urin
water
may
help
reduc
satur
crystal
compon
may
also
dilut
inhibitor
crystal
format
data
support
dynam
natur
calcium
oxal
precipit
test
provid
addit
inform
capac
urin
resist
induc
crystal
reflect
tradit
super
satur
calcul
elev
sodium
content
food
influenc
calcium
excret
appear
lower
urin
resist
induc
crystal
format
studi
relationship
rss
cot
long
term
risk
crystal
stone
format
warrant
j
nephrol
http
wwwniddknihgovhealthinformationurologicdiseaseskidneystoneseatingdietnutrit
sodium
access
jan
j
vet
intern
med
urol
re
j
urolog
j
vet
intern
med
ahil
prescript
multicar
dri
b
royal
veterinari
diet
urinari
dri
continu
flow
cystoscopi
facilit
preform
transurethr
cystoscopi
complex
prolong
intervent
procedurestransurethr
cystoscopi
tradit
perform
use
singl
cannula
system
allow
fluid
flow
one
direct
time
one
way
flow
cystoscop
work
well
small
anim
practic
year
still
work
well
diagnost
simpl
correct
procedur
system
work
well
advanc
complex
transurethr
intervent
procedur
especi
use
laser
one
way
flow
visual
field
quickli
obscur
debri
blood
smoke
repeat
fluid
exchang
requir
maintain
adequ
imag
qualiti
discontinu
procedur
drain
refil
bladder
time
consum
frustrat
increas
risk
bladder
trauma
flow
cannula
avail
cystoscop
allow
ingress
egress
fluid
occur
simultan
maintain
constant
bladder
distens
clear
visual
field
system
standard
instrument
human
cystoscopi
continu
flow
cannula
design
two
concentr
cannula
rather
tradit
singl
cannula
inner
cannula
inflow
deliv
continu
flow
fluid
directli
front
telescop
lens
maintain
visual
field
outer
cannula
separ
isol
lumen
simultan
egress
cannula
separ
luer
connector
stop
cock
continu
flow
maintain
clear
visual
field
decreas
oper
time
decreas
frustrat
level
decreas
risk
bladder
trauma
due
continu
flow
cannula
avail
degre
cystoscop
use
larg
dog
french
diamet
outer
cannula
french
work
channel
system
smaller
patient
requir
purchas
addit
telescop
cannula
system
degre
telescop
french
diamet
outer
cannula
work
length
french
work
channel
unfortun
continu
flow
cannula
avail
mprt
felin
lower
urinari
tract
diseas
flutd
common
problem
cat
object
current
studi
determin
preval
clinic
sign
caus
risk
factor
flutd
medic
record
cat
visit
chiang
mai
univers
small
anim
veterinari
teach
hospit
novemb
octob
review
cat
flutd
identifi
studi
perform
determin
risk
factor
flutd
flutd
cat
randomli
select
clinic
normal
cat
anim
potenti
risk
data
obtain
medic
record
cat
owner
interview
analyz
associ
flutd
multivari
logist
regress
analysi
perform
estim
odd
ratio
adjust
expect
confound
factor
preval
flutd
cat
chiang
mai
ci
common
clinic
sign
identifi
urethr
obstruct
hematuria
stranguria
pollakiruria
respect
common
diagnos
felin
idiopath
cystiti
fic
follow
urolithiasi
struvit
urinari
tract
infect
uti
respect
multivari
logist
regress
analysi
indic
flutd
like
diagnos
castrat
male
cat
conclus
fic
urolithiasi
common
diagnos
cat
flutd
castrat
male
cat
may
import
risk
factor
flutd
hyperthyroid
mask
chronic
kidney
diseas
ckd
hyperfiltr
muscl
loss
symmetr
dimethylarginin
sdma
shown
increas
earlier
creatinin
cat
ckd
unlik
creatinin
sdma
impact
lean
muscl
mass
reason
postul
sdma
could
sensit
indic
renal
function
hyperthyroid
cat
aim
studi
describ
relationship
sdma
creatinin
bodi
weight
evalu
sdma
potenti
renal
biomark
hyperthyroid
cat
cat
retrospect
identifi
us
idexx
refer
laboratori
databas
sdma
creatinin
measur
sampl
sdma
creatinin
compar
concentr
entir
studi
popul
cat
spearman
correl
test
conduct
cat
hyperthyroid
treat
group
identifi
decreas
minimum
bodi
weight
laboratori
result
avail
one
visit
hyperthyroid
cat
compar
control
group
euthyroid
cat
use
evalu
bodi
weight
creatinin
sdma
day
cat
met
criteria
euthyroid
grey
zone
hyperthyroid
boxplot
illustr
relationship
creatinin
sdma
concentr
neg
relationship
found
creatinin
p
although
also
slight
neg
relationship
sdma
statist
signific
p
mean
bodi
weight
hyperthyroid
treat
cat
n
pretreat
time
point
significantli
less
control
cat
n
p
valu
hyperthyroid
cat
significantli
lower
mean
weight
pretreat
day
day
versu
day
p
valu
creatinin
significantli
decreas
comparison
time
point
p
valu
creatinin
significantli
increas
day
comparison
time
point
p
valu
mean
creatinin
hyperthyroid
cat
significantli
less
control
cat
day
time
period
p
valu
sdma
significantli
decreas
comparison
time
point
p
valu
howev
increas
sdma
day
signific
differ
mean
sdma
concentr
throughout
remaind
treatment
period
addit
compar
control
cat
mean
sdma
hyperthyroid
cat
significantli
lower
p
time
point
creatinin
significantli
decreas
increas
concentr
wherea
sdma
sdma
creatinin
concentr
increas
immedi
period
treatment
creatinin
continu
increas
cat
gain
weight
contrast
sdma
remain
stabl
treatment
compar
control
cat
therefor
sdma
may
reliabl
biomark
renal
function
creatinin
hyperthyroid
cat
treatment
lower
urinari
tract
diseas
occur
commonli
dog
convent
therapi
involv
modifi
diet
pharmacolog
intervent
tradit
chines
western
herb
recommend
altern
complementari
treatment
purpos
studi
evalu
efficaci
herbal
supplement
hypothes
herbal
supplement
would
associ
increas
urin
volum
decreas
urin
satur
calcium
oxal
struvit
compar
placebo
fourteen
healthi
dog
evalu
use
random
placebo
studi
pairwis
fashion
dog
receiv
treatment
everi
hour
period
approxim
void
urin
sampl
collect
end
treatment
period
sampl
analyz
ph
sodium
potassium
chlorid
calcium
phosphor
magnesium
citrat
oxal
ammonia
creatinin
rel
supersatur
calcium
oxal
struvit
estim
use
iter
comput
program
equil
univers
florida
gainesvil
fl
data
assess
normal
distribut
use
pair
normal
distribut
wilcoxon
sign
rank
distribut
use
statist
analysi
data
analyz
use
statist
test
except
rel
supersatur
urin
volum
test
use
consid
signific
data
dog
use
due
incomplet
urin
collect
dog
femal
male
includ
labrador
mix
havanes
pit
bull
great
dane
mix
mix
unknown
breed
urin
satur
calcium
oxal
significantli
lower
dog
receiv
supplement
compar
placebo
supplement
placebo
p
differ
analyt
bodi
weight
urin
volum
sever
limit
studi
studi
short
durat
includ
small
number
healthi
form
dog
twelv
hour
urin
sampl
collect
owner
home
may
introduc
error
urin
volum
collect
addit
urin
collect
overnight
dog
drink
although
access
result
collect
low
volum
urin
signific
decreas
calcium
oxal
supersatur
even
limit
suggest
determin
rel
supersatur
better
determin
risk
urolith
format
electrolyt
miner
concentr
excret
herbal
supplement
may
benefici
manag
calcium
oxal
urolith
dog
dog
nephropathi
pln
commonli
prescrib
drug
thromboprophylaxi
standard
method
measur
respons
medic
addit
unknown
clopidogrel
metabolit
concentr
differ
pln
dog
dog
without
renal
diseas
purpos
studi
assess
respons
aspirin
clopidogrel
dog
pln
use
whole
blood
imped
platelet
aggregometri
pa
compar
clopidogrel
metabolit
concentr
healthi
pln
dog
pa
use
two
agonist
adenosin
diphosph
adp
arachidon
acid
aspi
salin
control
perform
six
healthi
dog
baselin
week
follow
clopidogrel
administr
establish
valu
identifi
respond
r
nr
decreas
adp
hour
post
clopidogrel
administr
defin
r
pa
perform
pln
dog
baselin
week
follow
clopidogrel
aspirin
administr
drug
concentr
pa
measur
hour
post
clopidogrel
administr
week
week
healthi
pln
dog
fourteen
dog
enrol
ten
pln
dog
receiv
clopidogrel
alon
three
receiv
aspirin
alon
one
dog
start
aspirin
switch
clopidogrel
repeat
measur
rm
analysi
anova
perform
subsequ
time
point
week
compar
baselin
aggregometri
pln
dog
rm
analysi
anova
perform
evalu
differ
drug
concentr
healthi
pln
dog
pln
dog
receiv
clopidogrel
aggregometri
differ
baselin
time
point
adp
differ
observ
aspi
time
point
dog
defin
clopidogrel
r
one
time
point
except
one
dog
show
respons
via
adp
aspi
pln
dog
receiv
aspirin
differ
baselin
time
point
either
adp
aspi
differ
drug
concentr
either
time
point
healthi
pln
dog
pa
may
repres
object
method
evalu
respons
clopidogrel
aspirin
therapi
pln
dog
pln
dog
appear
metabol
clopidogrel
similarli
healthi
dog
chronic
kidney
diseas
ckd
dog
common
clinic
entiti
character
mark
decreas
renal
function
human
sever
report
uremia
caus
renal
failur
affect
oral
fecal
microbiom
lack
inform
oral
fecal
microbiom
dog
ckd
therefor
object
present
studi
examin
chang
oral
fecal
microbiom
ckd
dog
eleven
dog
ckd
present
azotemia
month
healthi
dog
includ
studi
oral
swab
fecal
sampl
analyz
whole
genom
sequenc
use
illumina
miseq
platform
oral
microbiom
ckd
dog
show
chang
composit
isol
frequenc
proteobacteria
ckd
dog
decreas
convers
bacteroid
firmicut
increas
predomin
speci
oral
microbiom
healthi
dog
genera
neisseria
bacteroid
wherea
ckd
dog
bacteroid
porphyromona
speci
fecal
sampl
lower
bacteri
speci
rich
observ
ckd
dog
compar
healthi
dog
proport
fusobacteria
firmicut
proteobacteria
speci
increas
fecal
microbiom
ckd
dog
proport
bacteriodet
decreas
result
suggest
chronic
azotemia
might
trigger
alter
composit
oral
fecal
microbiom
dog
ckd
larg
studi
warrant
determin
chang
affect
manifest
gastrointestin
complic
associ
ckd
dyslipidemia
affect
human
chronic
kidney
diseas
ckd
associ
increas
mortal
progress
ckd
addit
risk
factor
ckd
develop
alter
lipoprotein
profil
document
dog
ckd
yet
investig
cat
purpos
studi
compar
serum
lipoprotein
profil
cat
ckd
healthi
control
hypothes
cat
ckd
would
higher
total
lipoprotein
ldl
lower
total
lipoprotein
hdl
compar
healthi
cat
healthi
cat
cat
ckd
prospect
enrol
studi
healthi
cat
urin
specif
graviti
greater
serum
creatinin
mgdl
normal
sdma
cat
ckd
compat
clinic
histori
serum
creatinin
mgdl
urin
specif
graviti
fast
serum
collect
analysi
lipoprotein
profil
use
continu
lipoprotein
densiti
profil
clpdp
techniqu
serum
cholesterol
triglycerid
also
measur
use
commerci
chemistri
analyz
area
curv
lipoprotein
trl
total
ldl
total
hdl
calcul
statist
analysi
data
analyz
use
wilcoxon
rank
sum
test
signific
set
p
thirteen
cat
ckd
six
healthi
control
met
inclus
criteria
base
creatinin
valu
time
studi
enrol
cat
ckd
classifi
intern
renal
interest
societi
iri
stage
cat
classifi
iri
stage
triglycerid
rich
lipoprotein
total
ldl
total
hdl
significantli
differ
cat
ckd
healthi
control
p
p
p
respect
serum
cholesterol
concentr
serum
triglycerid
concentr
within
refer
rang
cat
significantli
differ
group
p
p
respect
studi
suggest
dyslipidemia
may
occur
cat
ckd
impli
possibl
differ
pathophysiolog
ckd
cat
rel
dog
human
studi
larger
sampl
size
cat
advanc
ckd
need
confirm
find
urin
tradit
regard
steril
fluid
cultur
independ
techniqu
allow
explor
variou
bodi
site
includ
bladder
research
shown
urinari
microbiom
exist
speci
includ
healthi
dog
studi
aim
character
urinari
microbiom
healthi
adult
cat
urin
collect
via
cystocentesi
healthi
adult
domest
shorthair
cat
show
sign
urinari
tract
infect
cat
use
studi
includ
neuter
male
spay
femal
averag
age
year
averag
bodi
weight
kg
bacteri
genom
dna
extract
use
method
specif
sampl
region
amplifi
pcr
sequenc
use
illumina
miseq
platform
compar
silva
databas
rarefact
cutoff
read
per
sampl
use
otu
detect
major
phyla
rel
abund
urin
sampl
includ
proteobacteria
firmicut
actinobacteria
bacteroidet
cyanobacteria
identifi
genera
highli
variabl
among
cat
staphylococcu
spp
genu
present
sampl
genera
present
half
cat
includ
enterobact
spp
n
acinetobact
spp
n
streptococcu
spp
n
shigella
spp
n
acinetobact
spp
n
rel
abund
genera
vari
wide
among
cat
similar
report
speci
cat
urinari
microbiom
even
sign
clinic
infect
howev
constitut
healthi
urinari
microbiom
current
unknown
healthi
individu
urinari
chondroitin
sulfat
help
prevent
uropathogen
bacteri
adher
bladder
wall
peopl
exogen
chondroitin
sulfatehyaluron
acid
administ
intravesicularli
reduc
yearli
urinari
tract
infect
recurr
fold
dog
similar
bladder
instil
therapi
impract
requir
regular
catheter
extend
bladder
dwell
time
altern
chondroitin
sulfat
common
veterinari
dietari
supplement
describ
studi
aim
determin
whether
daili
oral
chondroitin
sulfat
administr
increas
canin
urinari
chondroitin
sulfat
concentr
uc
studi
enrol
client
own
dog
urin
sampl
collect
consecut
day
day
establish
baselin
uc
dog
receiv
twice
daili
chondroitin
sulfat
day
day
urin
sampl
collect
day
uc
quantifi
use
high
perform
liquid
chromatographi
tandem
mass
spectrometri
variabl
urin
output
henc
uc
dilut
account
divid
measur
uc
urin
creatinin
uc
ucrea
treatment
baselin
uc
ucrea
compar
calcul
fold
chang
urinari
chondroitin
sulfat
excret
supplement
oral
chondroitin
sulfat
supplement
increas
mean
uc
ucrea
p
differ
uc
observ
compar
first
day
last
day
supplement
day
p
data
indic
oral
chondroitin
sulfat
supplement
increas
uc
increas
occur
within
addit
intravesicular
instil
concentr
achiev
therapeut
benefit
persist
low
concentr
chondroitin
sulfat
supplement
prevent
canin
recurr
urinari
tract
infect
unknown
research
focu
diseas
progress
variabl
felin
autosom
domin
polycyst
kidney
diseas
adpkd
known
predict
renal
diseas
esrd
feasibl
addit
biomark
avail
evalu
efficaci
drug
treatment
human
comput
tomographi
ct
magnet
reson
imag
mri
use
follow
adpkd
progress
evalu
total
kidney
volum
tkv
purpos
studi
examin
efficaci
biomark
imag
modal
evalu
diseas
progress
felin
adpkd
eleven
adpkd
cat
mutat
imag
use
ultrasonographi
ct
mri
cbc
serum
chemistri
urianalysi
symmetr
dimethylarginin
level
glomerular
filtrat
rate
also
measur
adpkd
cat
clinic
normal
except
presenc
multipl
bilater
renal
cyst
tkv
measur
ct
correl
estim
use
ultrasonographi
mri
tkv
correl
age
fraction
cyst
volum
fcv
ml
obtain
ct
moder
correl
age
month
spearman
rank
correl
coeffici
p
howev
fcv
per
age
show
outlier
renal
cyst
known
increas
time
cat
adpkd
howev
data
indic
cyst
progress
differ
rate
determin
fcv
per
age
cat
signific
increas
age
tkv
variabl
fcv
per
age
support
diseas
progress
individu
suggest
modifi
like
influenc
progress
fcv
evalu
diseas
progress
felin
adpkd
character
therapeut
efficaci
drug
adpkd
one
compon
assess
chronic
kidney
diseas
cat
creatinin
cr
concentr
blood
urin
measur
use
autom
system
base
reaction
assay
evid
speci
suggest
cr
reaction
clear
assumpt
accur
cat
studi
compar
autom
assay
method
mgdl
correct
part
methodolog
measur
cr
concentr
serum
scr
urin
ucr
cr
data
use
void
urin
volum
uvol
calcul
endogen
creatinin
glomerular
filtrat
rate
gfr
compar
serum
symmetr
dimethylarginin
sdma
concentr
uvol
healthi
domest
shorthair
cat
n
femal
yr
sd
occur
individu
hous
inert
litter
finish
blood
sampl
collect
scr
sdma
gfr
determin
use
cr
assay
method
mean
reaction
scr
ucr
gfr
overestim
p
ucr
p
overestim
becom
greater
increas
cr
concentr
overal
mean
se
rang
scr
ucr
gfr
base
enzym
method
mgdl
mgdl
mlminkg
bw
ucr
gfr
differ
age
sex
wherea
scr
differ
age
p
sex
p
older
cat
lower
scr
yr
versu
cat
yr
addit
uvol
rang
mlkgd
usg
rang
gml
differ
age
sex
wherea
sdma
rang
ugdl
differ
age
p
sex
p
lower
sdma
older
se
versu
cat
se
therefor
part
framework
success
manag
ckd
cat
time
select
diagnost
laboratori
measur
cr
use
enzym
method
appear
improv
accuraci
elimin
detect
compound
particularli
import
data
demonstr
cr
increasingli
overestim
jaff
method
cr
concentr
increas
studi
evalu
efficaci
safeti
novel
techniqu
place
esophagostomi
feed
tube
client
own
dog
unabl
voluntarili
consum
adequ
calori
nutrient
placement
perform
gener
anesthesia
distal
end
advanc
lower
esophag
sphincter
tunnel
devic
advanc
esophagu
tip
palpat
dorsolater
jugular
groov
soft
tissu
dissect
tip
advanc
skin
proxim
end
connect
distal
part
tunnel
devic
tunnel
pull
caudal
bring
proxim
end
outsid
patient
correct
placement
confirm
secur
skin
statist
analysi
perform
compar
time
placement
patient
bodi
weight
size
dog
enrol
median
weight
rang
kg
median
placement
time
second
rang
second
placement
time
significantli
p
weakli
associ
patient
bodi
weight
differ
placement
time
differ
size
p
median
durat
placement
day
remov
one
patient
due
infect
minor
complic
observ
patient
studi
confirm
eas
speed
safeti
novel
methodolog
placement
analysi
need
compar
advers
effect
placement
time
differ
placement
method
intermitt
fast
numer
benefit
speci
includ
increas
insulin
sensit
improv
neuron
repair
follow
spinal
injuri
increas
keton
aim
studi
examin
immunolog
metabol
hormon
effect
associ
dog
ten
healthi
dog
underw
three
isocalor
feed
regimen
latin
squar
design
daili
feed
kcal
dlf
diet
iflf
kcal
diet
ifhf
bodi
weight
intak
activ
lymphocyt
prolifer
macrophageneutrophil
phagocytosi
respiratori
burst
along
fast
blood
glucos
bhob
leptin
ghrelin
insulin
measur
nmr
spectroscopi
use
identifi
chang
fast
plasma
metabolom
dog
iflf
lost
weight
mean
lower
voluntari
food
intak
dog
activ
night
fed
daili
fed
intermitt
mean
fast
bhob
concentr
highest
ifhd
phase
lowest
dld
phase
mean
fast
plasma
glucos
greatest
fed
daili
lowest
ifhd
phase
intermitt
daili
feed
separ
metabolom
analysi
hormon
concentr
differ
biolog
signific
differ
immun
assay
dietari
phase
unlik
human
rodent
short
term
fast
dog
produc
detriment
immunolog
effect
increas
plasma
bhob
high
fat
diet
highlight
potenti
benefici
feed
regim
dog
spinal
diseas
obes
becom
common
health
problem
reduc
longev
increas
risk
mani
chronic
diseas
advers
affect
qualiti
life
dog
continu
calor
restrict
ccr
regimen
appli
obes
treatment
creat
daili
neg
energi
balanc
howev
ccr
lead
decreas
energi
expenditur
make
difficult
continu
lose
excess
bodi
fat
maintain
bodi
weight
weight
loss
object
studi
compar
effect
ccr
intermitt
calori
restrict
icr
regimen
bodi
fat
loss
loss
mainten
energi
requir
mer
obes
dog
thirti
natur
obes
dog
bc
random
two
group
base
mer
bodi
weight
bodi
fat
dog
ccr
group
fed
baselin
mer
month
dog
icr
group
fed
repeat
baselin
mer
one
week
baselin
mer
one
week
month
calor
restrict
group
adjust
baselin
mer
addit
month
icr
ccr
led
similar
bodi
fat
end
studi
vs
p
dog
ccr
group
significantli
p
lower
loss
mer
compar
baselin
mer
howev
dog
icr
group
numer
increas
loss
mer
p
obes
diabet
lead
disord
among
pet
north
america
signific
impact
anim
morbid
mortal
glycem
index
gi
measur
blood
glucos
respons
shown
human
significantli
impact
glucos
control
insulin
sensit
weight
manag
chronic
diseas
risk
purpos
research
determin
gi
commerci
avail
pet
food
contain
differ
carbohydr
sourc
addit
effect
postprandi
glycem
insulinem
respons
hormon
relat
satieti
also
investig
four
commerci
extrud
diet
contain
differ
carbohydr
sourc
test
diet
classifi
base
type
carbohydr
sourc
contain
tradit
grain
corn
wheat
whole
grain
oat
rye
barley
pea
lentil
chickpea
vegan
anim
ingredi
diet
test
eleven
healthi
adult
siberian
huski
control
glucos
solut
test
twice
per
dog
random
design
meal
control
provid
avail
carbohydr
postprandi
blood
sampl
minut
collect
measur
whole
blood
glucos
concentr
use
handheld
blood
glucos
monitor
serum
insulin
ghrelin
gastric
inhibitori
polypeptid
gip
peptid
leptin
total
peptid
pyy
pancreat
polypeptid
pp
concentr
also
analys
time
point
use
magnet
bead
multiplex
assay
glycem
index
calcul
increment
area
curv
iauc
glucos
test
diet
divid
iauc
control
glycem
indic
compar
use
anova
concentr
glucos
insulin
satieti
hormon
time
compar
treatment
use
anova
studi
approv
univers
guelph
anim
care
committe
aup
effect
diet
gi
insignific
p
although
numer
differ
observ
diet
contain
tradit
grain
present
highest
gi
diet
present
lowest
gi
whole
grain
diet
vegan
diet
gi
valu
respect
signific
effect
diet
observ
postprandi
glycem
respons
insulinem
respons
satieti
hormon
measur
p
lack
observ
differ
could
relat
gelatin
starch
extrus
process
result
high
content
rapidli
digest
starch
result
suggest
differ
carbohydr
sourc
commerci
extrud
diet
may
signific
effect
gi
satieti
dog
research
investig
appropri
use
gi
methodolog
human
necessari
due
high
variabl
postprandi
glucos
respons
observ
studi
unknown
health
benefit
low
glycaem
food
dog
obes
pet
dog
increas
problem
associ
morbid
shorten
life
span
poor
life
qualiti
overweight
dog
exhibit
postprandi
hyperlipidemia
interest
identifi
specif
metabolit
chang
studi
aim
investig
postprandi
metabolit
relat
lipid
metabol
test
identifi
alter
relat
overweight
dog
healthi
male
labrador
retriev
dog
includ
classifi
lean
bodi
condit
score
bc
scale
overweight
bc
overnight
fast
plasma
sampl
collect
dog
fed
meal
follow
postprandi
plasma
sampl
collect
hourli
hour
liquid
spectrometri
use
select
metabolit
evalu
base
rel
signal
area
mix
model
repeat
measur
analysi
dog
propionylcarnitin
stearoylcarnitin
increas
respons
food
intak
p
metabolit
decreas
p
resembl
find
human
overal
taurin
carnitin
acetylcarnitin
respons
lower
overweight
compar
lean
dog
p
notabl
lean
dog
acetylcarnitin
signal
area
higher
overweight
dog
fast
p
decreas
one
hour
postprandi
p
overweight
dog
respons
feed
conclus
lower
signal
area
taurin
carnitin
overweight
dog
suggest
possibl
defici
group
moreov
acetylcarnitin
pattern
overweight
dog
could
indic
decreas
fatti
acid
oxid
fast
metabol
inflex
food
intak
water
intak
hydrat
evalu
healthi
dog
offer
water
nw
supplement
fed
mainten
dri
food
maintain
bw
ad
libitum
tap
water
tw
bucket
baselin
day
urin
specif
graviti
usg
analyz
beagl
n
year
select
usg
equal
divid
group
balanc
usg
group
receiv
either
tw
nw
contain
whey
protein
poultri
flavor
glycerol
bowl
day
dose
dog
ratio
ml
kcal
med
day
ml
kcal
med
day
base
baselin
calori
intak
food
calori
total
liquid
intak
tli
gd
sum
nw
tw
bowl
bucket
water
record
daili
use
calcul
weekli
mean
intak
amount
usg
measur
day
linear
mix
effect
model
perform
main
effect
treatment
time
interact
calori
intak
differ
p
interact
signific
p
versu
baselin
signific
p
day
gml
gml
versu
baselin
gml
studi
indic
dog
offer
nw
supplement
free
access
tw
increas
tli
produc
dilut
urin
suggest
improv
overal
hydrat
diabet
mellitu
chronic
disord
result
hyperglycemia
hyperlipidaemia
insulin
defici
sometim
lead
fatal
complic
studi
evalu
effect
pea
barley
starch
sourc
lipid
profil
diabet
dog
twelv
diabet
dog
receiv
randomli
doubl
blind
way
three
diet
differenc
fat
level
starch
sourc
ba
mix
rice
pea
barley
g
pb
pea
barley
g
co
corn
g
plasmat
cholesterol
triglycerid
curv
perform
everi
hour
hour
begin
immedi
morn
meal
insulin
inject
day
diet
treatment
statist
test
perform
p
pea
diet
caus
lesser
plasmat
lipid
concentr
mainli
cholesterol
compar
corn
diet
tabl
pb
diet
result
lipid
valu
ba
diet
allow
decreas
lipid
level
higher
fat
content
diet
probabl
happen
due
better
glycem
control
diabet
dog
receiv
slow
assimil
starch
phenol
compound
present
pea
barley
ingredi
believ
pea
barley
could
interest
starch
sourc
hyperlipidem
diabet
dog
research
investig
nutrit
suffici
defici
promin
anim
nutrit
veterinari
literatur
past
decad
result
develop
complet
balanc
commerci
pet
food
regardless
trend
companion
anim
nutrit
often
shadow
trend
human
nutrit
percept
exist
among
veterinarian
mani
pet
owner
prefer
natur
holist
diet
process
food
purpos
studi
determin
dog
cat
owner
feed
pet
compar
studi
publish
ten
year
ago
laflamm
et
al
studi
involv
pet
owner
survey
laflamm
colleagu
questionnair
administ
student
phone
randomli
select
telephon
directori
present
questionnair
administ
onlin
distribut
pet
owner
social
media
survey
promot
gener
pet
own
pet
appreci
group
veterinari
nutrit
special
interest
group
open
share
reach
wide
audienc
acquir
sampl
repres
gener
popul
pet
pet
owner
studi
approv
research
ethic
board
particip
institut
reb
descript
data
report
percentag
signific
differ
two
studi
determin
use
chi
squar
analysi
signific
set
p
inform
australia
unit
state
includ
analysi
result
survey
summaris
tabl
data
compar
signific
differ
feed
practic
time
includ
increas
feed
homemad
raw
diet
decreas
daili
feed
treat
decreas
feed
commerci
diet
main
food
sourc
dog
cat
increas
exclus
feed
homemad
diet
also
detect
cat
essenc
trend
appear
shift
pet
nutrit
away
complet
balanc
diet
current
recommend
veterinarian
favour
human
food
raw
meat
diet
chang
practic
may
predispos
nation
pet
dietari
imbal
diseas
infecti
diseas
given
inform
clinician
gener
specialti
practic
must
awar
risk
associ
homemad
raw
diet
obtain
comprehens
dietari
histori
client
prepar
diagnos
treat
associ
diseas
refer
laflamm
dp
abood
sk
fascetti
aj
et
al
pet
feed
practic
dog
cat
owner
unit
state
australia
j
vet
med
assoc
purpos
studi
correl
percentag
protein
fat
crude
fiber
commerci
dri
dog
food
diet
major
bacteri
group
canin
microbiota
dysbiosi
index
fecal
sampl
collect
healthi
dog
n
owner
complet
survey
inform
health
statu
dietari
histori
nutrient
content
obtain
onlin
product
guid
inform
provid
pet
food
compani
contact
directli
dysbiosi
index
di
evalu
combin
quantit
polymeras
chain
reaction
valu
e
coli
streptococcu
turicibact
faecalibacterium
fusobacterium
blautia
clostridium
hiranoni
statist
signific
set
p
correl
abund
bacteri
taxa
macronutri
perform
use
spearman
correl
signific
set
p
result
indic
statist
signific
increas
crude
fiber
diet
decreas
fusobacterium
r
p
howev
correl
bacteri
group
protein
fat
correl
bacteri
group
chang
fiber
content
commerci
dri
food
diet
correl
protein
bacteri
group
signific
chang
e
coli
p
faecalibacterium
p
fusobacterium
p
dysbiosi
index
p
correl
fat
bacteri
group
signific
chang
e
coli
p
faecalibacterium
p
fusobacterium
p
dysbiosi
index
p
final
correl
crude
fiber
bacteri
group
signific
chang
e
coli
p
faecalibacterium
p
dysbiosi
index
p
conclus
signific
correl
found
crude
fiber
fusobacterium
result
suggest
macronutri
content
commerci
diet
modest
impact
abund
major
bacteri
taxa
canin
microbiota
studi
lipid
biolog
fluid
led
substanti
advanc
diagnosi
therapeut
human
obes
cancer
kidney
diseas
consid
condit
also
afflict
cat
hypothes
lipid
could
also
serv
biomark
studi
diagnos
diseas
cat
howev
studi
lipid
felin
plasma
limit
number
lipid
speci
mainli
fatti
acid
triacylglycerol
wherea
yet
unknown
felin
urin
contain
lipid
consid
gap
knowledg
object
studi
character
lipid
composit
plasma
urin
sampl
collect
clinic
healthi
cat
plasma
sampl
obtain
clinic
healthi
intact
femal
cat
collect
ml
blood
tube
contain
citrat
centrifug
x
g
min
urin
sampl
collect
cystocentesi
immedi
centrifug
x
g
min
everi
cat
given
baselin
complet
histori
physic
examin
laboratori
evalu
normal
complet
blood
count
serum
chemistri
urinalysi
lipid
analyz
use
liquid
chromatographyquadrupol
mass
spectrometri
total
lipid
character
felin
plasma
urin
sampl
origin
metabolit
mainli
food
endogen
compound
plasma
glycerophospholipid
show
higher
number
chemic
speci
detect
follow
sphingolipid
glycerolipid
fatti
acyl
sterol
lipid
urin
highest
structur
divers
observ
polar
lipid
name
glycerophospholipid
sphingolipid
chemic
speci
identifi
within
categori
respect
figur
show
rel
abund
lipid
categori
base
signal
intens
found
felin
plasma
urin
sampl
note
lipid
identifi
studi
report
previous
cat
first
studi
describ
lipid
composit
plasma
urin
healthi
cat
comprehens
mani
lipid
found
studi
use
biomark
human
medicin
differ
patholog
includ
linol
arachidon
acid
kidney
diseas
sm
sm
insulin
resist
nonalcohol
fatti
liver
diseas
lpc
lpc
pc
pc
pc
cholesterol
hepatocellular
carcinoma
among
other
thu
novel
inform
gener
studi
could
lead
discoveri
novel
biomark
candid
detect
studi
felin
diseas
individu
treatment
cat
glycat
reaction
carbonyl
group
reduc
sugar
free
amino
group
protein
process
plasma
protein
form
varieti
heterogen
structur
known
advanc
glycat
end
product
age
compound
associ
sever
patholog
includ
obes
diabet
cirrhosi
cardiovascular
diseas
renal
failur
neurolog
disord
contrast
human
medicin
littl
attent
given
age
veterinari
medicin
note
fructosamin
biomark
use
monitor
blood
sugar
concentr
provid
inform
earli
glycat
product
convers
carbonyl
group
form
earli
late
stage
protein
glycat
consid
fact
canin
albumin
contain
similar
glycosylat
amino
acid
lysin
arginin
human
hypothes
abnorm
high
level
glucos
dog
plasma
lead
format
age
process
protein
glycat
order
address
hypothesi
plasma
healthi
dog
enrich
glucos
level
similar
report
diabet
patient
good
poor
glycem
control
control
sampl
incub
day
high
level
glucos
glycat
plasma
protein
led
format
age
determin
assay
carbonyl
content
plasma
increas
p
glucos
manner
p
figur
posit
associ
concentr
fructosamin
p
fructosamin
level
obtain
studi
compar
found
dog
suffer
diabet
plasma
fructosamin
level
first
studi
report
content
protein
carbonyl
canin
plasma
result
demonstr
protein
carbonyl
form
higher
amount
dog
plasma
glucos
level
similar
diabet
patient
compar
plasma
control
although
result
obtain
use
ex
vivo
system
provid
new
inform
occurr
age
glycat
canin
plasma
protein
certainli
futur
studi
perform
use
sampl
diabet
patient
order
expand
knowledg
format
clinic
impact
compound
dog
studi
format
protein
carbonyl
due
glycat
protein
could
repres
new
tool
elucid
metabol
pathway
lead
format
age
consequ
aid
develop
new
therapeut
strategi
treatment
diabet
patient
dog
loyalti
one
greatest
intang
asset
organ
possess
improv
client
loyalti
primari
market
goal
signific
financi
impact
busi
quantit
studi
examin
mediat
role
commun
relationship
satisfact
loyalti
attitudin
behavior
veterinari
clinic
along
moder
role
trust
commit
perceiv
valu
relat
characterist
respons
collect
social
media
analyz
use
descript
inferenti
statist
result
show
attitudin
loyalti
al
strong
posit
relationship
commun
multipl
point
veterinari
clinic
wherea
relationship
behavior
loyalti
clear
addit
find
suggest
al
influenc
trust
veterinarian
commun
staff
member
commit
strong
posit
relationship
behavior
intent
increas
number
product
servic
consum
primari
veterinari
clinic
attenu
role
cost
receiv
veterinari
care
youngest
oldest
cohort
studi
exhibit
lowest
level
al
see
veterinarian
visit
higher
al
set
recommend
made
commun
point
within
veterinari
clinic
improv
al
find
help
veterinari
clinic
owner
manag
develop
implement
relationship
strategi
improv
loyalti
multipl
studi
found
veterinarian
higher
risk
suicid
compar
gener
popul
risk
factor
associ
psycholog
distress
veterinarian
includ
practic
associ
practic
less
year
practic
shelter
medicin
human
physician
patient
complaint
lead
increas
risk
depress
anxieti
suicid
secondari
effect
complaint
physician
includ
practic
medicin
defens
avoid
high
risk
procedur
patient
perform
unnecessari
diagnost
veterinari
medicin
due
need
owner
use
dispos
incom
lead
differ
potenti
sourc
conflict
veterinarian
client
purpos
studi
investig
effect
client
complaint
small
anim
veterinari
internist
welfar
job
satisfact
well
way
practic
veterinari
medicin
anonym
questionnair
made
avail
american
colleg
veterinari
intern
medicin
small
anim
intern
medicin
list
serv
januari
march
survey
obtain
avail
review
respond
receiv
client
complaint
within
preced
month
cost
care
common
reason
major
respond
worri
vari
degre
client
complaint
made
concern
almost
report
verbal
assault
client
within
preced
six
month
report
threaten
litig
major
report
chang
way
practic
veterinari
medicin
avoid
complaint
made
said
consid
chang
career
client
complaint
studi
confirm
client
complaint
common
sourc
distress
veterinari
internist
high
percentag
conflict
due
cost
care
illustr
central
problem
veterinari
medicin
issu
veterinarian
control
veterinarian
need
consid
client
educ
cost
care
achiev
also
need
way
forum
allow
veterinarian
openli
discuss
client
complaint
deal
support
environ
veterinari
medicin
becom
advanc
offer
expens
treatment
procedur
issu
client
complaint
commun
like
continu
grow
referr
internist
often
best
interest
patient
particularli
case
involv
chronic
refractori
undiagnos
condit
unfortun
mani
pet
owner
afford
cost
referr
instanc
gener
practition
challeng
treat
complic
case
limit
budget
owner
may
even
elect
euthanasia
due
cost
care
gener
practition
may
seek
guidanc
internist
order
discuss
diagnost
treatment
option
patient
need
referr
care
whose
owner
afford
consult
frequent
limit
singl
phone
convers
email
outcom
therefor
unknown
consult
internist
addit
strategi
improv
option
outcom
financi
challeng
case
may
benefici
gener
practition
patient
furthermor
increas
awar
prepared
veterinari
student
challeng
may
improv
abil
approach
case
effici
owner
limit
budget
descript
studi
perform
determin
use
consult
board
internist
case
internist
written
diagnost
therapeut
protocol
select
intern
medicin
condit
veterinari
student
particip
weekli
consult
develop
protocol
total
veterinarian
small
anim
veterinari
practic
particip
studi
practic
visit
three
time
cours
one
year
total
consult
conduct
collect
protocol
differ
intern
medicin
condit
given
practition
data
collect
particip
survey
veterinari
student
particip
veterinarian
prior
particip
veterinari
student
feel
confid
choos
best
diagnost
therapeut
approach
intern
medicin
case
owner
budget
could
afford
referr
student
felt
train
area
part
educ
particip
consult
protocol
develop
student
felt
confid
choos
best
approach
case
highli
like
use
protocol
gener
practic
lack
diagnosi
uncertainti
appropri
diagnost
need
special
procedur
three
common
reason
gener
practition
recommend
referr
particip
veterinarian
note
dog
owner
agre
referr
veterinarian
note
expens
primari
reason
owner
declin
referr
veterinarian
alway
comfort
case
sometim
comfort
veterinarian
express
desir
option
treatment
protocol
owner
afford
referr
complet
project
veterinarian
note
consult
protocol
highli
benefici
area
greatest
improv
comfort
level
treat
case
gener
practic
case
outcom
patient
care
veterinarian
believ
patient
qualiti
life
improv
want
continu
particip
consult
summari
intern
medicin
consult
diagnost
treatment
protocol
variou
intern
medicin
condit
benefit
veterinari
student
gener
practition
cost
veterinari
care
especi
referr
medicin
afford
mani
owner
veterinari
student
expos
challeng
train
approach
case
similarli
gener
practition
may
abl
success
effici
diagnos
treat
challeng
intern
medicin
case
propos
strategi
owner
declin
referr
studi
show
cavali
king
charl
spaniel
ckc
high
preval
chronic
fibros
pancreat
fibrot
renal
lesion
cn
perivascular
fibrosi
syringomyelia
hypothesis
ckc
irrespect
diseas
statu
would
increas
fibrosi
multipl
organ
compar
breed
sampl
ckc
collect
prospect
though
donat
scheme
avail
owner
veterinarian
collect
irrespect
diseas
state
antemortem
diagnosi
clinic
inform
obtain
possibl
liver
pancrea
kidney
lung
store
sampl
tissu
match
age
histopatholog
diagnosi
tissu
breed
dog
siriu
red
stain
highlight
fibrosi
perform
slide
digit
object
analysi
softwar
analys
red
stain
score
proport
tissu
volum
analys
blind
breed
patholog
diagnosi
forti
ckc
liver
pancrea
kidney
lung
liver
pancrea
kidney
lung
includ
compris
breed
signific
differ
organ
fibrosi
score
ckc
control
howev
ckc
moder
signific
correl
identifi
liver
fibrosi
pancrea
lung
fibrosi
addit
signific
correl
found
lung
renal
fibrosi
insuffici
case
multipl
organ
preclud
analysi
conclus
ckc
show
increas
fibrosi
compar
match
control
fibrosi
correl
across
organ
studi
indic
assess
multipl
organ
dog
breed
confirm
signific
find
absenc
abnorm
melanocyt
stria
vasculari
cat
white
w
gene
lead
degener
cochlea
pronounc
organ
corti
cochlear
hair
cell
result
hereditari
deaf
diagnos
behavior
andor
brainstem
auditori
evok
respons
baer
present
studi
auditori
function
assess
purebr
angora
cat
baer
test
sedat
auditori
threshold
determin
appli
stimuli
db
spl
moreov
stimuli
db
spl
consid
deaf
stimuli
consid
hear
total
angora
cat
male
femal
includ
studi
mean
age
angora
cat
unilater
deaf
hear
unilater
deaf
cat
male
right
left
deaf
femal
right
left
deaf
unilater
deaf
male
cat
blue
amber
eye
color
unilater
deaf
femal
cat
blue
amber
eye
color
remain
cat
hear
male
blue
eye
color
result
present
studi
reveal
angora
cat
partial
bilater
hereditari
deaf
one
report
avail
indic
angora
cat
unilater
deaf
bilater
deaf
baer
hand
anoth
studi
perform
behavior
test
angora
cat
report
bilater
conclus
epidemiolog
studi
perform
larger
popul
determin
preval
bilater
hereditari
deaf
along
gender
eye
color
associ
strain
gm
hear
disord
cat
classif
patholog
diagnosi
journal
felin
medicin
surgeri
ryugo
dk
felin
deaf
veterinari
clinic
north
america
small
anim
practic
cvejic
steinberg
ta
kent
ms
fischer
unilater
bilater
congenit
sensorineur
deaf
white
cat
j
vet
intern
med
doi
epub
feb
geigi
ca
heid
steffen
f
et
al
pleiotrop
gene
explain
deaf
blue
iris
white
cat
vet
j
may
epub
sep
comput
tomographi
ct
commonli
use
veterinari
medicin
play
import
role
diseas
identif
cancer
stage
differenti
normal
versu
diseas
affect
abdomin
lymph
node
ct
import
clinic
therapeut
decis
make
also
cancer
stage
prognost
purpos
studi
describ
presenc
number
size
shape
attenu
enhanc
pattern
abdomin
lymph
node
ct
healthi
cat
assess
correl
patient
characterist
sixteen
healthi
cat
without
clinic
biochem
evid
diseas
underw
sedat
ct
exam
entir
abdomen
number
size
shape
attenu
enhanc
pattern
presenc
intranod
fat
follow
lymph
center
evalu
two
reader
includ
radiologist
aortic
lumbar
renal
hepat
splenic
gastric
pancreaticoduoden
jejun
ileocec
colic
caudal
mesenter
medial
iliac
sacral
inguin
assess
compar
patient
characterist
pearson
correl
student
use
statist
analysi
total
abdomin
lymph
node
readili
identifi
ct
caudal
mesenter
colic
hepat
inguin
pancreaticoduoden
lymph
node
identifi
cat
bodi
weight
sex
associ
differ
overal
number
lymph
node
identifi
p
respect
lymph
node
size
shape
vari
lymph
center
nearli
lymph
node
homogen
contrast
enhanc
signific
neg
correl
identifi
length
p
width
p
abdomin
lymph
node
well
age
number
sacral
lymph
node
p
intranod
fat
present
lymph
node
ct
readili
permit
identif
character
felin
abdomin
lymph
node
studi
provid
subject
object
data
ct
characterist
abdomin
lymph
node
healthi
cat
size
shape
abdomin
lymph
node
vari
depend
lymph
center
evalu
younger
cat
larger
abdomin
lymph
node
greater
number
sacral
lymph
node
otherwis
vast
major
abdomin
lymph
node
soft
tissu
attenu
homogen
contrast
enhanc
occasion
intranod
fat
inform
consid
tri
identifi
diseas
lymph
node
ct
cancer
stage
purpos
publish
veterinari
guidelin
fluid
therapi
emphas
individu
approach
studi
evalu
daili
chang
fluid
rate
limit
aim
observ
prospect
studi
describ
chang
fluid
therapi
hospit
dog
period
veterinari
teach
hospit
hospit
dog
treat
intraven
fluid
studi
period
elig
inclus
initi
fluid
therapi
rate
mlkgd
fluid
type
adjust
fluid
rate
record
discharg
death
well
manag
servic
ecc
surgeri
acvim
base
specialti
data
normal
assess
use
test
analyz
p
consid
signific
two
hundr
dog
includ
receiv
fluid
therapi
median
durat
day
rang
day
mean
start
fluid
rate
mlkgd
end
fluid
rate
mlkgd
p
throughout
hospit
almost
dog
receiv
crystalloid
fluid
lactat
ringer
solut
common
dog
three
dog
treat
hydroxyethyl
starch
dog
receiv
mainten
type
fluid
fluid
rate
adjust
averag
per
hospit
although
dog
fluid
rate
chang
dog
manag
surgeon
lower
averag
start
fluid
rate
mlkgd
manag
acvim
specialti
criticalist
mlkgd
p
aspect
fluid
therapi
p
fluid
therapi
approach
similarli
throughout
veterinari
teach
hospit
although
daili
fluid
rate
decreas
hospit
daili
fluid
rate
chang
infrequ
adequ
fluid
resuscit
hemorrhag
shock
essenti
expand
volum
improv
global
region
oxygen
deliveri
thu
proper
fluid
select
import
hyperton
salin
colloid
newli
propos
clinic
use
effect
optim
ratio
still
question
studi
introduc
hydroxyethyl
salin
hhe
compar
four
convent
fluid
lactat
ringer
solut
lr
hydroxyethyl
starch
he
hyperton
salin
hs
hydroxyethyl
salin
hhe
dog
experiment
hemorrhag
twelv
healthi
dog
repeatedli
use
full
recoveri
least
twice
dog
bled
remain
mean
arteri
blood
pressur
mmhg
minut
resuscit
group
lr
he
hs
hhe
hhe
intravascular
volum
expans
use
evan
blue
dye
cardiac
output
stroke
volum
preload
stroke
volum
variat
puls
pressur
variat
central
venou
pressur
hemodynam
indic
system
oxygen
oxygen
extract
ratio
central
venou
oxygen
satur
lactat
base
excess
electrolyt
ph
monitor
baselin
minut
hemorrhag
minut
fluid
resuscit
statu
examin
thoroughli
stewart
method
fencl
method
along
monitor
nitric
oxid
plasma
measur
studi
evalu
effect
hhe
control
hemorrhag
shock
dog
model
compar
four
convent
fluid
three
aspect
volum
expans
system
tissu
perfus
respons
statu
aspect
volum
expans
lr
he
hhe
resuscit
significantli
larger
volum
hs
hhe
lr
he
consid
intravascular
volum
p
hemodynam
data
coincid
volumetr
result
three
percent
hhe
well
four
fluid
provid
suffici
system
oxygen
perfus
yet
examin
conduct
hemorrhag
shock
model
base
oxygen
debt
infus
hhe
benefici
acidot
state
hemorrhag
shock
without
dilut
acidosi
owe
transient
hypernatremia
hyperchloremia
conclus
data
suggest
hhe
support
suffici
volum
expans
without
overload
return
system
oxygen
indic
lactat
control
level
superior
resuscit
benefit
statu
inflammatori
stabil
reperfus
injuri
convent
resuscit
fluid
thu
hhe
could
best
altern
solut
compens
dosag
disadvantag
convent
crystalloid
colloid
administr
oxid
stress
primarili
assess
activ
antioxid
enzym
concentr
endogen
antioxid
byproduct
oxid
damag
byproduct
lipid
peroxid
determin
best
marker
oxid
injuri
rodent
model
oxid
stress
stabl
easili
measur
urin
peopl
gold
standard
measur
urinari
ga
spectrometri
anim
major
studi
util
immunosorb
assay
elisa
measur
previou
studi
compar
two
method
small
popul
dog
cat
hors
cow
poor
agreement
method
identifi
dog
hors
cow
howev
fair
agreement
method
identifi
cat
object
studi
evalu
agreement
elisa
measur
urinari
larg
popul
cat
includ
rang
healthi
clinic
ill
cat
skelet
matur
cat
recruit
health
statu
cat
determin
physic
examin
complet
blood
count
cbc
serum
chemistri
profil
thyroid
hormon
urinalysi
cat
defin
system
ill
evid
ill
identifi
physic
examin
persist
fever
inject
mucou
membran
andor
evid
inflamm
andor
organ
system
dysfunct
urin
collect
free
catch
cat
unless
otherwis
indic
due
diseas
process
system
ill
cat
urinari
measur
elisa
urin
sampl
fifti
cat
enrol
studi
cat
determin
healthi
determin
system
ill
urin
sampl
detect
level
signific
neg
correl
identifi
two
method
signific
correl
identifi
healthi
system
ill
cat
compar
analysi
pass
bablok
regress
show
poor
agreement
two
method
comparison
demonstr
relationship
proport
bia
concentr
urinari
measur
elisa
significantli
lower
system
ill
cat
compar
healthi
cat
signific
differ
identifi
urinari
measur
result
indic
method
recommend
assess
urinari
cat
expect
increas
urinari
system
ill
cat
identifi
caution
still
warrant
interpret
test
regardless
method
futur
research
use
identifi
normal
refer
rang
variabl
urinari
cat
mesenchym
stem
cell
msc
use
studi
treatment
variou
diseas
applic
diseas
garner
interest
variou
method
enhanc
immunomodul
effect
human
msc
use
howev
similar
approach
canin
msc
rel
unexplor
accordingli
evalu
immunomodulatori
effect
mechan
canin
msc
treat
canin
msc
stimul
hour
produc
condit
media
cm
lipopolysaccharid
lp
raw
cell
msc
h
cm
express
rna
assess
quantit
revers
transcript
pcr
protein
level
assess
western
blot
express
induc
nitric
oxid
synthas
ino
significantli
anova
decreas
raw
cell
canin
msc
compar
raw
cell
alon
furthermor
effect
canin
msc
significantli
increas
compar
canin
msc
express
cyclooxygenas
prostaglandin
likewis
significantli
increas
prime
canin
msc
level
ino
protein
raw
cell
prime
canin
msc
decreas
increas
cell
treat
inhibitor
conclus
compar
canin
msc
cell
prime
caus
greater
reduct
releas
cytokin
raw
cell
mechan
upregul
pathway
endocannabinoid
system
ec
compris
endogen
signal
molecul
known
endocannabinoid
receptor
bind
recent
decad
research
found
relationship
ec
memori
nocicept
inflamm
appetit
metabol
interest
provid
framework
eventu
develop
safe
effect
cannabinoid
therapi
veterinari
speci
paper
sought
character
two
predomin
cannabinoid
quantif
local
tissu
sampl
acquir
live
adult
dog
present
surgeri
depart
procedur
relat
tissu
obtain
follow
collect
tissu
sampl
place
either
formalin
sampl
store
process
formalin
sampl
submit
histopatholog
process
tissu
sampl
collect
collect
formalin
rna
extract
tissu
store
convert
cdna
quantifi
use
quantit
pcr
qpcr
data
report
ratio
gene
express
housekeep
gene
immunohistochemistri
run
use
antibodi
select
stain
verifi
western
blot
previous
undescrib
find
immunohistochemistri
limit
receptor
stain
darkli
endotheli
cell
membran
tissu
stain
scatter
throughout
parenchyma
local
microscop
cell
membran
quantif
show
high
express
gene
blood
brain
testicl
ovari
uteru
low
express
kidney
lung
liver
lymph
node
express
valu
gene
somewhat
limit
show
high
express
blood
lymph
node
mani
find
previou
studi
confirm
high
concentr
gray
matter
high
concentr
blood
lymph
node
studi
also
found
unexpectedli
high
quantiti
male
femal
gonad
addit
unexpectedli
low
level
express
found
lung
liver
compar
human
mous
model
result
invit
futur
investig
reproduct
applic
cannabinoid
well
possibl
upregul
follow
exogen
exposur
explain
rel
low
express
liver
lung
tissu
quantif
specif
region
canin
brain
may
also
prove
use
develop
pharmaceut
cannabinoid
itraconazol
azol
antifung
medic
essenti
treatment
deep
mycos
develop
hepatotox
may
limit
clinic
util
anecdot
glutathion
precursor
eg
may
amelior
hepatotox
induc
itraconazol
dog
purpos
studi
determin
effect
glutathion
cytotox
vitro
cell
model
canin
hepatocyt
suspens
x
cellsml
treat
combin
itraconazol
reduc
glutathion
cytotox
determin
hour
incub
use
commerci
lactat
dehydrogenas
assay
measur
leakag
intracellular
enzym
dead
cell
differ
cytotox
assess
anova
without
glutathion
cytotox
increas
time
concentr
itraconazol
p
similarli
cytotox
increas
higher
concentr
itraconazol
compar
lower
concentr
time
point
p
hour
glutathion
demonstr
reduct
cytotox
cell
treat
itraconazol
p
effect
seen
earlier
time
point
hour
higher
concentr
drug
find
suggest
glutathion
may
decreas
cytotox
canin
hepatocyt
prospect
clinic
studi
need
determin
whether
glutathion
precursor
use
treatment
prevent
hepatotox
dog
addit
result
establish
cytotox
itraconazol
canin
hepatocyt
vitro
may
use
model
studi
pathogenesi
advers
drug
reaction
immunosuppress
mycophenol
mofetil
mmf
recent
gain
popular
veterinari
medicin
mmf
activ
moieti
mycophenol
acid
mpa
revers
inhibitor
inosin
monophosph
dehydrogenas
impdh
impdh
inhibit
ultim
lead
suppress
lymphocyt
prolifer
goal
studi
evalu
pharmacodynam
pd
mpa
week
vari
oral
dose
mmf
healthi
cat
pd
mpa
evalu
follow
oral
administr
mmf
po
bid
po
bid
po
tid
week
cat
blood
sampl
taken
prior
first
administr
mmf
hour
treatment
day
hour
last
oral
dose
mmf
isol
peripher
blood
mononuclear
cell
pbmc
perform
use
standard
method
blood
draw
sampl
cryopreserv
later
thaw
subsequ
flow
cytometri
analyz
batch
percentag
posit
stain
cell
antibodi
determin
flow
cytometri
total
isol
pbmc
number
variabl
cat
test
initi
oral
mpa
day
day
hour
last
dose
oral
mmf
minim
chang
averag
lymphocyt
count
bid
bid
group
mild
reduct
lymphocyt
cat
treat
tid
mmf
overal
ratio
nearli
bid
bid
tid
treatment
group
studi
describ
pd
oral
administr
mmf
healthi
cat
littl
chang
lymphocyt
count
bid
group
mild
reduct
tid
group
lymphocyt
ratio
show
littl
chang
group
result
studi
show
appreci
reduct
cell
suppress
may
due
short
treatment
period
due
presenc
lymphocyt
cat
healthi
futur
studi
evalu
pd
mpa
clinic
affect
felin
patient
receiv
mmf
canin
mast
cell
tumor
mct
common
malign
skin
cancer
dog
combin
anticanc
drug
includ
vinblastin
prednison
tyrosin
kinas
inhibitor
toceranib
masitinib
along
surgeri
andor
radiat
therapi
commonli
use
treat
mct
chemotherapi
result
unpredict
clinic
outcom
respons
therapi
drug
toxic
patient
variabl
genet
polymorph
enzym
might
affect
drug
metabol
clinic
outcom
mani
singl
nucleotid
polymorph
snp
human
locu
character
recent
studi
highlight
potenti
variat
suscept
sever
common
phenotyp
includ
cancer
object
studi
analyz
sequenc
canin
gene
ncbi
access
thirteen
dog
mct
grade
investig
pattern
sequenc
variat
relat
clinic
respons
therapi
fisher
exact
test
use
assess
correl
snp
clinic
respons
patient
receiv
vinblastin
show
sign
toxic
includ
vomit
anorexia
thrombocytopenia
three
set
point
mutat
found
patient
silent
n
missens
n
chang
amino
acid
frameshift
mutat
n
code
sequenc
three
patient
show
missens
n
frameshift
mutat
n
present
recurr
mct
vinblastin
chemotherapi
could
repres
step
toward
predict
clinic
respons
anticanc
chemotherapi
cyclosporin
csa
one
effect
commonli
use
immunosuppress
variabl
clinic
efficaci
seen
patient
due
signific
variat
drug
disposit
process
adjust
drug
dose
base
csa
therapeut
drug
monitor
tdm
facilit
success
patient
manag
object
studi
determin
popul
tdm
paramet
serum
csa
compar
disposit
clinic
control
canin
patient
csa
tdm
inform
collect
clinic
pharmacolog
laboratori
databas
octob
septemb
statist
analys
comput
use
sa
version
sa
institut
cari
nc
disposit
plasma
drug
concentr
serum
csa
individu
clinic
respons
compar
patient
control
clinic
sign
versu
uncontrol
diseas
common
diseas
treat
enceph
n
hemolyt
anemia
thrombocytopenia
n
inflammatori
bowel
diseas
ibd
n
n
eg
atop
dermat
anal
furunculosi
uveiti
csa
peak
level
control
ngml
versu
uncontrol
patient
ngml
fail
demonstr
statist
differ
p
control
patient
hr
significantli
longer
uncontrol
patient
hr
p
signific
variabl
found
peak
csa
level
prednisolon
leflunomid
ketoconazol
diseas
also
increas
variabl
variabl
csa
disposit
support
need
tdm
establish
patient
therapeut
rang
test
test
market
diagnos
monitor
chronic
kidney
diseas
cat
dog
object
studi
determin
serum
concentr
sdma
creatinin
increas
cat
kidney
damag
femal
cat
alloc
experiment
group
control
group
meloxicam
group
cat
control
meloxicam
group
treat
salin
meloxicam
respect
serum
sdma
idexxtm
creatinin
concentr
assess
administr
treatment
histopatholog
perform
kidney
cat
meloxicam
group
sever
tubular
chang
observ
cat
start
administr
treatment
cat
compar
serum
concentr
creatinin
mgdl
sdma
unexpectedli
sdma
concentr
rose
normal
refer
rang
cat
kidney
damag
time
requir
sdma
creatinin
surpass
refer
concentr
similar
cat
studi
first
one
report
chang
serum
concentr
sdma
healthi
cat
develop
damageresult
studi
suggest
serum
concentr
sdma
detect
kidney
tubular
damag
induc
repeat
administr
meloxicam
earlier
creatinin
cat
ii
clinician
may
unabl
detect
extens
kidney
tubular
damag
cat
use
sdma
creatinin
least
glomerulu
sever
affect
fluconazol
commonli
prescrib
dog
cat
yet
pharmacokinet
data
limit
studi
determin
fluconazol
pharmacokinet
dog
cat
clinic
diseas
studi
univers
hospit
patient
prescrib
oral
fluconazol
confirm
suspect
fungal
diseas
enrol
dose
protocol
determin
treat
clinician
one
three
serum
sampl
collect
opportunist
time
per
fluconazol
dose
interv
sampl
multipl
visit
encourag
sampl
store
frozen
analyz
valid
liquid
chromatographi
mass
spectrometri
method
forti
dog
mean
rang
bodi
weight
kg
cat
bodi
weight
kg
enrol
patient
provid
sampl
rang
yield
canin
felin
sampl
diagnos
includ
histoplasmosi
blastomycosi
fungal
kerat
cryptococcosi
coccidioidomycosi
aspergillosi
protothecosi
cutan
fungal
six
dog
two
cat
treat
suspect
fungal
diseas
pend
diagnost
result
serum
concentr
dose
normal
vari
wide
directli
proport
oral
clearanc
clf
clf
fluconazol
cat
mlminkg
compar
mean
mlminkg
research
cat
renal
hepat
diseas
appar
effect
clf
serum
concentr
clf
progress
increas
month
cat
hypertroph
cardiomyopathi
clf
dog
mlminkg
dog
hepat
andor
renal
diseas
respect
similar
clf
wide
variabl
plasma
concentr
may
affect
clinic
efficaci
advers
effect
despit
risk
expens
cytolog
cultur
bronchoalveolar
lavag
fluid
balf
essenti
correct
identif
treatment
bacteri
pneumonia
blood
cultur
could
altern
balf
cultur
studi
object
determin
agreement
cultiv
bacteria
balf
blood
canin
bacteri
pneumonia
six
dog
bacteri
pneumonia
balf
septic
suppur
inflamm
andor
posit
aerobicanaerob
cultur
prospect
enrol
blood
cultur
obtain
within
hour
balf
collect
exclus
criteria
includ
antibiot
prior
day
weight
ensur
adequ
blood
volum
collect
cultur
clinic
sign
includ
fever
cough
tachypnea
regurgit
ptyalism
hematemesi
hemoptysi
cbc
peripher
neutrophilia
neutropenia
note
band
neutrophil
toxic
common
balf
cytolog
degener
neutrophil
intracellular
bacteria
observ
secondari
bacteri
pneumonia
associ
multipl
singl
organ
balf
cultur
escherichia
coli
pseudomona
putida
klebsiella
pneumonia
streptococcu
cani
stenotrophomona
maltophilia
achromobact
xylosoxidan
pseudomona
oleovoran
pneumonia
singl
organ
identifi
cultur
pasturella
cani
haemophilu
haemoglobinophilu
blood
cultur
posit
blood
balf
e
coli
klebsiella
pneumonia
streptococcu
cani
three
dog
euthan
three
dog
recov
complet
blood
cultur
appear
insensit
surrog
balf
cultur
canin
bacteri
pneumonia
futur
analysi
bank
balf
blood
microbiom
analysi
dog
may
prove
reward
discrimin
felin
mediastin
mass
pleural
effus
thorac
radiographi
may
challeng
studi
object
determin
carina
displac
caudal
dorsal
cat
mediastin
mass
mass
compar
cardiogen
pleural
effus
cpe
pleural
effus
ncpe
thorac
diseas
normal
medic
record
osu
vmth
mu
vhc
review
advanc
imag
necropsi
requir
inclus
mass
cpe
ncpe
group
three
evalu
radiologist
cardiologist
year
veterinari
student
blind
diagnosi
obtain
measur
later
radiograph
number
intercost
space
first
rib
carina
ic
distanc
caudal
aspect
manubrium
carina
mc
standard
vertebr
score
draw
mc
fourth
thorac
vertebra
count
number
includ
vertebr
bodi
vs
distanc
first
rib
carina
rc
two
factor
anova
use
data
report
cat
includ
mass
group
increas
ic
mc
vs
rc
compar
group
compar
normal
cat
cpe
ncpe
increas
ic
cpe
cat
increas
mc
rc
radiograph
measur
may
aid
clinician
differenti
mediastin
mass
pleural
effus
cat
despit
widespread
use
vaccin
bordetella
bronchiseptica
bb
infect
still
commonli
diagnos
dog
lower
airway
infect
fatal
pneumonia
chronic
present
may
observ
effici
treatment
requir
aerosol
gentamicin
histor
describ
maxim
local
drug
deliveri
minim
system
absorpt
clinic
respons
standard
protocol
report
object
studi
compar
clinic
respons
two
differ
protocol
aerosol
gentamicin
dog
confirm
respiratori
bb
infect
diagnosi
bb
infect
base
compat
clinic
sign
posit
bacteri
cultur
pcr
bronchoalveolar
lavag
fluid
dog
recruit
year
period
dog
gentamicin
aerosol
minut
twice
daili
week
use
face
mask
variou
type
ultrason
nebul
either
dose
mgkg
gentamicin
dilut
part
salin
use
protocol
fix
amount
undilut
gentamicin
protocol
first
recheck
week
treatment
either
stop
pursu
increment
clinic
cure
clinic
cure
defin
resolut
clinic
sign
absenc
cough
radiograph
lesion
improvementresolut
proport
dog
clinic
cure
first
recheck
median
total
durat
treatment
compar
treatment
protocol
addit
effect
factor
age
breed
bacteria
includ
cyno
presenc
alveolar
lesion
previou
steroid
therapi
sever
neutrophilia
lavag
cure
treatment
durat
analys
test
dog
recruit
male
femal
median
age
month
median
bw
kg
brachycephal
breed
yorkshir
chihuahua
dog
dog
previous
treat
oral
antimicrobi
therapi
poor
respons
twenti
dog
alveolar
pattern
thorac
radiograph
suggest
bronchopneumonia
differ
demograph
clinic
data
dog
includ
protocol
treatment
well
toler
dog
undesir
effect
observ
clinic
cure
first
recheck
tend
frequent
observ
dog
treat
protocol
dog
compar
protocol
dog
median
durat
treatment
shorter
protocol
week
rang
compar
protocol
week
rang
none
clinic
patholog
paramet
studi
associ
clinic
respons
conclus
oral
antimicrobi
therapi
aerosol
gentamicin
appear
safe
promis
treat
dog
bb
infect
particularli
case
refractori
oral
antimicrobi
therapi
protocol
use
undilut
solut
minut
allow
deliveri
gentamycin
amount
proport
individu
minut
volum
could
offer
shorter
durat
treatment
aerodigest
diseas
may
occur
without
obviou
esophagealgastrointestin
sign
though
well
character
human
dog
due
poor
clinic
recognit
diagnost
limit
studi
object
evalu
dog
present
primari
clinic
complaint
cough
videofluoroscop
swallow
studi
vfss
dog
primari
complaint
cough
thorac
radiograph
vfss
present
univers
missouri
includ
retrospect
exclus
criteria
includ
cough
cardiac
origin
esophagealgastrointestin
sign
regurgit
vomit
belch
within
preced
month
abnorm
vfss
categor
gastroesophag
reflux
ger
hiatal
hernia
dysmotil
aspir
case
met
inclus
criteria
median
iqr
age
year
identifi
breed
sex
predisposit
median
iqr
durat
cough
month
thorac
radiograph
unremark
dog
evid
aspir
pneumonia
abnorm
vfss
detect
dog
abnorm
includ
ger
dog
larg
volum
ger
dog
later
diagnos
laryng
paralysi
dog
diagnos
via
vfss
slide
hiatal
hernia
pharyng
andor
esophag
hypomotil
found
dog
megaesophagu
note
dog
macroaspir
identifi
dog
final
respiratori
diagnos
dog
abnorm
vfss
includ
chronic
bronchiti
laryng
paralysi
laryng
polyp
dog
primari
caus
cough
respiratori
origin
canin
aerodigest
disord
occur
without
obviou
sign
esophagealgastrointestin
diseas
vfss
use
adjunct
diagnost
dog
cough
tracheal
collaps
devast
diseas
primarili
affect
small
breed
dog
medic
manag
fail
surgic
therapi
cervic
tracheal
ring
andor
tracheal
stent
may
use
palliat
clinic
sign
tracheal
ring
may
prefer
case
cervic
thorac
inlet
collaps
order
prevent
complic
granul
tissu
persist
cough
stent
fractur
howev
tracheal
collaps
consid
progress
dog
initi
improv
follow
tracheal
ring
placement
may
recurr
airway
obstruct
requir
stent
palliat
purpos
studi
evalu
characterist
outcom
dog
receiv
tracheal
stent
follow
earlier
placement
tracheal
ring
electron
medic
record
search
dog
underw
placement
tracheal
ring
record
retriev
record
dog
subsequ
underw
placement
tracheal
stent
evalu
breed
age
placement
ring
durat
ring
stent
identifi
dog
underw
tracheal
ring
placement
studi
period
includ
yorkshir
terrier
yorkshir
terrier
two
dog
ring
stent
place
singl
hospit
prior
discharg
one
dog
euthan
ring
placement
follow
develop
suspect
ard
dog
discharg
follow
isol
tracheal
ring
placement
nine
yorkshir
terrier
subsequ
underw
tracheal
stent
placement
median
year
rang
year
follow
initi
placement
tracheal
ring
dog
underw
tracheal
ring
stent
significantli
p
younger
dog
ultim
procedur
time
origin
ring
placement
year
year
one
dog
underw
procedur
seizur
die
home
two
day
follow
discharg
two
dog
subsequ
euthan
due
progress
airway
obstruct
granul
tissu
one
dog
die
due
pneumonia
tracheal
stent
may
perform
earlier
ring
placement
dog
progress
airway
diseas
younger
age
initi
ring
placement
well
yorkshir
terrier
may
increas
likelihood
undergo
subsequ
tracheal
stent
epiglott
retrovers
er
displac
epiglotti
lumen
larynx
result
inspiratori
airflow
limit
andor
distress
unclear
often
er
primari
diseas
dog
versu
condit
develop
secondarili
upper
airway
obstruct
diseas
goal
studi
describ
concurr
diseas
manag
outcom
dog
er
electron
medic
record
system
search
epiglott
retrovers
epiglott
entrap
diagnosi
made
upon
sedat
oral
examin
tracheoscopi
without
doxapram
administr
record
review
data
collect
descript
analysi
thirteen
dog
met
inclus
criteria
follow
breed
repres
yorkshir
terrier
one
chihuahua
havanes
miniatur
schnauzer
parson
russel
terrier
pomeranian
pug
shih
tzu
toy
poodl
seven
dog
male
neuter
six
femal
spay
mean
age
year
mean
weight
kg
two
dog
er
evid
concurr
upper
airway
diseas
remain
eleven
dog
combin
concurr
tracheal
collaps
elong
soft
palat
laryng
paralysi
concurr
elong
soft
palat
common
treatment
includ
perform
dog
epiglottectomi
perform
one
dog
four
dog
staphylectomi
one
dog
underw
arytenoid
later
procedur
dog
recov
discharg
epiglott
retrovers
may
contribut
respiratori
distress
commonli
associ
airway
diseas
addit
dog
er
may
help
reduc
clinic
sign
attribut
er
object
studi
compar
effect
alfaxalon
propofol
laryng
function
evalu
laryng
function
numer
object
score
system
via
computer
softwar
ten
healthi
beagl
dog
randomli
assign
receiv
either
propofol
alfaxalon
crossov
prospect
studi
propofol
administ
mgkgmin
intraven
alfaxalon
administ
mgkgmin
intraven
dog
mouth
could
open
videolaryngoscopi
two
week
later
dog
evalu
use
anesthet
agent
video
analyz
glotantool
imag
j
softwar
valu
area
rima
glottidi
major
length
axi
l
figur
process
second
increment
final
second
record
normal
measur
comput
al
repres
elongated
rima
glottidi
small
larg
valu
correspond
thin
thick
shape
along
length
axi
breath
greatest
laryng
movement
identifi
differ
maxim
minim
valu
breath
cycl
calcul
shape
valu
rang
pixel
length
differ
maxim
minim
valu
rang
pixel
length
final
statist
model
show
signific
drug
effect
variabl
shape
alfaxalon
ci
propofol
propofol
prove
superior
evalu
laryng
function
healthi
beagl
softwar
program
provid
object
number
comparison
